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ABSTRACT 
 
 
RNA plays key roles in essential biological processes, such as protein synthesis, 
transcriptional regulation, splicing and retroviral replication. The structural diversity of RNA 
molecules and the lack of known RNA repair mechanisms make these biopolymers a 
challenging, yet very important target for therapeutic intervention. In particular, the increasing 
problems of bacterial resistance to antibiotics make the search for novel RNA binders of 
crucial importance. Among known RNA binders, aminoglycosides were among the first to be 
recognized as effectors of RNA functions. Despite the established bactericidal properties of 
aminoglycoside antibiotics, their therapeutic use is limited, as internal administration of 
aminoglycoside antibiotics at high doses results in clinical side effects. The 1,3-
hydroxylamine motifs and deoxystreptamine moiety, present in all aminoglycosides, are the 
elements of recognition of RNA. Binding properties of these compounds is believed to be a 
three-dimensional electrostatic complementarity rather than highly specific contacts between 
the aminoglycosides and an RNA receptor site. Macrolides are a second class of compounds 
that bind to the ribosome. A large variety of natural compounds displaying various biological 
activities are recorded through literature. Most of them, share a macrocyclic lactone ring.  
Macrolides and aminoglycosides, despite their high potency, remain structurally highly 
sophisticated. The exploration of new pathways toward molecules of lower structural 
complexity was performed.  
Starting from a non iterative method for the synthesis of 15 carbon polyolic chains, (2R,4S)-
1,5-bis[(2RS,4SR)-6-(benzyloxy)methoxy]tetrahydro-2H-pyran-2-yl]pentane-2,4-diol, a new 
intermediate, was isolated and selectively functionalised. In addition, efficient tools for the 
selective protection of hydroxyl moieties on polyol chains were developed allowing the 
synthesis of a library of structurally diverse 1,3-hydroxylamine and deoxystreptamine 
containing compounds. Deoxystreptamine dimers were found to be better RNA binders than 
2-deoxystreptamine itself, while linear aminopolyols were found to be good linker candidates 
for the synthesis of deoxystreptamine dimers. Dynamic combinatorial libraries with a 
bacterial RNA fragment as biological target were implemented for the identification of new 
potent RNA binders. 
Based on macrolactonisation reaction or ring closing metathesis, efficient synthetic routes 
were explored for the synthesis of polyhydroxylated macrolactones requiring the isolation of 
few synthetic intermediate and limited protecting groups’ manipulations. Glycolipids analogs 
were also produced on bis amides formation or ring closing metathesis for the synthesis of 
macrocyclic rings containing a bis(hemiacetal) scaffold and diamino or diamido linkers. 
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RESUME 
 
 
L’ARN joue un role clé dans de nombreux processus biologiques essentiels, tels que la 
synthèse de protéines, la régulation de la transcription, de l’épissage et de la réplication des 
virus. La diversité structurelle des molécules d’ARN et l’absence de mécanisme de réparation 
de ces dernières font de ce biopolymère une cible thérapeutique importante bien que difficile 
d’accés. Le problème de la résistance bactérienne aux antibiotiques rend la recherche de 
nouveaux ligands de l’ARN particulièrement urgente. Parmi les ligands connus de l’ARN, les 
aminoglycosides ont été les premiers à être reconnues comme agissant sur l’ARN. Malgré 
leurs propriétés bactéricides reconnues, leur utilité thérapeutique reste limitée, étant donné 
qu’une administration à haute dose donne lieu à des effets thérapeutiques secondaires. Les 
motifs 1,3-hydroxylamine et déoxystreptamine, commun à tous les aminoglycosides sont les 
éléments de reconnaissance du RNA. Celle-ci se fait par une reconnaissance tridimensionnelle 
de la répartition des charges et non par des interactions de contact spécifiques entre 
aminoglycosides et un site récepteur de l’ARN. Les macrolides sont une seconde classe de 
composés se liant au ribosome. Une grande variété de produits naturels présentant diverses 
propriétés biologiques sont connus dans la littérature. La majorité d’entre eux sont des 
macrolactones. 
Macrolides et aminoglycosides, malgré leurs activités biologiques, restent des molécules 
ayant des architectures complexes.  
L’exploration de nouvelles voies de synthèse vers des molécules ayant des structures 
simplifiées a été entreprise au cours de ce travail. 
Partant de la synthèse non-itérative de la chaîne polyolique à 15 carbones, le (2R,4S)-1,5-
bis[(2RS,4SR)-6-(benzyloxy)methoxy]tetrahydro-2H-pyran-2-yl]pentane-2,4-diol, un nouvel 
intermédiaire, a été isolé et fonctionnalisé sélectivement. Des méthodologies efficaces pour la 
protection sélective d’alcool sur la chaîne polyolique ont été développées pour permettre la 
synthèse d’une librairie de composés contenant les motifs 1,3-hydroxyamines et 
deoxystreptamine. Les dimères de la déoxystreptamine ont une meilleure affinité pour l’ARN 
que la déoxystreptamine elle-même. Les aminopolyols linéaires quant à eux se sont révélés 
être de bon candidats pour la synthèse de dimères de la deoxystreptamine. Enfin il a été 
montré que l’utilisation de fragments d’ARN dans des librairies dynamiques combinatoires 
était possible pour identifier de nouveaux ligands de l’ARN. 
L’utilisation de macrolactonisations et de métathèses cyclisantes, ont donné lieu à de 
nouvelles voies de synthèses pour l’obtention de macrolactones polyhydroxylées requerrant 
peu d’étapes de synthèse et de manipulations de groupements protecteurs. Des analogues de 
glycolipides ont aussi été obtenus par bis couplage amidiques ou métathèse cyclisante pour 
fermer des macrocycles contenant des bis(hémiacetal) et des groupement amino ou amido. 
 
 
MOTS-CLES 
 
 
• Mimes d’aminoglycosides 
• Activité antibactérienne 
• Librairies dynamiques combinatoires 
• Polycétides fonctionnalisés 
• Macrolides 
• Protections sélectives 
• Ligands de l’ARN 
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CHAPTER I INTRODUCTION 
 
The objective of this work is to develop efficient synthetic pathways to a large variety of new 
mimics of natural products. Aminoglycosides are among the most popular antibacterial agents. 
This introduction aims at defining the challenges of the problem. For that purpose, the 
biological target and mode of action of aminoglycosides will be briefly described before a 
short review on the existing compounds that exhibit the same biological properties as 
aminoglycosides. The methods employed for the measurement of aminoglycosides and 
analogues activity will be described. Finally, the reasons for the design of new 
aminoglycosides mimics will be reviewed and a way to proceed toward the rapid identification 
of potent biologically active compounds will be exposed. 
 
1 The cell 
 
The cell is the structural and functional unit of all living organisms, and is sometimes called 
the "building block of life".1 Some organisms, such as bacteria, are unicellular, consisting of a 
single cell. Other organisms, such as humans, are multicellular. All cells share several 
properties: 
• Reproduction by cell division. 
• Use of enzymes and other proteins coded by deoxyribonucleic acid (DNA) genes and 
made via messenger ribonucleic acid (RNA) intermediates and ribosomes. 
• Metabolism, including taking in raw materials, building cell components, converting 
molecules and releasing by-products. The functioning of a cell depends on its ability 
to extract and use chemical energy stored in organic molecules. This energy is derived 
from metabolic pathways. 
• Response to external and internal stimuli such as changes in temperature, pH or 
nutrient levels. 
• Cell contents are enclosed within a cell surface membrane that contains proteins and a 
lipid bilayer. 
There are two types of cells, eukaryotic and prokaryotic. Prokaryotic cells are usually 
singletons, while eukaryotic cells are usually found in multi-cellular organisms. 
Prokaryotes are distinguished from eukaryotes on the basis of nuclear organization, 
specifically their lack of a nuclear membrane. Prokaryotes also lack most of the intracellular 
                                                     
1 Bruce, Alberts Molecular Biology of the Cell fourth edition 2002, published by Garland Science. 
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organelles and structures that are characteristic of eukaryotic cells (an important exception is 
the ribosomes, which are present in both prokaryotic and eukaryotic cells). Most of the 
functions of organelles, such as mitochondria, chloroplasts, and the Golgi apparatus, are taken 
over by the prokaryotic plasma membrane. Prokaryotic cells display three architectural 
regions: 
• appendages called flagella;  
• a cell envelope consisting of a capsule, a cell wall, and a plasma membrane;  
• a cytoplasmic region that contains the cell genome (DNA), ribosomes and various sorts 
of inclusions.  
The plasma membrane (a phospholipid bilayer) separates the interior of the cell from its 
environment and serves as a filter and communications beacon. 
Prokaryotes can carry extrachromosomal DNA elements called plasmids, which are usually 
circular. Plasmids can carry additional functions, such as antibiotic resistance. Eukaryotic 
cells are about 10 times the size of a typical prokaryote and can be as much as 1000 times 
greater in volume.  
The major difference between prokaryotes and eukaryotes is that eukaryotic cells contain 
compartments in which specific metabolic activities take place. Most important among these 
is the presence of a cell nucleus, a membrane-delineated compartment that houses the 
eukaryotic cell's DNA. It is this nucleus that gives the eukaryote its name, which means "true 
nucleus". The eukaryotic DNA is organized in one or more linear molecules, called 
chromosomes, which are associated with proteins. All chromosomal DNA is stored in the cell 
nucleus, separated from the cytoplasm by a membrane. 
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2 The genetic material 
 
Two different kinds of genetic material exist: deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA) (Figure 1).  
 
Figure 1: From DNA to proteins (from the free encyclopaedia Wikipédia). 
 
Most organisms use DNA for their long-term information storage, but some viruses (e.g., 
retroviruses) have RNA as their genetic material. The biological information contained in an 
organism is encoded in its DNA or RNA sequence. RNA is also used for information transport 
(e.g., messenger RNA: mRNA) and enzymatic functions (e.g., ribosomal RNA: rRNA) in 
organisms that use DNA for the genetic code itself.  
 
Prokaryotic genetic material is organized in a simple circular DNA molecule (the bacterial 
chromosome) in the nucleoid region of the cytoplasm. Eukaryotic genetic material is divided 
into different linear molecules named chromosomes inside a discrete nucleus, usually with 
additional genetic material in some organelles like mitochondria and chloroplasts. 
The cell nucleus is the most conspicuous organelle found in a eukaryotic cell. It houses the 
cell's chromosomes, and is the place where almost all DNA replication and RNA synthesis 
occur. The nucleus is spheroid in shape and separated from the cytoplasm by a double 
membrane called the nuclear envelope. The nuclear envelope isolates and protects cell's DNA 
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from various molecules that could accidentally damage its structure or interfere with its 
processing. During processing, DNA is transcribed, or copied into a special RNA, called 
mRNA. This mRNA is then transported out of the nucleus, where it is translated into a specific 
protein molecule. In prokaryotes, DNA processing takes place in the cytoplasm.2 
 
3 RNA-DNA protein synthesis, biological background 
 
3.1 From DNA to RNA 
 
To carry out its information-storage function, DNA must do more than copy itself before each 
cell division. It must also express its information, putting it to use so as to guide the synthesis 
of other molecules in the cell. This occurs by a mechanism leading first and foremost to the 
production of two other key classes of polymers: RNAs and proteins. The process begins with 
a templated polymerization called transcription, in which segments of the DNA sequence are 
used as templates to guide the synthesis of shorter molecules of the closely related polymer 
ribonucleic acid RNA. The primary role of most of these transcripts is to serve as 
intermediates in the transfer of genetic information: they act as messenger RNA (mRNA) to 
guide the synthesis of proteins according to the genetic instructions stored in DNA (Figure 
1). RNA molecules have distinctive structures that can also provide them with other 
specialized chemical abilities. Like DNA, RNA is a linear polymer made of four different 
types of nucleotide subunits linked through phosphodiester bonds. It chemically differs from 
DNA in two respects: (1) the nucleotides in RNA are ribonucleotides, i.e. they contain the 
sugar ribose rather than deoxyribose; (2) it contains the uracil base instead of thymine in 
DNA (Scheme 1).3 
 
                                                     
2 Voet, D.; Voet, J. G. Biochemitry, DeBoek 3rd edition 1996, ISBN 2-8041-4795-9 
3 a) Pain, V. M. Eur. J. Biochem. 1996, 236, 747. b) Brenner, S.; Jacob, F.; Meselson, M. Nature 1960, 190, 576-
581. 
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3.2 Different types of RNA 
 
During the translation of RNA into proteins, the information in the sequence of a messenger 
RNA molecule is read out in groups of three nucleotides, i.e. a codon, at once by a special 
class of small molecules, the transfer RNAs (tRNA). Each type of tRNA holds, at one end, a 
specific aminoacid and, at the other end, a specific sequence of three nucleotides (anticodon) 
that allows recognition, trough base-pairing of a particular codon (Figure 2).4 
 
 
 
 
 
 
 
 
 
 
Figure 2: Transfer RNA: schematic. 
 
For the synthesis of proteins, a succession of tRNA molecules charged with their appropriate 
amino acids have to be brought together with a mRNA molecule and matched up by base-
                                                     
4 a) Crick, F.; Burnett, L.; Brenner, S.; Watts-Tobin, R. J. Nature 1961, 192, 1227. b) Nirenberg, M. Nobel 
lectures in Molecular Biology 1977, 335-360. 
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pairing through their anticodons with each of its successive codons. Then amino acid have to 
be linked together to extend the growing protein chain, and the tRNAs, relieved in their 
burdens, have to be released. This whole complex process is carried out by a giant 
multimolecular machine, the ribosome, consisting of two main chains of RNA, called 
ribosomal RNAs (rRNA) and more than 50 different proteins.5 
 
3.3 From RNA to protein: the key role of ribosomal RNA 
 
The first molecule produced during transcription is a pre-mRNA synthesized by enzymes 
called RNA polymerases, produced in the nucleus, from DNA. To be exportable out of the 
nucleus, it seems that a mRNA must be bound by the appropriate set of proteins. A few 
percent of the dry weight of a mammalian cell is RNA; of that, only about 3-5% is mRNA. 
The most abundant RNAs in cells are the ribosomal RNAs (rRNAs). They form the core of the 
ribosome. Ribosomal components are designated by their “S values”, which refers to their rate 
of sedimentation in an ultracentrifuge.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: A comparison of the structures of prokaryotic and eucaryotic ribosomes. 
 
There are four types of eukaryotic rRNAs (Figure 3), each present in one copy per ribosome.6 
Three of the four (18S, 5.8S, and 28S) are made by chemical modification and cleavage of a 
                                                     
5 Green, R.; Noller, H. F. Annu. Rev. Biochem. 1997, 66, 679.  
6 Fedor, M. J. Curr. Biol. 1998, 8, R441. 
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single large rRNA precursor. The fourth rRNA (5S RNA) is synthesized from a separate 
cluster of genes by a different polymerase, and does not require chemical modification. 
Extensive chemical modifications occur in the 13000-nucleotide-long rRNA precursors before 
the rRNAs are cleaved out of it and assembled into ribosomes in an organelle called nucleolus. 
The nucleolus is the site where other RNAs are produced and other RNA-protein complexes 
are assembled. For example, the tRNAs that carry the amino acids for protein synthesis are 
processed there as well. 
To maintain the correct reading frame and to ensure accuracy, protein synthesis is performed 
in the ribosome. Eucaryotic and prokaryotic ribosomes are very similar in design and function. 
Both are composed of a large and a small subunit that fit together to form a complete ribosome 
with a mass of several millions Daltons. The small subunit provides a network on which the 
tRNAs can be accurately matched to the codons of the mRNA, while the large subunit 
catalyses the formation of the peptide bond that links the amino acids together into a 
polypeptide chain.7 When not actively synthesizing proteins, the two subunits of the ribosome 
are separated. They join together on a mRNA molecule to initiate the synthesis of a protein. 
The mRNA is then pulled through the ribosome; as its codons encounter the ribosome’s active 
site, the mRNA nucleotide sequence is translated into an amino acid sequence using the 
tRNAs as adaptators to add each amino acid in the correct sequence to the end of the growing 
polypeptide chain. When a stop codon is encountered, the ribosome releases the protein and its 
two subunits separate again. These subunits can then be used to start the synthesis of another 
protein on another mRNA molecule. A ribosome contains four binding sites for RNA 
molecules. One is for the mRNA and three (called A-site, P-site, and E-site) are for the tRNAs 
(Figure 4).  
 
 
 
 
 
 
 
 
 
Figure 4: Highly schematic representation of a ribosome. 
                                                     
7 Ibba, M.; Söll, D. Annu. Rev. Biochem. 2000, 69, 617-650. 
Large ribosome  
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A tRNA molecule is held tightly at the A- and P-sites only if its anticodon forms base pairs 
with a complementary codon on the mRNA molecule that is bound to the ribosome. The A- 
and P-sites are close enough together for their two tRNA molecules to be forced to form base 
pairs with adjacent codons on the mRNA molecule. This feature of the ribosome maintains the 
correct reading frame on the mRNA.8 Once protein synthesis has been initiated, each new 
amino acid is added to the elongating chain in a cycle of reactions containing three major 
steps. The following description of the chain elongation process begins at a point at which 
some amino acids have already been linked together and there is a tRNA molecule in the P-
site on the ribosome, covalently joined to the end of the growing polypeptide. 
In step 1, a tRNA carrying the next amino acid in the chain binds to the ribosomal A-site by 
forming base pairs with the codon in mRNA positioned there, so that the P-site and the A-site 
contain adjacent bound tRNAs (Figure 5). 
 
 
Figure 5: Highly schematic representation of translation process. 
 
In step 2, the carboxyl end of the polypeptide chain is released from the tRNA at the P-site (by 
cleavage of the high-energy bond between the tRNA and its amino acid) and joined to the free 
amino group of the amino acid linked to the tRNA at the A-site, forming a new peptide bond. 
                                                     
8 a) Bell, C. E.; Eisenberg, C. E. Biochemistry 1996, 35, 1137-1149. b) Nissen, P; Hansen, J.; Ban, N.; Moore, P. 
B.; Steizt, T. Science 2000, 289, 920-930. 
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This central reaction of protein synthesis is catalysed by a peptidyl transferase catalytic 
activity contained in the large ribosomal subunit. This reaction is accompanied by several 
conformational changes in the ribosome, which shift the two tRNAs into the E- and P-sites of 
the large subunit. In step 3, another series of conformational changes moves the mRNA 
exactly three nucleotides through the ribosome and resets the ribosome so it is ready to receive 
the next amino acyl tRNA. Step 1 is then repeated with a new incoming aminoacyl tRNA, and 
so on. This three-step cycle is repeated for each amino acid that is added to the polypeptide 
chain until a stop codon is encountered.9 
 
4 RNA as a pharmacological target 
 
Many human diseases are associated with misfunction of RNA-processing events. At least 
15% of all human genetic disorders involve aberrant mRNA processing.10 Despite some 
scepticism, RNA is a well-established drug target. In particular ribosomal RNA has been 
identified as the receptor for many antibiotics. 
The sequence of eukaryotic mRNA molecules is often tissue-specific or even disease-specific 
due to alternative RNA processing events, providing the opportunity for hitting selectively an 
RNA in a desired tissue or cell line. For example, a potential drug target is human telomerase, 
a complex ribonucleoprotein involved in chromosome maintenance that is selectively active in 
cancer cells. Its RNA component is investigated as a potential target for new antitumor 
agents.11 The bacterial ribosome has been identified as a receptor for antibiotics blocking 
protein synthesis since the discovery of streptomycin in the 1940s, but new antibacterial 
agents are urgently needed to overcome the problem of drug resistance that severely limits the 
effectiveness of the current antibiotics arsenal. A distinct advantage of RNA in antibacterial 
and antiviral treatment is that the occurrence of drug resistance by point mutations in RNA 
motifs that are highly conserved among bacteria or different viral strains is likely to be slow.  
Many antibiotics bind ribosomal RNA rather than its associated proteins.12  
The atomic details of the interactions of a class of antibiotics, the aminoglycosides, with 
ribosomal RNA were first revealed by NMR studies13 and then X-ray crystallography (Figure 
6),14 which have provided information for the design of new ribosome-targeted antibacterial 
                                                     
9 Jenni, S.; Ban, N. Curr. Opin. Struct. Biol, 2003, 13, 212-219. 
10 Smith, C. W. J.; Valcarel, J. Trends Biochem. Sci. 2000, 25, 381-388. 
11 Herbert, B. S.; Pitts, A. E.; Baker, S. I.; Hamilton, S. E.; Wright, W. E.; Shay, J. W.; Corey, D. R. Proc. Natl. 
Acad. Sci. USA 1999, 96, 14276-14281. 
12 Moazed, D.; Noller, H. F. Nature 1987, 327, 389-394. 
13 Fourmy, D.; Recht, M.; Blanchard, S. C.; Puglisi, J. D. Science 1996, 274, 1367-1371. 
14 Ban, N.; Nissen, P.; Hansen, J.; Moore, P. B.; Steitz, T. A. Science 2000, 289, 905-920. 
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drugs. Structural data on antibiotics that bind the large subunit are not yet available. However, 
crystallographic studies of the complexes of the small 30S subunit with antibiotics15 
(streptomycin, paromycin, tetracycline, hygromycin B) have provided remarkable insight into 
the mechanism of action of these drugs. 
 
Figure 6: Three-dimensional structure of the bacterial decoding site in complex with an 
aminoglycoside (paromomycin) (from Prof. A. Vasella: Rashmi, P.; Böttger, E. C.; Vasella, A. 
Helv. Chem. Acta 2005, 88, 2967-2985). 
 
The 30S subunit has a crucial role in decoding, i.e. matching the sequence of the mRNA with 
its corresponding aminoacylated tRNA, and it also contributes to the translocation of the 
tRNA and associated mRNA during elongation of the polypeptide chain. Antibiotics targeting 
the 30S subunit affect one of these two functions. For example, tetracycline primarily binds to 
the aminoacyl tRNA site and ejects the aminoacylated tRNA from the ribosome through steric 
clash.9 Paromycin and Neomycin B bind near the decoding region and flip out two bases 
implicated in decoding, thus reducing accuracy during protein synthesis.16 
                                                     
15 a) Carter, A. P.; Clemons, W. M. J.; Morgan-Warren, R. J.; Brodersen, D. E.; Wimberley, B. T.; 
Ramakrishnan, V. Nature 2000, 407, 327-339. b) Brodersen, D. E.; Clemons, W. M. J.; Carter, A. P.; Morgan-
Warren, R. J.; Wimberley, B. T.; Ramakrishnan, V. Cell 2001, 103, 1143-1154. c) Leontis, N. B.; Westhof, E. 
RNA 2001, 7, 499. d) François, B.; Szychowski, J.; Sekhar Adhikari, S.; Pachamuthu, K.; Swayze, E. E.; Griffrey, 
R. H.; Migawa, M. T.; Westhof, E.; Hanessian; S. Angew. Chem. 2004, 43, 6735-6738. e) Vincens, Q.; Westhof, 
E. ChemBioChem 2003, 4, 1018-1023. f) Vincens, Q.; Westhof, E. Biopolymers 2003, 70, 42-57. 
16 Yoshizawa, S.; Fourmy, D.; Puglisi, J. D. Science 1999, 285, 1722-1725. 
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5 Known RNA ligands 
 
5.1 Nonaminoglycoside ligands 
 
5.1.1 Ligands of the small subunit (30S) 
 
Pactamycin, Tetracyclines and Viomycin are the most popular nonaminoglycoside ligands 
(Scheme 2).17 Tetracyclines 1 are an important class of antibiotics that are still frequently used 
in therapy of bacterial infections. At the primary binding site of tetracycline, the drug interacts 
with 16S rRNA.10 Viomycin 2 is a cyclic heptapeptide antibiotic of the tuberactinomycin 
family that contains several unusual amino acids. Upon binding to the ribosome, this antibiotic 
stabilizes subunit cohesion and inhibits translocation by sequestration of peptidyl-tRNA in the 
A site.18 
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Scheme 2: Nonaminoglycoside ligands of the small subunit. 
 
5.1.2 Ligands of the large ribosomal subunit (50S) 
 
The macrolides are macrocyclic lactone antibiotics that are widely used as drugs in 
antibacterial therapy. Most macrolides antibiotics belong to one of the three chemical classes 
comprising 14-, 15-, and 16-membered natural and synthetically modified lactones and 
azalides (Scheme 3).  
                                                     
17 Brodersen, D. E.; Clemons, W. M. J.; Carter, A. P.; Morgan-Warren, R. J.; Wimberley, B. T.; Ramakrishnan, 
V. Cell 2000, 103, 1143-1154. 
18 Wank, H.; Rogers, J.; Davies, J.; Schroeder, R. J. J. Mol. Biol. 1994, 236, 1001-1010. 
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Scheme 3: Nonaminoglycoside ligands of the large subunit. 
 
The macrolides bind to 23S rRNA at the entrance to the polypeptide exit tunnel, immediately 
adjacent to the peptidyl tranferase center, and thereby physically block the egress of nascent 
protein.19 The sugar substituents of the macrocyclic core scaffolds play a major role in the 
binding affinity of the antibiotics, attested by their significant contributions of one-half to two-
thirds of the intermolecular contact surface in the ribosome-drug complexes. The macrolides 
have an overall lower basicity than aminoglycosides, resulting in their favourable 
pharmacokinetic profiles and oral bioavailability. The low density of basic groups in the 
macrolides reflects their binding mode as ligands bridging between ribosomal RNA and 
proteins, which exploit the recognition of structural features at the interface of the 
ribonucleoprotein complexes. Anisomycin 4, chloramphenicol 6 and Lincomycin 8 bind 
competitively to the large ribosomal subunit.20 These antibiotics are partially isostructural, 
comprising an apolar moiety connected by a two-carbon linker to an amino or amide nitrogen 
atom. Binding of the lipophilic part into a hydrophobic pocket orients the nitrogen 
functionality such that it competes with the correct positioning of the amino-acyl-RNA 
acceptor. For instance, chloramphenicol blocks the peptidyl transferase activity by sterical 
                                                     
19 a) Sclünzen, F.; Zarivach, R.; Harms, J.; Bashan, A.; Tocilj, A.; Albrecht, R.; Yonath, A.; Franceschi, F. 
Nature 2001, 413, 814-821. b) Hansen, J.; Ippolito, J. A.; Ban, N.; Nissen, P.; Moore, P. B.; Steitz, T. Molecular 
Cell 2002, 10, 117-128. 
20 a) Porse, B. T.; Kirillov, S. V.; R.; Garrett, R. A. RNA 1999, 5, 1003-1013. b) Rodriguez-Fonseca, C.; Amils, 
R.; Garrett, R. A. J. Mol. Biol. 1995, 247, 224-235. 
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interference with the aminoacyl moiety in the A site and thereby prevents the formation of the 
transition state during peptide bond formation.21 
 
5.2 Aminoglycoside ligands 
 
The study of small molecule RNA effectors has primarily focused on the aminoglycosides 
(Scheme 4). These compounds were among the first to be recognized as effectors of RNA 
functions. Aminoglycosides-RNA interactions have been well-defined for 16S22 and 23S23 
ribosomal RNA. The antibacterial activity of these compounds is believed to result from their 
effect on the translational accuracy of protein synthesis.24 The nanomolar binding affinity and 
surprising selectivity that aminoglycosides have for their RNA targets has made the study of 
these compounds with RNA a typical case for the study of small molecule-RNA interactions.25 
Detailed structural studies of the aminoglycosides paromomycin and gentamicin with RNA 
sequences, have provided significant insight into the molecular motifs required to achieve 
selective RNA recognition.  
                                                     
21 Schlunzen, F.; Zarivach, R.; Harmsr, J.; Bashan, A.; Tocilj, A.; Albrecht, R.; Yonath, A.; Franceschi, F. Nature 
2001, 413, 814-821. 
22 Woodcock, J.; Moazed, D.; Cannon, D.; Davies, J.; Noller, H. F. EMBO J 1991, 10, 3099-3103. 
23 a) Egebjerg, J.; Garrett, R. A. Biochimie 1991, 73, 1145-1149. b) Oehler, R.; Polacek, N.; Steiner, G.; Barta, A. 
Nucleic Acids Res. 1997, 25, 1219-1224. c) Rodriguez-Fonseca, C.; Phan, H.; Long, K. S.; Porse, B. T.; Kirillov, 
S. V.; Amils, R.; Garrett, R. A. RNA 2006, 6, 744-754. 
24 Cabanas, M. J.; Vazquez, D.; Modolell, J. Eur. J. Biochem. 1978, 87, 21-27. 
25 Fourmy, D.; Recht, M.; Blanchard, S. C.; Dalquist, K. D.; Puglisi, J. D. J. Mol. Biol. 1996, 262, 421-436. 
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Scheme 4: Aminoglycoside ligands of the small subunit. 
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Biophysical studies of the system indicate that aminoglycoside-bound to 16S RNA induces a 
conformational change that stabilizes the structure of 16S rRNA.26 The effect of A-site 
stabilization on protein synthesis is a slower dissociation of the tRNA-16S-rRNA complex,27 
which prevents efficient proof reading during protein synthesis. The 16S rRNA in the small 
ribosomal subunit is the target for a variety of aminoglycoside antibiotics.28 The natural 
aminoglycosides share in common the 2-deoxystreptamine (2-DOS) or streptamine core 
carrying amino-sugar substituents at different positions. The 4,6-disubstituted 2-DOS 
derivatives of kanamycin 9 class and the 4,5-disubstituted 2-DOS compounds of the neomycin 
10 series are aminoglycoside antibiotics that have been best studied so far. 
 
In order to efficiently design aminoglycosides mimics structural and binding properties of 
naturally occurring aminoglycosides have to be examined and are described in the following 
section. 
 
6 Naturally occurring aminoglycosides 
 
6.1 Mechanism of aminoglycosides binding to RNA 
 
A variety of aminoglycoside antibiotics, containing the 2-deoxystreptamine core, are known to 
interfere with ribosomal function in prokaryotes. They bind to the decoding region (A site) of 
the 16S rRNA of the 30S subunit, thus interfering with the fidelity of translation and 
translocation by decreasing the dissociation rate of cognate aminoacylated tRNA from the 
ribosome. This ultimately disrupts bacterial protein biosynthesis. Despite the established 
bactericidal properties of aminoglycoside antibiotics, their therapeutic use is limited, as 
internal administration of aminoglycoside antibiotics at high doses results in clinical side 
effects (e.g. nephro- and ototoxicity associated with irreversible hearing loss).29 
On the basis of the study of interactions between 16S rRNA and aminoglycosides and other 
small molecules, it has been established that RNA presents a dynamic structure that is crucial 
for its functional features. The conformational changes in RNA induced by aminoglycoside 
                                                     
26 Yoshizawa, S.; Fourmy, D.; Puglisi, J. D. J. Mol. Biol. 1998, 277, 333-345. 
27 Cabanas, M. J.; Vazquez, D.; Modolell, J. Eur. J. Biochem. 1978, 87, 21-27. 
28 a) Spahn, C. M.; Prescott, C. M. J. Mol. Med. 1996, 74, 423-439. b) Purohit, P.; Stern, S. Nature 1994, 370, 
659-662. 
29 a) Al-Aloul, M.; Miller, H.; Alapati, S.; Stockton, P. A.; Ledson, M. J.; Walshaw, M. J. E. Pediatric Pulmology 
2005, 39, 15-20. b) Parlakpinar, H.; Tasdemir, S.; Polat, A.; Bay-Karabulut, A.; Vardi, N.; Ucar, M.; Yanilmaz, 
M.; Kavakli, A.; Acet, A. Cell. Biochem. and Function 2006, 24, 41-48. c) Hoda, J.-C.; Krause, R.; Bertrand, S.; 
Bertrand, S. Molec. Neurosc. 2006, 17, 65-70. d) Amici, M.; Eusebi, F.; Miledi, R. Neuropharmacol. 2005, 49, 
627-637. e) Rybak, L. P.; Whitworth, C. A. Drug Disc. Today 2005, 10, 1313-1321. 
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binding to the 16S A-site appear to represent a general mechanism for the activity of many 
small-molecule RNA effectors. Ribosomal RNA is mainly composed of irregular double-
helical stems and loops organised in a complex tertiary structure. Clefts between the different 
helices and loops form well-defined binding sites for small-molecule drugs. The ability of 
natural aminoglycoside antibiotics to recognize a variety of RNA targets has been attributed to 
structural electrostatic complementarities between the positive charges on the aminoglycoside 
scaffolds and the negative charge distribution in RNA folds.30 Yet this recognition 
phenomenon is far more sophisticated for aminoglycosides than for simple polyamines (e.g. 
spermine 15) possessing a comparable number of amino groups since these are less active.  
 
15
H2N NH
H
N NH2
 
 
The flexible polycationic aminoglycoside antibiotics preferentially bind to prokaryotic 
ribosomal RNA, but they also bind to unrelated RNAs (TAR and RRE HIV-1 RNA motifs)31. 
Electrostatic interactions are double-edged sword. They boost affinity at the price of reduced 
specificity and inefficient cellular uptake. 
Aminoglycosides such as apramycin, hygromycin, spectinomycin, streptomycin (11-14), 
provide rigid molecular scaffolds for the presentation of basic groups and hydrogen-bound 
donor moieties that participate in an intimate network of interactions with the ribosomal RNA 
targets. Molecular recognition of the aminoglycosides via polar hydrogen bonds is finely tuned 
by modulation of the basicity of amino groups,32 depending on the presence of vicinal 
hydroxyl groups, or additional guanidinium substituents (as in streptomycin 11). 
The reported structure-activity relationships of natural aminoglycosides suggest that the 
overall charge density presented by the aminoglycosides toward the RNA host is likely to be 
important for binding. Hence, aminoglycosides containing four amino groups (e.g., kanamycin 
A) show very little RNA binding capability, while the most active derivatives contain five or 
six amino groups (e.g., tobramycin and neomycin B 9-10, respectively).33 At physiological 
pH, these amino groups are predominantly charged,34 suggesting an important role for strong 
                                                     
30 Hermann, T.; Westhof, E. J. Mol. Biol. 1998, 276, 903-912. 
31 Hendrix, M.; Priestley, E. S.; Joyce, G. F.; Wong, C.-H J. Am. Chem. Soc. 1997, 119, 3641-3648. 
32 a) Tor, Y.; Hermann, T.; Westhof, E. E. Chem. Biol. 1998, 5, R277-R283. b) Wang, H.; Tor, Y. Angew. Chem. 
1998, 37, 109-111. 
33 a) von Ahsen, U.; Davies, J.; Schroeder, R. J. Mol. Biol. 1992, 226, 935-941. b) Wang, H.; Tor, Y. J. Am. 
Chem. Soc. 1997, 119, 8734-8735. c) Zapp, M. L.; Stern, S.; Green, M. R. Cell 1993, 74, 969-978. 
34 a) Dorman, D. E.; Paschal, J. W.; Merkel, K. E. J. Am. Chem. Soc. 1976, 98, 6885-6888. b) Szilagyi, L.; 
Pusztahelyi, Z. S.; Jakab, S.; Kovacs, I. Carbohydr. Res. 1993, 247, 99-109. 
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electrostatic interactions in RNA-aminoglycoside binding. It has been demonstrated that 
substituting an hydroxyl group by an amino group can convert a very poor RNA binder, such 
as kanamycin A (9, Scheme 4), to a reasonably strong one. Thus, 6”-amino-6”-
deoxykanamycin A (16) is as effective as kanamycin B (9, Scheme 4), a natural congener 
containing five amino groups. Modifying a stronger RNA binder such as tobramycin further 
enhances its affinity to RNA. Thus 6”-amino-6”-deoxytobramycin (18) is approximately five 
times more effective than its parent tobramycin (9, Scheme 4) as a ribozyme inhibitor. Even 
the binding affinity of neomycin B (10, Scheme 4), one of the strongest RNA binders, can be 
further enhanced by converting it to 5”-amino-5”-deoxyneomycin B (17).35 
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Scheme 5: Introduction of amino groups in naturally occurring aminoglycosides. 
 
These results suggest that increasing the overall charge of a ligand is an important mechanism 
for increasing RNA affinity. However this general view needs to be fine-tuned in order to 
explain differences in RNA binding affinity observed among related aminoglycoside 
antibiotics. Actually higher inhibitory activity is observed when a hydroxyl group proximal to 
an amine is removed. For instance derivatives lacking the 2”-, 4”-, and 4’- hydroxyl moieties 
19-22 are approximately five times more effective than the parent tobramycin in inhibiting the 
hammerhead ribozyme (Scheme 6).  
                                                     
35 Wang, H.; Tor, Y. J. Am. Chem. Soc. 1997, 119, 8734-8735. 
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Scheme 6: Deoxygenated aminoglycosides. 
In contrary, removal of the primary 6”-hydroxyl (22) results in a poorer RNA binder. These 
observations were attributed to the increased basicity of an amino group when a neighboring 
hydroxyl group is removed. Thus the deoxygenated aminoglycoside derivatives may possess a 
higher positive charge at a given pH when compared to their parent natural analogs. Many 
observations support the critical role of electrostatic interactions in RNA binding and suggest 
that altering the pKa of amino groups is a possible mechanism for modulating the RNA 
affinity of synthetic ligands. Moreover, it has been proven that several sites with different 
affinities may coexist in a given RNA molecule. The dimerisation of aminoglycosides opens 
up an avenue for the exploration of the existence of multiple binding sites within the tertiary 
structure of RNA molecules. In principle, if two binding sites are in close proximity, a dimeric 
derivative can bind simultaneously to the two sites, resulting in stronger binding affinity. 
Dimeric aminoglycosides have been designed and studied36 (Scheme 7). In general when two 
moderate or good RNA binders (e.g. tobramycin, neomycin B) are covalently linked, the 
ribozyme inhibitory activity of the dimer surpasses that of any natural aminoglycoside 
antibiotic.  
                                                     
36 Wang, H.; Tor, Y. Bioorg. Med. Chem. Lett. 1997, 7, 1951-1956. 
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Scheme 7: Dimers of naturally occurring aminoglycosides. 
 
Seemingly a certain saturation level is reached with regard to the number of amino groups and 
positive charges in a given ligand. Increasing the number of amino groups to eight or more 
does not result in stronger binding to the hammerhead ribozyme. To account for these results, 
it has been suggested by Uhlenbeck that five magnesium ions compete with a single neomycin 
B molecule for a binding site on the hammerhead ribozyme. Since the presence of these 
magnesium ions is critical for proper ribozyme function (including folding and catalysis), their 
replacement by neomycin B results in inhibition.37 Using molecular dynamic simulations 
based on a crystal structure of hammerhead ribozyme, Hermann and Westhof have uncovered 
a striking complementarity between the interionic Mg2+- Mg2+ distances on the ribozyme and 
the intermolecular distances between the charged ammonium groups on aminoglycosides.38 
Docking experiments have demonstrated that numerous conformers of a number of 
aminoglycosides can place the ammonium groups at the sites normally occupied by the Mg2+ 
ions. It was suggested that the covalently linked array of ammonium groups is capable of 
displacing three to four magnesium ions and complements the negative electrostatic potential 
created by the RNA fold. This model suggests three-dimensional electrostatic 
complementarity rather than highly specific contacts between the aminoglycosides and an 
RNA receptor site. 
The modelling studies suggest that the 1,3-hydroxylamine motif, present in most 
aminoglycosides, is an important RNA recognition motif for chelating phosphate and the 
                                                     
37 Clouet-d’Orval, B.; Stage, T. K.; Uhlenbeck, O. C. Biochemistry 1995, 34, 11186-11190. 
38 Hermann, T.; Westhof, E. J. Mol. Biol. 1998, 276, 903-912. 
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edges of nucleotide bases in RNA (Scheme 8). The other amines and hydroxyl moieties in 
aminoglycosides form hydrogen bonds and salt bridges with phosphate and RNA bases as 
well.39 
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Scheme 8: Binding motifs of aminoglycosides. 
 
6.2 Design of RNA binders, some ground rules 
 
Ideally, one would like to identify recognition rules and well-defined binding motifs, and use 
that knowledge for the design of specific RNA binders. While our understanding of RNA 
structure and folding, as well as the modes in which RNA is recognized by other ligands, is far 
from being comprehensive, significant progress has been made in the last decade. General 
recognition rules derived from studies of RNA-aminoglycoside interactions have been 
partially elucidated and are summarized below. 
Overall charge of a ligand appears to be critical for high binding affinity. Aminoglycosides 
that bind RNA most efficiently have at least six amino groups (neomycin B 10, 5”-amino-5”-
deoxyoneomycin B 17, dimers of aminoglycoside). However, increasing the number of amino 
groups does not lead to increased binding affinities in a small RNA molecule such as the 
hammerhead ribozyme. Larger RNA molecules that elaborate secondary and tertiary structural 
elements may provide larger or multiple binding sites. Increasing the size and charge of the 
recognition domain may therefore become beneficial when targeting large RNA molecules. 
Designing an organic molecule by incorporating a certain number of amino groups may be a 
naive approach. It is important to consider the basicity of every individual basic group and the 
intramolecular modulation of their pKa values in a given structure. Structure Activity 
Relationship (SAR) investigations of deoxygenated aminoglycosides demonstrated how the 
                                                     
39 a) Hendrix, M.; Alper, P. B.; Sears, P.; Wong, C.-H. J. Am. Chem. Soc. 1998, 120, 1965-1978. b) Wong, C.-H.; 
Tor, Y. J. Am. Chem. Soc. 1997, 119, 8734-8735. 
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presence of hydroxyl groups can influence binding affinity.40 Although hydroxyl groups may 
be involved in favourable intermolecular hydrogen bonds, placing them in close proximity to 
primary amino groups might significantly decrease the pKa values of ammonium groups. 
Therefore, if hydroxyl groups are to be incorporated into designed RNA binder, their positions 
have to be carefully engineered. 
Another significant factor for the design of an RNA binder is the choice of the molecular 
scaffold that governs the display of the recognition elements. Efficient RNA binding can be 
achieved by strategic incorporation of ammonium groups with predetermined three-
dimensional projection. Linear polyamines, such as spermine, are inferior RNA binder, when 
compared to aminoglycoside antibiotics. In general their binding affinities are lower and they 
are believed to bind non-specifically to RNA. The linear structures may be too flexible and the 
amino groups may be in unfavourable proximity. Consequently the ammonium groups may 
not be able to simultaneously satisfy the electrostatic complementarity on negatively charged 
surfaces within the three-dimensional structure of RNA receptors. In aminoglycosides 
antibiotics, the ammonium groups are located on relatively rigid six-membered rings that can 
adopt various orientations. The combination of fragment rigidity and inter-ring conformational 
flexibility may be the key to the high affinity of aminoglycosides for RNAs. Indeed, molecular 
dynamics simulations suggest that aminoglycoside antibiotics can bind to the hammerhead 
ribozyme by adopting numerous conformations and various projections of their charged 
ammonium residues.41 These positive charges are well suited to meet the required charge 
complementary to the RNA binding site. 
 
7 Synthetic ligands for RNA 
 
Due to their ability to recognize different RNA structures, aminoglycoside antibiotics provide 
obvious starting point and templates for the synthesis of novel RNA-directed ligands. 
Numerous attempts to obtain new ligands for the ribosomal A site have focused on simplifying 
the highly functionalized aminoglycosides structures. The goal of these approaches was to 
develop molecules of lower structural complexity, which, are amenable to straightforward 
medicinal chemistry exploration, have more favourable pharmacological profiles than 
aminoglycosides, and finally are less sensitive to bacterial resistance mechanisms. 
 
                                                     
40 Wang, H.; Tor, Y. J. Am. Chem. Soc. 1997, 119, 8734-8735. 
41 a) Wang, H.; Tor, Y. Angew. Chem. 1998, 110, 117-120. b) Wang, H.; Tor, Y. Angew. Chem. 1998, 37, 109-
111. c) Hermann, T.; Westhof, E. J. Mol. Biol. 1998, 276, 903-912. 
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7.1 Modifications of naturally occurring aminoglycosides  
 
Several approaches were developed based on modification of natural aminoglycoside-type 
ligands. Neamine derivatives,42 paromomycin,43 tobramycin,44 neomycin B,45 kanamycin and 
tobramycin (see structures Scheme 4),46 were hybridized to improve their resistance to 
bacteria or to increase their affinity for diverse RNA fragments (Scheme 9). Moderately 
potent compounds were found more frequently among analogues that retained the two-ring 
aminoglycoside system of neamine or paromomycin (10). For instance, fluorinated compound 
27 was found to be 20 times less active than paromomycin, affinity for Hepatitis C virus RNA 
of tobramycin analogue 30 was found to be 10 times higher than for naturally occurring 
tobramycin, dissociation constant value (Kd) of heterocyclic paromomycin derivative 29 (Kd < 
1μM) was higher than that of paromomycin (110 mM), but lower than that of apramycin 14 (2 
μM) and tobramycin 9 (2 μM). Compound 28 which contains an extra sugar ring as an 
additional element of rigidity, was more active against various bacterial strains than neomycin 
B. Finally, Bastida and co-workers have recently shown that conformationally locked 
aminoglycosides as neomycin 31 and 32 (Kd 1.1μM and 0.9μM resp.), displayed a lower 
biological activity with respect to native neomycin-B (Kd 0.07μM), but the conformational 
restriction induced provide an effective protection against aminoglycosides inactivation in 
vitro and in vivo.47 
                                                     
42 Vourloumis, D.; Winters, G. C.; Simonsen, K. B.; Takahashi, M.; Ayida, B. K.; Shandrick, S.; Zhao, Q.; Han, 
Q.; Hermann, T. ChemBioChem 2005, 6, 58-65. 
43 a) Pathak, R.; Bottger, E. C.; Vasella, A. Helv. Chim. Acta 2005, 88, 2967-2985. b) François, B.; Szychowski, 
J.; Sekhar Adhikari, S.; Pachamuthu, K.; Swayze, E. E.; Griffrey, R. H.; Migawa, M. T.; Westhof, E.; Hanessian; 
S. Angew. Chem. 2004, 43, 6735-6738. c) Ding, Y.; Hofstadler, S. A.; Swayze, E. E.; Sisen, L.; Griffrey, R. H. 
Angew. Chem. 2003, 42, 3409-3412. 
44 Liang, F.-S.; Wang, S.-K; Nakatani, T.; Wong, C.-H. Angew. Chem. 2004, 43, 6496-6500. 
45 a) Fridman, M.; Belakhov, V.; Lee, L. V.; Liang, F.-S.; Wong, C.-H.; Baasov, T. Angew. Chem. 2005, 44, 447-
452. b) Fridman, M.; Belakhov, V.; Yaron, S.; Baasov, T. Org. Lett. 2003, 20, 3575-3578. c) Lee, J.; Kwon, M.; 
Lee, K. H.; Jeong, S.; Hyun, S.; Shin, K. J.; Yu, J. J. Am. Chem. Soc. 2004, 126, 1956-1957. 
46 Clique, B.; Ironmonger, A.; Whittaker, B.; Colley, B.; Titchmarsh, J.; Stockley, P.; Nelson, A. Org. Biomol. 
Chem. 2005, 3, 2776-2785. 
47 a) Bastida, A.; Hidalgo, A.; Chiara, J. L.; Torrado, M.; Corzana, F.; Perez-Canadillas, J. M.; Groves, P.; 
Garcia-Junceda, E.; Gonzales, C.; Jiminez-Barberos, J.; Asensio, J. L. J. Am. Chem. Soc. 2006, 128, 100-116. b) 
Bastida, A.; Hidalgo, A.; Chiara, J. L.; Torrado, M.; Corzana, F.; Canada, J.; Garcia-Junceda, E.; Jiminez-
Barberos, J.; Asensio, J. L. J. Am. Chem. Soc. 2005, 127, 8278-8279. 
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Scheme 9: Modifications of naturally occurring aminoglycosides. 
As mentioned above, dimers of naturally occurring aminoglycosides have been designed and 
synthesized. They all display enhanced affinity for RNA in comparison with the monomeric 
counterparts (Scheme 10). To simplify these complex dimeric structures, the simplest 
naturally occurring aminoglycoside, i.e. neamine, has been dimerised48 through amino-
containing linkers. All bivalent compounds were found to be stronger binders than neamine 
itself, with affinity comparable to that of complex aminoglycosides like kanamycin or 
gentamicin (see structures Scheme 4). The most active compounds 33-34 were linked with a 
12 or 13-carbon long chain containing amino and hydroxyl functionalities. 
 
                                                     
48 Sucheck, S. J.; Wong, A. L.; Koeller, K. M.; Boehr, D. D.; Draker, K.; Sears, P.; Wright, G. D.; Wong, C.-H. J. 
Am. Chem. Soc. 2000, 122, 5230-5231. 
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Scheme 10: Neamine dimers. 
 
More recently, an extended study on neamine dimers49 was reported, showing the 
antimicrobial potency of such compound against several bacterial strains. This study confirms 
that a 12 or 13 carbon linear linker is optimal for that kind of aminoglycosides. Despite the 
success met with the latter derivatives, synthetic aminoglycoside analogues rarely matched 
RNA binding affinity and antibacterial potency of the more complex natural aminoglycosides 
such as neomycin B. 
 
7.2 Deoxystreptamine (DOS) based aminoglycosides mimetics 
 
The ultimate challenge in ligand design for RNA targets such as the bacterial A site are 
approaches that abandon the conventional aminoglycoside chemistry in favour of novel RNA-
friendly scaffolds that are not compromised by undesirable pharmacological profiles and 
bacterial resistance. Deoxystreptamine (DOS, 35) derivatives were designed towards this goal. 
DOS, the common central motif of all aminoglycoside compounds, has been reported to bind 
weakly to two base units within a disrupted RNA helix.50 Solution studies carried out with 
DOS have shown that it will bind to RNA fragment, albeit with a very low affinity (>1mM).51 
Several 2-DOS52 and dideoxystreptamine53 containing derivatives were synthesized and 
studied for their affinity toward RNA fragments. The decoration of DOS by alkylamino chains 
instead of carbohydrates affords derivatives that bind significantly to 16S A-site rRNA target 
and have the ability to inhibit bacterial translations (Scheme 11). For example compound 36 
                                                     
49 Liang, C.-H.; Romero, A.; Rabuka, D.; Sgarbi, P. W M.; Marby, K. A.; Duffield, J.; Yao, S.; Cheng, M. L.; 
Ichikawa, Y.; Sears, P.; Hu, C.; Hwang, S.-B.; Shue, Y.-K.; Sucheck, S. Bioorg. Med. Chem. Lett. 2005, 15, 
2123-2128. 
50 Yoshizawa, s.; Fourmy, D.; Eason, R. G.; Puglishi, J. D. Biochemistry 2002, 41, 6263-6265. 
51 Yoshizawa, s.; Fourmy, D.; Eason, R. G.; Puglishi, J. D. Biochemistry 2002, 41, 6263-6265. 
52 a) Wang, X.; Migawa, M. T.; Sannes-Lowery, K. A.; Swayze, E. E. Bioorg. Med. Chem. Lett. 2005, 15, 4919-
4922. b) Ding, Y.; Hofstadler, S. A.; Swayze, E. E.; Griffrey, R. H. Chem. Lett. 2003, 32, 908-909. b) Ding, Y.; 
Hofstadler, S. A.; Swayze, E. E.; Griffrey, R. H. Org. Lett. 2001, 3, 1621-1623. 
53 Vourloumis, D.; Winters, G. C.; Simonsen, K. B.; Takahashi, M.; Ayida, B. K.; Shandrick, S.; Zhao, Q.; 
Barluenga, S.; Qamar, S.; Han, Q.; Hermann, T. Bioorg. Med. Chem. Lett. 2002, 12, 3367-3372. 
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have a dissociation constant binding with 16S A-site rRNA (Kd 2.5μM) lower than that of 
Neamine 10 (Kd 5μM). 
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Scheme 11: 2-DOS derivatives. 
 
Derivatives containing heterocyclic rings (Scheme 11) show poor binding affinity, compound 
37 (Kd 100μM) having a dissociation constant four times higher than Neamine (Kd 24μM). 
Results on molecules 35-37 were obtained using the mass spectrometry method (see section 
9), for this reason Neamine Kd values are not comparable because of measurement methods 
difference. These results suggest that carefully designed analogues of DOS may display high 
affinity for selected RNA fragments. However they are rarely active in vitro. 
Dideoxystreptamine derivatives show poor RNA affinity. 
As for aminoglycosides, dimerisation of DOS has emerged as an efficient way to increase 
RNA affinity and specificity of DOS scaffold. Particularly, Hergenrother’s group has recently 
reported the results of a systematic study designed to identify general RNA hairpin loop-
binding small molecules. Tethering two DOS units with various linkers through click 
chemistry afforded a library of DOS-dimers (Scheme 12). Two compounds 38 and 39 were 
found to have the requisite flexibility and functionality to bind RNA tetraloops and octaloops 
with a high degree of specificity over other loop sizes and other secondary structures. 
Moreover these hairpin loops are not recognized by classical aminoglycosides.54 
 
                                                     
54 a) Thomas, J. R.; Liu, X.; Hergenrother, P. J. J. Am. Chem. Soc. 2005, 127, 12434-12435. b) Thomas, J. R.; 
Liu, X.; Hergenrother, P. J. J. Am. Chem. Soc. 2004, 126, 9196-9197. 
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7.3 Carbohydrate based mimetics 
 
Another approach developed by Boons and Griffrey for the design of aminoglycosides 
mimetics was to synthesize disaccharides containing several amino groups (Scheme 13). 
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Scheme 13: Carbohydrate mimetics of neamine. 
 
It has been shown that these derivatives can bind to a prototypical segment of 16S rRNA with 
affinities similar to that of neamine,55 especially compound 40 that has a 11 μM binding 
constant comparable to that of neamine (7μM). Following the same approach, Hermann and 
Vourloumis56 have synthesized carbohydrate based deoxystreptamine mimetics of type 41 
showing low affinity for rRNA (Scheme 13). These poor results were attributed to the 
increased flexibility of the designed structures.  
                                                     
55 Venot, A.; Swayze, E. E.; Griffrey, R. H.; Boons, G.-E. ChemBioChem 2004, 5, 1228-1236. 
56 Simonsen, K. B.; Ayida, B. K.; Vourloumis, D.; Takahashi, M.; Winters, G. C.; Barluenga, S.; Qamar, S.; 
Shandrick, S.; Zhao, Q.; Hermann, T. ChemBioChem 2003, 4, 879-885. 
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Based on crystallography data, 3-amino-methyl-piperidine derivatives have been designed to 
mimic the spatial arrangement of amino groups in 2-DOS (Scheme 14).57  
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Scheme 14: 3-amino-methyl-piperidine derivatives as DOS mimetics. 
 
The best candidates of these series, as A-site RNA binders and inhibitors of bacterial in vitro 
translation, display a 3-aminomethyl piperidine core (42 as general structure, with R1 or R2 
equal to amino-glucosamine substituents). 
 
7.4 Aminoglycoside-intercalator ligands 
 
An alternative approach to the design of RNA-targeting ligands consists in combining binding 
motifs as aminoglycosides-acridine 43 (Scheme 15).58 This compound aimed at exploiting 
additive effect for increased RNA affinity by combining target-specific motifs, such as an 
aminoglycoside, with a generic nucleic acid binding motif, such as the intercalator acridine. 
Although these conjugate compounds often display higher RNA affinity than the parent 
aminoglycosides, their importance is mainly as tools for studying ligand-RNA interactions, 
since the increased molecular mass and chemical complexity limit their potential as lead 
structures for drug development. Simpler compounds containing polyamine scaffolds and 
aromatic intercalators as phenothiazine-amine 4459 and acridine-polyamine 45,60 have also 
been studied for their RNA affinity. These compounds inhibit HIV-1 Tat-TAR interaction 
(Scheme 15) with high potency. Even simple linear aminols binds with high affinity to the A-
site bacterial decoding region. Compound 46 (Kd 1.01μM) was found to be almost 2-fold more 
potent than paromomycin (Kd 1.87μM).61 Nevertheless linear aminols are known to bind 
unspecifically to RNA because they bind DNA as well.62 
                                                     
57 Simonsen, K. B.; Ayida, B. K.; Vourloumis, D.; Takahashi, M.; Winters, G. C.; Barluenga, S.; Qamar, S.; 
Shandrick, S.; Zhao, Q.; Hermann, T. ChemBioChem 2003, 4, 886-890. 
58 Kirk, S. R.; Luedtke, N. W.; Tor, Y. J. Am. Chem. Soc. 2000, 122, 980-981. 
59 Du, Z.; Lind, K. E.; James, T. L. Chem. Biol. 2002, 9, 707-712. 
60 Swayze, E. E.; Griffey, R. H. Exp. Opin. Therapeutic Patents 2002, 12, 1367-1374. 
61 Tok, J. B. H.; Rando, R. R. J. Am. Chem. Soc. 1998, 120, 8279-8280. 
62 a) Tsuboi, M. Bull. Chem. Soc. Japan 1964, 37, 1514-1522. b) Sakai, T. T.; Torget, R.; Freda, C. E.; Cohen, S. 
S. Nucl. Acid Res. 1975, 2, 1005-1022. 
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Scheme 15: Aminoglycoside-intercalator ligands. 
 
7.5 Oxazolidinone ligands 
 
Oxazolidinones are currently the only known fully synthetic antibiotics that target the rRNA of 
the bacterial ribosome63 (Scheme 16).  
 
N
F
O
N O
O
NH
O
Linezolid 47
N
F
N
N O
O
NH
O
Eperezolid 48
O
HO
 
Scheme 16: Oxazolidinone ligands. 
 
While they were discovered about 20 years ago,64 the first oxazolidinone antibiotic, linezolid, 
has been approved for therapeutic use only recently (2000).65 Meanwhile the mechanism of 
action of the oxazolidinones has been elucidated, although their precise binding site on the 
ribosome remains elusive. Affinity determination and NMR experiments have shown that the 
                                                     
63 a) Kloss, P.; Xiong, L.; Shinabarger, D. L.; Mankin, A. S. J. Mol. Biol. 1999, 294, 93-101. b) Aoki, H.; Ke, L.; 
Poppe, S. M.; Poel, T. J.; Waever, W. A.; Gadwood, R. C.; Thomas, R. C.; Shinabarger, D. L.; Ganoza, M. C. 
Antimicrob. Agents. Chemother. 2002, 46, 1080-1085. 
64 Slee, A. M.; Wounola, M. A.; McRipley, R. J.; Zajac, I.; Zavada, M. J.; Bartholomew, P.; Gregory, W. A.; 
Forbes, M. Antimicrob. Agents. Chemother. 1987, 31, 1791-1797. 
65 Babachyn, M. R.; Ford, C. W. Angew. Chem. Int. Ed. 2003, 42, 2010-2023. 
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antibiotics bind to 50S but not 30S subunits. The affinity of oxazolidinones 47-48 to isolated 
50S subunits is in the high micromolar range, which does not truly reflect their antibacterial 
potency.66 
 
7.6 Miscellaneous 
 
Similar to the aminoglycosides, macrocyclic antibiotics such as macrolides have served as 
templates for the design of novel potential antibacterial and antiviral compound series 
targeting RNA.  
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Scheme 17: Miscellanous RNA ligands. 
 
Peptide chemistry or alkylation of amino functionalities have been used mostly to construct 
synthetic macrocycles, such as the antibacterial 14-membered amides67 and the 13-membered 
polyamines 49,68 which were investigated as HIV-1 Tat-TAR inhibitors (Scheme 17). The 
tricyclic quinoxaline-2,3-dione derivative 50 was found to be a potent RNA binder with the 
lowest molecular mass known so far. This compound disrupted the Tat peptide-RNA 
interaction at 1.3 μM concentrations, comparable to the potency of neomycin B.69 
 
8 Conclusion 
 
With the increasing understanding of RNA tertiary structure, a promising approach that 
emerges for the design of high affinity and selective binders consists in the combination of 
                                                     
66 a) Zhou, C. C.; Swaney, S. M.; Shinabarger, D. L.; Stockman, B. J. Antimicrob. Agents. Chemother. 2002, 46, 
625-629. b) Shinabarger, D. L.; Marotti, K. R.; Murray, R.W.; Lin, A. H.; Melchior, E. P.; Swaney, S. M.; 
Dunyak, D. S.; Demyan, W. F.; Buysse, J. M. Antimicrob. Agents. Chemother. 1997, 41, 2132-2136. 
67 Jefferson, E. A.; Arakawa, S.; Blyn, L. B.; Miyaji, A.; Osgood, S. A.; Ranken, R.; Risen, L. M.; Swayze, E. E. 
J. Med. Chem. 2002, 45, 3816-3819. 
68 An, H.; Haly, B. D.; Cook, P. D. Bioorg. Med. Chem. Lett. 1998, 8, 2345-2350. 
69 Mei, H.-Y.; Cui, M.; Heldsinger, A.; Lemrow, S. M.; Loo, J. A.; Sannes-Lowery, K. A.; Sharmeen, L.; 
Czarnik, A. Biochemistry 1998, 37, 14204-14212. 
New efficient synthetic routes toward functionalised polyketides. 
   
30
various binding motifs. The resulting derivatives can be a dimeric form of a known binder or 
can consist of two distinct moieties that bind to RNA through different modes (e.g., grove 
binding and intercalation). In both cases the length and nature of the linker is critical. Higher 
binding affinities can be expected owing to a favourable entropic factor compared with the 
binding of the two monomeric counterparts.  
 
9 Methods to measure the affinity of small molecules for RNA 
 
All the previously described derivatives were tested for their affinity toward RNA. Different 
techniques are currently developed and used. 
 
9.1 Mass spectrometry (MS) 
 
Electro Spray Ionisation is a very gentle ionization technique that propagates noncovalent 
complexes formed in solution into the gas phase where they can be characterized by mass 
spectrometric analysis. ESI-MS has previously been used to determine the stoichiometry and 
dissociation constants for protein–protein interactions, protein–ligand interactions, and 
protein–oligonucleotide interactions.70 
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FT-ICR MS) can resolve 
very small mass differences, providing determination of molecular mass with precision and 
accuracy.71 Because each small molecule with a unique elemental composition carries an 
intrinsic mass label corresponding to its exact molecular mass, identifying closely related 
library members bound to a macromolecular target requires only a measurement of exact 
molecular mass. Several research groups have demonstrated that levels of free and bound 
ligands and substrates can be quantified directly from their relative abundances as measured 
by ESI-MS. Moreover these measurements can be used to quantitatively determine molecular 
dissociation constants that agree with solution measurements. Jorgensen and co-workers72 
have demonstrated that the relative ion abundance of the noncovalent complexes formed 
between D- and L-tripeptides and vancomycin antibiotics can be used to measure solution-
                                                     
70 a) Greig, M. J.; Gaus, H.; Cummins, L. L.; Sasmor, H.; Griffrey, R. H. J. Am. Chem. Soc. 1995, 117, 10765-
10766. b) Lim, H. K.; Hsieh, Y. L.; Ganem, B.; Henion, J. J. Spectrom. 1997, 30, 708-714. c) Gao, J.; Cheng, X.; 
Chen, R.; Sigal, G.B.; Bruce, J. E.; Schwartz, B. L.; Hofstadler, S. A.; Anderson, G. A.; Smith, R. D.; Whitesides, 
G. M. J. Med. Chem. 1996, 39, 1949-1955. d) Ayed, A.; Krutchinsky, A. N.; Ens, W.; Standing, K. G.; 
Duckworth, H. W. Rapid Commun. Mass Spectrom. 1998, 12, 339-344. 
71 Marshall, A. G.; Hendrickson, C. L.; Jackson, G. S. Mass. Spectrom. Rev. 1998, 17, 1-35. 
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binding constants. Griffey and co-workers73 have shown that ESI-MS method can be used to 
determine the RNA binding sites of small molecules.  
Sannes-Lowery and co-workers74 studied the binding of neomycin and streptomycin to TAR 
RNA. Three neomycin molecules were bound sequentially to TAR when the concentration of 
neomycin increased. Sannes-Lowery and co-workers used ESI-MS to determine the solution 
dissociation constants (Kd) and binding stoichiometry for tobramycin and paromomycin with 
16S. Two non-equivalent 16S binding-sites were observed for tobramycin, which allowed the 
proper binding model to be employed in the calculation of the Kd values. This paper highlights 
the unique information provided by direct observation of noncovalent complexes by ESI-MS 
and suggests that these Kd values are more accurate than solution Kd values measured using 
indirect detection schemes. Hofstadler and co-workers75 developed a high throughput 
screening method for the study of non-covalently bound drug candidates to model RNA 
sequences using FT-ICR MS. Mixtures of three RNA targets with 25 compounds were 
analysed by ESI-FT-ICR MS using flow injection analysis. In the absence of active drug, only 
responses to the RNA targets were observed. However, with the addition of lividomycin (a 
commercially available antibiotic), a known aminoglycoside binder to the 16S RNA binding 
site, an abundant new peak emerged corresponding to the noncovalent complex of the 16S 
RNA with lividomycin.  
 
9.2 Fluorescence-based approach for detecting antibiotic binding 
 
The system is based on the use of a fluorescent reporter group attached to a target RNA 
construct, which is sensitive to changes in the local environment. It has been reported that the 
A site RNA undergoes a local change in the presence of aminoglycosides.76 Several recent 
studies as well as earlier reports77 have shown that ligand-induced conformational changes in 
RNA can be monitored in solution through the use of attached dye molecules. A fluorescein 
molecule attached to the 5’ end of the A site (Figure 7) has the ability to act as a reporter 
                                                     
73 Griffey, R. H.; Greig, M.; An, H.; Sasmor, H.; Manalili, S. J. Am. Chem. Soc. 1999, 121, 474-475. 
74 Sannes-Lowery, K. A.; Griffey, R. H.; Hofstadler, S. A. Anal. Biochem. 2000, 280, 264. 
75 a) Griffey, R. H.; Hofstadler, S. A. Curr. Opin. Drug Discovery Dev. 2000, 3, 423-431. b) Griffey, R. H.; 
Hofstadler, S. A.; Sannes-Lowery, K. A.; Crooke, S. T.; Ecker, D. J.; Sasmor, H.; Manalili, S. Anal. Chem. 1999, 
71, 3436-3440. 
76 a) Fourmy, D.; Recht, M. I.; Blanchard, S. C.; Puglisi, J. D. Science 1996, 274, 1367-1371. b) Fourmy, D.; 
Yoshizawa, S.; Puglisi, J. D. J. Mol. Biol. 1998, 277, 333-345. 
77 a) Llano,-Sotelo, B.; Chow, S. C. Bioorg. Med. Chem. Lett. 1999, 9, 213-216. b) Jhaveri, S. D.; Kirby, R. D.; 
Conrad, R.; Maglott, E. J.; Bowser, M.; Kennedy, R. T.; Glick, G.; Ellington, A. D. J. Am. Chem. Soc. 2000, 122, 
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when antibiotic binds to RNA.78 More recently, the use of a fluorescent base analogue 2-
aminopurine (2AP) (Figure 7) has proved to be a powerful tool for the detection and 
characterization of antibiotic-induced conformational changes in ribosomal RNA.79 2AP 
fluorescence was shown by Ross and co-workers80 to be modulated by hydrophobic stacking 
interactions and dynamic collisions with other bases. Thus aminoglycoside-induced changes in 
the fluorescence of a target labelled RNA provide a means for monitoring and quantifying the 
destacking of the labelled base that accompanies drug-RNA complex formation. 
 
 
 
 
 
 
 
 
 
 
Figure 7: Sequence and secondary structure of the A site of E. Coli ribosomal RNA labelled 
with fluorescein at the 5’ end, in red the position of 2AP. 
 
Finally, RNA-affinity measurement can be obtained using a pyrene-labeled paromomycin 
analogue whose fluorescence is quenched through specific interactions with RNA fragment. 
Upon addition of a tested molecule on a paromomycin-RNA complex, fluorescence intensity 
increase due to a competing binding between the tested molecule and paromomycin. This 
method allowed the identification of simple polyamines as RNA binders.81 
A particularly efficient high-throughput screening method using fluorescence analysis was 
recently developed. Microarrays are powerful platforms for conducting high-throughput 
screenings, and a vast number of applications using this technology have been described. For 
example, DNA oligonucleotide arrays allow the monitoring of the expression levels of almost 
every gene in an entire organism.82 Protein arrays can be used to detect protein-protein 
interactions and enzymatic modification of proteins.83 Small molecule arrays have resulted in 
                                                     
78 a) Llano,-Sotelo, B.; Azucena, E. F.; Kotra, L. P.; Mobashery, S.; Chow, C. S. Chemistry and Biology 2002, 9, 
455-463. b) Thomas, J. R.; De Nap, M. L.; Wong, M. L.; Hergenrother, P. J. Biochemistry 2005, 44, 6800-6808. 
79 Kaul, M.; Barbieri, C. M.; Pilch, D. S. J. Am. Chem. Soc. 2004, 126, 3447-3453. 
80 Rachofsky, E. L.; Osman, R.; Ross, J. B. A. Biochemistry 2001, 40, 946-956. 
81 Tok, J. B.-H.; Rando, R. R. J. Am. Chem. Soc. 1998, 120, 8279-8280. 
82 a) Steinmetz, L. M.; Davis, R. W. Biotechnol. Genet. Eng. Rev. 2000, 17, 109. b) Schena, M.; Shalon, D.; 
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the rapid identification of compounds that bind to proteins, thus enabling chemical genetics 
experiments.84 More recently, carbohydrate arrays probing carbohydrate-protein interactions 
were described.85  
Binding of small molecules to RNAs has been recently examined in this format. The ability to 
rapidly screen compounds for binding to RNAs allows the identification of new RNA-binding 
ligands. These molecules may serve as improved therapeutics. Seeberger and co-workers86 
have developed an assay that allows, for aminoglycoside-RNA and aminoglycoside-protein 
interactions, to be detected in a microarray format. Aminoglycoside antibiotics have been 
arrayed onto glass microscope slides, and these compounds’ abilities to bind both RNAs and 
proteins have been probed by incubating arrays with a fluorescently labeled oligonucleotide 
mimic of the bacterial rRNA A-site. Unbound RNAs and proteins were washed from the 
surface, and binding was detected with fluorescence. After initially focusing on binding of 
aminoglycosides to short RNA oligonucleotide, a larger RNA, about 400 nucleotides in length, 
was employed to detect hybridization on arrayed aminoglycosides, showing that binding of 
large RNAs to arrayed compounds can be detected. Moreover binding of proteins to 
aminoglycosides was measured using a fluorescently labelled protein. Indeed aminoglycosides 
elicit their antibiotic effect by binding to rRNA, but they also interact with proteins and lipids, 
and these interactions have been implicated in causing toxicity. Studying how 
aminoglycosides interact with proteins may serve as models to probe aminoglycoside toxicity. 
Finally a microarray method was developed to identify drug resistant antibiotics.87 Enzymatic 
modification is the most common mechanism leading to aminoglycoside resistance. The result 
of aminoglycoside modification is a large decrease in binding affinity to the therapeutic target. 
The development of high-throughput methods to identify compounds that weakly bind to 
resistance causing proteins and strongly bind to therapeutic targets facilitates the discovery of 
improved antibiotics. Using microarray technology with resistance-causing proteins allows the 
identification of antibiotics that are more susceptible to be modified and to induce resistance. 
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9.3 NMR method 
 
Over the past few years, NMR spectrometry has been established as a powerful and reliable 
means for identifying lead molecules, predominantly in the context of protein targets88 and 
RNA binder identification.89 Very recently, the potential of 19F detection for NMR-based 
binding and functional screenings has been recognized.90 
A new concept for the identification of RNA binders by 19F NMR spectroscopy was developed 
by Konrat and co-workers.91 The approach relies on site-specific labeling of RNA with 2’-
deoxy-2’-fluoro (2’-F) nucleosides, thereby replacing the 2’-hydroxy group with a fluorine 
atom. If the 2’-F label is positioned at the binding site, then ligand binding could be observed 
by NMR (Δδ ≈ 1.5 ppm). 
Since most of the known RNA ligands follow the concept of adaptive recognition,92 their 
binding alters the local RNA conformation to a certain extent. Because the chemical 
environment of the 2’-F atom is expected to be different for the free versus complexed RNA, 
different chemical shift values for the corresponding resonances are expected. In this sense, a 
key feature of the approach relies on the strategic positioning of the individual 2’-F labels 
within the RNA sequence of interest.93 The RNA sequence was labeled with a 2’-
fluoroadenosine label in the loop, which is known to bind the aminoglycoside tobramycin with 
nanomolar dissociation constant, and a 2’-fluorocytidine was placed in the stem, which is not 
involved in the binding event. At submillimolar concentration, two distinct 19F NMR signals 
were observed for the free RNA that were easily assigned by reference sequences containing 
one or the other 2’-F label. When the RNA sequence was titrated with aliquots of tobramycin, 
one of the resonances decreased while a new signal appeared downfield indicating that ligand 
binding occurred in the slow-exchange mode. The binding was complete after addition of one 
equivalent.  
                                                     
88 a) Feelding, L. Curr. Top. Med. Chem. 2003, 3, 39-53. b) Rastinejad, F.; Evilia, C.; Lu, P. Methods Enzymol. 
1995, 261, 560-575. 
89 Yu, L.; Oost, T. K.; Schkeryantz, J. M.; Yang, J.; Janowick, D.; Fesik, S. W. J. Am. Chem. Soc. 2003, 125, 
4444-4450. 
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91 Kreutz, C.; Kählig, H.; Konrad, R.; Micura, R. Angew. Chem. 2006, 45, 3450-3453. 
92 Hermann, T.; Patel, D. J. Science 2000, 287, 820-825. 
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9.4 Surface Plasmon Resonance (SPR) 
 
Surface Plasmon Resonance stems one of the basic principles of optics:94 total internal 
reflectance, or TIR. This is illustrated in Figure 8 as occurring at the interface between 
materials with differing refractive indices, n1 and n2. Total reflection occurs above a critical 
angle, θ , when n1 > n2. At the same time, an evanescent electromagnetic wave propagates 
away from the interface, as shown below. Surface Plasmon Resonance (or SPR) occurs when a 
thin conducting film is placed at the interface between the two optical media. At a specific 
incident angle, greater than the TIR angle, the surface plasmons (oscillating electrons at the 
edges of the metal) in the conducting film resonantly couple with the light because their 
frequencies match. Since energy is absorbed in this resonance, the reflected intensity I shows a 
drop at the angle where SPR is occurring, as shown in the Figure 8. 
 
 
Figure 8: Schematic representation of Surface Plasmon Resonance. 
 
The resonance wavelength can be determined very precisely by measuring the light reflected 
by a metal surface. At most wavelengths the metal acts as a mirror, reflecting virtually all the 
incident light. At the wavelength that fulfills the resonance conditions, the incident light is 
almost completely absorbed. The wavelength at which maximum light absorption occurs is the 
resonance wavelength. The coupling of light into a metal surface results in the creation of a 
plasmon, a group of excited electrons, which behave like a single electrical entity. The 
plasmon, in turn, generates an electrical field, which extends about 100 nm above and below 
the metal surface. The characteristic of this phenomenon, which makes SPR an analytical tool, 
is that any change in the chemical composition of the environment within the range of the 
plasmon field causes a change in the wavelength of light that resonates with the plasmon. That 
is, a chemical change results in a shift in the wavelength of light, which is absorbed rather than 
                                                     
94 a) Wood, R. W. Phil. Magn. 1902, 4, 396-402. b) Kretschmann, E.; Raether, H. Naturforsch. 1968, 23A, 2135-
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reflected, and the magnitude of the shift is quantitatively related to the magnitude of the 
chemical change.95 
The concentrations of specific molecules can be quantitatively measured by observing the SPR 
shifts that occur when the molecules bind to the surface of a sensor. In a sensor, the gold 
grating surface is coated with binding molecules which may be antibodies, DNA probes, 
enzymes or other reagents chosen because they react exclusively with a selected target, analyte 
or molecule. When the sensor is exposed to a sample that contains analyte molecules, they 
bind to the sensor’s surface via their specific interaction with the binding molecules. The 
amount of binding that occurs is proportional to the concentration of analyte in the sample. 
This changes the composition of the medium at the surface and produces a SPR shift. The 
magnitude of the shift is proportional to the amount of binding that takes place. Comparison of 
the observed SPR shift with a stored calibration curve yields a quantitative measurement of the 
concentration of the analyte in the sample. SPR is a powerful technique to measure 
biomolecular interactions in real-time in a label free environment. While one of the 
interactants is immobilized on a sensor surface, the others are free in solution and pass over 
the surface. Association and dissociation are measured in arbitrary units and displayed in a 
curve called sensorgram. Originally used to monitor the interaction between 
biomacromolecules, advances in the sensitivity of the SPR technique resulted in its application 
to the detection of small molecules interacting with biomacromolecules.96 For example SPR 
was applied to determine dissociation constants between aminoglycoside antibiotics and 
RNA.97 In contrast to other methods, SPR is able to detect interactions in real time and does 
not require derivatization of aminoglycosides. Moreover, the response level indicates the 
amount of bound ligand, enabling calculation of stoichiometry. 
 
All these tools were developed to rapidly discover new drugs against infections. Indeed, 
bacteria become resistant to antibiotics and to overcome this evolution, new drugs with new 
mechanisms of action have to be developed. 
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10 The rise of antibiotic-resistant infections 
 
10.1 The emergence of resistant bacterial infections 
 
When penicillin became widely available during the Second World War, it was a medical 
miracle, rapidly vanquishing the biggest wartime killer i.e. infected wounds. But just four 
years after drug companies began mass-producing penicillin in 1943 microbes began to appear 
resistant to the drug. Antibiotics resistance spread fast. Between 1979 and 1987, for example, 
only 0.02 percent of pneumococcus strains infecting the surveyed patients were penicillin-
resistant. Today, 6.6 percent of pneumococcus strains are resistant. The same phenomenon 
was observed on β-lactam antibiotics.98 
 
Table 1: Percentage of Staphylococcus aureus samples resistant to β-lactam antibiotics (from 
the Public Health Laboratory Service of England). 
 
 
 
10.2 How does antibiotic resistance emerge 
 
The increased prevalence of antibiotic resistance is an outcome of evolution. Any population 
of organisms, bacteria included, naturally includes variants with unusual traits, in this case, the 
ability to withstand an antibiotic’s attack on a microbe. When a person takes an antibiotic, the 
drug kills the defenceless bacteria, leaving behind or “selecting” those that can resist it. These 
renegade bacteria then multiply, increasing their numbers a million fold in a day, becoming 
the predominant microorganism. The antibiotic does not technically cause the resistance, but 
allows it to happen by creating a situation where an already existing variant can flourish. A 
patient can develop a drug-resistant infection either by directly contracting a resistant bug to 
begin with, or by having a resistant microbe emerge in the body once antibiotic treatment 
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begins. Drug-resistant infections increase risk of death, and are often associated with 
prolonged hospital stays, and sometimes complications. Overuse of broad-spectrum 
antibiotics, such as second- and third-generation cephalosporins, greatly hastens the 
development of methicillin resistance. Other factors contributing towards resistance include 
incorrect diagnosis, unnecessary prescriptions, improper use of antibiotics by patients, and the 
use of antibiotics as livestock food additives for growth promotion.99 
 
10.3 How does bacteria acquire resistance 
 
Bacteria display three basic ways to combat antibiotic attacks, all involving some changes in 
their DNA. The most common way by which bacteria develop resistance is spontaneous 
mutation. Although, most mutations result in the death of the bacteria, one surviving mutant 
will found a new generation within 20 minutes.  
A second method, which is considered to be the most dangerous mechanism of acquiring drug-
resistance, is conjugation. In this case, the bacteria are actually acquiring the resistance 
through a reproductive process. This process occurs between two bacteria and involves the 
activity of bacteria plasmids. Plasmids are circular molecules of extra chromosomal DNA that 
carry the genetic information of bacteria. They are frequently involved in passing on mutations 
for antibiotic resistance. Plasmids can jump from one bacterium to another. In the process, 
they may drop pieces of their DNA including genes for resistance, which can also give deadly 
bacteria. 
Transduction is a third method by which bacteria can acquire resistance. Transduction 
involves a transfer of genetic information during an attack by a bacteriophage (a virus that 
attacks bacteria). The phage binds to a site on the bacterial membrane. It then injects and 
replicates its DNA inside the bacterium. The virus will then either multiply until it bursts the 
bacterial cell, or incorporate the genes it carries into the DNA of the bacterium. If this 
information contains a gene for antibiotic resistance, the host cell progeny will then pick up 
the resistance and pass it on to all future generations. During transduction, bacteriophages can 
also pick up pieces of the host cell’s DNA. So, a phage without resistance gene could also 
obtain it from the host cell. 100 
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10.4 Mechanisms of resistance 
 
Figure 9: The four mechanisms of antibiotic resistance. 
 
The four main mechanisms by which microorganisms exhibit resistance to antimicrobial 
agents are (Figure 9): 
1. Drug inactivation or modification: e.g. enzymatic deactivation of Penicillin G in some 
penicillin-resistant bacteria through the production of β-lactamases. 
2. Alteration of target site: e.g. alteration of the binding target site of penicillins in 
methicillin-resistant Staphylococcus aureus and other penicillin-resistant bacteria. 
3. Alteration of metabolic pathway: e.g. some sulphonamide-resistant bacteria do not 
require para-aminobenzoic acid, which is an important precursor for the synthesis of 
folic acid and nucleic acids. Instead, like mammalian cells, they turn to utilizing 
preformed folic acid. 
4. Reduced drug accumulation: by decreasing drug permeability and/or increasing active 
efflux. Active efflux is a mechanism responsible for extrusion of toxic substances and 
antibiotics outside the cell. Efflux systems function via an energy-dependent 
mechanism to pump out unwanted toxic substances through specific efflux pumps that 
are proteinaceous transporters localized in the cytoplasmic membrane of all kinds of 
cells. Some efflux systems are drug-specific while others may accommodate multiple 
drugs and thus contribute significantly to bacterial multidrug resistance.101 
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10.5 The greatest fear: resistance to Vancomycin 
 
When microbes began resisting penicillin, medical researchers fought back with chemical 
cousins, such as methicillin and oxacillin. By 1953, the antibiotic armamentarium included 
chloramphenicol, neomycin, tetracyclines, and cephalosporins. But today, researchers fear 
may be close to an end of the seemingly endless flow of antimicrobial drugs. At the centre of 
current concern is the antibiotic vancomycin, which is literally the drug of “last resort” for 
many infections. A 20-fold increase of Vancomycin-resistant enterococci was reported 
between 1987 and 1993.102 
 
Over the past 20 years, the production of novel, high-quality, efficient and safe antibiotics has 
slow down considerably. The increasing occurrence of resistant bacteria strains thus represents 
a major public health problem. It is therefore urgent to find new antibacterial structures, able 
to overcome toxicity and resistance drawbacks. For that purpose, developing efficient and 
rapid methodologies for the identification of such molecules is a great challenge. 
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11 Dynamic Combinatorial Libraries (DCL) 
 
To increase the rate of antibiotics structure discovery, an innovative method for high 
throughput screening of biologically active compounds, beside microarrays, would be the use 
of dynamic combinatorial chemistry. This method represents an elegant alternative to classical 
combinatorial chemistry. As we wish to apply this concept for the discovery of new RNA 
binders, a rapid review of the principle and possibilities of dynamic combinatorial library is 
given in this section. 
 
11.1 The DCC principle 
 
Dynamic combinatorial chemistry (DCC) has experienced an explosive growth in recent 
years.103 It provides a powerful methodology for exploring the molecular geometrical and 
interactional spaces through molecular diversity generation especially for the discovery of new 
biologically active substances and medical drugs. Virtual combinatorial chemistry104 relies on 
a reversible connection process for the spontaneous and continuous generation of all possible 
combinations of a set of basic components, thus making virtually available all structural and 
interactional features that these combinations may present. 
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Figure 10: Schematic representation of the concepts behind dynamic combinatorial chemistry 
and virtual combinatorial libraries. 
 
A target site can select among all possible entities, the one that possesses the feature most 
suitable for the formation of the optimal complex (Figure 10). 
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11.2 Generation of dynamic diversity 
 
The generation of dynamic libraries can, in essence, be accomplished using any type of 
reversible physical or chemical mechanism, as long as the respective interconverting states can 
be properly controlled and the final products identified. The most important processes involve 
molecular/supramolecular interchanges, where chemical bonds are continuously formed and 
broken. Functional groups that stabilize reversible covalent connections are crucial for the 
generation of dynamic libraries, and several are available (Table 2), each with particular 
characteristics, advantages and drawbacks. Addition–elimination reactions at carbonyl groups 
(or derived groups) are by far the most important class of reaction, especially imine 
exchange,105 and to a lesser extent (hemi)acetal/aminal,106 thioacetals,107, transacylation108 and 
aldol reactions.109 Conjugate addition to carbonyl compounds could also be considered.110 
Fine-tuning of the formation and exchange kinetics can be achieved by changing the electronic 
properties of the carbonyl compound and of the nucleophile. For example, primary amines 
undergo rapid imine formation and exchange with common aldehydes, but the equilibrium in 
this case is towards the starting materials in aqueous medium. With hydroxylamines and acyl 
hydrazides, the situation is the opposite: the stability of the imines is high, whereas the kinetic 
of the reactions is slow.  
                                                     
105 a) Huc, I.; Lehn, J. M. Proc. Natl. Acad. Sci. USA 1997, 94, 2106-2110. b) Klekota, B.; Hammond, M. H.; 
Miller, B. Tetrahedron Lett. 1997, 38, 8639-8642. c) Polyakov, V. A.; Nelen, M. I.; Nazarpack-Kandlousy, N.; 
Ryabov, A. D.; Eliseev, A. V. J. Phys. Org. Chem. 1999, 12, 357-363. d) Cousins, G. R. L.; Poulsen, S.-A.; 
Sanders, J. K. M. Chem. Commun. 1999, 1575-1576. e) Bunyapaiboonsri, T; Ramström, O.; Lohmann, S.; Lehn, 
J. M.; Peng, L.; Goeldner, M. ChemBioChem 2001, 2, 438-444. f) Cousins, G. R. L.; Furlan, R. L. E.; Ng, Y.-F.; 
Redman, J. E.; Sanders; J. K. M. Angew. Chem. 2001, 40, 423-428. g) Hochgurtel, M.; Biesinger, R.; Kroth, H.; 
Piecha, D.; Hofmann, M.; Krause, F.; Schaaf, O.; Nicolau, C.; Eliseev, A. V. J. Med. Chem. 2003, 46, 356. 
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Mahler, S. G; Okumura, K. Org. Lett. 2005, 7, 4483. 
107 Sutton, L. R.; Donaubauer, W. A.; Hampel, F.; Hirsch, A. Chem. Commun. 2004, 1758. 
108 a) Brady, P. A.; Bonar-Law, R. P.; Rowan, S. J.; Suckling, C. J.; Sanders, J. K. M. Chem. Chem. Commun. 
1996, 319-320. b) Brady, P. A.; Rowan, S. J.; Sanders, J. K. M. Angew. Chem. 1996, 35, 2143-2145. c) Rowan, 
S. J.; Lukerman, P. S.; Reynolds, D, J.; Sanders, J. K. M. New J. Chem. 1998, 22, 1015-1018. d) Monvisade, P.; 
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6, 293. 
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Table 2: Dynamic processes for potential use in DCC system. 
 
Reversible covalent bond 
formation 
Equilibria 
Imine formation O N
R
H2N R
 
Hemiketal formation O HO R OR
OH
 
Transacylation 
R1X
O
R2Y
OY R2 X R1
 
Disulphide formation SH HS S S
 
Diels-Alder reaction 
 
Metathesis reaction 
R1
R1 R2
R2
R1 R2
R1 R2
 
Boronic ester formation R B(OH)2
R1HO
HO R2
O
B
O
R1
R2
R
 
Metal coordination Mm+ nL [MLn]m+  
 
In the case of alkene and alkyne metathesis, recent advances in catalyst development have 
enabled the use of this reaction in dynamic systems, even in aqueous solutions.111 Exchange 
reactions at non-carbon centres could also be used, such as alcohol-bor(on)ate112 and, to some 
extent, alcohol-vanadate exchange, and especially thiol–disulphide interconversion.113 
Kinetically labile hydrogen and coordinative bonds have been exploited with success by 
chemists for the self-assembly of various supramolecular architectures. The relatively 
predictable directionality offered by both metal-ligand and hydrogen bonds has traditionally 
been exploited to direct self-assembly processes to well-defined target structures.114 
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11.3 Adaptive DCLs 
 
The first among these approaches are the true adaptive DCLs, in which generation of the 
constituents is carried out in the presence of the target, resulting in amplification of the best-
bound species so that screening takes place simultaneously in the same compartment. All 
dynamic characteristics of the system can be used here, and adaptation and amplification can 
be obtained. Given the reversible, dynamic characteristics of a DCC system, it can respond to 
disturbances and adapt to internal changes or to external triggers. These changes could be 
either physical or chemical in nature, such as addition or removal of other components, and 
changes in pH, temperature or electric potential, all potentially forcing the system to adjust to 
the new prerequisites. This adaptability, which is enabled by the reversibility of the processes, 
gives the system the potential to be amplified. For example, if one constituent in the DCL 
interacts better than the others with a certain target, then this constituent will be withdrawn 
from the equilibrating pool, and all of the components that make up this constituent will also 
be masked by the binding. Because of the equilibrium situation, the system has to rearrange 
itself to produce more of this constituent at the expense of the other species in the library. On 
re-equilibration, the most active constituent, i.e. the best binder, will therefore experience a 
certain degree of amplification, in comparison to the situation in which no target molecule is 
added. The degree of amplification depends on several parameters, notably binding strength 
and design of the library. Generally, amplification is measured by HPLC. 
 
11.4 Examples of adaptative DCLs: ligands for biomolecules 
 
Of the range of exchange reactions available to date, only relatively few are suited for use with 
biomolecules. At present, disulfide exchange is one of the reactions that has been used most 
widely in this context.115 Imine exchange is also extensively used in the presence of 
biomolecules,116 although a reduction step is normally required to convert the hydrolytically 
labile imines into amines. In contrast to imines, hydrazones are stable at physiological pH, but 
their formation and exchange typically require acidic conditions, which are incompatible with 
most biological targets. Finally, thioester exchange117 and enzymatic reactions such as the 
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exchange of peptidic bonds118 and aldol reactions119 are also compatible with biological 
targets. 
 
11.4.1 Targeting peptides and proteins 
 
As mentioned above, imine formation and exchange (transimination) are especially attractive 
reactions that are fairly compatible with water, and are characterized by rapid formation 
equilibria and fast exchange rates.  
 
R H
O
R' NH2
N
R
R'
HN
R
R'
+
Na(BH)3CNCarbonic anhydrase
S
O
O
NH2
NH
51  
Scheme 18: Dynamic combinatorial library of imines interacting with carbonic anhydrase. 
 
So, as a first example, an imine system based on three different aldehydes and four different 
primary amines was used with the enzyme carbonic anhydrase, resulting in a library of twelve 
different constituents120 (Scheme 18). One of the imine combinations 51 was found to bind 
preferentially to the enzyme and its formation was markedly amplified with respect to the 
concentration in the absence of any enzyme. However, because of the imine instability, other 
types of C=N bond have been studied that can be isolated without reduction. Among these, 
acyl hydrazones seem particularly attractive; their formation is reversible using mild acid 
catalysis, and stable enough at higher pH. For example, a DCL composed of interconverting 
acyl hydrazones was generated and screened for inhibition of acetylcholinesterase (Scheme 
19).121  
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Scheme 19: Dynamic deconvolution of acyl hydrazone libraries of potent inhibitors of 
acetylcholinesterases. 
 
Starting from a small set of 13 initial hydrazides and aldehydes building blocks, a library of 66 
different species could be obtained in a single operation. Of all possible acyl hydrazones 
formed, active compounds that contained two terminal cationic recognition groups separated 
by a spacer of appropriate length could be rapidly identified using a dynamic deconvolution 
procedure that was based on the sequential removal of starting building blocks. A very potent 
bis-pyridinium inhibitor (52) was selected from the process (Ki = 1.09 nM).  
A slightly different approach was used in a disulfide library screened against the lectin 
concanavalin A,122 a protein that generally binds a trimannoside carbohydrate (Scheme 20). A 
library of different sugars linked to a thiol was used to mimic the natural binder. Modest 
amplification of dimers of type 53 containing two mannose units was observed in the presence 
of the lectin template. 
O NH
O
S
S
O
R4a
R4e
HO
R2e
R5
O NH
OO
R4a
R4e
HO
R2e
R5
n
n
53
R2e, R2a, R4e, R4a, R5 : -H, -OH or -CH2OH
R2a
R2a
 
Scheme 20: Structures of the disulfide-linked carbohydrate dimer as concanavalin A mimics. 
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Flitsch, Turner, and co-workers123 have used N-acetylneuraminic acid aldolase, which 
catalyses the aldol reaction between a ketone and the formal aldehyde of an aldose, thus 
forming and cleaving a C-C bond (Scheme 21).  
 
O O
R1
HO OH
OH
COONa
R2
HO Me COONa
O
HO
R1
OH
R2
HONANA
aldolase
R1 = -OH, NHOAc
R2 = -CH2OH, -H
54
+
55 56
 
Scheme 21: Enzyme-mediated reversible aldol reaction. 
 
Using up to four different aldoses 54 in the presence of an excess of ketone 55, they generated 
a DCL in which up to four aldol products were formed. These model DCLs were screened 
against the lectin wheat germ agglutinin and amplification of the library member with affinity 
for the lectin was observed. 
Danieli and coworkers124 used two potential antitumor compounds, i.e. Thiocolchicine 58 and 
Podophyllotoxin 59, that were tethered with thiol-containing linkers of various lengths 57 
(Scheme 22). 
57
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Scheme 22: Chemical structure of homo- and heterodimers of Thiocolchicine 58 and 
Podophyllotoxin 59. 
 
The nonpolar nature of the building blocks necessitated the use of organic solvents to form 
soluble DCLs. The mixtures were then exposed to two proteins that served as models for the 
desired target proteins, tubulins, which are themselves not compatible with organic solvents. 
Target induced shifts in the equilibrium distribution were observed. 
In a recent study, a DCL of two disulfide building blocks based on glycoside and dipeptide 
moieties was screened against the protein wheat germ agglutinin (WGA) 125 (Scheme 23).  
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Scheme 23: Disulfide building blocks (60 and 61) and amplified species 62 in a DCL screened 
against wheat germ agglutinin. 
 
WGA is a protein used for detecting the naturally occurring reversible modification of a serine 
or threonine residue with a molecule of N-acetylglucosamine, a process involved in the 
regulation of protein activity. In presence of the template WGA, N-acetylglucosamine-
containing species were amplified, with molecule 62 being amplified over 2-fold. ESI-MS 
analysis of the DCL also showed the presence of a 62-WGA complex. 
Receptor-type proteins, such as lectins, can also be targeted with DCLs (Scheme 24). For 
example, a prototype library of four different interchanging stereoisomers can be generated 
from the Fe2+-assisted assembly of a carbohydrate-decorated bipyridine unit (N-
acetylgalactosamine-bipyridine, GalNAc-bpy).126 On interaction with a range of GalNAc-
selective lectins, the distribution of these isomers was adjusted depending on lectin. 
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Scheme 24: Library of four different interchanging stereoisomers generated from the Fe2+-
assisted assembly of a carbohydrate-decorated bipyridine unit. 
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Not only biological macromolecules, but also cell-surface ligands or other small biogenic 
species could be targeted with DCLs. In a recent example, the bacterial cell wall building-
block peptide D-Ala-D-Ala was probed with a library of Vancomycin derived elements.127 As 
the vancomycin dimer is known to bind to its ligand much more efficiently than the monomer, 
DCLs were made by linking two peptide-binding units with a linker chain. Disulphide 
interchange or alkene metathesis was used in the linker to introduce reversibility into the 
system, and in this way, libraries of up to 36 members could be constructed. The final library 
components were tested for antibacterial activity against a series of vancomycin-resistant 
bacterial strains, and several components were found to be active. 
 
11.4.2 Nucleotides as targets 
 
Metal-coordination interactions cover a wide range of stabilities, and several of them are 
sufficiently prone to scrambling in aqueous media. In one such example, Zn2+ was used in 
conjunction with a library of salicylaldimines (64) and probed against binding to immobilized 
duplex DNA128 (Scheme 25).  
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Scheme 25: Library of Zn2+ complexes interacting with duplex DNA. 
 
Thirty-six different combinations of Zn2+ complexes (65) were generated from six starting 
elements in buffered aqueous solution. Two of the salicylaldimines were active, one of which 
shown a higher binding to the double-stranded nucleotide than all of the other library 
constituents. A binding constant in the lower micromolar range could also be recorded. 
McNaughton and Miller have recently developed an interesting new method in which they 
immobilize the building blocks on a resin and combine them with the same building blocks in 
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solution.129 Starting from monothiol building blocks, based on known sequence-specific DNA 
binders, a DCL of disulfides was prepared and screened using a fluorescently modified DNA 
template. The beads that contain library members that have affinity for the template will light 
up, allowing relatively straightforward identification of the building blocks that are part of 
good binders. 
Recently, monothiols containing one, two, or three pyrrole units inspired by distamycin 66 
were used to identify a high-affinity binder for both duplex and quadruplex DNA (Scheme 
26).130 In presence of duplex or quadruplex DNA, homo- and heterodimers of building blocks 
67b and 67c were strongly amplified. Glutathione redox buffer was used to decrease the self-
association of building blocks, which would compete with binding of the dimers to the target. 
Duplex DNA melting temperatures were determined in the presence of the selected library 
members to gauge their relative binding affinities. The observed melting temperatures were 
correlated with the amplification factors. 
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Scheme 26: Distamycin and thiol building blocks inspired by its structure. 
 
Despite the recent success encountered with the development of DCLs for the identification of 
new ligands for biopolymers, the use of RNA fragments in such experiments still remains a 
challenge. 
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 CHAPTER II RESEARCH PROJECT 
 
Collections of natural compounds are generally considered as a rich source of valuable 
biologically active substances.131 Many current drugs either mimic naturally occurring 
molecules or have structures that are fully or in part taken from such natural motifs.132 It is 
evident that natural substances offer a wealth of biostructural information that can be used to 
guide drug discovery and molecular design projects.133 Over the years, however, interest of the 
pharmaceutical industry in natural products research has been a somewhat cyclical 
phenomenon. Most recently, the lead compound generation and drug discovery processes have 
been significantly impacted by emerging approaches such as advanced genomics,134 high-
throughput screening,135 combinatorial chemistry and biology,136 computer-assisted de novo 
drug design,137 solid support synthesis and diversity oriented synthesis.138  
The aim of this study is to develop efficient pathways to a large variety of compounds, as new 
mimics of natural products, based on an already established methodology. Polyketides and 
aminoglycosides are among the most popular antibacterial agents. Structural features and 
mode of action of these compounds are well known. With the raise of new antibiotic resistance 
mechanisms, new structures have to be designed to find antibacterial agents that are less 
susceptible to be modified by bacteria and to generate drug resistance. Moreover, macrolides 
and aminoglycosides, despite their high potency, remain structurally highly sophisticated. 
Structure simplifications would allow the synthesis of a larger quantity of compounds analogs. 
The study is divided in two parts: 
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In the first part of this study, various strategies will be developed to set up general 
methodologies for the synthesis of linear (68) and non-linear (69) aminofunctionalised 
polyketides (Scheme 27). In fact, the structure-activity relationships for the natural 
aminoglycosides suggest that electrostatic interactions are key factors that govern RNA 
binding properties.139 Therefore, the 1,3-hydroxyamines can be effective substructures for 
molecular recognition of both phosphodiesters and purines moieties.140 In deed an interesting 
and common feature of almost all aminoglycoside antibiotics, as neomycin, is the presence of 
trans-1,3-hydroxyamine or cis-1,3-hydroxyamine units interacting strongly via multiple 
hydrogen bonds with both the phosphodiester backbone and the purine base of guanine. 
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Scheme 27: Synthesis of aminofunctionalised polyketides as aminoglycosides mimics. 
 
In order to enhance the affinity and specificity of RNA ligands, a promising strategy would be 
to apply the “bivalent ligand” approach.141 Numerous molecules composed of two 
pharmacophore units separated by a spacer were reported to exhibit higher activities and 
selectivities than the pharmacophore unit alone.142 To exploit the presence of multiple binding 
sites in a large RNA molecule, dimeric deoxystreptamine (DOS) moieties (71), known to be 
the element of recognition of aminoglycosides, were planned to be synthesized using polar 
linkers. The influences of the polarity and rigidity of the linker were evaluated during this 
study (Scheme 28). A suitable method for the RNA affinity evaluation of the designed 
structures should be defined.  
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Scheme 28: Synthesis of bivalent DOS-based RNA ligands. 
 
The ultimate goal of this project is the identification of RNA binders through dynamic 
combinatorial library (DCL),143 best ligands being amplified among a library of 
interconverting imines 75 in the presence of an RNA fragment (Scheme 29). Associations 
presenting high molecular recognition toward the studied biopolymer were identified through 
a target-driven phenomenon.144 This represents a great advantage because, contrary to 
classical methods used for the identification of RNA binders, the compounds are synthesized 
in proportions reflecting their affinity towards RNA, allowing the direct identification of the 
best ligand in the mixture. Till now, DCL has never been used with RNA fragment as 
biological target. 
 
RNA fragment
R H
O
R' NH2
N
R
R'
HN
R
R
'
+
Na(BH)3CN
7573 74 76  
Scheme 29: Identification of RNA binders through dynamic combinatorial library. 
 
In the second part of the study, macrolides-like structures containing macrolactones (77), 
hemiketal (78), polyhydroxylated and polypropionates structural features (79) (Scheme 30) 
were designed to prove the versatility of our polyol synthesis methodology and the available 
possibilities for diversity-oriented synthesis.  
                                                     
143 Lehn, J.-M. Chem. Eur. J. 1999, 5, 2455-2463. 
144 a) Hasenknopf, B.; Lehn, J.-M.; Kneisel, B. O.; Baum, G.; Fenske, D. Angew. Chem. 1996, 35, 1838-1840. b) 
Berl, V.; Huc, I.; Lehn, J.-M.; DeCian, A.; Fisher, J. Eur. J. Org. Chem. 1999, 3089-3094. 
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Natural products, like Leucascandrolides, Bryostatin, Erythromycin or glycolipids contain 
these substructures arranged in highly complex architectures. To synthesize rapidly diverse 
structures, short synthetic routes were developed. 
 
O
OH
n
O
O
HO
OH n
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Scheme 30: Polyketides-like compounds. 
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CHAPTER III SYNTHESIS OF AMINOPOLYOLS 
 
1 Overview on reported aminopolyols synthesis 
 
Although many methods for the synthesis of polyol subunits have attracted much attention,145 
only short aminopolyol fragments (up to seven carbon chains) have been prepared. 
For example, Berner and co-workers reported a stereospecific synthesis of the α-amino-γ,ε-
dihydroxypimelic acid 83 (Scheme 31) based on a Lewis acid catalysed stereoselective 
carbonyl-ene reaction between an imidazolidinone 80 and glyoxalate 81 for the installation of 
chain functionalities.146 
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Scheme 31: (2S,4S,6S)-2-amino-4,6-dihydroxypimelic acid synthesis. 
 
A more general strategy includes a 1,3-dipolar cycloaddition of nitrile oxides (84) to alkenes 
(85) allowing the construction of a variety of functionalized carbon skeletons. The 
isoxazolines cycloadducts (87) may serve as precursors for γ-amino alcohols (88) by complete 
reduction of the ring (Scheme 32).147 
 
Cl
N
HO O N OH NH2-HCl
N
O
84
85
86 87 88  
Scheme 32: Synthesis of 1-amino-3-hydroxyl moieties. 
                                                     
145 a) Schetter, B.; Mahrwald, R. Angew. Chem. 2006, 45, 7505-7525. b) Bode, S. E.; Wolberg, M.; Mueller, M. 
Synthesis 2006, 557-588. c) Misske, A. M.; Hoffmann, H. R. M. Chem. Eur. J. 2000, 6, 3313-3330. d) Hanessian, 
S.; Giroux, S.; Mascitti, V. Synthesis 2006, 1057-1076. 
146 Mehlführer, M.; Thirring, K.; Berner, H. J. Org. Chem. 1997, 62, 4078-4081. 
147 Jäger, V.; Schohe, R. Tetrahedron 1984, 40, 2199-2210. 
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The isoxazoline-based approach was applied to the stereoselective synthesis of triol (93) or 3-
amino-1,5-diols alcanes (94) using the same pathway (Scheme 33).148 The success of the 
process relies on the stereocontrolled cycloaddition of nitrile oxides to olefins to release 4,5-
dihydroisoxazoles (89), and their stereoconservative conversions by reductive ring openings.  
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Scheme 33: Synthesis of 1,3,5-polyols and aminopolyols using isoxazoline intermediates. 
 
Other methodologies allowing the synthesis of short aminopolyols with a 1,2-aminoalcohol 
substructure have been published, some examples are briefly reported below.  
Zabel149 disclosed a method relying on an asymmetric Michael addition between an alkene 
bearing a chiral moiety at the allylic position (95) and an amine. The intermediate adduct is 
not isolated and undergoes a ring closure yielding aziridine 96 with a 1,3-dioxolan moiety at 
the α-position, with high stereoselectivity. The key intermediate 96 leads to aminopolyols 97 
by selective reduction, deprotection and aziridine ring opening (Scheme 34). 
 
95
O O
CO2Et
NH3
-HX O
O
CO2Et
N
H
OH OTBS
OH NH2
OH
96 97  
Scheme 34: Synthesis of 4-amino-1,2,3,5-tetrols using aziridine intermediates. 
                                                     
148 a) Annunziata, R.; Cinquini, M.; Cozzi, F.; Restelli, A. J. Chem. Soc. Perkin Trans. 1 1985, 2293-2297. b) 
Cinquini, M.; Cozzi, F.; Gilardi, A. J. Chem. Soc. Chem. Commun. 1984, 8, 551-552. 
149 Dollt, H.; Zabel, V. Aust. J. Chem. 1999, 52, 259-270. 
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More recently, Saïto150 disclosed a new route toward 1,2-aminoalcohols based on an 
intramolecular [3+2] cycloaddition reaction of a silyl nitronate tethered to a vinylsilyl group 
98 (Scheme 35). 
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Scheme 35: Synthesis of 3-amino-1,2,4-triols using aziridine silyl nitronate tethered to a 
vinylsilyl group. 
 
Barbas151 has developed a diastereo- and enantioselective anti-Mannich-type reaction 
catalysed by pyrrolidine derivatives 104 or 120 that allows the synthesis of β-amino carbonyl 
derivatives and the direct, regiospecific and asymmetric synthesis of amino alcohols 105-106 
and 111-112 (Scheme 36). 
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Scheme 36: Synthesis of protected amino alcohols using a proline-based catalyst. 
                                                     
150 Ishikawa, T.; Kudo, T.; Shigemori, K.; Saïto, S. J. Am. Chem Soc. 2000, 32, 7633-7637.  
151 a) Chowdari, N. S.; Ahmad, M.; Albertshofer, K.; Tanaka, F.; Barbas III, C. F. Org. Lett. 2006, 8, 2839-2842. 
b) Zhang, H.; Mifsud, M.; Tanaka, F.; Barbas III, C. F. J. Am. Chem. Soc. 2006, 128, 9630-9631. 
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Finally, medium polyolic chains containing amino groups were synthesized in Enders’ 
group152 through diastereo- and enantioselective organocatalytic aldol reactions catalysed by 
(S)-proline (Scheme 37). 
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Scheme 37: Synthesis of medium chain aminopolyols. 
 
To the best of our knowledge, no non-iterative methodology allows the direct synthesis of long 
chain aminofunctionalised 1,3-polyols. The common strategy for the synthesis of such 
fragments relies on selective mesylation followed by azoturation-reduction steps on a polyol 
chain. For example, Enders153 transformed the diol 117, released with the RAMP/SAMP 
hydrazone methodology, by azoturation/reduction of the selectively deprotected alcohols to 
provide diamino-alcohol 118 (Scheme 38). 
 
116
OH OH
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Scheme 38: Synthesis of 1,3-diamino-2-alcohol using diol released through the RAMP/SAMP 
hydrazone methodology. 
 
In our group, a synthetic pathway was reported for the preparation of 1-aminopentadecane-
3,5,7,9,11,13,15-heptols (119) and of 1,15-diaminopentadecane-3,5,7,9,11,13-hexols (120) 
(Scheme 39).154  
 
119
* * * * * *
OH NH2OH OH OHOH OH OH
* * * * * *
NH2 NH2OH OH OHOH OH OH
120  
Scheme 39: Synthesis of amino and diamino-polyols. 
                                                     
152 Enders, D.; Grodal, D. Angew. Chem. Int 2005, 44, 1210-1212. 
153 Enders, D.; Jegelka, U.; Dücker, B. Angew. Chem. 1993, 32, 423-425. 
154 Gerber-Lemaire, S.; Popowycz, F.; Glanzmann, C.; Vogel, P. Synthesis 2002, 14, 1979-1986. 
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This route relies on the methodology previously developed in Vogel’s group for the synthesis 
of long chain polyols. However, this synthesis remained lengthy and the positions where 
amine groups could be introduced were limited to chain ends. We were thus interested in 
developing new efficient strategies for the stereoselective synthesis of a panel of amino 
functionalised polyketides. 
 
2 Design and synthesis of linear long-chain aminofunctionalised polyketides 
 
2.1 The non-iterative polyol synthesis 
 
Schwenter and Vogel155 first reported a non-iterative asymmetric synthesis of long-chain 1,3-
polyols. This method involved a double [3+4] cycloaddition between 1,1,3-trichloro-2-
oxyallyl cation and 123 (Scheme 40). 2,2-Methylenebis(furan) 123, was prepared through a 
nucleophilic addition of furfuryl alcohol 121 on furane 122. 1,1,3,3-Tetrachloroacetone 125, 
was obtained by reduction of 1,1,1,3,3,3-hexachloroacetone 124 with palladium on barium 
sulfate. 
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Scheme 40: Synthesis of starting materials and [4+3] cycloaddition. 
 
After the double [3+4] cycloaddition, a reductive workup yielded a 45/55 mixture of meso-126 
and threo-126 diketones. The threo-126 derivative crystallised in cold furane from a 3/1 
mixture of meso/threo cycloadducts. Meso-126 was further purified by crystallisation in cold 
water and it was converted into semi-protected tetraol 127. This diolefin was desymmetrised 
into diol 128 by Sharpless asymmetric dihydroxylation with high enantiomeric excess 
(Scheme 41).156 Further transformations allowed the preparation, in principle, of all possible 
                                                     
155 Schwenter, M. E.; Vogel, P. Chem. Eur. J. 2000, 6, 4091-4103. 
156 Sharpless, K. B.; Kolb, H. C.; Van Nieuwenhze, M. S. Chem.Rev. 1994, 94, 2483-2547. 
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stereoisomers of pentadecane-1,3,5,7,9,11,13,15-octol 130.157 Nevertheless this method 
required the successive functionalisation of both cycloheptene rings by dihydroxylation and 
oxidative ring opening. 
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Scheme 41: Strategy for polyketide synthesis using Sharpless desymmetrisation. 
 
A shorter route was disclosed for the synthesis of the polyolic chains by Gerber and Vogel. 
This method is based on the double ozonolysis of threo 3,3’-methylenebis{6-
[(benzyloxy)methoxy]cyclohept-3-en-1-ol}. This chemistry significantly reduces the number 
of steps necessary to convert bicycloadduct threo-126 into enantiomerically pure long-chain 
polyketides.158 For that reason, this method was employed for the synthesis of the polyol 
precursors that will be used in the present study. 
 
In the rest of the manuscript, P stands for benzyloxymethyl group (BOM). 
 
For the preparation of such polyols, diketone threo-126 was first reduced into the 
corresponding diol using K-selectride with complete endo-stereoselectivity (Scheme 42). 
Diacetate 131, released through acetylation under classical conditions, was treated with BCl3 
to give the corresponding bis-chloroborate, which was then treated with BOMCl and DIPEA 
in the presence of a catalytic amount of tetrabutylammonium iodide, to provide 132. 
Dechlorination under radical conditions, using Bu3SnH and AIBN, gave 133, which was 
finally methanolysed in MeOH with K2CO3 to give diol 134. This 6 steps procedure was 
achieved in 30% overall yield and could be performed on a large scale (20 g). 
                                                     
157 Schwenter, M. E.; Vogel, P. J. Org. Chem. 2001, 66, 7869-7872. 
158 Gerber-Lemaire, S.; Vogel, P. Eur. J. Org. Chem. 2003, 2959–2963. 
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Scheme 42: Synthesis of diolefin precursor. 
 
Diolefin 134 can be obtained in enantiomerically pure form through an enzymatic resolution 
of racemic diol 135 (Scheme 43). Transacetylation in the presence of lipase from Candida 
Cylindracea provided enantiomerically pure diacetate 131 and diol 135 in 98% and 97% 
enantiomeric excesses.159 These intermediate are then converted into optically active diolefin 
(+) and (-)-134. 
O O
O O
threo-126
K-selectride, 
THF, -78°C-25°C
 87%
OH OH
O O
(  )-135  
Scheme 43: Synthesis of diol 135. 
The key step to synthesize the polyol chain relied on the ozonolysis of diolefin 134. Reductive 
treatment with Me2S and then with NaBH4 under Nazaraka’s conditions160 on the 
intermediate, generated polyol 136, which was classically protected as its bis-acetonide 137 
(Scheme 44). The configuration of the newly formed 1,3-diols was assigned as C5,C7-anti and 
C9,C11-syn. 
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PO OP 1. O3, CH2Cl2, -78°C2. DMS (4 eq.), -78°C
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    NaBH4 (8 eq.)
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Scheme 44: Double ozonolysis cleavage of diolefin 134. 
                                                     
159 Csaky, A. G.; Vogel, P. Tetrahedron: Asymmetry 2000, 11, 4935-4944. 
160 Narazaka, K.; Pai, F.-C. Tetrahedron 1984, 12, 2233–2238. 
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To enlarge the scope of this methodology, the same treatment was performed on meso diolefin 
138 (Scheme 45). However, when ozonolysis and Narazaka’s reduction were performed, two 
polyols 139 and 140 were obtained and separated by chromatography. Meso polyol 140 was 
the major product of the mixture, but the ratio of the two products 139 and 140 varied from 1/1 
to 1/5. 
OHOH
PO OP
1. O3, CH2Cl2, -78°C
2. DMS, -78°C
3. Et2BOMe, NaBH4
    THF/MeOH, 0°C -25°C
OH OHOP OP' OPOP' OP' OP'
OH OHOP OP' OPOP' OP' OP'138 52% over 3 steps
73%
P = BOM, P' = H
P = BOM, P'P' =CMe2
2,2-DMP/Acetone, 
PPTS cat., 0°C
140
142
71%
P = BOM, P' = H
P = BOM, P'P' =CMe2
2,2-DMP/Acetone, 
PPTS cat., 0°C
139
141
 
Scheme 45: Synthesis of polyols from diolefin 138. 
 
Several attempts were intended to improve this ratio by variations of the reduction conditions. 
It seemed that the reaction time, the quality of Et2BOMe, the reaction temperature and the 
addition rate of Et2BOMe influenced the product ratio. Finally, changing the reducing agent to 
Zn(BH4)2 did not improve the selectivity of the reduction. For these reasons, we turned our 
attention to threo starting diolefins for further studies. 
 
2.2 Selective protection of hydroxyl groups of polyolic chains 
 
To introduce amino groups at defined positions of a linear polyol skeleton, selected hydroxyl 
groups of the chain should be replaced by amino groups (Scheme 46).  
 
* * * * * *
OH NH2 OH NH2 NH2 OH OH OH
* * * * * *
OP1 OH OP2 OH OH OP3 OP4 OP5
143 144
P1,2,3,4,5 = protecting groups
 
Scheme 46: Retrosynthetic analysis for the conversion of polyols into aminopolyols. 
 
Semi-protected polyols 144 were thus designed by selective introduction of protecting groups 
on the chain allowing the synthesis a large variety of aminofunctionalised polyketides 
containing amino groups, preferentially at internal positions of the skeleton. Semi-protected 
polyols can then be mesylated and the corresponding mesylates can be displaced by azido 
groups, as direct precursor of the long chain aminopolyols.  
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In the following section several tools that have been developed for the selective introduction 
of protecting groups on polyolic chains are presented. 
 
2.2.1 Selective protection of alcohols starting from a linear polyol chain 
 
2.2.1.1 Protection and deprotection of orthogonal protecting moieties 
 
In a first approach, the selective introduction of protecting groups on a linear polyolic chain 
was envisioned. To differentiate primary alcohols from secondary ones known selective 
protection methods were employed. Selective silylation of primary alcohols yielded 145 and 
introduction of acetonides on secondary alcohols released diol 137 in 85% and 70% yield, 
respectively (Scheme 47). 
 
137
145
OH OP O O O O OP OH
136, P = BOM
2,2-DMP/Acetone, PPTS, 
0°C 
70%
OH OP OH OH OH OH OP OH
TBSO OP OH OH OH OH OP OTBS
TBDMSCl, Imidazole, 0°C
85%
 
Scheme 47: First examples of polyol protections. 
 
More complexity in the semi-protected structures was introduced through a selective 
deprotection of the BOM moieties taking advantage of protecting group orthogonality. After 
transformation of the primary alcohols into acetates, hydrogenolysis of the BOM groups was 
first attempted with Pd(OH)2 on charcoal, but with no success. The use of Raney Nickel, a 
stronger catalyst, led to the clean removal of both BOM ethers to provide diol 147 (Scheme 
48). 
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OH OHOP O OPO O O
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OAc OAcOP O OPO O O
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Scheme 48: Selective deprotection of benzyloxymethyl ethers. 
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Nevertheless, with these kinds of structures, the repeating targeted 1,3-amino alcohol motifs 
are quite limited. It would be more interesting to protect selectively some of the secondary 
alcohols, leaving the others unprotected. 
 
2.2.1.2 Selective hydrolysis of anti-acetonides 
 
It is known from the literature that syn-1,3-diol-acetonides preferentially adopt a chair 
conformation, while, for steric reasons, anti-1,3-diol-acetonides are generally forced into a 
more strained twist-boat conformation.161 Differences in the reactivity of diastereomeric syn- 
and anti-1,3-diolacetonides are scarcely described. However, Paterson and Scott observed that 
acetonide protection of an anti-1,3-diol building block may be too labile under several 
hydrogenolysis conditions, while the acetonide moiety of the syn-configured counterpart 
proved to be inert under the same conditions.162 In the course of a kinetic conformational 
analysis conducted on diastereomerically pure 1,3-dioxanes, Pihlaja showed that anti-2,4-
pentandiol-acetonide hydrolyses 26 times faster than the corresponding syn diastereoisomer 
(diluted hydrochloric acid, 25°C).163 Pihlaja assigned strain release in the ring cleavage step to 
account for this difference, and it is reasonable to assume that this explanation applies 
generally to the hydrolysis of syn- and anti-1,3-diol-acetonides. Release of strain has been 
invoked as an accelerating factor in the hydrolysis of other strained acetals and ketals as 
well.164 An original solution for the selective protection of some of the secondary alcohols 
would be to use a selective acetonide hydrolysis. This type of reaction would liberate only two 
of the four secondary alcohols of our polyolic system. However, it remains a difficult task to 
achieve selective deprotection of one 1,3-diol subunit in a long chain polyolic fragment. 
Despite the fact that differences in the rate of hydrolysis of diastereoisomeric 1,3-diol-
acetonides have been reported, very few applications of these kinetic data have been proposed. 
Inspired by the work of Müller and co-workers165 on the diastereoisomer-differentiating 
hydrolysis of 1,3-diol-acetonides, mild and general condition for the selective cleavage of 
anti-1,3-diol-acetonides in the presence of syn-1,3-diol-acetonides on the same molecule was 
developed. 
                                                     
161 a) Pihlaja, K.; Kivimäki, M.; Myllyniemi, A.-M.; Nurmi, T. J. Org. Chem. 1982 47, 4688-4692. b) 
Rychnovsky, S. D.; Rogers, B. N.; Richardson, T. I. Acc. Chem. Res. 1998, 31, 9-17. c) Kleinpeter, E. Adv. 
Heterocycl. Chem. 1998 69, 217-269.  
162 Paterson, I.; Scott, J. P. J. Chem. Soc., Perkin Trans. 1 1999, 1003-1014. 
163 Pihlaja, K. Ann. Univers. Turkuensis Ser. A1 1967, 114. 
164 a) Atkinson, R. F.; Bruice, T. C. J. Am. Chem. Soc. 1974, 96, 819- 825 and references therein. b) Fife, T. H.; 
Natarajan, R. J. Am. Chem. Soc. 1986, 108, 8050-8056. 
165 Bode, S. E.; Müller, M.; Wolberg, M. Org. Lett. 2002, 4, 619–621. 
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In order to explore various conditions for the selective cleavage of anti-1,3-diol-acetonides, 
diacetonide 137 was used as a polyolic fragment model (Scheme 49). 
 
OH OP O O O O OP OH
137, P = BOM
Table 3
OH OP OH OH O O OP OH
148
OH OP OH OH OH OH OP OH
136
+
 
Scheme 49: Selective hydrolysis of anti-1,3-diol-acetonide. 
 
The conditions reported by Müller for the selective hydrolysis of simple anti-diol-acetonide 
(Table 3, entry 1) was first applied. Unfortunately, a low conversion was observed and 
prolonged reaction time led to the unselective deprotection of both anti- and syn-diol-
acetonides. Pyridinium p-toluene sulfonate was then used to promote acetonide cleavage in 
CH2Cl2, but only led to the recovery of the starting polyol 137 (entries 2–3). Addition of 
methanol as a co-solvent afforded a moderate 40% yield of the expected mono acetonide 148, 
together with the fully deprotected tetraol 136 (60%). The same lack of selectivity was 
observed in the presence of camphorsulfonic acid and p-toluenesulfonic acid, at 0°C, in 
CH2Cl2 (entries 5 and 7). Acidic alumina was ineffective to promote acetonide cleavage (entry 
6). Finally, we found out that the use of 5 mol % of p-toluenesulfonic acid at 20°C in CH2Cl2, 
yielded mono acetonide 148 in 80% yield, without concomitant undesired cleavage of the syn-
1,3-diol acetonide (entry 8).  
 
Table 3: Conditions for the selective cleavage of anti-acetonides. 
 
Entry Conditions 148 yielda 
136 
yielda 
137 
yielda 
1 2M HCl 0.05 eq., CH2Cl2 (0.15 M), 25°C   21% 
2 PPTS 0.2 eq., CH2Cl2 (0.05 M), 0°C   100%
3 PPTS 0.6 eq., CH2Cl2 (0.05 M), 25°C   100%
4 PPTS 0.6 eq., CH2Cl2 / MeOH (3:1, 0.05 M), 0°C 40% 60%  
5 CSA 0.7 eq., CH2Cl2 (0.1 M), 0°C 37% 53%  
6 Acidic alumina, CH2Cl2 (0.1 M), 25°C   100%
7 p-TsOH 0.2 eq., CH2Cl2 (0.05 M), 0°C 46% 29%  
8 p-TsOH 0.05 eq., CH2Cl2 (0.05 M), 3 h, -20°C 80%   
a) Isolated yields. 
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In order to validate the applicability of these conditions, another diacetonide derivative was 
prepared according to the previously reported methodology (Scheme 50).166  
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Scheme 50: Synthesis of a new polyacetonide. 
 
Ozonolysis of dialkene 138 followed by reductive treatment with Me2S and then with an 
excess of Me4NBH(OAc)3 promoted an anti-β-hydroxy ketone reduction (Scheme 50).167 The 
resulting mixture of hemiacetals was not purified but subsequently reduced to the 
corresponding polyol 139. Treatment with 2,2-dimethoxypropane and acetone, in the presence 
of a catalytic amount of p-toluenesulfonic acid, released diacetonide 141.  
The conditions described above were successfully applied to this derivative, resulting in the 
selective cleavage of the anti-1,3-diol-acetonide to provide monoacetonide 149 in 69% yield 
(Scheme 51).  
 
OH OHOP OPOO O O OH OHOP OPOHOH O O
p-TsOH 5%, CH2Cl2, -20 °C
                 69%
149141
TBSO OTBSOP OPOO O O
150
TBSO OTBSOP OPOHOH O O
151
p-TsOH 5%, 
CH2Cl2, -20°C
       68%
 
Scheme 51: Selective hydrolysis of anti-1,3-diol-acetonides. 
 
In synthetic studies, silyl groups are among the most widely used protecting moieties for 
alcohols. For that purpose we also tested the compatibility of our conditions with tert-
butyldimethylsilyl groups as exemplified by the selective deprotection of the 1,3-anti diol 
moiety from the silylated polyol 150 (Scheme 51).168 In the presence of 5 mol % of p-
toluenesulfonic acid, monoacetonide 151 was isolated in 68% yield. No trace of deprotection 
of the primary alcohols was observed. 
 
                                                     
166 Gerber-Lemaire, S.; Vogel, P. Eur. J. Org. Chem. 2003, 2959-2963. 
167 Evans, D. A.; Chapman, K. T.; Carreira, E. M. J. Am. Chem. Soc. 1988, 110, 3560-3578. 
168 Popowycz, F. These de l’EPFL n° 2866, 2003. 
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2.2.1.3 Selective acetylation of primary alcohols in the presence of secondary ones 
 
In order to selectively introduce other protecting groups, the primary alcohols protection of 
polyketide chains without affecting internal secondary alcohols was investigated. Dr. MER 
Sandrine Gerber has already developed a useful enzymatic desymmetrisation of a meso-polyol 
using Candida cylindracea lipase (4800 U.mmol–1) in vinyl acetate.169  
 
Table 4: Selective enzymatic transesterification of primary alcohols. 
 
Substrate Product Yielda
137
136
OH OP O O O O OP OH
OH OP OH OH OH OH OP OH
OP OH O OPOH O OHOH
148
OAc OP O O O O OP OAc
OAc OP OH OH OH OH OP OAc
OP OH O OPOH O OAcOAc
153
152
146
 
Quant.
General conditions: substrat dissolved in vinyl acetate and treated with Candida Cylindracea lipase 
(4800 U.mmol–1) at 25 °C for 2 h. a) Isolated yield. 
 
Interestingly, this procedure could be applied for the selective acetylation of primary alcohols 
of semi-protected polyols with excellent yields, thus providing a simple and efficient method 
for the selective acetylation of primary alcohols in the presence of free secondary hydroxyl 
moieties. In all cases, the corresponding diacetates 146, 152-153 were released in quantitative 
yields (Table 4).  
In summary, a larger diversity of semi-protected derivatives was synthesized in order to 
introduce protecting groups at specific internal positions of polyol chains. It was next 
envisioned that partially reduced intermediates might be isolated during the 
ozonolysis/reduction cascade applied to diolefin 134. These derivatives, containing more rigid 
features, may constitute original templates for studying selective protecting methods. 
Therefore, the ozonolysis-reduction cascade was investigated in more details. 
 
                                                     
169 Vogel, P.; Gerber-Lemaire, S.; Carmona, A. T.; Meilert, K. T.; Schwenter, M.-E. Pure and Applied Chemistry 
2005, 77, 131-137. 
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2.2.2 Isolation of a bis(hemiacetal) intermediate 
 
Based on previously reported results on the synthesis of heptahydroxypentadecanals, diolefin 
134 was submitted to ozonolysis followed by reductive treatment with Me2S and then with an 
excess of Et2BOMe and NaBH4 at reduced temperature (-30°C), following Narazaka’s 
conditions for the syn reduction of β-hydroxy ketones (Scheme 52).  
 
1. O3, DCM, -78°C
2. DMS , -78°C
3. Et2BOMe, NaBH4,
    THF/MeOH, -30°C to -10°C
                    55%
O OOH OH
OPPO
OH OH
1. MeOH, CSA cat.
2. 2,2-DMP, Acetone, 
    APTS cat., 0°C
      74% over 2 stepsO OO O
OPPO
O O
Me Me
134
155
154OHOH
PO OP
 
Scheme 52: Isolation of a new bis-hemiketal intermediate. 
 
A new bis(hemiacetal) intermediate 154 was isolated in 55% yield over three steps. In the 
original study for the synthesis of polyol chains, it has been established that the linear octol 
chain can be directly obtained by performing the reductive treatment at 25°C. Lowering the 
reaction temperature allowed the isolation of this new intermediate, which was characterized 
after treatment with camphorsulfonic acid in methanol, followed by protection of the diol 
moiety as an acetonide. Pyranosides 155 were isolated as a mixture of four isomers due to the 
presence of two anomers at each hemiketal moiety. Only two sets of signals, in a 2/1 ratio 
(corresponding to the anomers in a 2/1 ratio), could be distinguished on the NMR spectra of 
155. This is due to the quasi-symmetry of the molecule. Moreover, typical 13C NMR signals170 
for a syn acetonide were observed (δ Me = 31.6 and 21.3 ppm), thus confirming the structure 
of the corresponding diol 154.  
                                                     
170 Rychnovsky, S. D.; Rogers, B. N.; Richardson, T. I. Acc. Chem. Res. 1998, 31, 9-17. 
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Finally, a Wittig type olefination was performed on bis(hemiacetal) 154 using the stabilised 
ylide 156, prepared according to the conditions of Aspinall and co-workers171. Bis(hemiacetal) 
was reacted at 80°C with phosphonium ylide 154. This ylide was generated by reaction of 
tributylphosphine with methyl bromoacetate, followed by deprotonation with 2 M aqueous 
NaOH. This kind of transformation, known in carbohydrate chemistry,172 allowed the isolation 
of bis-α,β-insaturated methyl ester 157 as an inseparable mixture of E/Z diastereoisomers, E 
being the major isomer (Scheme 53). 
 
156
154 157
O OOH OH
OPPO
OH OH
72%
OP OH OH OPOH OH
O
MeO
Bu3P
O
OMe O
OMe
Toluene, 80°C
 
Scheme 53: Wittig type olefination of bis(hemiacetal). 
 
The isolation of bis(hemiacetal) 154 and its further transformation led us to propose plausible 
intermediates for the ozonolysis/reduction sequence on diolefin 134.  
 
                                                     
171 Aspinall, I. H.; Cowley, P. M.; Mitchell, G; Raynor, C. M.; Stoodley, R. J. Chem. Soc., Perkin Trans. 1 1999, 
2591-2599. 
172 a) Kochetkov, N.; Dmitriev, B. A. Tetrahedron. 1965, 21, 803. b) Railton, C. J.; Clive, D Carbohydr. Res. 
1996, 281, 69. 
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2.2.3 Pathway for the ozonolysis/reduction sequence 
 
Considering these results, it seems that the diketodialdehyde 158 released after double olefin 
cleavage with ozone is in equilibrium with a diketone (159) (Scheme 54).  
 
134 159158
OHOH
PO OP 1. O3, DCM, -78°C
2. DMS , -78°C
OH
OPPO
OH
O O
O O
O OO O
OPPO
OH OH
Et2BOMe, NaBH4
-30°C to -10°C
O OHO O
OPPO
OH O
O OO OH
OPPO
OH OH
O OOH OH
OPPO
OH OH
O OHO OH
OPPO
OH O
Et2BOMe, NaBH4
-30°C to -10°C
Syn
Syn
Et2BOMe, NaBH4
-30°C to -10°C
OH OO O
OPPO
O OH
O OOH O
OPPO
OH OH
O OOH OH
OPPO
OH OH
OH OOH O
OPPO
O OH
Et2BOMe, NaBH4
-30°C to -10°C
Syn
Syn
IDENTICAL
154
162
161
160
159
164163
162 OH OO OH
OPPO
O OHSyn
O OOH OH
OPPO
OH OH
Et2BOMe, NaBH4
-30°C to -10°C
NOT OBSERVED
 
Scheme 54: Pathway for the ozonolysis/reduction sequence. 
 
The reversibility of ketal formation process and/or complexation of the alcohol with borane 
derivative allowed the re-opening of one hemiketal and the syn selective reduction of the 
ketone complexed with a boron atom to afford 161. This ketone was more readily reduced 
than the aldehyde because of electronic effects due to complexation with boron. The second 
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reduction was then directed by the newly formed and readily available alcohol of 162, leaving 
the second hemiketal unaffected, to yield 154. Narazaka’s reduction of the remaining ketone in 
162 directed by the endocyclic hydroxyl group of 162, would release product 164. This 
product was not isolated, probably because the rate of a reduction directed by a free hydroxyl 
group is faster than a reduction directed by a hydroxyl group trapped as an hemiacetal. 
 
Taking advantage of the sugar-like structure of 154, this intermediate was used as a key 
template for the selective introduction of protecting groups. 
 
2.2.4 Selective protection of alcohol starting from a new bicyclic compound 
 
Bis(hemiacetal) 154 can be considered as a deoxysugar. It is well established in carbohydrate 
chemistry that the reactivity of secondary hydroxyl groups depends strongly on their acidity 
and their nucleophilicity that are modulated by intramolecular hydrogen-bonds.173 Yoshida 
and co-workers174 first reported the evaluation of the relative reactivity of secondary hydroxyl 
groups in monosaccharides. In this study, Yoshida attributed the difference of reactivity 
between hydroxyl groups to intramolecular hydrogen bonds. The enhanced reactivity of the 3-
hydroxyl group can also be explained by this hydrogen-bond network (Scheme 55).  
 
O
O
OO H R
OH
HO
H
1
3
5
 
Scheme 55: Intramolecular hydrogen-bond network as proposed by Yoshida and co-workers. 
 
Several methods have been developed so far for the selective acetylation or benzoylation of 
carbohydrates,175 but examples of selective silylation are scarce.176 Moitessier and co-workers 
disclosed a new method using novel hydrogen-bond acceptor protecting groups. To modulate 
the 4-OH and 3-OH reactivity, a nitrogen atom mediates a network of hydrogen bonds 
                                                     
173 Haines, A. H. Adv Carbohydr. Chem. Biochem. 1976, 33, 11. 
174 a) Kurahashi, T.; Mizutani, T.; Yoshida, J.-I. Tetrahedron. 2002, 58, 8669. b) Kurahashi, T.; Mizutani, T.; 
Yoshida, J.-I. J. Chem. Soc., Perkins Trans. 1 1999, 465. 
175 a) Kattnig, E.; Albert, M. Org. Lett. 2004, 6, 9945-948. b) Hu, G.; Vasella, A. Helv. Chem. Acta 2003, 86, 
4369-4391. d) Griswold, K. S.; Miller, S. J. Tetrahedron Lett. 2003, 44, 8869-8875. 
176 a) Chun, M.-K.; Orlova, G.; Goddard, J. D.; Schlaf, M.; Harris, R.; Beveridge, T. J.; White, G.; Hallett, R. J. 
Am. Chem. Soc. 2002, 124, 10508-10518. b) Graziani, A.; Passacantilli, P.; Piancatelli, G., Tani, S. Tetrahedron 
Lett. 2001, 42, 3857-3860. c) Arias-Perez, M. S.; Lopez, M. S.; Santos, M. J. J. Chem. Soc., Perkins Trans. 2 
2002, 1549-1552. d) Olgivie, K. K.; Hakimelahi, G. H. Carb. Res. 1983, 115, 234-239. 
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between the hydroxyl groups and the newly designed pyridyl-containing protecting group.177 
Taking advantage of this induced hydrogen-bond network, a regioselective acetylation of 
alcohol at position 4 was achieved without protecting any secondary hydroxyl groups of the 
carbohydrate moiety. Selective silylation of position 5 was achieved in high isolated yields 
and regioselectivity using these protecting groups to yield semi-protected pyranoside 166 
(Scheme 56). 
 
165
O
OMe
O
O
O
N
N
OH
Tol
Tol
H
H
O
OMe
O
O
O
N
N
O
Tol
Tol
H
H
TBS
TBSOTf, 2,6-lutidine
CH2Cl2, -78°C
             67%
166
168167
O
O
OH
O
O
N
O
Tol
Tol
H Me
H
Ac2O, DMAP
-78°C
85%
O
O
O
O
O
N
O
Tol
Tol
H Me
H
Ac
 
Scheme 56: Hydrogen-bond induced selectivity according to Moitessier and co-workers. 
 
Suspecting internal hydrogen-bond on the isolated bis(hemiacetal) 154, silylation reaction was 
performed under conditions favouring internal hydrogen-bonds, i.e. high dilution in an apolar 
solvent at low temperature. The use of TBDMSOTf/lutidine reagents for the silylation at 
-78°C gave no result, but at -50°C, a highly regioselective silylation occurred (Scheme 57). 
Indeed, after reduction of both hemiketal moieties with NaBH4 in methanol, a single product 
was identified on TLC and isolated in 53% yield over 2 steps. 13C NMR spectrum reveals that 
a single diastereoisomer has been formed. To know which one of the two alcohols had been 
protected, an acetonide protecting group was introduced. Depending on the position that had 
been silylated, a syn- or an anti-acetonide should be identified. 
                                                     
177 a) Moitessier, N.; Chapleur,Y. Tetrahedron Lett. 2003, 44, 1731-1735. b) Moitessier, N.; Englebienne, P.; 
Chapleur,Y. Tetrahedron 2005, 61, 6839-6853. 
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1. TBDMSOTf (0.5 M) 1.5 eq., 
    2,6-lutidine, CH2Cl2, -50°C
2. NaBH4, 25°C
         53% over 2 steps
2,2-DMP/Acetone, APTS, 0°C
                88%
O OOH OH
OPPO
OH OH
OP OH OH OPOTBSOH OHOH
OP OH O OPOTBSO OHOH
OP OH OH OPOH OTBS OHOHor
OP O OH OPO OTBS OHOH
NOT OBSERVED171 172
170169
154
154
O OOTBSOH
OPPO
OH OH
O
OH
OPO HO
H
OPO
OH
TBDMSOTf (0.5 M) 1.5 eq., 
2,6-lutidine, CH2Cl2, -50°C
4 2"
173  
Scheme 57: Selective silylation of bis(hemiacetal). 
 
Isolation of compound 171 containing a syn-acetonide indicated the position that has been 
silylated. Such selective protection is directed by intramolecular hydrogen bond between the 
hydroxyl moiety at C4 and the intracyclic oxygen atom at C2” to release intermediate 173 
(Scheme 57). Polyols 169 and 171 are typical examples of semi-protected skeletons that can be 
used for the selective introduction of amino groups at internal and/or terminal position of the 
chain. 
Taking advantage of the double protection introduced by hemiketal moieties, protection of the 
central diol of the chain was envisaged (Scheme 58).  
 
154 174
O OOH OH
OPPO
OH OH
 Ac2O/Py (1/1), 
 DMAP, 25°C 
                  
      Quant.
O OOAc OAc
OPPO
OAc OAc
 1. CH3CN wet, 
     BF3.OEt2 (2.2 eq.), 0°C
 2. NaBH4, MeOH, 25°C
 
          38% over 2 steps
OP OH OH OPOAc OAc OHOH
 regioisomers +
175  
Scheme 58: Selective deacetylation of the hemiketal moieties. 
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Bis(hemiacetal) 154 was acetylated under classical conditions. Anomeric acetates of 174 were 
removed using the Lewis base promoted selective deprotection conditions developed by 
Danishefsky.178 The resulting bis(hemiacetals) were reduced with NaBH4 in MeOH at 0°C.  
Unfortunately, a mixture of two inseparable isomers (175) was isolated, probably due to 
acetate migration during the hemiketals reduction.  
 
2.3 Conversion of semi-protected polyols into aminofunctionalised polyketides 
 
Based on these different tools, a small library of semi-protected polyols was synthesized. The 
semi-protected polyol 171 was used for the introduction of three amino groups on the 
polyketide skeleton (Scheme 59).  
 
 
176171
OP OH O OPOTBSO OHOH OH NH2 OH OHOH OH NH2NH2
1. MsCl, NEt3, CH2Cl2, 0°C
2. NaN3, DMF, 60°C
3. Pd(OH)2/C cat., 
    MeOH, H2 (1 atm.)
4. CF3COOH/H2O (4/1)
        27% over 4 steps  
Scheme 59: Aminopolyol with terminal amino groups. 
 
The remaining alcohols were esterified with CH3SO2Cl, and displacement of the resulting 
trimesylate with sodium azide provided a triazide. This intermediate was directly submitted to 
catalytic hydrogenation, using 1 atm. hydrogen and Pd(OH)2 on activated charcoal in MeOH, 
followed by acidic removal of the protecting groups to deliver triaminopentol 176. 
During our study, amino groups were also easily introduced at the terminal positions of linear 
polyols (Scheme 60). For instance, diol 137 was submitted to a sequence of esterification with 
CH3SO2Cl followed by treatment with sodium azide to release an intermediate diazido 
derivative, which was subsequently reduced by catalytic hydrogenation and deprotected under 
acidic conditions to yield diaminohexol 177. We next targeted the introduction of amino 
groups at three internal positions of the polyolic system. For that purpose, the monosilylated 
derivative 169 was acetylated with vinyl acetate in the presence of Candida cylindracea lipase 
(4800 U.mmol–1) to allow the selective transacetylation of the primary alcohols with 
quantitative yield (Scheme 60). 
                                                     
178 Askin, D.; Angst, C; Danishefsky, S. J. Org. Chem. 1987, 52, 622. 
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137 177
OP O O OPO O OHOH OH OH OH OHOH OH NH2NH2
1. MsCl, NEt3, CH2Cl2, 0°C
2. NaN3, DMF, 60°C
3. Pd(OH)2/C cat., 
    MeOH, H2 (1 atm.)
4. CF3COOH/H2O (4/1)
        23% over 4 steps
OH NH2 NH2 OHOH NH2 OHOH
1. MsCl, NEt3, CH2Cl2, 0 °C
2. NaN3, DMF, 60 °C
3. K2CO3, MeOH, 25 °C
4. Pd(OH)2/C cat., MeOH, H2 (1 atm.)
5. CF3COOH/H2O (4/1)
        20% over 5 steps179
169
OP OH OH OPOTBSOH OHOH
178
OP OH OH OPOTBSOH OAcOAc
Candida Cylindracea
(4800u.mmol-1)
Vinyl acetate, 25°C
           Quant.
 
Scheme 60: Synthesis of linear di- and tri-aminopolyols 
 
Derivative 178 was then converted into an intermediate triazide as discussed above. The acetyl 
groups were then methanolysed under classical conditions (K2CO3 in MeOH), without 
intermediate purification, and the azido groups were reduced by catalytic hydrogenation. The 
remaining protective moieties were finally removed by acidic hydrolysis (CF3COOH/H2O). 
This sequence released triaminopentanol 179, with amino groups selectively introduced at 
internal positions of the linear backbone. 
It is noteworthy that the sequence transforming semi-protected polyols into di- and tri-
aminopolyols can be performed without intermediate purification, providing good yields of the 
targeted derivatives. 
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3 Design and synthesis of cyclic aminopolyols 
 
3.1 Synthetic pathway from deoxysugar 154 
 
Linear and flexible skeletons lack the rigidity factor required to mimic aminoglycosides. The 
design of more rigid structures was thus envisaged. Starting from the bis(hemiacetals) 154 
previously isolated, more conformationally restricted aminopolyols were synthesized using 
classical protecting groups manipulations. Indeed compound 180, released by protection of 
both anomeric centers in acidic MeOH and was converted into a diazide intermediate as 
previously exemplified (Scheme 61). The azides were reduced by catalytic hydrogenation 
affording 181. Unfortunately, BOM deprotections using acidic conditions or reductive 
hydrogenation with Raney nickel were unsuccessful. Acetyl groups were thus considered for 
the protection of the alcohols at C4 and C4’. 
 
154
O OOH OH
OPPO
OMe OMe
1. MsCl, NEt3 , CH2Cl2
2. NaN3, DMF, 60°C
3. Pd(OH)2, 
    H2 (1atm.) MeOH
   45% over 3 steps
O ONH2 NH2
OPPO
OMe OMe
O OOH OH
OPPO
OH OH
APTS, MeOH, 25°C
           Quant.
181
180
TFA/H2O
or 
H2, Raney Nickel
X
182
1. 2,2-DMP/Acetone, 
     APTS cat., 25°C  70%
2. Raney nickel, MeOH, 
    H2 (1 atm.)  90%
1. Ac2O/Py., DMAP
2. MeOH, APTS cat.
3. MsCl, NEt3 , CH2Cl2
4. NaN3, DMF, 60°C
5. MeOH, K2CO3   75% over 5 steps
6. Pd(OH)2, MeOH, H2 (1 atm.)  83%
O OO O
OHHO
OMe OMe
O ONH2 NH2
OH
OMe OMe183
4' 4
HO
 
 
Scheme 61: Synthesis of more rigid diaminopolyols. 
 
Catalytic hydrogenation of 155 in the presence of Raney nickel afforded 182 by reduction of 
the benzyloxymethyl ethers (Scheme 61). Acetylation of the resulting diol (Ac2O/pyridine, 
DMAP cat.), followed by acidic removal of the acetonide moiety, allowed introduction of 
azido groups at C2’ and C4’. Methanolysis of the acetates followed by catalytic hydrogenation 
in the presence of Pd(OH)2 on activated charcoal provided diamino bis(methyl pyranosides) 
183. 
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Finally, amino groups were introduced at C4 and C4’ positions using Mitsunobu type 
conditions in the presence of triphenylphosphine, diethyl azodicarboxylate and diphenyl 
phosphoryl azide. Classical mesylation and azoture diplacement using sodium azide was not 
effective on this compound, leading to degradation of the starting material. Final cleavage of 
the acetonide moiety and reduction of the diazide into a diamine provided compound 184 
(Scheme 62). 
 
182
1. PPh3, DEAD, DPPA,
    THF, 0°C to 25°C
2. H2, Pd(OH)2/C, MeOH, 25°C
3. MeOH, APTS, 25°C
           36% over 3 steps
O OOH OH
NH2H2N
OMe OMe184
4' 4
 
Scheme 62: Rigid amino polyol with amino groups on the cyclic skeleton. 
 
Compound 154 was always synthesized as a mixture of four isomers, due to the presence of 
two anomers at each hemiketal moiety, in a 2/1 ratio. In order to isolate a single anomer, this 
derivative was treated with p-toluenesulfonic acid in iso-propanol. Unfortunately no 
isomerisation toward the most stable isomer occurred. Nevertheless, we anticipated that C-
glycosilation of compound 154 may provide useful derivatives for further functionalisations.  
 
3.2 C-glycosilation and further transformation of 154 
 
The procedure of Leighton and co-workers,179 using allyltrimethylsilane and titanium 
dichlorodiisopropanolate as Lewis acid, did not promote the C-glycosilation of the 
peracetylated bis(hemiacetal), derived from 154. Hopefully, when the reaction was performed 
under diluted conditions180 using BF3.OEt2 as Lewis acid and allyltrimethyl silane, the bis-
allyl derivative 187 was isolated as a single isomer in 71% over 2 steps (Scheme 63). 
                                                     
179 Hornberger, K. R.; Hamblett, C. L.; Leighton, J. L. J. Am. Chem. Soc. 2000, 122, 12804-12899. 
180 Kagawa, N.; Ihara, M.; Toyota, M. Org. Lett. 2006, 5, 875-878. 
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185
1. MeOH, K2CO3, 25°C
2. 2,2-DMP/acetone, 
    APTS, 0°C
    77% over 2 steps
O OO O
OPPO
186
1. O3, CH2Cl2, -78°C
2. DMS, -78°C
3. NaBH4, MeOH, 25°C
      68% over 2 steps
O OO O
OPPO
OHOH 187
154
1. Ac2O/Py.(1/1), DMAP, 25°C
2. CH3CN, BF3.OEt2, 4 ÅMS, 0°C
             71% over 2 steps
O OOH OH
OPPO
OH OH
TMS
O OOAc OAc
OPPO
185
4"
2"
4"'
6'"6"
2'"
1. MsCl, NEt3, CH2Cl2, 0°C
2. NaN3, DMF,60°C
3.H2, Pd(OH)2/C, MeOH, 25°C
            70% over 3 steps
O OO O
OPPO
NH2NH2 188
O OOH OH
OHHO
NH2NH2
TFA/H2O, 4/1, 25°C
            31%
189  
Scheme 63: C-glycosilation of the key intermediate 154. 
 
The equatorial arrangement of the substituents at C2”, C4”, C6”, C2’”, C4’”, C6’” positions was 
established by 2D-NOESY experiment. Acetate protecting groups were removed under basic 
conditions. The resulting 1,3-diol was protected as an acetonide (186). Ozonolysis of the 
diolefin followed by reductive treatment first with dimethylsulfide, then with sodium 
borohydride, provided diol 187 in 68% yield (Scheme 63). This intermediate was further 
transformed using the sequence described in section 3.2.3. A new diamino polyol 189 with a 
rigid structure was thus isolated after deprotection of the BOM and acetonide groups. 
 
4 Design and synthesis of DOS dimers 
 
Introduction of deoxystreptamine (DOS) was planned to increase the affinity of the previously 
described aminopolyol fragments. Indeed, DOS (71) is known to be a central RNA recognition 
element and, as it has already been discussed, pharmacophore dimerisation has proven to be an 
efficient way to develop new RNA binders. Moreover, DOS dimers have already been 
described by Hergenrother and co-workers.181 In their work, a facile protocol for the 
                                                     
181 a) Thomas, J. R.; Liu, X.; Hergenrother, P. J. J. Am. Chem. Soc. 2005, 127, 12434-12345. b) Thomas, J. R.; 
Liu, X.; Hergenrother, P. J. J. Am. Chem. Soc. 2004, 126, 9196-9197. 
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dimerisation of deoxystreptamine has been developed by using the copper-catalysed 1,3-
dipolar cycloaddition of alkynes and azides. To study the influence of the polarity and 
flexibility of the linker on the affinity toward RNA, a synthetic method is described in the next 
section allowing the synthesis of a library of DOS dimers through peptide coupling reactions. 
Diamino linkers (192-195, 188) were coupled with a DOS containing carboxylic acid 191. 
 
DOS 71 was synthesized according to the procedure of Georgiadis and co-workers182 through 
acidic degradation of Neomycin (Scheme 64).  
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Scheme 64: Synthesis of DOS dimers. 
 
Amino groups were protected as azides through copper mediated azide transfer. Acetonide 
introduction afforded alcohol 190 as a racemic mixture according to the procedure of Wong 
and co-workers.183 SN2 reaction between corresponding alcoolates and methyl bromoacetate 
allowed the easy introduction of an ester moiety which was then saponified into the desired 
carboxylic acid 191 (which is a racemic mixture). To study the polarity and flexibility 
influence of the linker, five diamines (entry 1 to 5 Erreur ! Source du renvoi introuvable.) were 
involved in peptide coupling reactions with carboxylic acid 191.  
                                                     
182 Georgiadis, M., P.; Constantinou-Kokoyou, V. J. Carb. Chem. 1991, 10, 739. 
183 a) Greenberg, W. A.; Priestley, E. S.; Sears, P. S.; Alper, P. B.; Rosenbohm, C.; Hendrix, M.; Hung, S.-C.; 
Wong, C.-H. J. Am. Chem. Soc. 1999, 121, 6527. b) Titz, A.; Radic, Z.; Schwardt, O.; Ernst, B. Tet. Lett. 2006, 
47, 2383. 
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Table 5: Diamino linkers coupled to 3 and yields of the coupling reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
Method A: 1. PyBOP, NEt3, 2. MeOH/TFA/H2O, 3. MeOH, H2, Pd(OH)2/C. Method B: 1. PyBOP, NEt3, 2. 
AcOH, H2, Pd(OH)2/C, 3. MeOH/TFA/H2O. 
 
Acetonides deprotection using TFA/H2O followed by azides reduction afforded products 196-
200 (Scheme 65). Diamides 196-198 were purified by classical flash chromatography whereas 
products 199 and 200 were obtained after deprotected by hydrogenolysis in acidic medium and 
treatment with TFA/H2O. Indeed, it has been observed that BOM and anti-acetonides were not 
easily cleaved under the classical conditions used for the polyamines linkers. These two 
compounds were purified by semi-preparative HPLC. Starting from racemic 191, a meso and a 
racemic threo mixture was expected after bis coupling reaction, nevertheless, 13C-NMR 
analysis of compounds 196-198 showed a single set of signals, probably because the 
stereogenic centers are distant in the dimers. Compounds 199-200 were described as the most 
abundant diastereoisomer. 
Entry Linker Method Yield over 
3 steps (%) 
1 H2N NH2 192  A 50 
2 H2N NH NH2 193  A 42 
3 H2N NH
H
N NH2 194 A 19 
4 OP O O OPO O NH2NH2 195
 
B 4 
5 O OO O
OPPO
H2N NH2
188
 
B 23 
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Scheme 65: Structures of the isolated DOS dimers 
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5 RNA affinity measurement 
 
Measurement of RNA affinity of these compounds by mass spectrometry methods was first 
experimented on an RNA fragment synthesized in Prof. Pitsch’s laboratories. 
 
5.1 RNA fragment synthesis 
 
The RNA fragment that has been synthesized was the model commonly used of Escherichia 
coli 16S A-site rRNA 201 (Scheme 66).  
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Scheme 66: Escherichia coli 16S A-site rRNA.  
 
Subsequently, all protecting groups required during the assembly procedure were removed and 
the RNA fragment was cleaved from the solid support. This kind of synthesis was routinely 
employed on a DNA synthesizer in Pr. Pitsch’s laboratories. The required fragment was 
synthesized with the help of Dr. Frederic Meylan. The growing oligonucleotide, loaded on a 
solid support resin was washed with solutions of reagent in the following manner:  
• detritylation using 1,1-dichloroacetic acid,  
• coupling reaction between the newly formed alcohol and the 
diisopropylphophoramidite derived building block promoted by BTT (benzylthio-
tetrazole),  
• quenching the unreacted growing chain (capping) to avoid the multiplication of 
growing oligonucleotide chains,  
• oxidation of the trialkylphosphite 205 into phosphonate 206 
A new cycle allowed the addition of the next nucleobase. After the synthesis of the 
oligonucleotide fragment, deprotection steps allowed the nucleotide deacetylation (Scheme 
67), cleavage from the solid support and cyanoethyl deprotection. Finally TBAF mediated tom 
(triisopropyloxymethyl) hydrolysis released the RNA fragment. HPLC purification provided 
the expected RNA fragment stored as a 37 μM stock solution in water. 
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The automated chemical synthesis of oligoribonucleotide was carried out on solid phase by 
stepwise addition of appropriately activated and protected building blocks until obtention of 
the desired sequence (Scheme 67).184  
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Scheme 67: Conditions for the assembly and stepwise deprotection of RNA sequences. 
                                                     
184 Pitsch, S.; Weiss, P. A.; Jenny, L.; Stutz, A.; Wu, X. Helv. Chem. Acta 2002, 84, 3773-3795. 
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5.2 Mass spectrometry 
 
Neomycin, known to be a strong RNA binder, was mixed with a 16S rRNA fragment solution 
as preliminary experiment. The resulting solution was analysed using MALDI-TOF-MS on the 
matrix usually used to detect RNAs (2,4,6-trihydroxy acetophenone/ethanol/diammonium 
hydrogen citrate). Only the RNA fragment mass was observed. The complex substrate/RNA 
was not detected probably because the MALDI-MS conditions were not suitable to study such 
a kind of electrostatic association. Actually, ESI-MS is reported to be a method of choice to 
study RNA complexation by small molecules. Unfortunately it was not possible to reproduce 
the conditions developed by Griffrey, Hofstadler and co-workers reported on a FT-ICR-MS.185 
Several tests were performed using ESI-MS apparatus. Under classical conditions (phosphate 
buffer or water) neither RNA, nor RNA/substrate complex were detected. The use of more 
basic conditions (6 M urea buffer, pH 11)186 allowed detection of the RNA fragment but not of 
the RNA/neomycin complex. This is probably, because under these basic conditions no 
ammonium group subsists on aminoglycosides thus reducing their affinity for the negatively 
charged RNA fragment. Another explanation would be that the ESI-MS apparatus was neither 
equipped with an ion trap nor with an infusion syringe. Another method was envisioned to 
measure binding affinities of the synthesized molecules. 
 
5.3 Microarray method 
 
It was decided to microarray the compounds that must be tested and to apply the conditions 
developed by Seeberger and co-workers.187 This analysis was performed by Tim Horlacher 
(ETH, Zürich, Seeberger group). Compounds 196-198 and 177, 183 were arrayed with a 
robotic arrayer onto an amino-coated glass slide treated with tetraethyleneglycol 
disuccinimidyl dissuccinate. For each immobilization, the arrayer delivered 2 nL of 10 mM 
compound solutions to defined positions on the surface. Slides were incubated with 500 
pmoles of fluorescently labeled oligonucleotide mimic of the bacterial 16S rRNA A-site 310 
and of the human oligonucleotide 18S 211 (Scheme 68). Unbound oligonucleotides were 
washed from the slides before fluorescence measurement. All experiments were conducted in 
triplicates. 
                                                     
185 a) Griffey, R. H.; Greig, M.; An, H.; Sasmor, H.; Manalili, S. J. Am. Chem. Soc. 1999, 121, 474-475. b) 
Griffey, R. H.; Hofstadler, S. A. Curr. Opin. Drug Discovery Dev. 2000, 3, 423-431. c) Griffey, R. H.; 
Hofstadler, S. A.; Sannes-Lowery, K. A.; Crooke, S. T.; Ecker, D. J.; Sasmor, H.; Manalili, S. Anal. Chem. 1999, 
71, 3436-3440. 
186 Pieles, U.; Zürcher, W.; Moser, H. Nucleic Acids Res. 1993, 21, 3191-3196. 
187 Disney, M. D.; Seeberger, P. H. J. Am. Chem. Soc. 2004, 10, 3308-3314. 
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Scheme 68: Fluorescently labeled oligonucleotide mimic of bacterial 16S RNA and human 
18S. 
 
Aminopolyols 177 and 183 were first tested for their RNA affinity, Figure 11 summarises the 
fluorescence intensity measured. Interestingly, compound 177 showed higher affinity for 16S 
RNA than Neomycin (two fold higher) which is known for its capacity to bind tightly RNA 
fragments. This result was quite surprising since no fluorescence was detected for the more 
rigid diamine 183. But this point can be explained by a poor affinity of the compound for the 
glass slide surface given the high steric hindrance around amine moieties. However the linear 
diaminopolyol 177 had nearly 7 times more affinity for RNA than spermidine proving that this 
compound without being highly negatively charged had polyamines can bind RNA. Moreover, 
results from microarray on 18S RNA indicated that aminopolyols displayed a lack of 
selectivity for RNA binding. Indeed, 177 bound 16S RNA and 18S RNA as well. This result 
was not a surprise as linear structures cannot induce selective RNA binding by lack of rigid 
recognition elements. These data suggest that the synthesis of aminofunctionalised polyketides 
open door to a new class of RNA binders. Nevertheless, further studies are necessary to 
improve selectivity toward bacterial RNA.  
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Figure 11: Binding evaluation of 177 and 183. 
 
In Figure 12, results from microarray RNA binding evaluation of DOS dimers are 
summarised. It clearly appeared by comparison of DOS fluorescence signal with the signal 
measured for each compound that dimerisation increased the binding affinity for RNA even if 
modest affinity were measured in comparison to Neomycin for example. Compounds 196-198 
had different behaviour concerning their binding selectivity. Diamide 197 bound strongly to 
16S RNA (four times more than DOS) and no fluorescence signal was measured on 18S 
whereas diamide 198 seemed to bind equally well 16S and 18S RNAs. This indicated that 
optimal conditions can be found by variation of chain length and polarity of the linker to 
obtain strong and selective RNA binder.  
 
 
 
 
 
 
 
 
Figure 12: Binding evaluation of compounds 196-198. 
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In vivo activity testing was also performed on E. coli. Products were incubated in bacteria 
cultures on agar and were checked for bacteria growth inhibition by visual observation of 
bacteria cultures. None of DOS dimers and aminopolyols was active in vivo, probably due to 
inefficient uptake by the bacteria. Additional binding measurement using another method 
could also be performed to confirm the trends revealed using microarray methods. This study 
was a preliminary work to discover new ways to synthesise and study aminoglycoside mimics 
based on polyol methodology, for that reason, no time consuming investigations were 
performed on methods such as SPR or NMR. Indeed, these methods require beside special 
instruments, specially labelled and customised RNA fragment that are not easily accessible. 
However, this study proved that dimerisation of DOS using flexible and polar linkers 
increased the affinity of DOS for RNA. Moreover diaminopolyol 195 or analogues seemed to 
be good candidates as linkers for the dimerisation of DOS as they induced strong RNA 
binding, their unselectivity toward RNA fragments could be overcome by introduction of DOS 
moieties. 
 
New efficient synthetic routes toward functionalised polyketides. 
   
88
6 Design of dynamic combinatorial libraries to identify new RNA binders 
 
The rapid identification of potent RNA binders by dynamic combinatorial library was 
investigated. As described in Chapter I, DCLs have been implemented in a variety of chemical 
systems and applied to different targets. 
When a set of building blocks is allowed to combine through reversible bond formation, a 
library under thermodynamic control is created. Upon addition of a receptor, the receptor 
binds the tightest-binding library members, removing them from solution and acting as a trap 
for given ligands. The equilibrium shifts to increase the amount of these tightest binding 
library members according to the Le Chatelier’s principle. In adaptative DCL, generation of 
constituents of the library is carried out in the presence of the target, resulting in amplification 
of the best bound species so that screening and synthesis take place simultaneously in the same 
experiment.188 Earlier studies showed that reversible exchange of imines formed from 
aldehyde and amine building blocks can be influenced by biological targets promoting 
increased formation of strongly binding imines. Due to their relative thermodynamic 
instability in the presence of water, libraries based on imine exchange tended to give poor 
yield of adducts that are unstable toward analysis by chromatography methods using water. 
However, on addition of a thermodynamic sink, i.e. NaBH3CN, a selective reducing agent for 
imines,189 the scaffold components will be removed from solution, rearrangement will occur to 
produce more of the best binders and larger quantities of library members. On re-equilibration, 
the most active constituents will therefore experience a certain degree of amplification, in 
comparison with the situation in which no template molecule is added. A direct correlation of 
the most amplified members with the best binders is encountered when their concentration is 
kept low compared to the total concentration of the building blocks.190 Imines have been 
successfully used as active members of DCL in aqueous medium because they are present in 
only very small amounts compared to the starting building blocks191 and the equilibrating 
mixture of components can be conveniently turned off for composition analysis by a simple 
reductive step. 
                                                     
188 a) Ramström, O.; Lehn, J.-M. Nature 2002, 1, 26-36. b) Cheeseman, J. D.; Corbett, A.; Gleason, J. L.; 
Kazlauskas, R. J. Chem. Eur. J. 2005, 11, 1708-1716. 
189 Borch, R. F.; Bernstein, M. D.; Dupont Durst, H. J. Am. Chem. Soc. 1971, 93, 2897-2904. 
190 a) Grote, Z.; Scopelliti, R.; Severin, K. Angew. Chem. 2003, 42, 3821. b) Corbett, P. T.; Otto, S.; Sanders, J. 
K. M. Chem. Eur. J. 2004, 10, 3931. c) Corbett, P. T.; Otto, S.; Sanders, J. K. M. J. Am. Chem. Soc. 2005, 127, 
9390. d) Zameo, S.; Vauzeilles, B.; Beau, J.-M. Angew. Chem. 2005, 117, 965. e) Huc, L.; Lehn, J.-M. Proc. 
Natl. Acad. Sci. USA 1997, 94, 2106. 
191 a) Cordes, E. H.; Jenks, W. P. J. Am. Chem. Soc. 1963, 85, 2843. b) Hine, J.; Via, F. A. J. Am. Chem. Soc. 
1972, 94, 190. c) Godoy-Alcantar, C.; Yatsimirsky, A. K.; Lehn, J.-M. J. Phys. Org. Chem. 2005, 18, 979. 
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The aim of this work was to prove that RNA affinity for positively charged molecules is 
sufficient to discriminate good to poor RNA ligands among a library of interconverting 
imines. In the following section 16S A-site (201), RNA was used as the DCL target. The 
libraries’ composition was analysed by LC-MS. Indeed, as RNA fragments are accessible in 
tiny amounts, the target was introcuced in catalytic amount. When the target concentration is 
restricted under standard conditions,192 calculations shown that the best binders will go 
undetected because their concentration will remain far below the detection limits. The only 
solution would be to have a large excess of the starting building blocks with respect to the 
target in order to increase the concentration of the imine binders. Such conditions have already 
been used by Beau and co-workers,193 Eliseev and co-workers194 and Lehn and co-workers195 
in the presence of enzymes as templates. A DOS containing aldehyde and several amines were 
chosen to build the libraries. Up today, the use of RNA fragments in DCLs has never been 
reported in literature. 
 
6.1 Choice of building blocks 
 
Preliminary tests using simple aldehydes and amines were performed to determine conditions 
to generate dynamic libraries in the presence of RNA molecules. It appeared from these first 
results that analysis of libraries containing polyamines and polyols required a reverse-reverse 
phase HPLC column. Such kind of column is specially designed for highly polar compounds. 
Moreover, a mass detection method in addition to the UV classical detection was found 
necessary for product identification. Nevertheless this type of tool did not prevent the separate 
synthesis of some of the potential library’s members to confirm their retention time in the 
chromatogram by co-injection when the product was badly detected by mass spectrometry. 
Finally aromatic moiety in the resulting members of the library allowed UV detection and the 
relative quantification of compounds by comparison of the chromatogram in presence and in 
absence of RNA target. The design of such a library required the choice of amines, the 
synthesis of an aldehyde and the synthesis of the members of the library. 
                                                     
192 a) Huc, L.; Lehn, J.-M. Proc. Natl. Acad. Sci. USA 1997, 94, 2106. b) Zameo, S.; Vauzeilles, B.; Beau, J.-M. 
Angew. Chem. 2005, 117, 965. 
193 a) Valade, A.; Urban, D.; Beau, J.-M. ChemBioChem 2006, 117, 1023-1027. b) Valade, A. Sélection de 
ligands de galactosyltransférases par chimie combinatoire dynamique, Thèse de doctorat, Université Paris XI-
Orsay, 2004. 
194 Hochgürtel, M.; Biessinger, R.; Kroth, H; Piecha, D.; Hofmann, M. W.; Krause, S.; Schaff, O.; Nicolau, C.; 
Eliseev, A. V. J. Med. Chem. 2003, 46, 356-358. 
195 Ramström, O.; Lehn, J.-M. ChemBioChem 2000, 1, 41-48. 
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6.1.1 Aldehyde 
 
The aldehyde containing partner of the library was chosen so that it contained both an 
aromatic and a DOS moieties to allow UV-detection of the newly formed amines and 
amplification phenomenon since DOS is a RNA recognition element.  
The synthetic route to the aldehyde partner was carefully designed to allow the isolation of a 
molecule containing an aldehyde moiety and amino groups such as 215 (Scheme 69). From 
preliminary results, it appeared that the expected aromatic aldehyde was reduced under azides 
reduction conditions (Pd(OH)2 under 1 atm.). Purification of the deprotected compound on 
silica gel chromatography was not possible unless using NH4OH/H2O/CH3CN eluent which 
was detrimental for the aldehyde. Considering these points, the following synthesis was 
developed. Aromatic dimethyl acetal 213 was coupled with alcohol 190 trough SN2 type 
reaction. Reduction of the azides followed by deprotection of the dimethyl acetal and 
acetonides released the aldehyde 215 as a racemic mixture purified by direct introduction of 
the crude oil on a semi-preparative HPLC column. 
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Scheme 69: Synthesis of the aldehyde. 
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6.1.2 Amines  
 
The amines that were chosen for the generation of the libraries contained hydroxyl and amino 
groups to enhance the natural affinity of DOS for RNA through electrostatic interactions 
(Scheme 70). 
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Scheme 70: Amines introduced in DCL. 
Amine 220 was synthesized starting from proline derivative 222 by protection of the alcohol 
as a silyl ether, reduction of the ester and conversion of the resulting alcohol into an amino 
group (azide mediated displacement of a methanesulfonyl ester and reduction of the azide). 
Amine 221 was provided by Dr Hélène Fiaux.196 
 
6.2 Synthesis of reference compounds 
 
Reference compounds for HPLC detection were synthesized by SN2 type coupling of aromatic 
halide 225 with racemic alcohol 190 followed by silyl ether deprotection (Scheme 71).  
                                                     
196 Hélène Fiaux, EPFL thesis n°3793. 
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Scheme 71: Synthesis of reference compounds. 
 
The resulting alcohol was oxidised under Swern’s conditions to provide an intermediate 
aldehyde that was submitted to reductive amination with each of the mentioned amines 216-
221. Deprotection and azide reduction afforded a small panel of racemic DOS derivatives that 
served as references in the following LC-MS experiments. 
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Table 6: Structure of reference compounds. 
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6.3 Results 
 
6.3.1 Principle and method 
 
To demonstrate that it was possible to detect the amplification of a member of a DCL induced 
by a catalytic amount of RNA, the following experiments were designed and analysed by LC-
MS. All the experiments were performed in the conditions described above. Aldehyde 215 and 
three equivalents of each amine were mixed in a 20 mM phosphate buffer so that the final 
aldehyde concentration was 1 mM. 14 Eq. of NaBH3CN were added according to the 
conditions developed through literature and the resulting mixture was equilibrated for 21 days 
at 25°C.  
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Figure 13: Principle of DCL with RNA. 
 
In a first experiment, two amines (192 and 217) and the aldehyde 215 were mixed and 
equilibrated. In a second experiment, the same amines and aldehyde were mixed together with 
a catalytic amount of RNA (0.03 eq.). These two experiments allowed the evaluation and 
relative quantification of the RNA effect on the mixture. Finally, amines 192 and 217 and 
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aldehyde 215 and catalytic quantities of RNA were equilibrated in presence of 1 eq. of 
Neomycin with respect to the aldehyde. We reasoned that if an imine combination was 
favoured among the interconverting imines of the library, then, introduction of a good RNA 
binder such as Neomycin will block the process of imine amplification and no difference will 
be observed in comparison to a DCL without RNA (Figure 13). This third experiment 
constituted a positive test, to determine whether the changes in the library composition are 
related to RNA binding or not. The three mixtures were analysed by LC-MS using a reverse-
reverse phase column. Mass detection of the two adducts 229 and 235 formed in the library 
was possible but no detection of dimer structure was possible, probably because the aldehyde 
was in default in the mixture.197 The compositions of the mixtures are summarised in Figure 
14. 
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Figure 14: Composition of library produced in the DCL experiments with 215, 192 and 217. 
 
These results confirmed that in presence of RNA, the composition of the mixture after 
equilibration was modified due to interaction with RNA. Indeed, the reference library’s 
composition is identical to that of the positive test in which RNA is bounded to Neomycin 
preventing interactions with imines from the library. Evaluation of products amplification 
factors is presented in Figure 14, showing that product 235 is four times more amplified than 
229.  
                                                     
197 Valade, A.; Urban, D.; Beau, J.-M. ChemBioChem 2006, 117, 1023-1027. 
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As illustrated in Figure 13, the amplification of amines resulted from interactions between 
RNA fragment and imines. These interactions can be summarized as the following succession 
of reactions: 
[RCHO] + [R'NH2] [RNA] + [Imine] [RNA.Imine] [Amine]
Reduction
 
 
In several DCL reported thus far in literature the biological target, which are enzymes, uses 
stoichiometric amount of the target. In our case, RNA was introduced in catalytic amount. 
Adaptation of the reasoning adopted by Beau and Valade on galactosyltransferase inhibitors198 
discovery using DCL, a verification of the impact of RNA low concentration on the system 
was checked. Considering literature data on equilibrium constants of imine formation in water, 
the percentage of imines in solution would be of 0.001%. In our case, knowing the 
concentration of aldehyde (1 mM), the concentration of imines would amount 10 nM. As the 
concentration of RNA was 30 μM, it is possible to deduce the concentration of the complex 
RNA-Imine from the dissociation constant of DOS derivatives reported through literature Kd = 
300mM (for good ligands)199 with the formula: 
 
Kd =
[RNA].[Imine]
[RNA.Imine]  
 
The concentration of the complex RNA.Imine can be evaluated to roughly 1 nM. Taking into 
account the volume of injection in LC-MS (20 μL), the quantity of amplified amine would be 
of 0.02 picomoles. The detection limit of compound 229 was determined at 9 μM which 
represent 180 pmoles. Amine amplification would be undetectable since the detection limite is 
9000 times higher than the quantity of amplified imine. But intermediary injections of the 
libraries showed that the amplified amine was accumulating continuously. Concentration of 
229 after 21 days was evaluated to be 347.6 μM, which was 10 times higher than RNA 
concentration. One plausible explanation is that the amine is badly recognized by RNA. After 
imine reduction, the resulting amine does not interact with RNA anymore, which induces a 
displacement of the equilibrium and amine accumulation. 
                                                     
198 Valade, A.; Urban, D.; Beau, J.-M. ChemBioChem 2006, 117, 1023-1027. 
199 Ding, Y.; Hofstadler, S. A.; Swayze, E. E.; Griffrey, R. H. Chem. Lett. 2003, 32, 908-909. 
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These first experiments established that it is possible to use RNA fragments as templates in a 
DCL experiment. Identification and quantification of the members of the library was 
measurable by LC-MS and amplification of one member has been observed and attributed to 
catalytic activity of RNA. 
 
6.3.2 Toward a generalisation  
 
Two other libraries containing amines 217 and 219, in the presence or in the absence of RNA, 
were designed under the same conditions as previously mentioned. Compounds 229 and 231 
were detected by LC-MS. Results are summarized in Figure 15. 
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Figure 15: Composition of library produced in the DCL experiments with 215, 217 and 219. 
 
In that case, the amplification of compound 231 (58%) was concomitant with the diminution 
of 229 (27%).  
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Finally a 3 amines library with 216, 220 and spermidine 236 was designed under similar 
conditions. Detection of compounds 237 or 238 was not possible in the reference library. 
However, in the presence of RNA, small quantities of 237 were detected by mass spectrometry 
but UV quantification of this compound remained difficult on the chromatogram. Results are 
summarized in Figure 16. 
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Figure 16: Composition of library produced in the DCL experiments with 215, 216, 220 and 
236. 
 
In conclusion, these prospective experiments have shown that RNA can be efficiently used in 
dynamic combinatorial libraries with a DOS containing aldehyde partner and amines leading 
to rapid identification of new RNA ligands. It should be emphasised that the key result of any 
DCL experiment is the information about the most effective structural combinations of 
building blocks. Because selection is induced on imines, rather than amines, various structural 
analogues of the imines, such as amides, can be synthesized and tested as stable ligands. 
Indeed, after reduction, the isolated molecule (amine) is no longer the binder selected by the 
template. Vogel’s group has reported that imines can model the inhibitory activities of the 
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corresponding amines,200 Rayner and co-workers201 reported the same properties for 
oligonucleotide complexes. Nevertheless, one cannot generally expect that the binding 
behavior of the isolated amine is necessarily correlated to the corresponding behaviour of the 
imine that was selected. For instance Beau and co-workers reported a higher affinity for amide 
derivatives of their lead compound than the parent amine.202 The reduced products have 
different structural and electronic properties and thus their interaction with the receptor may be 
worse, or better, than the parent imine from which there are derived. 
Moreover, one cannot exclude the hypothesis that the observed phenomenon of amplification 
could be related to a catalytic effect of RNA. Actually, RNA could have the ability to catalyse 
the imine formation more efficiently for some amine than for others. In this case the role of 
RNA would be to bring the aldehyde and the amine that has the higher affinity for RNA 
together and the amplification factor would correspond to the degree of preference of RNA for 
amines. In this hypothesis, the resulting imine could be an excellent RNA binder or not. 
Considering their instability in water, direct analysis of imines has not been performed till 
now. The only method available to prove that electrostatic interactions are the source of the 
observed amplification is to separately test compounds 231, 232, 235 and 237 for their RNA 
affinity using one of the methods described in Chapter I. These measurements will be 
performed in order to validate the use of DCLs for the discovery of new RNA binders.  
Nevertheless, the structural characteristics of amplified compounds 231, 232, 235 and 237 
shown that introduction of amino and hydroxyl functionalised moieties on a DOS motif 
allowed to increase RNA affinity. Further developments of this promising approach will be 
carried out, in particular the search for imine formation catalysts that are compatible with 
RNA structures. 
 
                                                     
200 Gerber-Lemaire, S.; Popowycz, F.; Rodriguez-Garcia, E.; Asenjo, A. T. C.; Robina, I.; Vogel, P. 
ChemBioChem 2002, 3, 466-472. 
201 Bugaut, A.; Toulme, J. J.; Rayner, B. Angew. Chem. 2004, 43, 3144-3146. 
202 Valade, A.; Urban, D.; Beau, J.-M. ChemBioChem 2006, 117, 1023-1027. 
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7 Conclusion and perspectives 
 
The methodology previously developed in Vogel’s group for the synthesis of linear 1,3-
polyols allowed the preparation of complex linear and non-linear amino functionalised polyols 
requiring few purification steps. A new bis(hemiacetal) intermediate was isolated and used, 
with other developed methods, as a powerful tool for the selective introduction of protecting 
moieties on the polyol chain. Introduction of deoxystreptamine moiety on polyamines and 
linear and non linear aminopolyols was enabled through peptide coupling reaction to afford 
highly functionalised polar molecules. These derivatives were tested for their RNA binding 
properties in collaboration with Tim Horlacher from Pr. Seeberger group using microarray 
technique. This method allowed us to confirm that DOS dimer shows enhanced affinity for 
RNA. A more straightforward method for RNA affinity measurement in solution, like mass 
spectrometry, would be a better solution to screen a larger variety of compound.  
 
Finally dynamic combinatorial library assisted identification of RNA binders was developed 
on simple examples proving that RNA can be introduced as target in DCL. Rapid and efficient 
identification of amplified members among an interconverting imine library was possible 
using LC-MS method. Validation of the method by testing the amplified compound for their 
RNA affinity is the next step of the study. A generalisation of the method using larger number 
of amines in the library has to be performed in the future. More studies on the mechanism of 
RNA interaction with the library members should be performed to confirm that amplification 
is directly related to electrostatic charge complementarity with RNA. Structural optimisation 
of the lead compounds identified by this method will provide new powerful RNA binders. 
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CHAPTER IV SYNTHESIS OF MACROLIDE-LIKE DERIVATIVES 
 
1 Polyketides natural products 
 
The term 'polyketide' (PK) is used to describe natural products assembled from units of small 
carboxylic acids such as acetate and propionate.203 Compared with other classes of natural 
products such as isoprenoids, alkaloids, and shikimate-derived compounds, PKs have been 
intensively studied for several aspects of biology and chemistry. This is largely due to their 
vast diversity of chemical structures, their range of biological activities that impacts human 
health,204 and the mystery surrounding their presence in the biological systems that produce 
them.205 Between 5000 and 10000 polyketides are known and about 1% of them possess 
therapeutic biological activities, which is five times as many as the average in natural 
products.206 Pharmaceutically important polyketide drugs include antibiotics, cancer 
chemotherapeutics, cholesterol lowering agents and antifungals. 
From a chemical perspective, the most striking characteristic of the PK family is their 
structural diversity. The range of structures includes macrolides, macrocycles, aliphatic and 
cyclic compounds, as well as simple or complex polycyclic aromatic compounds. The 
structural diversity is further heightened by the existence of hybrids composed of PKs 
condensed with amino acids or peptides, which adds further to the range of pharmacological 
and toxicological activities.207 PKs have been isolated from various sources including bacteria, 
fungi and, to a lesser extent, plants.  
PKs are often described as secondary metabolites. The term "secondary metabolite" refers to 
compounds whose utility to the producing organism is unknown, since they do not appear to 
provide a function that is required for growth. This is unlike primary metabolites such as 
sugars, peptides, proteins, fatty acids, and sterols, which are essential for growth and survival 
of the producing organism. The evolution of secondary metabolism is a matter of great 
biological interest as microbes devote significant energy and resources to the biogenesis of 
products that often appear to have no obvious role for the organism's survival. 
Polyketides can be classified into smaller subgroups: fatty acids, polypropionates and aromatic 
polyketides.208 Polypropionates are furthermore divided in three groups: polyether antibiotics, 
                                                     
203 Birch, A. J. Science 1967, 156, 407-411. 
204 Simpson, T. J. Chem. Indust. 1995, 407-411. 
205 Vining, L. C. Gene 1992, 115, 135-140. 
206 Rohr, J. Angew. Chem. 2000, 39, 407-411. 
207 a) Du, L.; Shen, B. Curr. Opin. Dnig Discov. Devel. 2001, 4, 215-228. b) Du. L., Sanchez, C.; Shen, B. Metab. 
Eng. 2001, 3, 78-85. 
208 Koskinen, A. Asymmetric Synthesis of Natural Products 1993, John Wiley & Sons Ltd., Chichester. 
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macrolides and spiroketals. Lonomycin C, Erythromycin A and Spongistatin A are 
representative compounds of each group respectively (Scheme 72).  
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Scheme 72: Representative structures of polypropionates and their three subgroups. 
 
Macrolide antibiotics are a relatively large group of polyketides all characterized by the 
macrocyclic lactone core incorporated in the structure.209 Within the macrolides, one can 
distinguish four main types of structures: the polyoxo, polyene, ionophore and ansamycin 
macrolides. Pikromycin, Nystatin A1, Nonactin and Rifamycin S are representative derivatives 
of each group respectively (Scheme 73). 
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Scheme 73: Representative structures of macrolides and their four subgroups. 
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There are several structural features which are universal among all polyketides: they usually 
contain a mixture of 1,2- (246), 1,3-diols (247) in addition to polypropionate subunits (248) 
(Scheme 74).  
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Scheme 74: Structural features of polypropionates. 
 
2 Macrolides and the macrocyclic structures 
 
Macrolides commonly contain medium to large ring systems.210 These are more frequently 
encountered in natural than in artificial drugs. Indeed, macrocycles constitute a significant part 
of natural product(-derived) drugs. Naturally occurring macrocycles often have very complex 
structures and remarkably high activities (Scheme 75). The variety in ring sizes and chemical 
constitution is overwhelming. Indeed, natural macrocyclic lactones present a large spectrum of 
interesting properties from perfumery, to phytotoxicity, to pheromone or insecticide activity, 
to medicinal (antibiotic, cytotoxic, antiangiogenesis) properties and a wide range of structures 
from 8-membered ones such as octalactins211 to the 60-membered quinolidomicins.212 From 
their first isolation in the 1950s, macrolide antibiotics, such as erythromycin,213 were widely 
used to treat bacterial infections, and because of their safety and efficacy, they are still the 
preferred therapeutic agents for treatment of respiratory infections. Some polyene 
macrolactones, such as tacrolimus or FK-506214 (immunosuppressive), are currently used as an 
alternative to cyclosporine in the cases of rejection refractory to cyclosporine following organ 
transplantation.215 Actin-binding marine macrocyclic lactones (for example mycalolide) are 
also a large class of natural products possessing potent antitumor activities.216 Amphotericin 
B, isolated from Streptomyces nodosus, is used against systemic fungal infections, and its 
mode of action involves binding with the cell membrane sterols, especially ergosterol.217 
Leucascandrolide A displayed significant in vitro cytotoxicity, as well as significant antifungal 
                                                     
210 Lee, M.-L.; Schneider, G. J. Comb. Chem. 2001, 3, 284-289. 
211 Tapiolas, D. M.; Roman, M.; Fenical, W.; Stout, T. J.; Clardy, J. J. Am. Chem. Soc. 1991, 113, 4682-4686. 
212 Hayakawa;Y.; Matsuoka, M.; Shin-ya, K.; Seto, H. J. Antibio. 1993, 46, 1557-1562. 
213 Henninger, T. C. Expert Opin. Ther. Pat. 2003, 13, 787-794. 
214 Alak, A. M. Ther Drug Monit 1997, 19, 338-351. 
215 Woodle, S. E.; Thistlethwaite, J.R.; Gordon, J. H. Transplantation 1996, 62, 594-599. 
216 a) Yeung, K. S.; Paterson, I. Angew. Chem., Int. Ed. Engl. 2002, 41, 4632-4637. b) Norcross, R. D.; Paterson, 
I. Chem. Rev. 1995, 95, 2041-2045. 
217 Terrell, C. L.;Hughes, C. E. Mayo Clin Proc. 1992, 67,69-91. 
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properties.218 Finally, the bryostatins are a family of potent antitumor agents,219 displaying a 
diverse range of biological effects in vitro and in vivo, including stimulation of T-cells and the 
immune system,220 stimulation of the hematopoietic system221 and activation of protein kinase 
C.222 
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Scheme 75: Macrocyclic natural products. 
                                                     
218 D’Ambrosio, M.; Guerriero, A.; Debitus, C.; Pietra, F. Helv. Chim. Acta 1996, 79, 51-60. 
219 a) Kraft, A. S. J. Natl. Cancer Inst. 1993, 85, 1790-1792. b) Pettit, G. R. J. Nat. Prod. 1996, 59, 812-821. c) 
Stone, R. M. Leukemia Res. 1997, 21, 399-401. 
220 a) Trenn, G.; Pettit, G. R.; Takayama, H.; Hu-Li, J.; Sitkovsky, M. V. J. Immunol. 1988, 140, 433-439. b) 
Tuttle, T. M.; Inge, T. H.; Bethke, K. P.; McCrady, C. W.; Pettit, G. R.; Bear, H. D. Cancer Res. 1992, 52, 548-
553. d) Mohr, H.; Pettit, G. R.; Plessing-Menze, A. Immunobiology 1987, 175, 420. e) Drexler, H. G.; Gignac, S. 
M.; Pettit, G. R.; Hoffbrand, A. V. Eur. J. Immunol. 1990, 20, 119-127. 
221 a) Tallant, E. A.; Smith, J. B.; Wallace, R. W. Biochim. Biophys. Acta 1987, 929, 40-46. b) May, W. S.; 
Sharkis, S. J.; Esa, A. H.; Gebbia, V.; Kraft, A. S.; Pettit, G. R.; Sensenbrenner, L. L. Proc. Natl. Acad. Sci. 
U.S.A. 1987, 84, 8483-8487. e) Sharkis, S. J.; Jones, R. J.; Bellis, M. L.; Demetri, G. D.; Griffin, J. D.; Civin, C.; 
May, W. S. Blood 1990, 76, 716-720. 
222 a) Smith, J. B.; Smith, L.; Pettit, G. R. Biochem. Biophys. Res. Commun. 1985, 132, 939-945. b) Berkow, R. 
L.; Kraft, A. S. Biochem. Biophys. Res. Commun. 1985, 131, 1109-1116. c) DeVries, D. J.; Herald, C. L.; Pettit, 
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The relatively high occurrence of macrocycles in nature may be rationalised by the fact that they 
constitute an equilibrium or compromise between conformational preorganisation (i.e. less entropy loss 
upon binding to their target) and flexibility to achieve optimal binding properties to their biological 
targets, which also explains their often unrivaled activities. 
 
3 Macrocyclic structures in glycolipids derivatives 
 
Macrocyclic glycolipids with antibiotic and cytotoxic activities are also important members of 
this family. 
Resin glycosides, in general, are conjugates between complex oligosaccharide entities and 
(11S)-hydroxyhexadecanoic acid (“jalapinolic acid”) as the common aglycon in virtually all 
members of this series.223 The latter is frequently tied back to form a characteristic 
macrolactone ring spanning two or more sugar units of the backbone. Further carboxylic acids 
may complement the peripheral acylation pattern. Until recently, the structural complexity of 
these mixtures seriously hampered the isolation of their individual constituents. Despite the 
considerable advances in carbohydrate chemistry achieved in recent years, the total synthesis 
of bioactive glycoconjugates is still far from routine. 
Tricolorin A and G (Scheme 76) are prototype members of this sort of amphiphilic 
glycoconjugates224. They have been isolated as the allelochemical principles of Ipomoea 
tricolor Cav., a plant used in traditional agriculture in Mexico as a cover crop to protect sugar 
cane against invasive weeds. This compound also displays general cytotoxicity against several 
cancer cell lines (ED50 ≈ 2.2 µg·mL-1 against human breast cancer) and is able to antagonize 
phorbol ester binding to protein kinase C (PKC, IC50 ≈ 43 µM).225 Woodrosin I is an ether 
insoluble resin glycoside isolated from the stems of Ipomoea Toberosa, which seems highly 
promising in view of the existing data on the use of glycolipids in general for the treatment of 
severe immune disorders.226 
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Scheme 76: Glycolipids derivatives. 
 
Sophorolipids (SLs) are a group of microbial glycolipids produced by yeasts, such as Candida 
bombicola, Yarrowia lipolytica, Candida apicola, and Candida bogoriensis.227 Sophorolipids 
occur as mixtures of macrolactones that are acetylated to various extents at the primary 
hydroxyl position of the sophorose ring.228 Chemoenzymatic transformations allowed the 
isolation of pure compounds from the natural mixture. This resulted in a family of new SL 
analogs that extends and diversifies the structural features present in the natural compounds.229 
It was shown that the natural SL mixture, selected pure congeners, and/or SL derivatives have 
antibacterial and antifungal activity,230 function as immunomodulators for the treatment of 
septic shock,231 display anticancer activity232 and possess anti-HIV virucidal activities.233 
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4 Importance and synthesis of macrolides 
 
Natural products, predominantly secondary metabolites, play a key role in modern drug 
development. Their high success rate was confirmed by recent reports indicating that natural 
products, together with their derivatives, mimics, and other compounds derived or inspired by 
them, represent approximately 35–40% of all current trade drugs.234 The proportion of these 
compounds in screening efforts, however, constitutes less than 1%. In some areas, such as 
antibiotic and anticancer agent research, up to 75% of all drugs are natural products-derived. 
One obvious reason for this success is the million years of adaptation and natural selection of 
these products within the biological world, i.e. our current natural products inherited an 
evolutionary advantage. Moreover, the premise that natural products are generally polar with 
an intrinsic low bioavailability profile may be unfounded. Lee and Schneider estimated that 
known natural products follow Lipinski’s “rule of five”235 for bioavailability equally well as 
current trade drugs do.236 This is hardly surprising considering that these compounds are 
required to exert a certain biological effect in nature (which will, however, not necessarily be 
the same as that on the pharmacological target) and must be able to reach a specific site of 
action. Accordingly, natural products have been suggested to be excellent starting points for 
library construction in drug development.237 Many approaches led to the discovery of active 
compounds.238 Moreover, many synthetic pathways have been developed for the synthesis of 
natural products and analogues. They have been extensively reviewed239 over the past.  
The aim of this work is not to produce a specific naturally occuring target but to prove that the 
polyol synthetic route previously developed can be the starting point toward a diversity of 
structurally related natural compounds. For this reason classical synthetic routes toward 
natural products are not described. 
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5 Targeted structures 
 
The synthetic pathway starting from 2,2’-methylenedifuran and 1,1,3,3-tetrachloroacetone to 
15-carbon long chain polyols240 has already been applied for the total synthesis of fragments 
or precursor fragments of biologically relevant compounds such as RK-397241 and Spongitatin 
1.242 
In the present study, we envisioned to apply this methodology to the synthesis of a variety of 
macrocyclic structures such as polyhydroxylated macrocycles, deoxysugar containing 
macrocycles as glycolipids mimetics and cyclic polypropionates. Our strategy relied on the 
construction of the polyketide backbone followed by ring closure using either a 
macrolactonisation process or ring closing metathesis (RCM).243 These two reactions are the 
most frequently used for the production of large functionalised rings ranging from 14 to 25 
membered structures.244  
 
6 Synthetic studies toward polypropionates 
 
In order to extend the molecular diversity that could be reached through the non-iterative 
methodology developed thus far for the long chain polyols preparation, we investigates the 
non-iterative synthesis of fragments containing propionate subunits and 1,3-diol moieties. 
These fragments are often found in natural products. 
 
6.1 Retrosynthetic scheme 
 
The synthesis of fragments of type 260 using the already developed methodology, i.e. 
ozonolysis/reduction sequence, required the generation of desymmetrised oxabicycles (264). 
Oxidation of the remaining alcohol would allow the formation of a ketone that could be further 
functionalised at α-positions (Scheme 77). 
                                                     
240 Gerber-Lemaire, S.; Vogel, P. Eur. J. Org. Chem. 2003, 2959-2963. 
241 Gerber-Lemaire, S.; Carmona, A. T.; Meilert, K.; Vogel, P. Eur. J. Org. Chem. 2006, 891-900. 
242 Gerber-Lemaire, S.; Vogel, P. Eur. J. Org. Chem. 2004, 5040-5046. 
243 Parenty, A.; Moreau, X.; Champagne, J.-M. Chem. Rev. 2006, 106, 911-939. 
244 Wessjohann, L. A.; Ruitjer, E.; Garcia-Riviera, D.; Brandt, W. Mol. Div. 2005, 9, 171-186. 
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Scheme 77: Retrosynthetic analysis. 
 
6.2 Synthesis of mono-protected oxabicycle precursors 
 
6.2.1 Meso bicycloheptene desymmetrisation 
 
It has been proven that diketone meso-126 can be desymmetrised using a late 
desymmetrisation on diolefin meso-127 by means of Sharpless asymmetric dihydroxylation to 
produce diol (-)-128 in high enantiomeric purity (Scheme 78). 
 
meso-127 (-)-128
OH OH
ORRO
OAc OAc
ORRO
OH
OH
AD-mixß
R = PMBz
O O
O O
meso-126
with R = PMBz  
Scheme 78: Late desymmetrisation of meso-127. 
 
Our goal was to investigate an earlier desymmetrisation to produce mono protected diol of 
type 264 in good optical purity. For that purpose diol 265, resulting from the endo-selective 
reduction of meso-126, was chosen as substrate for this study. Among several methods 
reported in the literature for desymmetrisation of meso diol,245 we focused on enzymatic 
methods.246 
                                                     
245 a) Hoffmann, R. Angew. Chem. 2003, 42, 1096-1109. b) Trost, B. M.; Mino, T. J. Am. Chem. Soc. 2003, 125, 
2410-2411. c) Willis, M. C. Chem. Commun. 1999, 1765-1784. d) Jiang, L.; Burke, S. D. Org. Lett. 2002, 4, 
3411-3414. 
246 a) Carrea, G.; Riva, S. Angew. Chem. 2000, 39, 2226-2254. b) Hegemann, K.; Fröhlich, R.; Haufe, G. Eur. J. 
Org. Chem. 2004, 2181-2192. c) Ghanem, A.; Aboul-Eneim, H. Y. Tetrahedron: Asymmetry 2004, 15, 3331-
3351. d) García-Urdiales, E.; Alfonso, I; Gotor, V. Chem. Rev. 2005, 105, 313-354. 
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Transacetylation of diol 265 was attempted in the presence of several commercially available 
lipases (Scheme 79, Table 7), using vinyl acetate as solvent. Lipases from Pseudonomas 
fluorescens, Pseudonomas cepacia, Aspergillus niger, Aspergillus orizae and Rizopus orizae 
were uneffective to catalyze the transesterification of 265 (Table 7, entries 1-5)  
 
(-)-266
O O
O O
K-selectride, 
THF, -78°C-25°C
 87%
OH OH
O O
OH OAc
O O
Conditions
 see table 4
meso-126 265  
Scheme 79: Enzymatic desymmetrisation of meso-diol 265. 
 
Lipase from Candida rugosa afforded a low conversion into the desired mono-acetate (-)-266 
with an enantiomeric excess of 76% and lipase from Candida antarctica afforded the desired 
mono-acetate (-)-266 with an enantiomeric excess of 88%. Unfortunately this enzyme was too 
expensive to be used in large scale. Finally, lipase from Candida cylindracea afforded 
formation of mono-acetate (-)-266 with enantiomeric excesses ranging from 80 to 89%. The 
best results were obtained at 40°C (10 h, 4000 U/mmol, 44% yield, 50% recovered starting 
diol). Increasing the amount of enzyme (entry 8) or the temperature (entry 11) resulted in loss 
of enantioselectivity. With addition of co-solvents such as toluene or chloroform, the 
transesterification did not occur. 
 
Table 7: Lipase catalysed transesterification of 265 
 
a) Assays were performed with 50 mg of diol (0.08 M in vinyl acetate). b) Isolated yields. c) Determined by 1H 
NMR of Mosher’s ester. d) Unreacted starting material was recovered. 
 
Entrya Lipase Quantity 
(u/mmol) 
T (°C) Reaction 
time (h) 
eeb Yield
c, d 
(%) 
1 Pseudomonas fluorescens 4800 25 12  
2 Pseudomonas cepacia 14400 25 36  
3 Rizopus orizae 4800 25 24 
4 Aspergillus orizae 4800 25 24 
5 Aspergillus niger 3000 25 10  
NON 
REACTIVE 
ENZYMES 
6 Candida rugosa 3500 25 11 76 17 
7 Candida antarctica 3180 25 11 88 41 
8 Candida cylindracea 5800 25 1.5 80 34 
9 Candida cylindracea 4000 25 6 85 44 
10 Candida cylindracea 4000 40 6 89 44 
11 Candida cylindracea 4000 60 10 81 40 
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The absolute configuration of mono-acetate (-)-266 was determined by circular dichroism of 
the tris(paramethoxybenzoate) (+)-268 derived from (-)-266 through a sequence involving 
transformations that do not modify the initial stereogenic centers (Scheme 80). Esterification 
of the free secondary alcohol in the presence of para-methoxybenzoyl chloride followed by 
treatment with BCl3, protection of the resulting diol and reductive dechlorination (Bu3SnH, 
AIBN) of the dichlorodiol intermediate afforded derivative (+)-268, bearing para-
methoxybenzoate chromophores. The complementary enantiomer was similarly obtained after 
introduction of a pivaloyl moiety on (-)-266 and selective hydrolysis of the acetate at C3' 
position (Scheme 80). 
 
(-)-266
O
OH
O
OAc
PMBzCl, Pyridine, DMAP
85 %
O
OPMBz
O
OAc
1. BCl3, CH2Cl2, 0°C
2. PMBzCl, Pyridine, DMAP
3. AIBN, Bu3SnH, Toluene, 80°C
             70% over 3 steps
OPMBz OAc
OPMBzPMBzO
(+)-268
267
1. PivCl, Pyridine/CH2Cl2 1/3
    DMAP cat., 25°C
2. MeOH, K2CO3, 25°C
       55% over 2 steps
1. BCl3, CH2Cl2, 0°C
2. PMBzCl, Pyridine, 
    DMAP cat., 25°C
3. Bu3SnH, AIBN cat., 80°C
       22% over 3 steps
OPiv OPMBz
OPMBzPMBzO
O
OPiv
O
OH
(+)269
(-)-270  
Scheme 80: Synthesis of compounds (+)-268 and (-)-270 for circular dichroism analysis. 
 
Circular dichroism (CD) spectrum of (+)-268 (Figure 17) showed a double Cotton effect 
(Δε267 = +6, Δε241 = -2) that results from the exciton coupling between the two aromatic 
chromophores at C4' and C6' to produce a positive couplet.247  
                                                     
247 Harada, N.; Nakanishi, K. Circular Dichroic Spectroscopy Exciton Coupling in Organic Chemistry; 
University Science Books: Hill Valley, CA, 1983. 
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Figure 17: CD spectra of (+)-268 and (-)-270 in MeCN. 
 
This result is expected for all possible conformations of (+)-268 (Scheme 81) and is consistent 
with the fact that the point of inflexion of the CD curve is close to λ = 257 nm, the wavelength 
of maximum absorption in the UV spectrum. 
 
P = PMBz
PO
H
H
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Scheme 81: Possible conformers of (+)-268 and (-)-270. 
 
Furthermore, circular dichroism (CD) spectrum of (-)-270 (Figure 17) showed a double 
Cotton effect (Δε264 = -4.5, Δε246 = +3.2) to produce a negative couplet, as expected for all 
possible conformations of this derivative (Scheme 81). In this case, the point of inflexion of 
the CD curve is also close to λ = 255 nm, the wavelength of maximum absorption in the UV 
spectrum. 
These data allowed the establishment of the (1R,4'S,6R,6'S)- and the (1S,4'R,6S,6'R)- 
configuration of (+)-268 and (-)-270, respectively and thus the (1S,1'R,3S,3'R,5S,5'R)-
configuration of mono-acetate (-)-266. 
(+)-268 (λmax = 257 nm) (-)-270 (λmax = 257 nm) 
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Figure 18: X-ray diffraction analysis of (-)-271. 
 
This result was finally confirmed by X-ray cristallography of the (S)-camphanoyl ester 
derivative of (-)-271 (Figure 18).248 
 
6.2.2 Desymmetrisation of threo-bicycloheptene 
 
The threo diketone 126 can be converted into enantiomerically pure diacetate (+)-131 and diol 
(-)-135, using Candida Cylindracea lipase, enantiomerically enriched mono-protected 
compound (-)-272 was formed during the enzymatic resolution and isolated with low yields.249 
 
O O
O O
threo-126
K-selectride, 
THF, -78°C-25°C
 87%
OH OH
O O
(  )-135
Candida Cylindracea
           Lipase
OAc
OHOH
O O
OAcOH
O O
OAcOAc
O O
   (+)-131, 27%, 98% ee    (-)-135, 28%,  98% ee    (-)-272, 41%, 80% ee  
Scheme 82: Threo enzymatic desymmetrisation. 
 
Taking advantage of their C2-symmetry compound (+)-131 and diol (-)-135 were respectively 
mono-deprotected and mono-protected250 to synthesized larger scale of enantiomerically 
enriched 272 and its enantiomer 273 (Scheme 83). 
                                                     
248 Crystallographic data (excluding structure factors) for the structure have been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication number CCDC 270615. Copies of the data can be 
obtained, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK. 
249 Csaky, A. G.; Vogel, P. Tetrahedron: Asymmetry 2000, 11, 4935-4944. 
250 a) Clarke, P. A. Tetrahedron Lett. 2002, 43, 4761-4763. b) Clarke, P. A.; Kayaleh, N. E.; Smith, M. A.; Baker, 
J. R.; Bird, S. J.; Chan, C. J. Org. Chem. 2002, 67, 5226-5231. 
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K2CO3 0.5 eq.,
MeOH (0.1 M), 36 h, 25°C
OHOH
O O
OAcOAc
O O
   (+)-131
   (-)-135
CeCl3 20 mol%, Ac2O 10 eq.,
THF (0.1 M), 11 d, 25°C
OR1OR
O O
     272 R = H, R1 = Ac 36%
(-)-131 R = R1 = Ac 29%
(-)-135 R = R1 = H 11%
OR1OR
O O
      273 R = H, R1 = Ac 41%
(+)-131 R = R1 = Ac 11%
(+)-135 R = R1 = H 23%  
Scheme 83: Mono acetylation of (-)-135 and (+)-131. 
 
6.3 Synthesis of polypropionate precursors 
 
Starting from (-)-272 and (-)-266, silylation of the remaining alcohol followed by acetate 
methanolysis and alcohol oxidation afforded hydroxyketones (-)-273 and (-)-274, in 61 and 
67% yield respectively (Scheme 84). α-Functionalisation of the ketone moiety was then 
investigated, either through hydroxylation or methylation.  
 
(-)-272
1. TESCl, DMF, imidazole, 25°C
2. MeONa, MeOH, 25°C
3. TPAP cat., NMO, CH2Cl2, 25°C
             61% over 3 steps
O
OH
O
OAc
(-)-273
O
OTES
O
O
(-)-266
1. TESCl, DMF, imidazole, 25°C
2. MeONa, MeOH, 25°C
3. TPAP cat., NMO,CH2Cl2, 25°C
             67% over 3 steps
O
OH
O
OAc
(-)-274
O
OTES
O
O
 
Scheme 84: Synthesis of (-)-273 and (-)-274 ketones. 
 
α-Hydroxyl carbonyl compounds can be prepared by several methods such as the electrophilic 
α-hydroxylation of enolate using chiral oxaziridines as oxidizing agent,251 asymmetric 
dihydroxylation of enol ethers developed by Sharpless and co-workers,252 asymmetric 
                                                     
251 a) Davis, F. A.; Chen, B. C. Chem. Rev. 1992, 92, 919, and references therein. b) Enders, D; Reinhold, U. 
Synlett 1994, 792. 
252 Morikawa, K.; Park, J.; Andersson, P. G.; Hashiyama, T.; Sharpless, B. J. Am. Chem. Soc. 1993, 115, 8463. 
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epoxidation of silyl enol ether with a chiral dioxirane253 or asymmetric epoxidation of enol 
ether with a chiral Mn-salen catalyst.254 More generally, α-hydroxy carbonyl compounds are 
obtained by oxidation of either silyl enol ethers using organic peracids,255 singlet oxygen,256 
osmium tetraoxide,257 hypervalent iodine,258 leads salts,259 chiral ketone/oxone systems260 and 
ozonolysis261 or directly using an enolate. Direct enolate oxidation has been explored with 
molecular oxygen,262 molybdenum peroxide-pyridine-hemethylphosphoramide (MoOPH),263 
dimethyldioxirane264 and proline based asymmetric α-aminoxylation of carbonyl 
compounds.265 
Ketone (-)-273 was submitted to different oxidizing conditions after transformation into the 
corresponding silyl ether. Hydroxylation by m-CPBA or OsO4266 resulted in intractable 
mixtures. L-proline catalysed α-hydroxylation of (-)-274 using nitrosobenzene unsuccessful 
even at high temperature. For these reasons we turned our attention to α-methylation of the 
ketone moiety. 
Following the conditions developed by Hoffmann and co-workers for the synthesis of 
Altohyrtin A based on 8-oxabicyclo[3.2.1]oct-6-en-3-one,267 ketone (-)-273 was convert into 
the corresponding lithium enolate. In situ addition of methyliodide as methylation agent gave a 
mixture of two inseparable regioisomeric α-methylated ketones 275 and a small amount of 
α,α’-dimethyl ketone (-)-277 (Scheme 85). The three compounds mixture was further 
submitted to the same conditions leading to α,α’-dimethyl ketone (-)-277 and a small amount 
of α,α,α’-trimethyl ketone 276. This sequence was performed without purification of the 
intermediate mixture 275/(-)-277. In order to optimize the formation of α,α’-dimethyl ketone 
(-)-277 the best conditions consisted in isolating the mixture of mono methylated intermediate 
275 after the first step and to treat this pure mixture with LDA/MeI. (-)-277 was isolated in 
49% overall yield. The same method was used to functionalise ketone (-)-279 in 54% overall 
yield (Scheme 85). 
                                                     
253 Adam, W.; Fell, R. T.; Saha-Moller, C. R.; Zhao, C.-G. Tetrahedron: Asymmetry. 1998, 9, 397. 
254 Fukuda, T.; Katsuki, T. Tetrahedron Lett. 1996, 37, 4389. 
255 Rubottom, G. M.; Vazquez, M. A.; Pelegria, D. R. Tetrahedron Lett. 1974, 15, 4319. 
256 Rubottom, G. M.; Nieves, M. I. L. Tetrahedron Lett. 1972, 13, 2423. 
257 McCormick, J. P.; Tamasik, W.; Johnson, M. W. Tetrahedron Lett. 1981, 22, 607. 
258 Moriarty, R. M.; Prakash, O.; Duncan, M. P. Synthesis 1985, 943. 
259 Rubottom, G. M.; Gruber, J. M.; Mong, G. M. J. Org. Chem. 1976, 41, 1673. 
260 Zhu, Y.; Tu, H.; Shi, Y. Tetrahedron Lett. 1998, 39, 7819. 
261 Clark, R. D.; Heathcock, C. H. Tetrahedron Lett. 1974, 15, 2027. 
262 Gardner, J. N.; Carlon, F. E.; Gnoj, O. J. Org. Chem. 1968, 33, 3294. 
263 Vedejs, E.; Engler, D. A.; Telschow, J. E. J. Org. Chem. 1978, 43, 188. 
264 Guertin, K. R.; Chan, T. -H Tet.Lett. 1991, 32, 715-718. 
265 Bøgevig, A.; Sundén, H.; Córdova, A. Angew. Chem., Int. Ed. 2004, 43, 1109-1112. 
266 Bunn, B. J.; Cox, P. J.; Simpkins, N. S. Tet. Lett. 1993, 49, 207-218. 
267 Kim, H.; Hoffmann, H. R. M. Eur. J. Org. Chem. 2000, 2195-2201. 
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Scheme 85: α-Functionalisation of ketone (-)-273 and (-)-274. 
 
In order to generate precursors of polypropionate subunits, functionalisation of α,α’-
dimethylketone (-)-277 was attempted. Reduction of the ketone moiety using the conditions 
previously reported by Vogel and Schwenter (K-selectride) was uneffective. However, the use 
of DIBAL-H resulted in the stereoselective reduction of the ketone moiety to provide the 
corresponding endo-alcohol which was protected as a silyl ether (Scheme 86).  
 
(-)-277 O
OTES
O
OTBS
1. DIBAL-H, CH2Cl2, 0°C
2. TBDMSOTf, 2,6-lutidine, 
    CH2Cl2, 0°C
         49% over 2 steps
O
OAc
O
OAc
(-)-280
1. DIBAL-H, CH2Cl2, 0°C
2. 60% aq. HF, CH3CN, 0°C
3. Ac2O/Py 1/1, DMAP cat.
       66% over 3 steps
(+)-281
O
Me
Me
H
H
OSi
H
H
H
R
Si = TBDMS
1
7
6
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Scheme 86: Functionalisation of α,α’-dimethylketone (-)-277. 
 
The configuration of the newly formed stereocenter was determined by 2D-NOESY 
experiment on the bis-silyl derivative (-)-280. Correlation peaks were observed between the 
signal of H-C4 and H-C6 and between the signals of H-C3 and H-C6. These observations 
established the endo configuration of the newly formed alcohol. 
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As Dr. Marc-Etienne Schwenter previously established,268 acetate protecting groups may 
assist the BCl3-mediated oxa-bridge opening, such protecting groups were introduced after 
silyl ether cleavage using aqueous hydrogen fluoride in CH3CN (Scheme 86). The resulting 
diol was acetylated using classical conditions to release (+)-281 in 66% yield (3steps). 
 
Following the procedure of Dr. MER Sandrine Gerber269 for the oxa-bridge opening, diacetate 
(+)-281 was treated with a 1M solution of BCl3 at 0°C and the released intermediate diol was 
subsequently treated with BOMCl and iPr2NEt. Unfortunately a complex mixture of products 
was isolated from the reaction medium. The steric hindrance around the newly formed alcohol 
was probably the reason for this unsuccessful protection. To activate the chloride derivative, 
sodium iodide was introduced in the reaction mixture to promote an in situ Finkelstein 
reaction to afford BOMI which is more reactive toward nucleophilic attacks. No improvement 
was observed. Protection of the diol as a benzyl ether with benzyl-2,2,2-trichloroacetimidate 
resulted in decomposition of the starting material. As these conditions did not improve the 
course of the reaction, it was decided to protect the alcohols with esters following the method 
developed by Dr. Schwenter.270 After oxa-bridge opening, the resulting diol was directly 
treated with an excess of PMBzCl in pyridine with a catalytic amount of DMAP. (+)-282 
Resulting from the protection of the less hindered alcohol was the major product isolated after 
24 h (Scheme 87). The fully protected compound 283 was isolated after treatment of (+)-282 
with PMBzCl in pyridine, but in very poor yield. Heating the reaction mixture resulted in 
decomposition of the starting material.  
 
1. BCl3, CH2Cl2, 0°C
2. PMBzCl, Py., 
    DMAP cat., 25°C
  56% over 2 steps
O
OAc
O
OAc
(+)-281
OAc OAc
(+)-282
OH
Cl
PMBzO
Cl
OAc OAc
OPMBz
Cl
PMBzO
Cl
PMBzCl, Py., 
DMAP cat., 25°C
        14%
(+)-283  
Scheme 87: Oxa-bridge opening. 
                                                     
268 Schwenter, M.-E., EPFL, these de doctorat n° 2371, 2001. 
269 Gerber-Lemaire, S; Vogel, P. Eur. J. Org. Chem. 2003, 2959-2963. 
270 Schwenter, M.-E.; Vogel, P. J. Org. Chem. 2001, 66, 2959-2963. 
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Compound (+)-282 was treated under radical conditions to reduce the C-Cl bonds but 
decomposition of the starting material was observed. Further conditions should be explored to 
improve the yield of (+)-283 formation. Furthermore, as this intermediate was found to be 
stable, one should try to investigate further functionalisation directly on the dichlorinated 
compound (+)-283. 
 
7 Synthesis of polyketide-like macrocycles 
 
Our first approach, planning to start from a linear polyol chain and to close the ring through 
macrolactonisation implied that a seco-acid of type 285 (Scheme 88) should be synthesized. A 
chemical differentiation of the terminal alcohols of the polyolic chain was thus required to 
release a mono-protected polyketide of type 286. 
 
285
O OHOP OP2 OPOP1 OP3 OP4
P1,2,3,4,5 = protecting groups286
HO
OH OP5OP OP2 OPOP1 OP3 OP4
O
O
PO
OP3
P1O
P2O
OP4
PO
284
 
Scheme 88: Retrosynthetic analysis. 
 
7.1 Desymmetrisation of the polyol chain 
 
In a first study, chemical differentiation of the terminal polyol chain alcohols was performed 
through mono-protection. Monosilylation was attempted on di-acetonide 137 (Scheme 89). 
When polyol 137 was treated under classical conditions (TBDMSCl, NEt3, DMF), a small 
amount of mono-silylated polyol was formed. Several conditions were tested on polyol 137 to 
obtain higher yields of mono-silylation of the primary alcohols of the chain (Scheme 89). 
Several silylating agents and bases were tested at different concentrations. Unfortunately the 
best yield reached was in the range of 30% (entry 1).  
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Scheme 89: Mono-silylation of the protected polyol 137. 
 
Mono-silylation of the unprotected polyol 136 was also tried but resulted in low conversions 
and poor yields of the desired monosilylated polyol (Scheme 90).  
 
OH OHOP OH OPOH OH OH
OH OTBSOP OH OPOH OH OH
OTBS OTBSOP OH OPOH OH OH
Conditions
see table 2
136
289
145  
 
Scheme 90: Mono-silylation of the unprotected polyol 136. 
 
In addition to low yields, observed mono-silylated compounds were isolated as a mixture of 
inseparable diastereoisomers. For these reasons, we turned out our attention toward an 
enzymatic differentiation.  
Composition of the 
resulting mixture (%) Entry Conditions 
137  287 288 
1 TBDMSOTf (0.1 M) 0.9 eq. (slow addition), 2,6-lutidine 1.5 eq., -30°C 10% 34% 22% 
2 BuLi (0.8 M) 0.9 eq., TESOTf 0.9 eq., NEt3 1 eq., -78°C 
54% 10% 20% 
3 LDA (0.05 M) 1 eq., TBDMSOTf (0.1 M) 0.9 eq., NEt3 1 eq., -78°C 
40% 11% 22% 
Composition of the 
resulting mixture (%) Entry Conditions 
136 289 + 145 
1 BuLi (0.8 M) 0.9 eq., TBDMSOTf (0.1 M) 0.9 eq., NEt3 1 eq., -78°C to 0°C 
40% 20% 
2 NaH 1.5 eq., TBDMSOTf (0.1 M) 0.9 eq., NEt31 eq., -78°C to 0°C 52% 31% 
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Dr. MER Sandrine Gerber has already desymmetrised meso polyol 142 with good yields and 
enantiomeric excess using enzymatic transesterification in vinyl acetate (Scheme 91).271  
 
142
OH OHOP O OPO O O OAc
Candida Cylindracea lipase,
          25°C, OAc OHOP O OPO O O
83%, ee 90% 290  
 
Scheme 91: Enzymatic desymmetrisation of meso polyol 142. 
 
Moreover, selective acetylation of primary alcohols in the presence of secondary ones has 
already been reported in Chapter III. So, in a first study, polyol 136 was submitted to different 
enzymes in vinyl acetate to determine adequate conditions for mono transacetylation (Scheme 
92).  
 
OH OHOP O OPO O O
OH OAcOP O OPO O O
OAc OAcOP O OPO O O
Conditions
OAc137
291
146  
 
 
 
 
 
 
 
 
Scheme 92: Mono acetylation of polyol 136. 
 
From the first experiments, Candida Cylindracea lipase gave higher conversion with lower 
quantities of enzymes. Using 4800 u.mmol-1 of enzyme provided almost 40% yield of mono 
acetylated derivative 291 but the reaction had to be carefully monitored to avoid complete 
conversion to bis acetate 146. Lowering the enzyme concentration (entry 4) allowed a better 
control of the reaction and afforded 55% yield of 291. At this point of the synthesis the mono-
                                                     
271 Vogel, P.; Gerber-Lemaire, S.; Carmona, A.; Meilert, K. T.; Schwenter, M.-E. Pure Appl. Chem. 2005, 77, 
131-137. 
Composition of the 
resulting mixture (%) Entry Conditions 
136 291 146 
1 Lipase from Pseudomonas Fluorescens, 19200 u.mmol-1, 24 h 12% 40% 13% 
2 Lipase from Hog Pancreatic,  
19200 u.mmol-1, 24 h 
Unreactive enzyme 
3 Lipase from Candida Cylindracea  
4800 u.mmol-1, 15 mn 
0% 39% 43% 
4 Lipase from Candida Cylindracea  
4000 u.mmol-1, 40 mn 
20% 55% 12% 
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acetylated polyol 291 was characterized as a mixture of two diastereoisomers in a 1/1 ratio 
corresponding to the acetyl group introduction at both polyolic chain termini. All our attempts 
to separate these two isomers were unsuccessful.  
 
7.2 Macrolactonisation of polyol chains 
 
Preparation of a seco-acid precursor from 291 required first a protecting group exchange for 
easier isolation before the macrolactonisation step. The remaining free alcohol of 291 was 
protected as a silyl ether and the acetate was removed under classical conditions (K2CO3 in 
MeOH) (Scheme 93). Oxidation of alcohol 287 under Ley’s conditions,272 followed by 
treatment with sodium chlorite released the corresponding carboxylic acid. Deprotection of the 
silyl ether with aqueous HF in acetonitrile afforded the seco-acid 292. Attempts of 
macrolactonisation under Yamagushi’s conditions were unsuccessful.  
 
OH OAcOP O O OO OP
29O
1. TBDMSOTf, 2,6-lutidine,
    CH2Cl2, -30°C
2. MeOH, K2CO3 cat.
       41% over 2 steps
TBSO OHOP O O OO OP
287
1. TPAP cat., NMO, 4ÅMS
2. NaClO2 , NaH2PO4
    tBuOH/H2O (3/1), -78°C  
 
          33% over 2 steps
OH OOP O O OO OP
292
OH1. HF, CH3CN/H2O, 0°C
2. iPrNEt, 2,4,6-triClBzCl
    C6H6, 25°C
3. DMAP, C6H6, 80°C
Degradation
 
Scheme 93: Synthesis of seco-acid 292. 
 
It seemed that the conformational strain induced by the two acetonide protective groups 
disfavored the ring closing reaction. To avoid problems these constraints, a similar sequence 
was performed with methyl ether protecting groups. 
For that purpose, diolefin 134 was submitted to the sequence of ozonolysis-reduction followed 
by selective silylation of the primary alcohols on the crude intermediate hexol to provide the 
semi-protected polyol 145 (Scheme 94). The remaining secondary alcohols were transformed 
into methyl ethers in the presence of sodium hydride and methyl iodide. The silyl ethers were 
cleaved in the presence of aqueous HF in acetonitrile. At this point, conversion of 293 into a 
                                                     
272 a) Griffith, W. P.; Ley, S. V.; Withcombe, G. P.; White, A. D. Chem. Commun. 1987, 1625-1627. b) Ley, S. 
V. Synthesis. 1994, 639-666. 
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seco-acid precursor for the macrolactonisation reaction required the differentiation of both 
terminal alcohols.  
 
OH OH
OPPO
TBSO OTBSOP OPOH OH OH OH
OH OHOP OPOMe OMe OMe OMe
OAc OHOP OPOMe OMe OMe OMe
293
OAc OHOP OPOMe OMe OMe OMe
+
294
295
1. O3, CH2Cl2, -78°C
2. DMS , -78°C
3. Et2BOMe, NaBH4,
    THF/MeOH, 0°C to 25°C
    
4. TBSCl, imidazole, DMF, 0°C    
               53% over 4 steps 1. NaH, MeI, THF, 0°C-25°C
2. MeCN, aq. HF (40%), 0°C
        50% over 2 steps
Candida Cylindracea
           Lipase
           
           52%
OAc
145
134
CO2H
OH OP OPOMe OMe OMe OMe
296 (2 diastereoisomers)
O
O
PO
OMe
MeO
MeO
OMe
PO
O
O
PO
OMe
MeO
MeO
OMe
PO
+
297 298
syn
1. TPAP cat., NMO, 4ÅMS
2. NaClO2, NaH2PO4
    tBuOH/H2O (3/1), -78°C
    
3. K2CO3, MeOH, 25°C
    
        33% over 3 steps
1. iPrNEt, 2,4,6-triClBzCl
    C6H6, 25°C
2. DMAP, C6H6, 80°C
             Quant.
 
Scheme 94: Synthesis of 16 membered macrolactones. 
 
Considering our previous results, 293 was treated with Candida Cylindracea lipase in vinyl 
acetate to release mono acetylated diols 294 and 295 as a mixture of two diastereoisomers in a 
2/1 ratio. All our attempts to separate these two compounds were unsuccessful. Nevertheless, 
the synthetic route was further explored and this mixture of isomers was submitted to a two-
step oxidation using Swern’s conditions followed by treatment with sodium chlorite to afford a 
carboxylic acid intermediate. (Scheme 94). Hydrolysis of the acetate afforded the seco-acids 
296. Macrolactonisation under Yamagushi’s conditions273 provided a 1/1 mixture of the 
stereoisomeric macrolactones 297 and 298 in quantitative yield. 
                                                     
273 Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamagushi, M.; Bull. Chem. Soc. Jpn. 1979, 52. 
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Nevertheless, this method required many protecting group manipulations and a shorter 
pathway, requiring no protection was developed starting from the bis(hemiacetal) 154 
mentioned in Chapter III. 
Reduction of the bis(hemiacetals) using sodium borohydride at 25°C resulted in the 
quantitative linear hexol formation. However, lowering the reduction medium temperature to -
20°C allowed selective reduction of one hemiketal moiety to afford tetrol 299 as a mixture of 
regioisomers (Scheme 95) 
 
O OOH OH
OPPO
OH OH
NaBH4, MeOH
Quant.
OP OH OH OPOH OH OHOH
NaBH4, MeOH, -20°C
71%
O OH OPOH OH
PO
OH
OH
299
136154
Toluene, 80°C
        74%
OP OH OH OPOH OH OH
O
MeO
Bu3P
O
OMe
300
OO
OP OH OH
OH
OH
OP
1. Pd/C cat., H2, EtOAc, 25°C
2. LiOH, MeOH, 25°C 
3. 2,4,6-trichloroBzCl, DIPEA
4. DMAP, PhH, reflux 
          32% over 4 steps
302 single isomer
301
 
Scheme 95: Synthesis of 18-membered macrolactone. 
 
Taking advantage of the chemical differentiation introduced on hemiacetal 299, a Wittig type 
olefination was attempted using the stabilised ylide 300 prepared according to the conditions 
of Aspinal and co-workers.274 This reaction, well known in carbohydrate chemistry,275 
released the corresponding α,β-insaturated methyl ester 301 as a mixture of E/Z inseparable 
diastereoisomers, E being the major isomer (E/Z 10/1). The olefin was reduced through 
catalytic hydrogenation and the methyl ester was saponified to produce a seco-acid. This 
intermediate was submitted to a macrolactonisation process under Yamagushi’s conditions to 
provide the 18-membered macrolactone 302 as the major compound as a single 
diastereoisomer. Other derivatives, probably resulting from macrolactonisations involving 
secondary alcohols were also isolated in trace amounts. The presence of impurities after a first 
                                                     
274 Aspinall, I. H.; Cowley, P. M.; Mitchell, G; Raynor, C. M.; Stoodley, R. J. Chem. Soc., Perkin Trans. 1 1999, 
2591-2599. 
275 a) Kochetkov, N.; Dmitriev, B. A. Tetrahedron. 1965, 21, 803. b) Railton, C. J.; Clive, D Carbohydr. Res. 
1996, 281, 69. 
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column chromatography required a second chromatography purification which led to the 
isolation of one pure stereoisomer.  
This shorter route did not require protecting group introduction of the hydroxyl moieties and 
thus afforded a straightforward access to 18-membered macrolactones.  
 
7.3 Synthesis of polyhydroxylated tridecanes 
 
As the use of a macrolactonisation step required terminal alcohols differentiation of the 
polyolic chains, it was envisioned to investigate a RCM reaction for ring closure. The 
previously reported polyol 136 was oxidized under Ley’s conditions276 to provide the 
corresponding dialdehyde which was directly treated with triphenylphosphonium methyl ylide 
to afford diolefin 303 (Scheme 96). Treatment of this derivative with Grubbs II catalyst under 
diluted conditions277 led to open-chain cross-methatesis products 304 as a mixture of several 
diastereoisomers.  
 
OP O O OPO O OHOH
1. TPAP, NMO, CH2Cl2, 25°C
2. PPh3CH2Br, BuLi, THF, 25°C
            35% over 2 steps136
OP O O OPO O OPOOOP OO
anti anti
OP O O OPO O
303
304
Grubbs II cat., CH2Cl2, 70°C
                   39%
 
Scheme 96: First attempts of ring closing metathesis. 
 
Suspecting that the acetonide protecting groups prevented the diolefin precursor to cyclise, 
diacetonide 303 was treated with p-toluenesulfonic acid to release the corresponding tetrol 
305. This intermediate was reacted with Grubbs II catalyst, leading to a first reaction of cross-
metathesis followed by cyclisation of the “dimeric” intermediate through ring-closing 
metathesis to provide the polyhydroxylated tridecane 306 as a mixture of diastereoisomers, 
after reduction of the olefins (Scheme 97).  
                                                     
276 a) Griffith, W. P.; Ley, S. V.; Withcombe, G. P.; White, A. D. Chem. Commun. 1987, 1625-1627. b) Ley, S. 
V. Synthesis. 1994, 639-666. 
277 a) Evano, G.; Schaus, J. V.; Panek, J. S. Org. Lett. 2004, 6, 525-531. b) Lee, C. W.; Grubbs, R. H. Org. Lett. 
2000, 2, 2145-2147.  
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APTS,
 MeOH, 25°C
42%
OP OH OH OPOH OH
305
OP OH OH OHOH OP
OP OH OH OHOH OP
1. Grubbs II cat., CH2Cl2, 70°C
2. H2, Pd/C, EtOAc
         32% over 2 steps
303
306
 
Scheme 97: Synthesis of polyhydroxylated tridecanes. 
 
In summary, different synthetic routes were developed for the preparation of polyketide-like 
macrolides analogues through the efficient functionalisation of long-chain polyol 
intermediates. 
 
7.4 Synthesis of cyclic glycolipids analogues 
 
We next targeted the straightforward conversion of bis(hemiacetal) 154 into analogues of 
carbohydrate containing macrocycles. 
Our strategy was based on the double functionalisation of the hemiketal moieties of 154 
through a C-glycosylation reaction followed by bis-coupling with a linker to close the 
macrolides 308 (Scheme 98), such methodologies having already been disclosed.278 
 
O OOH OH
OPPO
OH OH154
O OOH OH
OPPO
FG FG
FG = Functional group
FG FG
Bis-coupling wilth a linker
307
308
307
 
Scheme 98: Synthetic plan. 
 
In a first approach, diolefin 185 was converted into the corresponding diol 309 in 60% yield. 
Coupling of diol 309 with bis-carboxylic acid were not met with success either using the 
                                                     
278 a) Janvier, P.; Bois-Choussy, M.; Bienayme, H.; Zhu, J. Angew. Chem. 2003, 42, 811-814. b) Owston, P. G.; 
Peters, R.; Ramsammy, E.; Tasker, P. A.; Trotter, J. Chem. Commun. 1980, 1218-1220. 
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method recently disclosed by Zurres and co-workers279 or using classical coupling agents 
under diluted conditions (Scheme 99). 
Alternatively, ozonolysis of 185 followed by oxidation of the resulting aldehyde moieties, in 
the presence of sodium chlorite, gave dicarboxylic acid 310 (Scheme 99). A bis-coupling 
reaction with linear polyamines such as 1,5-diaminopentane and 1,9-diaminononane, using 
PyBOP as coupling reagent under diluted conditions, afforded macrocyclic bis-amides 311 
and 312 after methanolysis of the acetyl groups. 
 
185
O
PO
OAc OAc O
OP
O
PO
OAc OAc O
OP
OH OH
no reaction
1. O3, CH2Cl2, -78°C
2. DMS , -78°C
3. MeOH, NaBH4, 25°C
     60% over 3 steps
HO2C(CH2)nCO2H, 
NEt3, coupling agents
309
O
PO
OAc OAc O
OP
CO2HHO2C
O
PO
OH OH O
OP
O
NHHN
O
(   )n
311  n = 1, 37%
312  n = 5, 46%
1. O3, CH2Cl2, -78°C
2. DMS , -78°C
3. NaClO2, NaH2PO4, 
    2-methylbut-2- ene,
     tBuOH/H2O, 25°C
    35% over 3 steps
1. H2N(CH2)5NH2 or  H2N(CH2)9NH2,
    DIPEA, PyBOP, DMF, 0°C
2. K2CO3, MeOH, 25°C
310 over 2 steps
 
Scheme 99: Synthesis of macrocyclic bis amides. 
 
We also envisaged the use of ring-closing metathesis280 for the formation of macrocycles 
containing deoxysugars. Esterification of diol 309 with methanesulfonyl chloride followed by 
displacement of the intermediate di-mesylate with allylamine and cleavage of the acetyl 
groups, provided diamine 313 (Scheme 100). Upon treatment with Grubbs II catalyst at low 
concentration (0.003 M), diolefin 313 underwent a ring-closing metathesis reaction. Contrarily 
to our previous studies on the cyclisation of linear polyketides (see section 4.6.3) which led to 
a cross-metathesis process prior to ring closure, no trace of cross-coupling derivatives were 
observed with bis-allyl intermediate 313. Subsequent reduction of the double bond by catalytic 
hydrogenation afforded the macrocyclic diamine 314. 
                                                     
279 Muthusamy, S.; Gnanaprakasam, B.; Zurres, E. Org. Lett. 2006, 5, 1913-1921. 
280 Lee, C. W.; Grubbs, R. H. Org. Lett. 2000, 2, 2145-2147. 
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HO OH
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OH OH O
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HN NH
O
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OAc OAc O
OP
OH OH
1. MsCl, NEt3, CH2Cl2, 0°C
2. Allylamine/DMF(1/3), 
    K2CO3, 40°C
3. MeOH, 25°C
     42% over 3 steps
1. Grubbs II, CH2Cl2, 50°C
2. H2, Pd/C, EtOAc/MeOH, 25°C
         48% over 2steps
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313
 
Scheme 100: Macrocyclisation through ring closing methathesis. 
 
In summary, efficient synthetic routes toward novel macrocyclic derivatives containing 
deoxysugar subunits and diamino- or diamido-alkyl linkers have been described. In particular, 
ring-closing metathesis and peptide coupling reactions under diluted conditions have proven to 
be suitable transformations for the construction of these macrocycles. 
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CHAPTER V CONCLUSIONS AND PERSPECTIVES 
 
The non-iterative methodology previously developed in Vogel’s group for the preparation of 
long chain polyols was successfully extended to the synthesis of a panel of amino 
functionalised polyketides. For that purpose, selective transformations on a new 
bis(hemiacetal) intermediate 154 (Scheme 102) as well as the development of tools for the 
differentiation of alcohol moieties in polyolic chains gave a rapid access to semi-protected 
polyketides. Conversion into linear and cyclic di-and tri-amino polyols was efficiently carried 
out as several steps could be performed without intermediate purifications. This new class of 
derivatives was envisaged as potential mimics of natural aminoglycosides antibiotics. 
Furthermore, conjugation of a primary ribosomal RNA recognition element, such as 2-
deoxystreptamine, with several polyamines and diaminopolyols through dimeric structures 
provided a small family of highly functionalised polar molecules. Evaluation of binding 
affinity of these new derivatives toward RNA fragments through microarray techniques 
demonstrated the ability of aminopolyols to bind to bacterial ribosomal 16S RNA. 
Nevertheless, this recognition process was not selective toward bacterial rRNA. The formation 
of 2-DOS dimers containing polar linkers revealed that variation of the length of the linkers 
could influence the binding affinity toward RNA fragments and induce selectivity toward 
bacterial rRNA. In order to develop a more rapid and less material consuming method for the 
identification of new RNA binders, a first exploratory study was performed to assess the 
possibility of using bacterial ribosomal RNA fragments as templates in dynamic combinatorial 
libraries. The combination of a 2-DOS containing aldehyde partner with several functionalised 
amines, in the presence of 16S A-site RNA, allowed the rapid identification by LC-MS 
spectrometry of amplified members in the interconverting imine libraries. Validation of this 
strategy should now be implemented by the individual testing of the amplified conjugates for 
their affinity toward RNA. This method can be further developed to generate new RNA binder 
candidates based on Neamine structure, taking advantage of the naturally higher affinity of 
Neamine for RNA than deoxystreptamine. Finally solid supported synthesis of 
deoxystreptamine derivatives could be an easy trick to synthesize larger variety of 2-DOS 
derivatives using the concept of diversity oriented synthesis developed by Schreiber.281 
Successive introduction of amides on a DOS scaffold should provide libraries of structurally 
related derivatives (Scheme 101) that could be tested for their RNA affinity using mass 
spectrometry method. This method has the advantage of providing the mass of the complex 
                                                     
281 Schreiber, S. L. Science 2000, 287, 1964-1969. 
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formed between the RNA fragment and the best binder among all derivatives, allowing the 
identification of the best binder of each library.  
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Scheme 101: Perspectives of the work. 
 
In the course of this project, efficient and short pathways were also developed for the synthesis 
of highly functionalised macrocycles from polyolic intermediates. These molecules constitute 
analogues of natural macrolides and cyclic glycolipids that may be further used as scaffolds 
for the preparation of biologically active compounds or analogues of Leucascandrolide 
following the work of Wender on Bryostatin.282  
                                                     
282 Wender, P.A.; DeBrabander, J.; Harran, P. G.; Jimenez, J.-M.; Koehler, M. F. T.; Lippa, B.; Park, C.-M.; 
Siedenbieler, C.; Pettit, G. R. Proc. Natl. Acad. Sci. USA 1998, 95, 6624-6629. 
New efficient synthetic routes toward functionalised polyketides. 131 
   
The achieved structural diversity starting from a common scaffold, illustrated the flexibility 
and versatility of the polyol synthesis methodology developed in the group (Scheme 102).  
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Scheme 102: Structural diversity starting from a common intermediate. 
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CHAPTER VI EXPERIMENTAL PART 
1 General methods 
 
• Commercial reagents (Fluka, Aldrich) were used without purification. Technical solvents were 
used for extraction without purification. For reactions, solvents were filtered prior to use 
(Innovative Technology). Water for HPLC or LC-MS use was of Milli-Q quality, collected after 
passing through a Millipore Milli-Q purification system (Volketswil, Switzerland). 
• All reaction were monitored by TLC: Merck silica gel 60 F254 plates; detection by UV light; 
molybdic Pancaldi reagent [21 g of (NH4)6MoO4, 1 g of Ce(SO4)2, 31 mL of H2SO4, 470 mL of 
H2O] or KMnO4 [3g of KMnO4, 20 g of K2CO3, 0.25 mL of AcOH, 300 mL of H2O]. Liquid/solid 
flash chromatography: columns of silica gel (0.040-0.63 mm, Merck No.9385 silica gel 60, 240-
400 mesh).  
• Optical rotations were determined at 25°C on a Jasco P-1020 polarimeter, [α] values are given in 
units of 10-1 deg.cm².g-1. 
• IR spectra: Perkin Elmer Paragon 1000 FT-IT spectrometer.  
• 1H NMR spectra: Bruker-ARX-400 and DPX-400 spectrometer (400 MHz); δ(H) in ppm relative to 
the solvent's residual 1H signal [CDCl3, δ(H) 7.27; C6D6, δ(H) 7.16; D2O, δ(H) 4.79; CD3OD, δ(H) 
3.31; DMSO, δ(H) 2.50] as internal reference; all 1H assignments were confirmed by 2D-COSY-45 
spectra.  
• 13C NMR Spectra: same instrument as above (100.6 MHz); δ(C) in ppm relative to solvent's C-
signal [C6D6, δ(C) 128.06; CDCl3, δ(C) 77.16; CD3OD, δ(C) 49.2; DMSO, δ(C) 39.4].  
• 19F NMR Spectra: same instrument as above (376.7 MHz); δ(F) in ppm relative to F-signal of 
internal standard [CFCl3, δ(F) 0]; all 13C assigments were confirmed by 2D-HMQC spectra.  
• MS: GC-MS spectrometer (Nermag R-10-10C, chemical ionization (NH3) mode m/z); MALDI-
TOF spectrometer (Axima-CFR+, Kratos, Manchester); ESI-Q spectrometer (Finnigan SSQ 710C, 
Thermoquest, UK); ESI-QT spectrometer (Ultima spectrometer, Micromass, Manchester). 
• Microanalysis: Ilse Beetz, D-96301 Kronach, Germany. 
• Semi-Preparative HPLC purification: Waters Delta Prep 4000 System with a Waters 600E System 
Controller and a Waters 2487 Absorbance detector, with a Vydac Nucleosil 218TP1022 C18 
particles (22mm). Flow rates of 12 mL.min-1 were used and the UV absorbance was monitored at 
214 nm. Gradient was linear (eluent A 0.09% TFA in water; eluent B 0.09% TFA in 90% aqueous 
acetonitrile). 
 
The names of molecules was determined according to the IUPAC naming rules, the numerotation of 
the chain in NMR spectra followed the IUPAC’s rules (the more oxidized end of the molecule bears 
the label 1). 
New efficient synthetic routes toward functionalised polyketides.  
   
 
134
2 Synthesis of aminopolyols 
 
(3RS)-4-{(4SR,6RS)-6-[{(4SR,6SR)-6-{(2RS)-2-({[(Phenylmethyl)oxy]methyl}oxy)-4-
hydroxybutyl}-2,2-dimethyl-1,3-dioxan-4-yl}methyl]-2,2-dimethyl-1,3-dioxan-4-yl}-3-
({[(phenylmethyl)oxy]methyl}oxy)-butan-1-ol (137) 
 
2 4 5'
2'
1"
2"'
5"'
2IV 4IV
OH OHOP O OPO O O
P = BOM  
 
Prepared according to Gerber-Lemaire, S.; Vogel, P. Eur. J. Org. Chem. 2003, 2959-2963. 
 
IR (film): ν~  = 3045, 2945, 2870, 1495, 1455, 1405, 1380, 1205, 1165, 1105, 1045, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.41-7.25 (2m, 10Harom.), 4.74-4.22 (m, 4H, CH2(BOM)), 4.66, 4.58 
(2s, 4H, CH2Ph), 4.18-4.86 (3m, 8H, H-C3,2IV,6’,6’”,4’,4’”), 3.72-3.64 (m, 4H, H2-C1,3IV), 1.88-1.40 (3m, 
14H, H2-C2,4,1”,1IV,3IV,5’,5”’), 1.34-1.29 (m, 12H, CH3-C2’, CH3-C2”’) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 140.3 (s, Carom.), 129.3, 129.1, 128.6 (3d, Carom.), 100.1, 98.4 (2s, 
C2’,2”’), 94.7, 94.6 (2t, CH2(BOM)), 74.4, 73.4 (2d, C3,2IV), 69.6 (t, CH2Ph), 65.8, 65.5, 64.8, 63.5 (4d, 
C4’,6’,4”’,6”’), 59.1 (t, C1,4IV), 43.4, 42.9 (2t, C5’,5”), 42.8 (t, C1”), 42.7, 42.3, 38.3, 38.2 (4t, C4,1IV,2,3IV), 
30.3, 19.8 (2q, CH3-C2’), 25.4, 24.9 (2q, CH3-C2”’) ppm. 
 
MALDI-TOF-MS: 661.9 (M + H)+. 
 
Anal. for C37H56O10 (660.842): calculated C 67.25, H 8.54; found C 67.23, H 8.79. 
 
 
1H NMR spectrum of 137 
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(3RS,5SR,7RS,9SR,11SR,13RS)-1,15-Bis-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-3,13-bis-
({[(phenylmethyl)oxy]methyl}oxy)pentadecane-1,5,7,11,15-hexol (145) 
 
2 14
TBSO OTBSOP OH OPOH OH OH  
 
Prepared according to Popowycz, F. Thèse de l’EPFL 2866(2003). 
 
IR (film): ν~  = 3415, 2930, 2855, 1670, 1470, 1385, 1255, 1095, 1040, 940, 835, 775, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.40-7.28 (2m, 10Harom.), 4.86-4.82 (m, 4H, CH2(BOM)), 4.67, 4.62 
(2s, 4H, CH2Ph), 4.32-3.89 (2m, 6H, H-C3,5,7,9,11), 3.77 (t, 4H, H2-C1,15, 3J = 6.5), 1.88-1.40 (3m, 14H, 
H2-C2,4,6,8,10,12,14), 0.92 (s, 18H, tBuMe2Si(TBDMS)), 0.08 (s, 12H, tBuMe2Si(TBDMS)) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 140.2 (s, Carom.), 129.5, 129.4, 128.2 (3d, Carom.), 96.5 (t, 
CH2(BOM)), 71.7 (t, CH2Ph), 75.4, 75.2, 71.2, 69.2, 69.0, 68.8 (6d, C3,5,7,9,11,13), 61.6 (t, C1,15), 48.9, 
48.4, 47.4, 47.1, 46.9, 45.3, 40.7 (7t, C2,4,6,8,10,12,14), 27.3 (q, tBuMe2Si(TBDMS)), 20.0 (s, 
tBuMe2Si(TBDMS)), -4.3 ((2q, tBuMe2Si(TBDMS)),) ppm. 
 
CI-MS: 810.1 (M + H)+. 
 
Anal. for C43H76O10Si2 (809.291): calculated C 63.82, H 9.47; found C 63.96, H 9.62. 
 
 
1H NMR spectrum of 145 
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(3RS)-4-[(4SR,6RS)-6-({(4SR,6SR)-6-[(2RS)-4-(Acetyloxy)-2-
({[(phenylmethyl)oxy]methyl}oxy)butyl]-2,2-dimethyl-1,3-dioxan-4-yl}methyl)-2,2-dimethyl-1,3-
dioxan-4-yl]-3-({[(phenylmethyl)oxy]methyl}oxy)butyl acetate (146) 
 
2 4 5'
2'
1"
2"'
5"' 2IV4IV
OAc OAcOP O OPO O O
 
 
To a solution of diol 137 (304 mg, 0.460 mmol) in a 1/1 mixture of pyridine/Ac2O (6 mL) was added 
DMAP (15 mg, 0.122 mmol, 0.3 eq.). The reaction mixture was stirred at 25°C for 3 h. After 
completion of the reaction, solvents were evaporated in vacuo. The resulting oil was purified by flash 
chromatography (60% of EtOAc in pentane) affording diacetate 146 as a yellow oil (316 mg, quant.). 
 
IR (film): ν~  = 3030, 1740, 1380, 1245, 1170, 1105, 1045 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.34, 7.31-7.28 (2m, 10Harom.), 4.80, 4.79 (2s, 4H, CH2(BOM)), 
4.66, 4.58 (2d, 4H, CH2Ph, 2J = 11.9), 4.18-4.16 (t, 4H, H2-C1,1IV, 3J = 6.5), 4.06-3.86 (4m, 6H, H-
C3,3IV,6’,6’”,4’,4’”), 2.00 (s, 6H, CH3(OAc)), 1.93-1.80 (m, 4H, H2-C2,2IV), 1.73-1.53 (m, 4H, H2-C4,4IV), 
1.52-1.41 (m, 4H, H2-C5’,5”’), 1.34-1.29 (m, 12H, CH3-C2’, CH3-C2”’), 1.15-1.08 (m, 2H, H2-C1”) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 172.9 (s, C=O(OAc)), 139.3 (s, Carom.), 129.4, 128.9, 128.7 (3d, 
Carom., 1J = 160, 163, 165), 101.5, 99.8 (2s, C2’,2”’), 95.6 (2t, CH2(BOM), 1J = 162), 70.8 (t, CH2Ph, 1J = 
142), 74.5, 73.6 (2d, C3,3IV, 1J = 150, 140), 67.1, 66.3, 64.9, 64.3 (4d, C4’,6’,4”’,6”’, 1J = 139, 144, 140, 
147), 62.4 (t, C1,1IV, 1J = 132), 43.3, 42.8 (2t, C4,4IV, 1J = 133, 135), 39.6, 37.6, 35.7 (2t, C1”,5’,5”’, 1J = 
127, 125), 35.5 (t, C2,2IV, 1J = 126), 20.9 (q, CH3(OAc), 1J = 129), 30.6, 20.3 (2q, CH3-C2’, 1J = 127, 
128), 25.4, 25.2 (2q, CH3-C2”’, 1J = 125) ppm. 
 
MALDI-TOF-MS: 767.3 (M + Na)+, 783.6 (M + K)+. 
 
Anal. for C41H60O12 (744.928): calculated C 66.12, H 8.12; found C 66.14, H 8.02. 
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1H NMR spectrum of 146 
 
1H NMR spectrum of 147 
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(3RS)-4-[(4SR,6RS)-6-({(4SR,6SR)-6-[(2RS)-4-(acetyloxy)-2-hydroxybutyl]-2,2-dimethyl-1,3-
dioxan-4-yl}methyl)-2,2-dimethyl-1,3-dioxan-4-yl]-3-hydroxybutyl acetate (147) 
 
2 4 5'
2'
1"
2"'
5"' 2IV4IV
OAc OAcOH O OHO O O
 
 
Diacetate 146 (300 mg, 0.403 mmol) was dissolved in MeOH (5 mL) and stirred for 7 h at 25°C with a 
catalytic amount of Raney nickel under 1 atm. of hydrogen. The mixture was filtered over a pad of 
silice and washed with EtOAc. The filtrate was concentrated in vacuo and the crude oil was purified 
by flash chromatography (CH2Cl2 / MeOH 98 / 2) affording 147 as a yellow oil (90 mg, 45% yield). 
 
IR (film): ν~  = 3450, 2920, 1740, 1740, 1730, 1715, 1385, 1245 cm-1. 
 
1H-NMR (400 MHz, C6D6): δ = 4.38-4.29 (m, 2H, H-C3,2IV), 4.20-4.14 (m, 4H, H2-C1,4IV), 4.03-4.39 
(m, 4H, H-C6’,4’,6”’,4”’), 1.65 (2s, 6H, CH3(OAc)), 1.65-1.60 (m, 4H, H2-C2,3IV), 1.49-1.35 (m, 10H, H2-
C4,5’,1”,5”’,1IV), 1.30-1.29 (4s, 12H, CH3-C2’, CH3-C2”’)) ppm. 
 
13C-NMR (100 MHz, C6D6): δ = 170.6 (s, C=O(OAc)), 100.6, 98.8 (2s, C2’,2”’), 61.8, 61.7 (2d, C3,2IV, 
1J = 149), 61.8, 64.4 (2t, C1,4IV, 1J = 149), 65.1, 65.3, 65.4, 67.1 (4d, C6’,4’,6”’,4”’, 1J = 140, 150, 178, 
169), 42.9, 42.6 (2t, C5’,5’’’, 1J = 131, 129), 38.8, 38.3, 37.4, 37.1, 37.1 (5t, C2,4,1”,1IV,3IV, 1J = 126, 123, 
128), 20.5 (q, CH3(OAc), 1J = 129), 30.5, 19.8 (2q, CH3-C2’, 1J = 126, 125), 24.8, 24.7 (2q, CH3-C2”’, 
1J = 121) ppm. 
 
MALDI-TOF-MS: 527.3 (M + Na)+, 543.7 (M + K)+. 
 
General procedure for the selective hydrolysis of anti-diol acetonides 
 
The polyacetonide derivative was dissolved in dichloromethane (concentration: 0.05 M) and cooled to 
-20°C. p-Toluenesulfonic acid (0.05 eq) was added and the mixture was stirred at -20°C for 3 h 
(monitoring by TLC). The reaction mixture was directly purified by flash chromatography (4% MeOH 
in CH2Cl2) to afford the monodeprotected derivative as a colourless oil. Otherwise, the reaction 
mixture could also be worked-up by pouring into a saturated aqueous solution of NaHCO3. The 
aqueous layer was extracted with CH2Cl2 (3 times). The combined organic extracts were dried 
(MgSO4) and concentrated in vacuo. The residue was purified as mentioned above. 
 
 
(3R,5R,7R)-8-{(4R,6S)-6-[(2R)-4-Hydroxy-2-({[(phenyl methyl)oxy]methyl}oxy)butyl]-2,2-
dimethyl-1,3-dioxan-4-yl}-3-({[(phenylmethyl)oxy]methyl}oxy)octane-1,5,7-triol (148) 
 
2'
4'
5'
6'1
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OH OHOP OH O O OPOH
8 1" 3"
4"
 
 
Starting from 137 (70 mg, 0.106 mmol), 148 (53 mg, 80%) was obtained as a pale yellow oil. 
 [ ]23405α = -223, [ ]23435α = -120, [ ]23577α = -22, [ ]23589α = -10 (c = 0.4, MeOH). 
 
IR (film): ν~  = 3415, 2940, 1650, 1430, 1380, 1265, 1200, 1160, 1100, 1035, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.38-7.24 (m, 10Harom.), 4.82 (s, 4H, CH2(BOM)), 4.64-4.60 (m, 4H, 
CH2Ph), 4.13-4.09 (m, 2H, H-C5,7), 4.08-3.96 (m, 4H, H-C3,4’,6’,2”), 3.67 (t, 4H, H2-C1,4”, 3J = 6.68), 
1.82-1.77 (m, 4H, H2-C2,3”), 1.69-1.65, 1.63-1.42, 1.2-1.05 (3m, 10H, H2-C4,6,8,5’,1”), 1.42, 1.29 (2s, 6H, 
CH3-C2’) ppm. 
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13C-NMR (100 MHz, MeOD): δ = 138.8 (s, Carom.), 128.4, 127.9, 127.7 (3d, Carom., 1J = 161, 160, 157), 
98.9 (s, C2’), 94.5, 94.4 (2t, CH2(BOM), 1J = 163), 73.5, 73.4, (2d, C3,2”, 1J = 143), 69.8 (t, CH2Ph, 1J = 
143), 67.5, 66.2 (2d, C5,7, 1J = 134, 153), 65.3, 64.4 (2d, C4’,6’, 1J = 164, 144), 58.5, 58.3 (t, C1,4”, 1J = 
141), 44.8, 44.4, 43.7, 43.1 (4t, C4,8,5’,1”, 1J = 126, 127, 124, 126), 38.4, 38.3 (2t, C2,3”, 1J = 122), 37.6 
(t, C6, 1J = 127), 29.6, 19.2 (2q, CH3-C2’, 1J = 126, 125) ppm. 
 
MALDI-TOF-MS: 643.5 (M+Na)+, 659.4 (M+K)+. 
 
Anal. for C34H52O10 (620.775): calculated C 65.78, H 8.44; found C 65.75, H 8.49. 
 
 
1H NMR spectrum of 148 
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(3RS,5RS,7SR)-8-{(4RS,6RS)-6-[(2SR)-4-Hydroxy-2-({[(phenyl methyl)oxy]methyl}oxy)butyl]-
2,2-dimethyl-1,3-dioxan-4-yl}-3-({[(phenylmethyl)oxy]methyl}oxy)octane-1,5,7-triol (149) 
 
2'
4'
5'
6' 1
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Starting from 141 (82 mg, 0.124 mmol), 149 (53 mg, 69%) was obtained as a pale yellow oil. 
 
IR (film): ν~  = 3415, 2945, 1650, 1430, 1285, 1200, 1160, 1100, 1035, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.38-7.15 (m, 10Harom.), 4.83-4.78 (s, 4H, CH2(BOM)), 4.67-4.60 
(m, 4H, CH2Ph), 4.12-3.95 (m, 6H, H-C5,7,3,4’,6’,2”), 3.70-3.65 (m, 4H, H2-C1,4”), 1.82-1.75 (m, 4H, H2-
C2,3”), 1.62-1.29, 1.23-1.08 (2m, 10H, H2-C4,6,8,5’,1”), 1.39, 1.30 (2s, 6H, CH3-C2’) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 138.3 (s, Carom.), 128.4, 128, 127.7 (3d, Carom., 1J = 159, 159, 162), 
99 (s, C2’), 94.6, 94.5 (2t, CH2(BOM), 1J = 169), 73.4, 72.8 (2d, C3,2”, 1JC,H = 139, 132), 69.8, 69.7 (t, 
CH2Ph, 1J = 147), 66.3, 66.0 (2d, C5,7, 1J = 139, 138), 65.1, 64.6 (2d, C4’,6’, 1J = 133, 145), 58.5, 58.4 
(t, C1,4”, 1J = 141), 45.8, 44.7, 43.7, 42.9 (4t, C4,8,5’,1”, 1J = 115, 117, 126, 125), 38.5, 38.3 (2t, C2,3”, 1J = 
122, 127), 38.1 (t, C6, 1J = 127), 29.6, 19.3 (2q, CH3-C2’, 1J = 127, 126) ppm. 
 
MALDI-TOF-MS: 643.3 (M+Na)+, 659.3 (M+K)+. 
 
Anal. for C34H52O10 (620.775): calculated C 65.78, H 8.44; found C 65.72, H 8.35. 
 
 
 
1H NMR spectrum of 149 
 
 
 
 
New efficient synthetic routes toward functionalised polyketides.  
   
 
141
(2RS,4RS,6RS)-8-{[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}-1-{(4RS,6SR)-6-[(2RS)-4-{[(1,1-
dimethylethyl)(dimethyl)silyl]oxy}-2-({[(phenyl methyl)oxy]methyl}oxy)butyl]-2,2-dimethyl-1,3-
dioxan-4-yl}-6-({[(phenylmethyl)oxy]methyl}oxy)octane-2,4-diol (151) 
 
2'
4'
5'
6'
15 37
OTBS OTBSOP OH O O OPOH
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Starting from 150 (90 mg, 0.101 mmol), 151 (58 mg, 68%) was obtained as a pale yellow oil. 
 
IR (film): ν~  = 3520, 2940, 2860, 1735, 1465, 1380, 1255, 1200, 1165, 1105, 1040, 840, 780, 740, 
700, 660 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.50-7.24 (m, 10Harom.), 4.83 (s, 4H, CH2(BOM)), 4.26, 4.63 (2s, 
4H, CH2Ph), 4.20-3.85 (2m, 6H, H-C2,4,6,4’,6’,2”), 3.74 (t, 4H, H2-C7,4”, 3J = 5.68), 1.78-1.40 (m, 4H, H2-
C7,3”), 1.78-1.40, 1.23-1.08 (3m, 10H, H2-C1,3,5,5’,1”), 1.42, 1.28 (2s, 6H, CH3-C2’), 0.92 (s, 18H, 
tBuMe2Si(TBDMS)), 0.13 (2s, 12H, tBuMe2Si(TBDMS)) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 138.3 (s, Carom.), 128.4, 127.9, 127.7 (3d, Carom., 1J = 159, 160, 158), 
98.9 (s, C2’), 94.6, 94.5 (2t, CH2(BOM), 1J = 162), 73.5 (2d, C6,2”, 1J = 138), 69.8 (t, CH2Ph, 1J = 142), 
67.5, 66.2 (2d, C2,4, 1J = 142, 134), 65.3, 64.4 (2d, C4’,6’, 1J = 141, 146), 59.7 (t, C8,4”, 1J = 142), 44.7, 
44.4, 43.8, 43.3 (4t, C1,5,5’,1”, 1J = 126, 127, 128, 125), 38.8 (2t, C7,3”, 1J = 126), 37.6 (t, C3, 1J = 125), 
29.6, 19.3 (2q, CH3-C2’, 1J = 127, 126), 25.4 (q, tBuMe2Si(TBDMS), 1J = 129), 24.1 (s, 
tBuMe2Si(TBDMS)), -6.2 (q, tBuMe2Si(TBDMS), 1J = 127) ppm. 
 
MALDI-TOF-MS: 871.6 (M+Na)+, 887.6 (M+K)+. 
 
Anal. for C46H80O10Si2 (849.292): calculated C 65.05, H 9.49, Si 6.61; found C 65.11, H 9.55, Si 6.54. 
 
 
1H NMR spectrum of 151 
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General procedure for the selective acetylation of primary alcohols 
 
To a solution of semi-protected polyol in vinyl acetate (concentration: 0.1 M), lipase from Candida 
Cylindracea (4800 u.mmol-1) were added at 25°C. The resulting brown suspension was stirred for 1 h 
at 25°C. The resulting mixture was filtered over a pad of celite®. Removal of the solvent in vacuo 
afforded a crude oil, which was purified by flash chromatography (3% of MeOH in CH2Cl2) affording 
the corresponding diacetates as pale yellow oils in quantitative yields. 
 
(3RS,5RS,7RS,9SR,11RS,13RS)-15-(Acetyloxy)-5,7,9,11-tetrahydroxy-3,13-
bis({[(phenylmethyl)oxy]methyl}oxy)pentadecyl acetate (152) 
 
OAc OAcOP OH OPOH OH OH
1
2468101214
15
 
 
IR (film): 3440, 2940, 1735, 1455, 1370, 1245, 1100, 1090, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): 7.37-7.25 (m, 10Harom.), 4.84, 481 (2d, 4H, CH2(BOM), 2J = 7.0, 6.9), 
4.63 (s, 4H, CH2Ph), 4.18 (t, 4H, H2-C1,15, 3J = 6.8), 4.04-3.98 (m, 6H, H-C3,5,7,9,11,13), 2.01 (s, 6H, 
CH3(OAc)), 1.90 (m, 4H, H2-C2,14), 1.64-1.50 (m, 10H, H2-C4,6,8,10,12) ppm. 
 
13C-NMR (100 MHz, MeOD): 172.9 (s, C=O(OAc)), 139.3 (s, Carom.), 129.4, 128.9, 128.7 (3d, Carom., 
1J = 160, 159, 160), 95.5 (t, CH2(BOM), 1J = 164), 74.1, 73.9, 70.1, 68.1, 67.8, 65.8 (6d, C3,5,7,9,11,13, 1J 
= 143, 144, 140, 140, 142, 146), 70.9 (t, CH2Ph, 1J = 144), 63.4 (t, C1,15, 1J = 151), 46.6, 46.4, 45.9, 
44.5, 44.2 (5t, C4,6,8,10,12, 1J = 120, 123, 127, 125, 126), 35.5 (t, C2,14, 1J = 127), 20.9 (q, CH3(OAc), 1J 
= 129). 
 
ESI-MS: 665.3 (M+H)+. 
 
MALDI-TOF-HRMS for (C35H52O12 + Na)+: calculated 687.3359; found 687.3356. 
 
 
1H NMR spectrum of 152 
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(3RS)-4-{(4SR,6RS)-6-[(2RS,4RS,6RS)-8-(Acetyloxy)-2,4-dihydroxy-6-
({[(phenylmethyl)oxy]methyl}oxy)butyl]-2,2-dimethyl-1,3-dioxan-4-yl}-3-
({[(phenylmethyl)oxy]methyl}oxy)butyl acetate (153) 
 
OAc OAcOPOOOHOHOP
8"
7" 5" 3" 1"
6' 4'
2'
4 2
1
 
 
IR (film): ν~  = 3500, 2940, 1735, 1450, 1375, 1245, 1040 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.37-7.15 (m, 10Harom.), 4.83, 4.80 (2d, 4H, CH2(BOM)), 2J = 7.2, 
7.4), 4.63 (s, 4H, CH2Ph), 4.19 (t, 4H, H2-C1,8”, 3J = 6.6), 4.17-4.07 (m, 2H, H-C2”,4”), 4.05-3.95 (m, 
4H, H-C3,4’,6’,6”), 2.00 (s, 6H, CH3(OAc)), 1.90-1.87 (m, 4H, H2-C2,7”), 1.70-1.47, 1.55-1.47, 1.23-1.08 
(3m, 10H, H2-C4,5’,1”,3”,5”), 1.43, 1.29 (2s, 6H, CH3-C2’) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 171.9 (s, C=O(OAc)), 138.0 (s, Carom.), 128.4, 127.9, 127.7 (3d, 
Carom.), 98.9 (s, C2’), 94.6, 94.5, (2t, CH2(BOM)), 73.5, 73.4, (2d, C3,6”), 69.8 (t, CH2Ph), 67.5, 66.4, 
65.3, 64.4 (4d, C4’,6’,2”,4”), 61.4 (t, C1,8”), 44.8, 44.5, 43.6, 43.0, 37.6 (5t, C4,5’,1”,3”,5”), 34.5, 34.4 (2t, 
C2,7”), 29.6, 19.9 (2q, CH3-C2’), 19.2 (q, CH3(OAc)) ppm. 
 
ESI-MS: 705.3 (M+H)+. 
 
MALDI-TOF-HRMS for (C38H56O12 + Na)+: calculated 727.3669; found 727.3665. 
 
C38H56O12 (704.844). 
 
 
1H NMR spectrum of 153 
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(4RS,6SR)-2,2-Dimethyl-4,6-bis{[(2SR,4SR)-6-(methyloxy)-4-
({[(phenylmethyl)oxy]methyl}oxy)tetrahydro-2H-pyran-2-yl]methyl}-1,3-dioxane (155) 
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α:α/β:β 2/1 
 
A solution of diolefin 134 (500 mg, 0.861 mmol) in dry CH2Cl2 (26 mL) was ozonolysed at -78°C for 
5 mn. A stream of dry O2 was then passed through the solution for 2 mn, and 250 μL of Me2S (3.445 
mmol, 4 eq.) were added dropwise. After stirring at -78°C for 10 mn, the solvent was evaporated at 
0°C in vacuo. The residue was taken up in THF/MeOH 3/1 (16 mL) at 0°C and 5.2 mL of a 1 M 
solution of diethylmethoxyborane in THF (5.766 mmol, 6 eq.) were added. The resulting mixture was 
stirred for an additional hour at 0°C and then cooled at -20°C. NaBH4 (260 mg, 6.891 mmol, 8 eq.) 
were added portionwise, and the temperature was kept below -20°C for 2 h. The reaction mixture was 
poured into water (25 mL) and extracted with EtOAc (20 mL, 3 times). The combined organic layers 
were dried over MgSO4 and concentrated in vacuo. Purification of the residue by flash 
chromatography (5% to 10% of MeOH in CH2Cl2) afforded bis(hemiacetals) 154 as a colourless oil 
(274 mg, 55% over 3 steps).  
Bis(hemiacetals) 154 (65 mg, 0.113 mmol) in MeOH (3 mL) was treated with 5 mg of 
camphorsulfonic acid (0.023 mmol, 0.2 eq.) at 25°C during 2 h. The reaction mixture was then poured 
into a saturated aqueous solution of NaHCO3 (10 mL) and extracted with EtOAc (10 mL, 3 times). 
The combined organic layers were washed with brine (20 mL), dried over MgSO4 and concentrated in 
vacuo. Purification of the residue by flash chromatography (5% of MeOH in CH2Cl2) afforded the 
corresponding methyl pyranosides as a colourless oil (58 mg, 85%). The resulting diol was dissolved 
in a mixture of acetone/2,2-dimethoxypropane (0.3 mL/3 mL) and 8 mg of p-toluenesulfonic acid 
(0.042 mmol, 0.4 eq.) were added to the mixture cooled at 0°C. The solution was stirred at 0°C for 1 h. 
The mixture was poured into a saturated aqueous solution of NaHCO3 (10 mL) and extracted with 
CH2Cl2 (10 mL, 3 times). The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. Purification of the residue by flash chromatography (3% of MeOH in CH2Cl2) afforded 155 as 
a colourless oil (52 mg, 87%). 
 
IR (film): ν~  = 2940, 1450, 1380, 1260, 1200, 1160, 1115, 1045, 980, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.25 (m, 10Harom.), 4.82 (s, 2H, H-C2’’), 4.81, 4.78 (2d, 4H, 
CH2(BOM), 2J = 5.6, 6.9), 4.60 (s, 4H, CH2Ph), 4.27 (m, 1H, H-C2’’, 3J = 8.2), 4.13-3.97 (m, 2H, H-
C6’’), 4.23-3.84 (2m, 4H, H-C4,4’’,6), 3.4, 3.3 (2s, 6H, CH3(OMe)), 2.3-1.9, 1.6-1.4 (2m, 10H, H2-
C3”,5’’,5), 1.7-1.5, 1.3-1.1 (2m, 4H, H2-C1’), 1.36, 1.26 (m, 6H, CH3-C2) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 140.4 (s, Carom.), 130.4, 130.0, 129.7 (3d, Carom., 1J = 160, 159, 160), 
101.5, 101.2 (2d, C2”,1J = 160, 162), [103.6, 103.5 (C2”Min.)], 95.0, 94.8 (2t, CH2(BOM), 1J = 163), 
[95.1, 94.9(CH2(BOM)Min.)], 72.0, 71.8 (2d, C6”,1J = 148, 144), [74.5, 74.4 (C6”Min.)], 71.5, 71.4 (2t, 
CH2Ph, 1J = 144), 68.2, 67.4, 66.4, 65.7 (4d, C4,6,4’’, 1J = 140, 139, 145, 144), [70.6, 70.0, 68.3, 67.5 
(C4,6,4’’Min.)], 56.2, 55.9 (2q, CH3(-OMe), 1J = 147, 142), [57.8, 57.7 (CH3(-OMe)Min.)], 45.3, 44.4 (2t, 
C1’, 1J = 127, 128), [44.6, 44.0 (C1’Min.)], 41.2, 40.6, 39.1 (3t, C3’’,5’’,5, 1J= 128, 130, 126), 31.6, 21.3 
(2q, CH3-C2, 1J = 123, 127) ppm. 
 
MALDI-TOF-MS: 667.3 (M+Na)+, 683.4 (M+K)+. 
 
Anal. for C36H52O10 (644.792): calculated C 67.06, H 8.13; found C 67.06, H 8.16. 
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1H NMR spectrum of 155 
 
 
 
1H NMR spectrum of 157 
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Dimethyl (2E,5RS,7RS,9RS,11SR,13RS,15RS,17E)-7,9,11,13-tetrahydroxy-5,15-
bis({[(phenylmethyl)oxy]methyl}oxy)nonadeca-2,17-dienedioate (157) 
 
1
6
OP OH OH OH OPOH
1214
3
81016
17
4
OMe
O
OMe
O
19
 
 
Phosphonium salt was prepared according to the procedure of Aspinall.1 
A solution of 154 (200 mg, 0.345 mmol) dissolved in toluene (3 mL) was added to the phosphorus 
ylide (1.724 mmol, 5 eq.). The resulting mixture was heated at 80°C for 3 h before being concentrated 
in vacuo. The crude oil was purified by flash chromatography (3-7% MeOH in CH2Cl2) affording α,β-
unsaturated methyl ester 157 (170 mg, 72% based on recovered staring material). E/Z mixture, E is the 
major compound. 
 
IR (film): ν~  = 3435, 2945, 2545, 1715, 1655, 1440, 1380, 1275, 1165, 1100, 1040, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.34-7.25 (m, 10Harom.), 7.02 (dt, 2H, H-C3,17, 3J = 7.2, 15.6), 5.92 
(d, 2H, H-C2,18, 3J = 15.6), 4.83 (s, 4H, CH2(BOM)), 4.67-4.58 (m, 4H, CH2Ph), 4.10-3.90 (m, 6H, H-
C5,7,9,11,13,15), 3.67 (s, 6H, CH3(OMe)), 2.57-2.45 (m, 4H, H2-C4,16), 1.74-1.46 (m, 12H, H2-C6,8,10,12,14,16) 
ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 167.3 (s, C1,19), 146.1 (2d, C3,17E, 1J = 156), 146.5 (2d, C3,17Z), 138.2 
(s, Carom.), 128.3, 127.9, 127.7 (3d, Carom, 1J = 160, 156, 160), 123.1 (d, C2,18E, 1J = 163), 120.8 (d, 
C2,18Z), 94.3, 94.2 (t, CH2(BOM), 1J = 163), 74.3, 74.1 (2d, C5,15, 1J = 141), 69.8, 69.7 (t, CH2Ph, 1J = 
144), 69.2, 67.1, 66.7, 64.7 (4d, C7,9,11,13, 1J = 144, 142, 141, 142), 50.9 (q, CH3(OMe)E, 1J = 147), 50.6 
(q, CH3(OMe)Z), 45.3, 44.9, 44.8, 43.2, 42.9 (5t, C6,8,10,12,14, 1J = 125, 125, 124, 124, 122), 38.1 (2t, 
C4,16E, 1J = 128, 129), 34.6 (2t, C4,16Z, 1J = 122) ppm. 
 
MALDI-TOF-MS: 710.9 (M+Na)+, 726.9 (M+K)+. 
 
Anal. for C37H52O12 (688.802): calculated C 64.52, H 7.61; found C 64.54, H 7.68. 
 
 
(3R,5R,7S,9S,11S,13R)-3,13-Bis({[(phenylmethyl)oxy]methyl}oxy)-9-{[(1,1-
dimethylethyl)(dimethyl)silyl]oxy}pentadecane-1,5,7,11,15-pentol (169) 
 
OH OHOP OTBS OH OH OPOH
1 15
 
 
To a solution of 154 (165 mg, 0.285 mmol) in CH2Cl2 (2.8 mL), cooled to -50°C, were added 2,6-
lutidine (100 μL, 0.855 mmol, 3 eq.) and a 0.5 M solution of tert-butyldimethylsilyl 
trifluoromethanesulfonate in CH2Cl2 (900 μL, 0.456 mmol, 1.6 eq.). The resulting mixture was stirred 
for 1.5 h at -40°C before being poured into a saturated aqueous solution of NaHCO3 (15 mL) and 
extracted with EtOAc (10 mL, 3 times). The combined organic layers were washed with brine (30 
mL), dried over MgSO4 and concentrated in vacuo. The crude oil was used in the following reaction 
without further purification. The crude oil was dissolved in MeOH (3 mL) and treated with NaBH4 (90 
mg, 2.280 mmol, 8 eq.) at 25°C for 1 h. The reaction mixture was poured into water (20 mL) and 
extracted with EtOAc (20 mL, 3 times). The combined organic layers were washed with brine (50 
mL), dried over MgSO4 and concentrated in vacuo. Purification of the residue by flash 
chromatography (4% of MeOH in CH2Cl2) afforded 169 as a pale yellow oil (106 mg, 53% over 2 
steps). 
                                                 
1 Aspinall, I. H.; Cowley, P. M.; Mitchell, G; Raynor, C. M.; Stoodley, R. J. Chem. Soc., Perkin Trans. 1 1999, 
2591-2599. 
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 [ ]23405α = +31, [ ]23435α = +26, [ ]23577α = +13 (c = 1.4, MeOH). 
 
IR (film): ν~  = 3445, 2930, 1645, 1450, 1255, 1100 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.22 (m, 10Harom.), 4.86 (brs, 4H, CH2(BOM)), 4.67 (brs, 4H, 
CH2Ph), 4.20-4.12 (m, 1H, H-C9), 4.09-3.92 (m, , 4H, H-C3,5,7,13), 3.89-3.81 (m, 1H, H-C11), 3.70-3.62 
(m, 4H, H2-C1,15), 1.91-1.77 (m 4H, H2-C2,14), 1.77-1.44 (m, 10H, H2-C4,6,8,10,12), 0.92 (s, 9H, 
tBuMe2Si(TBDMS)), 0.13 (2s, 6H, tBuMe2Si(TBDMS)) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 138.3 (s, Carom.), 128.4, 128.0, 127.7 (3d, Carom., 1J = 159, 160, 159), 
94.5 (2t, CH2(BOM), 1J = 163), 73.5, 73.3 (d, C3,13, 1J = 142), 69.8, 69.3 (2t, CH2Ph, 1J = 140, 142), 
67.8 (d, C11, 1JC,H = 146), 67.5 (d, C9, 1J = 140), 67.1, 64.9 (2d, C5,7, 1J = 143, 144), 58.5, 58.3 (2t, 
C1,15, 1J = 148, 147), 45.9, 45.4, 44.6, 44.0, 43.4 (5t, C4,6,8,10,12, 1J = 127, 125, 125, 124, 128), 38.4, 
38.3 (2t, C2,14, 1J = 126), 25.4 (q, tBuMe2Si(TBDMS), 1J = 129), 17.8 (s, tBuMe2Si(TBDMS)), -4.5, -
5.0 (2q, tBuMe2Si(TBDMS), 1J = 118) ppm. 
 
MALDI-TOF-MS: 716.7 (M+Na)+, 732.7 (M+K)+. 
 
Anal. for C37H62O10Si (694.97): calculated C 63.94, H 8.99, Si 4.04; found C 64.05, H 8.83, Si 3.90. 
 
 
1H NMR spectrum of 169 
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(3R,5S,7R)-3-({[(phenylmethyl)oxy]methyl}oxy)-8-((4S,6S)-6-{(2R)-2-
({[(phenylmethyl)oxy]methyl}oxy)-4-hydroxybutyl}-2,2-dimethyl-1,3-dioxan-4-yl)-7-{[(1,1-
dimethylethyl)(dimethyl)silyl]oxy}octane-1,5-diol (171) 
 
4' 6'
84 62
OH OHOP OTBS O O OPOH
1
1'' 3''
4''
2'
 
 
To a solution of 169 (60 mg, 0.086 mmol) in a mixture of acetone/2,2-dimethoxypropane (0.3 mL/3 
mL) cooled to 0°C, was added p-toluenesulfonic acid (5 mg, 0.026 mmol, 0.3 eq). The resulting 
mixture was stirred at 0°C for 1 h before being poured into a saturated aqueous solution of NaHCO3 
(10 mL) and extracted with EtOAc (10 mL, 3 times). The combined organic layers were washed with 
brine (30 mL), dried over MgSO4 and concentrated in vacuo. Purification of the residue by flash 
chromatography (3% of MeOH in CH2Cl2) afforded 171 as a pale yellow oil (62 mg, 75%). 
 [ ]23405α = +61, [ ]23435α = +52, [ ]23577α = +27, [ ]23589α = +26 (c = 0.95, CHCl3). 
 
IR (film): ν~  = 3440, 2945, 1460, 1430, 1380, 1255, 1200, 1160, 1040, 835, 780, 700 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 7.43-7.27 (m, 10Harom.), 4.86, 4.83 (2d, 4H, CH2(BOM), 2J = 7.6, 
8.4), 4.67 (2d, 4H, CH2Ph, 2J = 10.2, 11.4), 4.17-4.04 (2m, 4H, H-C2’’,3,7,5), 4.02-3.87 (2m, 2H, H-
C4’,6’), 3.86-3.77, 3.76-3.69 (2m, 4H, H2-C1,4’’), 1.89-1.72 (2m, 6H, H2-C1’’,3’’,2), 1.68-1.52, 1.23-1.08 
(2m, 8H, H2-C4,6,8,5’), 1.35, 1.33 (2s, 6H, CH3-C2’), 0.89 (s, 9H, tBuMe2Si(TBDMS)), 0.08 (2s, 6H, 
tBuMe2Si(TBDMS)) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 137.9, 137.8 (2s, Carom.), 128.9, 128.2 (2d, Carom., 1J = 160), 98.9 (s, 
C2’), 95.3, 95.1 (2t, CH2(BOM), 1J = 163), 74.2, 74.0 (2d, C3,2’’, 1J = 149), 70.4 (t, CH2Ph, 1J = 141), 
68.3 (d, C7, 1J = 140), 66.1, 65.9 (2d, C4’,6’, 1J = 137, 141), 65.2 (d, C5, 1J = 143), 59.9, 59.8 (2t, C1,4’’, 
1J = 146), 43.8, 43.2, 42.9, 42.6 (4t, C5’,4,6,8, 1J = 127, 124, 126), 38.3, 38.1, 38.0 (3t, C3’’,1’’,2, 1J = 126), 
30.5, 20.1 (2q, CH3-C2’, 1J = 123, 128), 26.2 (q, tBuMe2Si(TBDMS), 1J = 126), 18.3 (s, 
tBuMe2Si(TBDMS)), -4.2, -4.3 (2q, tBuMe2Si(TBDMS), 1J = 118) ppm. 
 
MALDI-TOF-MS: 757.4 (M+Na)+, 773.4 (M+K)+. 
 
Anal. for C40H66O10Si (735.03): calculated C 65.36, H 9.03, Si 3.82; found C 65.33, H 9.02, Si 3.79. 
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1H NMR spectrum of 171 
 
 
 
1H NMR spectrum of 176 
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General procedure for the transformation of semi protected polyols in fully deprotected 
aminopolyols. 
 
Semi protected polyol was dissolved in CH2Cl2 (0.1 M) and treated at 0°C with 4.5 eq. of 
triethylamine per free alcohol and 1.5 eq. of methanesulfonyl chloride per free alcohol. After 
completion of the reaction (1 to 2 h), the mixture was poured into a saturated aqueous solution of 
NH4Cl and extracted with EtOAc (3 times). The combined organic layers were washed with brine, 
dried over MgSO4 and concentrated in vacuo. The crude oil was used in the following reaction without 
further purification. The crude oil was dissolved in DMF (0.75 M) and heated at 60°C for 12 h with 5 
eq. of sodium azide per mesylate. The mixture was poured into water and extracted with EtOAc (3 
times). The combined organic layers were washed with brine, dried over MgSO4 and concentrated in 
vacuo. The crude oil was used in the following reaction without further purification. The crude oil was 
dissolved in MeOH an a catalytic amount of Pd(OH)2 on activated charcoal was added. The resulting 
suspension was vigorously stirred under 1 atm. of hydrogen at 25°C. After completion of the reaction 
(monitored by TLC: CH3CN/NH4OH), the mixture was filtered over a pad of celite® and concentrated 
in vacuo. The crude oil was used in the following reaction without further purification. The crude oil 
was dissolved in a 4/1 mixture of TFA/H2O. After completion of the reaction (monitored by TLC: 
CH3CN/NH4OH), solvents were removed under vacuo. The crude oil was purified by flash 
chromatography (CH3CN/NH4OH 2/1 to 1/2) affording the corresponding di- and tri-aminopolyols. 
 
(3R,5S,7R,9R,11R,13R)-1,11,15-Triaminopentadecane-3,5,7,9,13-pentol (176) 
 
1
24
NH2 NH2OH OH OH OH OHNH2
101214
15
68
 
 
Starting from 171 (322 mg, 0.439 mmol), 176 (40 mg, 27% over 4 steps) was obtained as a white 
foam. 
 [ ]23435α = +5.5, [ ]23589α = +3 (c = 0.19, MeOH). 
 
IR (KBr): ν~  = 3405, 1740, 1650, 1560, 1515, 1070 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 4.1-3.88 (m, 5H, H-C3,5,7,9,13), 3.46-3.34 (m, 1H, H-C11), 3.19-3.00 (m, 
4H, H2-C1,15), 1.95-1.54 (m, 14H, H2-C2,4,6,8,10,12,14) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 70.2, 69.8, 68.4, 68.3 (4d, C3,5,7,9,13), 46.3, 46.0, 43.8 (3t, C4,6,8,10,12), 
38.1, 38.0 (2t, C2,14), 39.6, 39.3 (2t, C1,11,15) ppm. 
 
MALDI-TOF-HRMS for (C15H35O5N3 + H)+: calculated 338.2653; found 338.2664. 
 
C15H35O5N3 (337.455). 
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(3RS,5SR,7RS,9SR,11SR,13RS)-1,15-Diaminopentadecane-3,5,7,9,11,13-hexol (177) 
 
1
2 4 10 12 14
15
6 8
NH2 NH2OH OH OH OH OHOH  
 
Starting from 137 (391 mg, 0.591 mmol), 177 (46 mg, 23% over 4 steps) was obtained as a white 
foam. 
 
IR (KBr): ν~  = 3040, 1655, 1565, 1435, 1075, 795 cm-1. 
 
1H NMR (400 MHz, D2O): δ = 4.02-3.94 (m, 6H, H-C3,5,7,9,11,13), 3.11-3.01 (m, 4H, H2-C1,15), 1.82-1.60 
(m, 14H, H2-C2,4,6,8,10,12,14) ppm. 
 
13C NMR (100 MHz, D2O): δ = 68.05, 66.6, 66.5, 66.3, 64.8 (5d, C3,5,7,9,11,13), 45.1, 44.9, 44.6, 44.4, 
43.8 (5t, C4,6,8,10,12), 38.2, 37.5 (2t, C1,15), 38.0, 37.9 (2t, C2,14) ppm. 
 
MALDI-TOF-HRMS for (C15H34O6N2 + Na)+: calculated 361.2315; found 361.2328. 
 
C15H34O6N2 (338.440). 
 
 
1H NMR spectrum of 177 
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(3R,5R,7S,9S,11S,13R)-15-(Acetyloxy)-9-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-5,7,11-
trihydroxy-3,13-bis({[(phenylmethyl)oxy]methyl}oxy)pentadecyl acetate (178) 
 
6812 1014
OAc OAcOP OTBS OH OH OPOH
15
4 2
1
 
 
Starting from 169 (134 mg, 0.191 mmol) the general procedure for selective acetylation afforded 178 
(150 mg, quant.) as a pale yellow oil. 
 [ ]23405α = +56, [ ]23435α = +47, [ ]23589α = +24 (c = 2.5, MeOH). 
 
IR (film): ν~  = 3460, 2945, 2860, 1740, 1460, 1430, 1370, 1250, 1100, 1040, 835, 780, 740, 700 cm-1. 
 
1H NMR (400 MHz, MeOD): δ = 7.35-7.24 (m, 10Harom.), 4.83, 4.79 (2d, 4H, CH2(BOM), 2J = 6.7, 
6.4), 4.62 (d, 4H, CH2Ph, 2J = 8.8), 4.18 (t, 4H, H2-C1,15, 3J = 6.2), 4.18-4.15 (m, 1H, H-C11), 4.11-3.95 
(m, 4H, H-C3,5,7,13), 3.91-3.78 (m, 1H, H-C9), 2.0 (s, 6H, CH3(OAc)), 1.93-1.85 (m, 4H, H2-C2,14), 
1.75-1.47 (m, 10H, H2-C4,6,8,10,12), 0.90 (s, 9H, tBuMe2Si(TBDMS))), 0.11 (2s, 6H, 
tBuMe2Si(TBDMS)) ppm. 
 
13C NMR (100 MHz, MeOD): δ = 171.9 (s, C=O(OAc)), 138.2 (s, Carom.), 128.4, 127.9, 127.7 (3d, 
Carom., 1J = 159, 160, 159), 94.5, 94.4, (2t, CH2(BOM), 1J = 163), 72.8 (d, C3,13,1J = 142), 69.9, 69.7 (t, 
CH2Ph, 1J = 140), 67.6 (d, C11, 1J = 146), 67.3 (d, C9, 1J = 140), 66.9, 64.8 (2d, C5,7, 1J = 143, 144), 
61.4 (t, C1,15, 1J = 148), 46.0, 45.4, 44.4, 43.8, 43.2 (5t, C4,6,8,10,12, 1J = 127, 125, 125, 124, 128), 34.4, 
34.3 (t, C2,14, 1J = 126), 25.4 (q, tBuMe2Si(TBDMS), 1J = 129), 24.1 (s, tBuMe2Si(TBDMS)), 19.9 (q, 
tBuMe2Si(TBDMS), 1J = 129), 19.2 (q, CH3(OAc), 1J = 129), -4.9, -5.3 (2q, tBuMe2Si (TBDMS), 1J = 
118) ppm. 
 
CI-MS (NH3): 780.2 (M+H)+. 
 
Anal. for C41H66O12Si (779.041): calculated C 63.21, H 8.54, Si 3.61; found C 63.27, H 8.60, Si 3.51. 
 
 
1H NMR spectrum of 178 
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(3S,5S,7S,9R,11S,13S)-5,9,11-Triaminopentadecane-1,3,7,13,15-pentol (179) 
 
15
1412
OH OHOH OH NH2 NH2 OHNH2
642
1
108
 
 
Starting from 178 (150 mg, 0.191 mmol), the general procedure for conversion into aminopolyols with 
intermediate deacetylation (K2CO3, MeOH) afforded 179 (13 mg, 20% over 5 steps) as a white foam. 
 [ ]23435α = +3.5, [ ]23589α = +1 (c = 0.11, MeOH). 
 
IR (KBr): ν~  = 3405, 1740, 1650, 1560, 1515, 1070 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 3.99-3.82 (m, 3H, H-C3,7,13), 3.73-3.52 (m, 7H, H-C5,9,11, H2-C1,15), 
1.97-1.43 (m, 14H, H2-C2,4,6,8,10,12,14) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 69.5, 69.2, 69.0 (3d, C3,7,13), 61.2, 60.9, 60.6, 60.5, 60.3 (2t, 3d, 
C1,5,9,11,15), 41.6, 41.5, 40.3, 39.5, 39.4, 39.3, 38.9 (7t, C2,4,6,8,10,12,14) ppm. 
 
ESI-MS: 338.6 (M+H)+. 
 
MALDI-TOF-HRMS for (C15H35O5N3 + Na)+: calculated 360.2474; found 360.2477. 
 
C15H35O5N3 (337.455). 
 
 
1H NMR spectrum of 179 
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(2RS,4SR)-1,5-Bis[(2RS,4SR)-6-(methyloxy)-4-({[(phenylmethyl)oxy]methyl}oxy)tetrahydro-2H-
pyran-2-yl]pentane-2,4-diamine (181) 
 
53
2' 4'
O O
OMeOMe
PO
NH2 NH2
OP12'4'
6' 6'
 
 
To a solution of 154 (175 mg, 0.302 mmol) in MeOH (3 mL) was added at 25°C, camphorsulfonic 
acid (15mg, 0.060 mmol, 0.2 eq.). After stirring for 2 h, the reaction mixture was poured into a 
saturated aqueous solution of NaHCO3 (20 mL) and extracted with EtOAc (20 mL, 3 times). The 
combined organic layers were washed with brine (30 mL), dried over MgSO4 and concentrated in 
vacuo. The crude oil was used in the following reaction without further purification. The crude oil was 
dissolved was dissolved in CH2Cl2 (3 mL) and treated, at 0°C, with triethylamine (380 μL, 2.722 
mmol, 9 eq.) and methanesulfonyl chloride (110 μL, 0.907 mmol, 3 eq.). After 1 h the mixture was 
poured into a saturated aqueous solution of NH4Cl (20 mL) and extracted with EtOAc (20 mL, 3 
times). The combined organic layers were washed with brine (30 mL), dried over MgSO4 and 
concentrated in vacuo. The crude oil was used in the following reaction without further purification. 
The crude oil was dissolved in 6 mL of DMF and heated at 60°C for 12 h with sodium azide (200 mg, 
3.024 mmol, 10 eq.). The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL, 3 
times). The combined organic layers were washed with brine (30 mL), dried over MgSO4 and 
concentrated in vacuo. The crude oil was used in the following reaction without further purification. 
The crude oil was dissolved in MeOH (2 mL), and the resulting solution was vigorously stirred under 
1 atm. of hydrogen at 25°C in the presence of a catalytic amount of Pd(OH)2 on activated charcoal. 
After 4 h the mixture was filtered over a pad of celite® and concentrated in vacuo. Purification of the 
residue by flash chromatography (5% to 10% of NH4OH in CH3CN) afforded 181 as a colourless oil 
(66 mg, 36% over 4 steps). 
 
IR (film): ν~  = 3370, 3295, 2935, 1670, 1450, 1385, 1165, 1115, 1040, 970, 740, 700 cm-1. 
 
1H-NMR (400 MHz, C6D6): δ = 7.33-7.22 (m, 10Harom.), 4.84-4.80 (m, 2H, H-C6’), 4.86, 4.82 (2d, 4H, 
CH2(BOM), 2J = 7 et 6.5), 4.68, 4.67 (s, 4H, CH2Ph), 4.43-4.34 (m, 2H, H-C2’), 4.11-4.06 (m, 1H, H-
C4’), 3.96-3.88 (m, 1H, H-C4’), 3.35, 3.30 (2s, 6H, CH3(OMe)), 3.40-3.24 (m, 2H, H-C2,4), 2.43-2.26, 
2.12-2.03 (2m, 4H, H2-C5’), 1.87-1.64, 1.61-1.33 (2m, 10H, H2-C3’,1,3,5) ppm. 
 
13C-NMR (100 MHz, C6D6): δ = 138.7, 138.6 (2s, Carom.), 128.6, 128.2, 128.0 (3d, Carom., 1J = 160, 158, 
163), 99.3 (2d, C6’, 1J = 156), 92.9, 92.8 (2t, CH2(BOM), 1J = 163), 69.9, 69.6 (2d, C2’, 1J = 140, 142), 
69.4, 69.3 (2t, CH2Ph, 1J = 143), 66.7, 64.5 (2d, C4’, 1J = 142), 54.6, 54.5 (2q, CH3(OMe), 1J = 147, 
142), 49.4, 47.6 (2t, C2,4, 1J = 127, 128), 45.8, 45.5, 45.1 (3t, C1,3,5, 1J = 128, 130, 126), 39.7, 39.4, 
37.6, 37.5 (4t, C3’,5’, 1J = 123, 127) ppm. 
 
MALDI-TOF-HRMS for (C33H50N2O8 + H)+: calculated 603.3698; found 603.3645. 
 
Anal. for C33H50N2O8 (602.759): calculated C 65.76, H 8.36, N 4.65; found C 64.05, H 7.95, N 4.60. 
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1H NMR spectrum of 181 
 
 
 
 
 
1H NMR spectrum of 182 
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(2SR,4SR,2’SR,4’SR)-2,2’-[[(4RS,6SR)-2,2-dimethyl-1,3- dioxane-4,6-diyl]bis(6-methylene)]bis(6-
methoxytetrahydro-2H-pyran-4-ol) (182) 
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2"
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α:α/β:β 2/1 
 
To a solution of 155 (110 mg, 0.169 mmol) in MeOH (1.5 mL), catalytic amounts of Raney Nickel 
were added and the resulting mixture was vigorously stirred under 1 atm. of hydrogen at 25°C. After 4 
h, the mixture was filtered over a pad of celite® and concentrated in vacuo. Purification of the residue 
by flash chromatography (5% MeOH in CH2Cl2) afforded 182 as a colourless oil (53 mg, 90%). 
 
IR (film): ν~  = 3390, 3350, 2920, 1605, 1450, 1370, 1105, 1025, 960, 925, 870, 735 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 4.83-4.78 (m, 2H, H-C6,6’), [4.32-4.28 (m, H-C6,6’,Min.)], 4.23-4.08 
(m, 2H, H-C4’’,6’’), 4.03-3.07 (3m, 4H, H-C4’,2’,4,2), 3.29 (s, 6H, CH3(OMe)), [3.46, 3.45 (2s, 
CH3(OMe)Min.)], 2.10-1.77, 1.28-1.07 (2m, 8H, H2-C3’,5’,3,5), 1.42, 1.34 (2s, 6H, CH3-C2”), 1.63-1.52, 
1.51-1.42 (2m, 6H, H2-C5’’, H2-C1’’’) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 99.9 (s, C2”), 99.5, 99.3 (d, C6,6’, 1J = 141), [101.7, 101.6 (C6,6’Min.)], 
66.3 (d, C2,2’, 1J = 140), 65.4, 64.5 (d, C5’’,4’’, 1J = 136), 63.5, 63.3 (d, C4’,4, 1J = 137), 54.2, 53.9 (2q, 
CH3(OMe), 1J = 145), [55.8, 55.7 (CH3(OMe)Min.)], 43.3, 42.5, 41.4 (3t, C1’’, C5’’, 1J = 129, 127, 128), 
40.7, 39.1, 37.8, 39.0 (4t, C5’,3’,5,3, 1J = 128, 129, 129, 126), 29.6, 19.2 (2q, CH3-C2”, 1J = 117, 121), 
[29.5, 19.1 CH3-C2”Min.] ppm. 
 
CI-MS: 405.1 (M+H)+. 
 
Anal. for C20H36O8 (404.495): calculated C 59.39, H 8.97; found C 59.5, H 9.02. 
 
(2RS,4SR)-2-{(2RS,4SR)-2,4-Diamino-5-[(2RS,4SR)-4-hydroxy-6-(methyloxy)tetrahydro-2H-
pyran-2-ylpentyl}-6-(methyloxy)tetrahydro-2H-pyran-4-ol (183) 
 
5'3'
2" 4"
O O
OMeOMe
HO
NH2 NH2
OH1'24
6 6"
 
 
To a solution of 182 (174 mg, 0.431 mmol) in a 1/1 mixture of pyridine/Ac2O (4 mL) was treated with 
10 mg of DMAP (0.086 mmol, 0.2 eq.). The mixture was stirred at 25°C for 1 h. Concentration in 
vacuo and purification by flash chromatography (3% of MeOH in CH2Cl2) afforded acetylated diol as 
a pale orange oil (160 mg, 76%). The resulting oil was dissolved in MeOH (3 mL) and treated with 12 
mg of p-toluenesulfonic acid (0.065 mmol, 0.2 eq.) at 25°C for 2 h. The mixture was poured into a 
saturated aqueous solution of NaHCO3 (10 mL) and extracted with CH2Cl2 (10 mL, 3 times). The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude oil was used in 
the following reaction without further purification. The crude oil was dissolved in CH2Cl2 (2 mL) and 
treated, at 0°C, with triethylamine (266 μL, 1.906 mmol, 9 eq.) and methanesulfonyl chloride (62 μL, 
0.635 mmol, 3 eq.). After 1 h the mixture was poured into a saturated aqueous solution of NH4Cl (20 
mL) and extracted with EtOAc (20 mL, 3 times). The combined organic layers were washed with 
brine (30 mL), dried over MgSO4 and concentrated in vacuo. The crude oil was used in the following 
reaction without further purification. The crude oil was dissolved in DMF (3.5 mL) and heated at 60°C 
for 12 h with sodium azide (137 mg, 2.118 mmol, 10 eq.). The mixture was poured into water (20 mL) 
and extracted with EtOAc (20 mL, 3 times). The combined organic layers were washed with brine (30 
mL), dried over MgSO4 and concentrated in vacuo. The crude oil was used in the following reaction 
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without further purification. The crude oil was dissolved in MeOH (3 mL) and treated at 25°C with 
K2CO3 (125 mg, 0.903 mmol, 3 eq.) for 4 h. The mixture was poured into water (20 mL) and extracted 
with EtOAc (20 mL, 3 times). The combined organic layers were washed with brine (30 mL), dried 
over MgSO4, concentrated in vacuo and purified by flash chromatography (3% of MeOH in CH2Cl2) 
affording a diol intermediate as a colourless oil (66 mg, 75% over 5 steps). To a solution of this oil in 
MeOH (3 mL), catalytic amounts of Pd(OH)2 on activated charcoal were added and the resulting 
mixture was vigorously stirred under 1 atm. of hydrogen at 25°C for 4h. The mixture was filtered over 
a pad of celite® and concentrated in vacuo. Purification of the residue by flash chromatography (20% 
of NH4OH in CH3CN) afforded 183 as a colourless oil (44 mg, 84%). 
 
IR (film): ν~  = 3350, 2925, 2505, 1450, 1385, 1115, 1040, 965 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 4.84 (brs, 2H, H-C6,6”), [4.42-4.35 (m, 1H, H-C6,6” Min.)], 3.96-3.80 (2m, 
4H, H-C2,4,2”,4”), [3.58-3.54 (m, 2H, H-C2,4,2”,4” Min.)], [3.43-3.38 (m, 3H, CH3(OMe)Min.)], 3.27, 3.25 (2s, 
6H, CH3(OMe)), [3.03-2.98 (m, 1H, H-C2’,4’ Min.)], 2.83-2.74 (m, 2H, H-C2’,4’), 2.1-1.8 (m, 4H, H2-
C3,3”), 1.75-1.30 (m, 6H, H2-C1’,3’,5’), 1.22-1.08, 0.75-0.9 (2m, 4H, H2-C5,5”) ppm. 
 
13C-NMR (100 MHz, D2O): δ = [101.4, 101.3 (2d, C6,6” Min., 1J = 171)], 99.4, 99.3 (2d, C6,6”, 1J = 172), 
66.0, 65.4, 63.3 (4d, C2,4,2”,4”, 1J = 140, 142, 141, 141), [65.9, 65.8, 63.3, 63.1 (4d, C2,4,2”,4”Min.)], [56.6 
(q, CH3(OMe)Min., 1J = 140)], 54.9 (q, CH3(OMe), 1J = 143), 51.8, 51.6 (2d, C2’,4’, 1J = 138), [46.2, 
45.0 (C2’,4’Min.)], 42.3, 41.9 (C1’,3’,5’), [40.2, 40.1 (C3,3”Min.)], 39.9, 39.7 (C3,3”), [38.9 (C5,5”Min.)], 37.9 (t, 
C5,5”, 1J = 123) ppm. 
 
ESI-MS: 363.2 (M+H)+. 
 
MALDI-TOF-HRMS for (C17H34N2O6 + H)+: calculated 363.2495; found 363.2485. 
 
C17H34N2O6 (362.46). 
 
 
1H NMR spectrum of 183 
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(2RS,4SR)-1,5-Bis[(2SR,4RS)-4-amino-6-(methyloxy)tetrahydro-2H-pyran-2-yl]pentane-2,4-diol 
(184) 
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To a solution of diol 182 (126 mg, 0.311 mmol) THF (3.5 mL) was added triphenylphosphine (180 
mg, 0.686 mmol, 2.2 eq.) at 0°C. After 5 mn, diethyl azodicarboxylate (108 μL, 0.685 mmol, 2.2 eq.) 
and diphenyl phosphoryl azide (150 μL, 0.685 mmol, 2.2 eq.) were added and the temperature was 
raised to 25°C. The reaction mixture was stirred for 14 h. After completion of the reaction, solvents 
were evaporated in vacuo. The residual oil was dissolved in MeOH (3 mL) and treated at 25°C with a 
catalytic amount of Pd(OH)2 on activated charcoal under 1 atm. of hydrogen during 2 h. After 
completion of the reaction, the suspension was filtered through a pad of celite® and the filtrate was 
concentrated in vacuo. Purification of the residue by flash chromatography (10% of NH4OH in 
CH3CN) afforded an intermediate diamine as a colourless oil (64 mg, 51%). A solution of this diamine 
(64 mg, 0.159 mmol) in H2O/TFA (0.2 mL/4 mL) was stirred at 25°C for 3 h. After completion of the 
reaction, the solution was concentrated in vacuo. Purification of the residue by flash chromatography 
(40% of NH4OH in CH3CN) afforded 184 as a white foam (41 mg, 71%). 
 
IR (KBr): ν~  = 2935, 2795, 1605, 1450, 1370, 1285, 1165, 1015, 815 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 4.85 (brs, 2H, H-C6,6’’), [4.72 (brs, H-C6,6’Min.)], 4.21-4.05 (m, 2H, H-
C2”,2’), 4.04-3.87 (2m, 2H, H-C2,4), 3.64-3.62 (m, 2H, H-C4’,4”), [3.43, 3.42 (2s, 3H, CH3(OMe)Min.)], 
3.32, 3.31 (2s, 6H, CH3(OMe)),1.99-1.94, 1.87-1.77 (2m, 8H, H2-C3’,5’,3”,5”), 1.74-1.62 (m, 6H, H2-
C1,3,5) ppm. 
 
13C-NMR (100 MHz, D2O): δ = [101.4, 101.3 (2s, C6’,6”Min.)], 102.2, 100.0 (2s, C6,6’), 68.8, 67.7 (2d, 
C2,4), 63.6, 62.3 (2d, C2’,2”), [58.7, 58.6 (2q, CH3(OMe)Min.)], 57.4, 57.3 (2q, CH3(OMe)), [46.9, 46.6 
(2d, C4’,4”Min.)], 46.4, 46.2 (2d, C4’,4”), 46.8, 44.2, 44.0 (3t, C1,3,5), [46.3, 44.7, 44.1 (3t, C1,3,5Min.)], 37.1, 
35.3, 33.3 (3t, C3’,5’,3”,5”) ppm. 
 
ESI-HRMS for (C17H34N2O6 + H)+: calculated 363.2495; found 363.2486. 
 
C17H34N2O6 (362.462). 
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1H NMR spectrum of 184 
 
 
 
1H NMR spectrum of 185 
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(1RS,3SR)-3-(Acetyloxy)-4-[(2SR,4RS,6SR)-4-({[(phenylmethyl)oxy]methyl}oxy)-6-prop-2-en-1-
yltetrahydro-2H-pyran-2-yl]-1-{[(2SR,4RS,6SR)-4-({[(phenylmethyl)oxy]methyl}oxy)-6-prop-2-
en-1-yltetrahydro-2H-pyran-2-yl]methyl}butyl acetate (185) 
 
4
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A solution of tetrol 154 (176 mg, 0.305 mmol) in a 1/1 pyridine/Ac2O solution (6 mL) was treated 
with 15 mg of DMAP (0.122 mmol, 0.4 eq.) at 25°C for 3 h. After completion of the reaction, solvents 
were evaporated in vacuo. Purification of the residue by flash chromatography (60% of EtOAc in 
pentane) afforded the corresponding peracetylated bis(hemiacetal) as a yellow oil (205 mg, quant.). A 
solution of this intermediate (205 mg, 0.305 mmol) in CH3CN (68 mL) were stirred for 30 mn with 1.4 
g of 4 Ǻ MS before the addition of allyltrimethysilane (525 μL, 3.303 mmol, 12 eq.). The resulting 
solution was stirred for an additional 30 mn and BF3.OEt2 (210 μL, 1.651 mmol, 6 eq.) was added at 
0°C. After stirring for 1 h at 0°C the reaction mixture was poured into a saturated aqueous solution of 
NaHCO3 (40 mL) and filtered through a pad of celite.® The filtrate was extracted with EtOAc (40 mL, 
3 times). The combined organic layers were washed with brine (70 mL), dried over MgSO4 and 
concentrated in vacuo. Purification of the residue by flash chromatography (30% of EtOAc in pentane) 
afforded diolefine 185 as a colourless oil (137 mg, 71% over 2 steps). 
 
IR (film): ν~  = 3410, 2100, 1450, 1370, 1240, 1190, 1140, 1060, 960, 830, 780 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.25 (m, 10Harom.), 5.80-5.74 (m, 2H, H-CA,A’), 5.10-4.98 (m, 
6H, H2-CB,B’, H-C1,3), 4.78 (s, 4H, CH2(BOM)), 4.60 (s, 4H, CH2Ph), 4.02-3.95 (m, 4H, H-C2”,2’”,6”,6’”), 
3.80-3.73 (m, 2H, H-C4”,4”’), 2.48-2.32, 2.24-2.13 (2m, 4H, H2-CC,C’), 2.07-1.96, 1.72-1.53 (2m, 4H, 
H2-C5”,5’”), 1.96-1.83, 1.36-1.27 (2m, 4H, H2-C3”,3’”), 1.83-1.73, 1.72-1.53 (2m, 6H, H2-C1’,2,4), 1.98 (s, 
6H, CH3(OAc)) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 171.5, 171.4 (s, C=O(-OAc)), 142.2 (s, Carom), 135.5, 135.4 (d, 
CA,A’, 1J = 150), 128.4, 128.0, 127.7 (3d, Carom, 1J = 160, 158, 160), 116.4, 116.3 (t, CB,B’, 1J = 160), 
92.9 (t, CH2(BOM), 1J = 160), 70.8, 70.7 (d, C4”,4”’, 1J = 146), 69.9, 69.8 (d, C6”,6”’, 1J = 145), 69.6 (t, 
CH2Ph, 1J = 140), 69.5, 69.0 (d, C1,3, 1J = 142), 66.8, 66.0 (d, C2”,2”’, 1J = 145), 39.9, 39.5 (t, C5”,5”’, 1J 
= 126, 125), 38.6 (t, C2, 1J = 128), 37.4, 37.3 (t, C3”,3”’, 1J = 129), 37.2, 37.1 (t, CC’,C, 1J = 122), 34.9 (t, 
C1’,4, 1J = 127), 20.4, 20.3 (q, CH3(OAc), 1J = 129) ppm. 
 
ESI-MS: 709.3 (M+H)+. 
 
MALDI-TOF-HRMS for (C41H56O10 + Na)+: calculated 731.3771; found 731.3769. 
 
C41H56O10 (708.88). 
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(4RS,6SR)-2,2-Dimethyl-4,6-bis-{[(2SR,4RS,6SR)-4-({[(phenylmethyl)oxy]methyl}oxy)-6-prop-2-
en-1-yltetrahydro-2H-pyran-2-yl]methyl}-1,3-dioxane (186) 
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To a solution of diolefine 185 (110 mL, 0.155 mmol) in MeOH (1.5 mL) was added K2CO3 (86 mg, 
0.621 mmol, 4 eq.) and the mixture was stirred at 25°C for 4 h. After completion of the reaction, the 
reaction mixture was poured into a saturated aqueous solution of NaHCO3 (20 mL) and extracted with 
EtOAc (20 mL, 3 times). The combined organic layers were washed with brine (40 mL), dried over 
MgSO4 and concentrated in vacuo. The residual oil was dissolved in a 3/1 mixture of 2,2-
dimethoxypropane/acetone (4 mL). The solution was treated with 6 mg of p-toluenesulfonic acid 
(0.030 mmol, 0.2 eq.) and stirred for 6 h at 25°C. After completion of the reaction, the solution was 
poured into a saturated aqueous solution of NaHCO3 (10 mL) and extracted with EtOAc (20 mL, 3 
times). The combined organic layers were washed with brine (30 mL), dried over MgSO4 and 
concentrated in vacuo. Purification of the residue by flash chromatography (40% of EtOAc in pentane) 
afforded diolefine 186 as a colourless oil (80 mg, 77% over 2 steps). 
 
IR (film): ν~  = 2940, 1740, 1645, 1450, 1380, 1200, 1165, 1105, 1045, 740, 700 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 7.39-7.27 (m, 10Harom.), 5.85-5.72 (m, 2H, H-C2’”), 5.08, 5.05 (2d, 
4H, H2-C3”’, 3J = 20.5, 9.1), 4.81 (brs, 4H, CH2(BOM)), 4.61 (brs, 4H, CH2Ph), 4.1-3.95 (m, 6H, H-
C4,6,2”,6”), 3.92-3.80, 3.83-3.72 (2m, 2H, H-C4”), 2.52-2.36, 2.27-2.15 (2m, 4H, H2-C1”’), 2.01-1.92 (m, 
2H, H2-C5), 1.93-1.89, 1.66-1.62, 1.58-1.45 (3m, 4H, H2-C3”), 1.89-1.83, 1.73-1.66 (2m, 4H, H2-C1’), 
1.66-1.62, 1.18-1.07 (3m, 4H, H2-C5”), 1.43, 1.37 (2s, 6H, CH3-C2) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 137.8 (s, Carom), 135.1, 135.0 (2d, C2”’, 1J = 150), 128.4, 127.8, 
127.7 (3d, Carom, 1J = 160, 158, 160), 116.9, 116.6 (2t, C3”, 1J = 152), 98.4 (s, C2), 92.5, 92.4 (t, 
CH2(BOM), 1J = 162), 71.7, 71.2 (2d, C4”, 1J = 146, 145), 69.5, 69.4 (2t, CH2Ph, 1J = 148), 69.3, 69.2 
(2d, C6”, 1J = 142), 65.9, 65.3 (2d, C4,6, 1J = 138, 136), 65.1, 64.7 (2d, C2”, 1J = 141, 142), 43.2, 42.2 
(2t, C3”, 1J = 125, 124), 38.3 (t, C5, 1J = 125), 37.6, 37.2 (2t, C5”, 1J = 127, 128), 36.7, 36.6 (t, C1”’, 1J = 
129), 35.0, 34.6 (2t, C1’, 1J = 128, 129), 30.3, 19.9 (2q, CH3-C2”, 1J = 123, 125) ppm. 
 
ESI-MS: 665.3 (M+H)+. 
 
MALDI-TOF-HRMS for (C40H56O8 + Na)+: calculated 687.3873; found 687.3873. 
 
Anal. for C40H56O8 (664.87): calculated C 72.26, H 8.42; found C 70.36, H 8.43. 
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1H NMR spectrum of 186 
 
 
1H NMR spectrum of 187 
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2,2’-([(4RS,6SR)-2,2-Dimethyl-1,3-dioxane-4,6-diyl]bis{methanediyl[(2SR,4RS,6SR)-4-
({[(phenylmethyl)oxy]methyl}oxy)tetrahydro-2H-pyran-6,2-diyl]})diethanol (187) 
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O3 was passed through a solution of diolefine 186 (200 mg, 0.301 mmol) in CH2Cl2 (9 mL) during 5 
mn at –78°C. When a blue coloration persisted in the mixture, O2 was passed through the solution to 
eliminate the excess of O3. DMS (90 μL, 1.204 mmol, 4 eq.) was added and the mixture was stirred for 
an additional 10 mn. Solvents were evaporated in vacuo at 0°C. The residual oil was dissolved in 
MeOH (3 mL) and treated at 25°C with NaBH4 (70 mg, 1.806 mmol, 6 eq.) during 1 h. The reaction 
mixture was poured into water (30 mL) and extracted with EtOAc (40 mL, 3 times). The combined 
organic layers were washed with brine (40 mL), dried over MgSO4 and concentrated in vacuo. 
Purification of the residue by flash chromatography (3% of MeOH in CH2Cl2) afforded diol 187 as a 
colourless oil (138 mg, 68% over 2 steps). 
 
IR (film): ν~  = 2940, 2550, 1725, 1455, 1380, 1270, 1200, 1165, 1105, 1040, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.45-7.10 (m, 10Harom.), 4.80 (brs, 4H, CH2(BOM)), 4.60 (brs, 4H, 
CH2(Ph)), 4.22-4.08 (m, 2H, H-C6’), 4.07-3.98 (m, 2H, H-C4’), 3.97-3.95 (m, 2H, H-C4’”,6”’), 3.92-3.77 
(m, 2H, H-C2’), 3.63, 3.61 (2t, 4H, H2-C1, 3J = 7.4), 2.05-1.75 (m, 8H, H2-C3’,5’), 1.70-1.45, 1.30-1.15 
(2m, 10H, H2-C1”,5”’,2), 1.44, 1.32 (2s, 6H, CH3-C2’”) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 138.4 (s, Carom), 128.4, 127.9, 127.6 (3d, Carom, 1J = 154, 159, 162), 
98.9 (s, C2”’), 92.9, 92.7 (t, CH2(BOM), 1J = 166, 165), 70.1, 70.0 (d, C4’, 1J = 142), 69.5 (t, CH2Ph, 1J 
= 145), 68.8, 68.7 (d, C6’, 1J = 146), 66.5, 65.4 (2d, C4”’,6”’, 1J = 143, 141), 65.8, 64.7 (d, C2’, 1J = 141, 
142), 59.0, 58.8 (2t, C1, 1J = 136, 137), 43.1, 42.1 (2t, C3”, 1J = 127, 126), 38.5 (t, C5”’, 1J = 129 ), 37.6 
(t, C2, 1J = 129), 36.0, 35.9, 34.8, 34.5 (4t, C3’,5’, 1J = 131, 128, 129, 126 ), 24.9, 19.2 (2q, CH3-C2’”), 1J 
= 125, 126) ppm. 
 
ESI-MS: 673.3 (M+H)+. 
 
MALDI-TOF-HRMS for (C38H56O10 + H)+: calculated 673.3952; found 673.3954. 
 
C38H56O10 (672.84). 
 
 
2,2’-([(4RS,6SR)-2,2-Dimethyl-1,3-dioxane-4,6-diyl]bis{methanediyl[(2SR,4RS,6SR)-4-
({[(phenylmethyl)oxy]methyl}oxy)tetrahydro-2H-pyran-6,2-diyl]})diethanamine (188) 
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To a solution of diol 187 (135 mg, 0.200 mmol) in CH2Cl2 (2 mL) were added NEt3 (250 μL, 1.806 
mmol, 9 eq.), methanesulfonyl chloride (60 μL, 0.602 mmol, 3 eq.) and the mixture was stirred at 0°C 
for 2 h. The reaction mixture was poured into a saturated aqueous solution of NaHCO3 (20 mL) and 
extracted with EtOAc (20 mL, 3 times). The combined organic layers were washed with brine (40 
mL), dried over MgSO4 and concentrated in vacuo. The residual oil was dissolved in DMF (2.5 mL) 
and treated with NaN3 (130 mg, 2.006 mmol, 10 eq.). The solution was stirred for 15 h at 60°C. The 
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reaction mixture was poured into water (20 mL) and extracted with EtOAc (20 mL, 3 times). The 
combined organic layers were washed with brine (30 mL), dried over MgSO4 and concentrated in 
vacuo. Purification of the residue by flash chromatography (2% of MeOH in CH2Cl2) afforded a 
diazide intermediate as a yellow oil (130 mg, 90% over 2 steps). This intermediate (130 mg, 0.180 
mmol) was dissolved in MeOH (4 mL) and treated at 25°C with a catalytic amount of Pd(OH)2 on 
activated charcoal under 1 atm. of hydrogen for 1 h. The reaction mixture was filtered through a pad of 
celite®. The filtrate was concentrated in vacuo. Purification of the residue by flash chromatography 
(10% of NH4OH in CH3CN) afforded diamine 188 as a colourless oil (95 mg, 78%). 
 
IR (film): ν~  = 2940, 1665, 1605, 1450, 1380, 1200, 1165, 1105, 1040, 745, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.25 (m, 10Harom.), 4.82 (brs, 4H, CH2(BOM)), 4.61 (brs, 4H, 
CH2Ph), 4.1-3.9 (2m, 6H, H-C4”,6”,2IV,6IV), 3.87-3.83 (m, 2H, H-C2IV), 2.85-2.77 (m, 4H, H2-C1), 2.2-
1.81 (m, 8H, H2-C2,3IV), 1.79-1.45 (m, 6H, H2-C1”’,5”), 1.33-1.1 (m, 4H, H2-C5IV), 1.44, 1.33 (2s, 6H, 
CH3-C2”) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 138.4 (s, Carom), 128.4, 127.9, 127.8 (3d, Carom, 1J = 160, 158, 162), 
98.9 (s, C2”), 93.0, 92.8 (2t, CH2(BOM), 1J = 163), 69.6 (t, CH2Ph, 1J = 143), 70.0, 69.8, 69.5, 69.1 
(4d, C4IV,4”,6”’, 1J = 131, 137, 143, 145), 66.6, 66.5 (2d, C2IV, 1J = 137, 141), 66.4, 64.9 (2d, C6IV, 1J = 
143, 144), 43.1, 41.9 (2t, C3IV, 1J = 128, 123), 38.3, 38.2 (2t, C5IV, 1J = 126, 127), 37.9, 38.8 (2t, C1, 1J 
= 120, 129), 36.8 (2t, C5”, 1J = 123, 119), 35.9, 35.8 (2t, C1”’, 1J = 123), 32.4 (2t, C2, 1J = 127), 29.6, 
19.4 (2q, CH3-C2”, 1J = 122) ppm. 
 
MALDI-TOF-HRMS for (C38H58N2O8 + H)+: calculated 671.4271; found 671.4276. 
 
C38H58N2O8 (672.84). 
 
 
1H NMR spectrum of 188 
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(2RS,4SR)-1,5-Bis[(2SR,4RS,6SR)-6-(2-aminoethyl)-4-hydroxytetrahydro-2H-pyran-2-
yl]pentane-2,4-diol (189) 
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To a solution of diamine 188 (33 mg, 0.097 mmol) in MeOH/TFA (0.2 mL/1 2 mL) was added a 
catalytic amount of Pd(OH)2 on activated charcoal and the suspension was stirred at 25°C for 3h under 
1 atm. of hydrogen. The reaction mixture was filtered through a pad of celite®. The filtrate was 
concentrated in vacuo. Purification of the residue by flash chromatography (40% of NH4OH in 
CH3CN) afforded diamine 189 as a white foam (12 mg, 31%). 
 
IR (film): ν~  = 2915, 1635, 1565, 1470, 1435, 1380, 1310, 1065, 815 cm-1. 
 
1H NMR (400 MHz, D2O): δ = 4.22-4.15 (m, 2H, H-C6’), 4.14-4.0 (m, 2H, H-C2’), 3.90-3.82 (m, 4H, 
H-C4,4’,2), 3.15-3.97 (m, 4H, H2-C2”), 2.3-2.18, 1.80-1.76 (2m, 4H, H2-C1”), 2.16-1.93, 1.32-1.17 (2m, 
4H, H2-C3’), 1.90-1.82, 1.62-1.49 (2m, 4H, H2-C5’), 1.75-1.63 (m, 6H, H2-C5,3,1) ppm. 
 
13C NMR (100 MHz, D2O): δ = 70.8, 70.7 (2d, C6’), 67.7, 67.1 (2d, C4’), 65.8, 65.7 (2d, C2,4), 63.7, 
63.6 (2d, C2’), 44.8 (t, C3), 42.5, 42.4 (2t, C1,5), 40.1, 39.3 (2t, C3’), 37.4, 37.3 (2t, C2”), 37.0, 36.9 (2t, 
C5’), 28.8, 28.7 (2t, C1’) ppm. 
 
ESI-MS: 391.4 (M+H)+. 
 
ESI-HRMS for (C19H38N2O6 + H)+: calculated 391.2813; found 391.2808. 
 
C19H38N2O6 (390.515). 
 
 
 
1H NMR spectrum of 189 
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(3aRS,4SR,5RS,7SR,7aRS)-5,7-Diazido-2,2-dimethylhexahydro-1,3-benzodioxolo-4-ol (190) 
 
6
5 3a
2
N3
N3
OH
O
O7a
 
 
A solution of Neomycin trisulfate (10 g, 11 mmol) in 48% HBr (60 mL) was heated under reflux for 
17 h. HBr was evaporated in vacuo and the remaining black oil was dissolved in water (60 mL) with 
activated charcoal. After mixing for 1 h the black solution was filtered though a pad of celite® and the 
filter was washed with water (180 mL). The brown aqueous solution was concentrated in vacuo. 
Methanol (60 mL) was added to the brown oil which solidified upon mixing. The white suspension 
was filtered and dried 12 h before being loaded on an anion resin exchanger column. Fraction with a 
basic pH were collected and lyophilised to obtain aminocyclitol as a white powder (2.43 g, 75%). To a 
solution of aminocyclitol (1.05 g, 6.474 mmol) in MeOH (64 mL) and NEt3 (9 ml, 65 mmol, 10 eq.) 
was added CuSO4 (52 mg, 0.324 mmol, 0.05 eq.). A 0.4 M solution of NaN3 in CH2Cl2 was added 
dropwise at 0°C, the green mixture was stirred for 24 h and concentrated in vacuo. The green oil was 
purified by flash chomatography (20% of pentane in EtOAc then 20% of MeOH in EtOAc) affording 
diazide as a white solid (1.25 g, 90%). A solution of triol (1.25 g, 5.836 mmol) in CH3CN (30 mL) and 
2,2-dimethoxypropane (30 mL) was treated with CSA (135 mg, 0.584 mmol, 0.1 eq.) at 25°C for 5 h. 
The reaction mixture was poured into a saturated aqueous solution of NaHCO3 (50 mL) and extracted 
with EtOAc (50 mL, 3 times). The combined organic layers were washed with brine (70 mL), dried 
over MgSO4 and concentrated in vacuo. Purification of the residue by flash chomatography (30% of 
EtOAc in pentane) afforded alcohol 190 as a white solid (1.09 g, 73%). 
Preparation of the 0.4 M solution of NaN3 in CH2Cl2: 
To a solution of NaN3 (6.01 g, 92.5 mmol) in CH2Cl2 (25 mL) and water (15 mL) was added Tf2O 
(3.05 mL, 18.5 mmol, 0.2 eq.) at 0°C for 5 h. The aqueous phase was extracted with CH2Cl2 (8 mL, 2 
times). The combined organic layers were washed with a saturated aqueous solution of Na2CO3 (15 
mL). 
 
IR (film): ν~  = 3410, 2100, 1450, 1370, 1240, 1190, 1140, 1060, 960, 830, 780 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 3.80-3.65 (m, 1H, H-C7), 3.63 (dd, 1H, H-C4, 3J = 6.9, 6.8), 3.46-
3.40 (m, 3H, H-C3a,5,7a), 2.2 (dt, 1H, H-C6, 3J = 4.8, 2J = 13.4), 1.45 (s, 6H, CH3-C2), 1.34 (dt, 1H, H-
C6, 3J = 12.2, 2J = 13.4) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 113.1 (2s, C2), 81.1, 80.9 (2d, C3a,7a), 75.2 (d, C4), 64.3 (d, C5), 58.9 
(d, C7), 34.8 (t, C6), 27.1, 26.9 (2q, CH3-C2) ppm. 
 
CI-MS: 255 (M+H)+. 
 
Anal. for C9H14N6O3 (254.25): calculated C 42.52, H 5.55, N 33.05; found C 42.58, H 5.52, N 33.01. 
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1H NMR spectrum of 190 
 
 
 
 
1H NMR spectrum of 191 
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{[(3aRS,4SR,5RS,7SR,7aRS)-5,7-Diazido-2,2-dimethylhexahydro-1,3-benzodioxolo-4-
yl]oxy}acetic acid (191) 
 
6
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2'
 
 
To a solution of alcohol 190 (1.085 g, 4.267 mmol) in CH3CN (20 mL) were added NaH 60% in 
mineral oil (340 mg, 8.535 mmol, 2 eq.) and methylbromoacetate (606 μL, 6.4 mmol, 1.5 eq.). The 
mixture was stirred at 25°C for 2 h. The reaction mixture was poured into a saturated aqueous solution 
of NH4Cl (50 mL) and extracted with EtOAc (50 mL, 3 times). The combined organic layers were 
washed with brine (70 mL), dried over MgSO4 and concentrated in vacuo. Purification of the residue 
by flash chomatography (20% of EtOAc in pentane) afforded an intermediate methylester as a 
colourless oil (445 mg, 64% based on recovered starting material). To a solution of methyl ester (445 
mg, 1.364 mmol) in THF (35 mL), MeOH (5 mL) and water (5 mL) was added a 1M LiOH solution 
(20 mL, 20 mmol, 15 eq.). The mixture was stirred at 25°C for 15 h. THF was removed in vacuo and 
the aqueous solution was saturated with NaCl, the pH of the solution was adjusted to pH 4-5 with 2M 
HCl and extracted with EtOAc (50 mL, 4 times). The combined organic layers were dried over MgSO4 
and concentrated in vacuo. Purification of the residue by flash chomatography (20% of MeOH in 
CH2Cl2) afforded acid 191 as a white foam (325 mg, 76%). 
 
IR (film): ν~  = 3215, 2920, 2500, 2355, 2100, 1730, 1595, 1450, 1060, 840, 785 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 4.31 (s, 2H, H2-C2’), 3.73 (ddd, 1H, H-C7, 3J = 4.7, 10.0, 11.7), 3.68 
(t, 1H, H-C4, 3J = 8.4), 3.64 (ddd, 1H, H-C5, 3J = 4.7, 8.4, 9.2), 3.55 (dd, 1H, H-C3a, 3J = 8.4, 9.2), 3.44 
(dd, 1H, H-C7a, 3J = 9.2, 10.0), 2.2 (dt, 1H, H-C6, 3J = 4.7, 2J = 13.4), 1.44, 1.43 (2s, 6H, CH3-C2), 1.34 
(dt, 1H, H-C6, 3J = 11.7, 2J = 13.4) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 174.4 (s, C1’), 112.4 (s, C2), 81.6 (d, C4, 1J = 155), 80.0, 79.9 (d, 
C3a,7a, 1J = 147), 68.1 (t, C2’, 1J = 145), 60.9 (d, C5, 1J = 143), 57.6 (d, C7, 1J = 145), 33.8 (t, C6, 1J = 
134), 26.1, 25.9 (2q, CH3-C2, 1J = 126) ppm. 
 
MALDI-TOF-HRMS for (C11H16N6O5 + Na)+: calculated 335.1080; found 335.1080. 
 
C11H16N6O5 (312.28). 
 
 
(3RS)-4-[(4SR,6RS)-6-({(4SR,6SR)-6-[(2RS)-4-amino-2-({[(phenylmethyl)oxy]methyl}oxy)butyl]-
2,2-dimethyl-1,3-dioxan-4-yl}methyl)-2,2-dimethyl-1,3-dioxan-4-yl}-2,2-dimethyl-1,3-dioxan-4-
yl]-3-({[(phenylmethyl)oxy]methyl}oxy)butan-1-amine (195) 
 
2 4 5'
2'
1"
2"'
5"'
2IV 4IV
NH2 NH2OP O OPO O O
 
 
The corresponding diazide compound was synthesited according to the procedure reported for the 
synthesis of 177 and recovered as a crude oil (413 mg) starting from diol 137 (440 mg, 0.666 mmol). 
The crude oil was dissolved in a 7/1 mixture of pyridine/aqueous NH4OH (14 mL) and treated at 25°C 
with a 1 M solution of PMe3 in THF (3.9 mL, 3.94 mmol, 4 eq) for 2 h. Solvents were then removed in 
vacuo. The crude oil was purified by flash chromatography (CH3CN/NH4OH 9/2) affording the 
corresponding diamino polyols 195 (440 mg, 72% over 3 steps). 
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IR (film): ν~  = 3045, 2990, 2505, 2205, 1690, 1680, 1605, 1455, 1430, 1380, 1295, 1225, 1200, 1160, 
1040, 940 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.36-7.27 (m, 10Harom.), 4.84-4.78 (m, 4H, CH2(BOM)), 4.63, 4.58 
(2s, 4H, CH2Ph), 4.07-3.95, 3.92-3.86 (2m, 4H, H-C4’,4’”,6’,6’”), 3.85-3.78 (m, 2H, H-C3,2IV), 2.77 (t, 4H, 
H-C1,4IV, 3J = 7.3), 1.80-1.57 (m, 4H, H2-C2,3IV), 1.57-1.45 (m, 4H, H2-C4,1IV), 1.45-1.38 (m, 6H, H2-
C5’,1’’,5’’’), 1.57, 1.53, 1.34, 1.29 (4s, 12H, CH3-C2’, CH3-C2”’) ppm. 
 
13C-NMR (101 MHz, MeOD): δ = 139.3 (s, Carom.), 129.5, 128.9, 128.7 (3d, Carom.), 100.1, 99.8 (2s, 
C2’,2”’), 95.7, 95.5 (2t, CH2(BOM), 1J = 166), 75.4, 74.4 (2d, C3,2IV, 1J = 140, 139), 70.8, 70.7 (2t, 
CH2Ph, 1J = 142), 66.9, 66.8, 64.8, 64.2 (4d, C4’,6’,4”’,6”’ , 1J = 140, 140, 145, 145), 43.7, 43.3, 42.9 (3t, 
C5’,1’’,5”, 1J = 125, 127, 127), 39.6, 38.5 (2t, C4,1IV, 1J = 126), 38.6 (2t, C1,4IV, 1J = 135), 30.5, 20.2 (2q, 
CH3-C2’’’, 1J = 122, 125), 25.4, 25.3 (2q, CH3-C2’, 1J = 134) ppm. 
 
ESI-HRMS for (C37H56O10 + H)+: calculated 659.4271; found 659.4263. 
 
C37H56O10 (660.842). 
 
 
 
1H NMR spectrum of 195 
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General procedure for the coupling of acid 191 with diamines 
 
To a solution of 2 eq. of acid 191 in CH2Cl2 (0.15 to 0.1 M) was added 6 eq. of NEt3 and 2.2 eq. of 
PyBOP at 25°C. 1 Eq. of diamines was added to this mixture and the white suspension was stirred for 
2 h. The reaction mixture was concentrated in vacuo. Purification of the residue by flash 
chomatography (4-10% of MeOH in CH2Cl2) afforded diamides as colourless oils. 
 
Method A for the deprotection of the resulting dimers 
 
Diamides were dissolved in MeOH/TFA/H2O 0.5/1/0.5 (2 to 4 mL) and stirred at 25°C for 3 h. The 
reaction mixture was concentrated in vacuo. Purification of the residue by flash chomatography (2-
10% of aqueous NH4OH in CH3CN) afforded tetrols as colourless oils. Tetrols were dissolved in 
MeOH (2 to 4 mL) with a catalytic amount of Pd(OH)2 on activated charcoal and stirred at 25°C under 
1 atm. of hydrogen for 3 h. The reaction mixtures were filtered though a pad of celite®, the filtrates 
were concentrated in vacuo. Purification of the residues by flash chomatography (40-60% of aqueous 
NH4OH in CH3CN) afforded products as a white foam. 
 
Method B for the deprotection of the resulting dimers 
 
Diamides were dissolved in AcOH (2 to 4 mL) and stirred with a catalytic amount of Pd on activated 
charcoal at 25°C under 1 atm. of hydrogen for 5 h. The reaction mixtures were filtered though a pad of 
celite® and the filtrates were concentrated in vacuo. The residues were dissolved in MeOH/TFA/H2O 
0.5/1/0.5 (2 to 4 mL) and stirred at 25°C for 5 h. The reaction mixtures were concentrated in vacuo. 
Purification of the residues by semi-preparative HPLC (0-100% of CH3CN in H2O/TFA in 30 mn at 
18 mL/mn) afforded aminopolyols as white foams. 
 
N,N’-Pentane-1,5-diylbis(2-{[(1S,2S,3R,4S,6R)-4,6-diamino-2,3-
dihydroxycyclohexyl]oxy}acetamide) (196) 
5
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Starting from 1,5-diaminopentane (19 μL, 0.16 mmol), intermediate of 196 (90 mg, 81%) was 
obtained a pale yellow oil. Following method A, starting from intermediate of 196 (70 mg, 0.105 
mmol), 196 (32 mg, 62% over 2 steps) was obtained as a white foam. 
 
IR (film): ν~  = 3380, 2940, 2505, 2105, 1655, 1550, 1450, 1375, 1260, 1235, 1110, 840 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 4.24, 4.14 (2d AB, 4H, H2-C2’, 2J = 15.3), 3.59, 3.41 (2t, 4H, H-C2,3, 3J 
= 9.3), 3.33 (t, 2H, H-C1, 3J = 9.3), 3.26, 3.11 (td, 4H, H-C4,6, 3J = 3.5, 9.3), 3.03 (t, 4H, H2-C1”,5”, 3J = 
6.8), 2.26 (dt, 2H, H-C5, 3J = 3.5, 2J = 12.4), 1.63 (d, 2H, H2-C5, 2J = 12.4), 1.4-1.3 (m, 4H, H2-C2”,4”), 
1.2-1.1 (m, 4H, H2-C3”) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 174.4 (s, C1’), 83.8 (d, C1, 1J = 148), 77.5, 74.8 (2d, C2,3, 1J = 146, 
141), 73.1 (t, C2’, 1J = 146), 52.3 (d, C4, 1J = 143), 51.5 (d, C6, 1J = 147), 41.5 (t, C1”,5”, 1J = 139), 30.6 
(t, C5, 1J = 127), 30.5 (t, C2”,4”, 1J = 125), 25.9 (t, C3”, 1J = 128) ppm. 
 
ESI-HRMS for (C21H42N6O8 + H)+: calculated 507.3142; found 507.3145. 
 
C21H42N6O8 (506.59). 
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Data for intermediate of 196: 
N,N’-Pentane-1,5-diylbis(2-{[(3aR,4S,5R,7S,7aR)-5,7-diazido-2,2-dimethylhexahydro-1,3-
benzodioxolo-4-yl]oxy}acetamide) 
 
6
5 3a
2
N3
N3
O
O
O7a
O
HN
H
N
O
N3
N3
O
O
O
2'
1'
1''
3''
5''
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IR (film): ν~  = 3380, 2940, 2505, 2105, 1655, 1550, 1450, 1375, 1260, 1235, 1110, 840 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 4.27, 4.18 (2d AB, 4H, H2-C2’, 2J = 15.6), 3.79 (ddd, 2H, H-C7, 3J = 
4.7, 10.0, 11.4), 3.73-3.66 (m, 2H, H-C5), 3.60 (t, 2H, H-C4, 3J = 8.6), 3.58 (dd, 2H, H-C3a, 3J = 4.7, 
8.6), 3.52 (dd, 2H, H-C7a, 3J = 4.7, 10.0), 3.40-3.35 (m, 4H, H2-C1”,5”), 2.26 (dt, 2H, H-C6, 3J = 4.7, 2J 
= 13.3), 1.62-1.52 (m, 4H, H2-C2”,4”), 1.46, 1.45 (2s, 12H, CH3-C2), 1.45-1.13 (m, 4H, H-C6, H-C3”) 
ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 171.1 (s, C1’), 112.6 (s, C2), 82.3 (d, C4, 1J = 155), 79.9, 79.5 (2d, 
C3a,7a, 1J = 147, 148), 70.0 (t, C2’, 1J = 145), 61.4 (d, C5, 1J = 147), 57.6 (d, C7, 1J = 144), 38.9, 38.8 (2t, 
C1”,5”, 1J = 137), 33.6 (t, C6, 1J = 134), 29.1 (t, C2”,4”, 1J = 121), 26.1, 26.0 (2q, CH3-C2, 1J = 126), 24.2 
(t, C3”, 1J = 125) ppm. 
 
ESI-HRMS for (C27H42N14O8 + H)+: calculated 691.3388; found 691.3384. 
 
C27H42N14O8 (690.33). 
 
 
1H NMR spectrum of 196 
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1H NMR spectrum of intermediate of 196 
 
 
 
 
1H NMR spectrum of 197 
 
 
New efficient synthetic routes toward functionalised polyketides.  
   
 
173
N,N’-(Iminodipropane-3,1-diyl)bis(2-{[(1S,2S,3R,4S,6R)-4,6-diamino-2,3-
dihydroxycyclohexyl]oxy}acetamide) (197) 
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Starting from 3,3’-diaminopropylamine (27 μL, 0.192 mmol), intermediate of 197 (113 mg, 82% 
over 2 steps) was obtained a pale yellow oil. Following method A, starting from intermediate of 197 
(75 mg, 0.117 mmol), 197 (32 mg, 51%) was obtained as a white foam. 
 
IR (film): ν~  = 3320, 3095, 2940, 2105, 1670 1440, 1370, 1260, 1135, 1065, 840, 800 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 4.30 (2d AB, 4H, H2-C2’, 2J = 15.4), 3.45-3.25 (m, 6H, H-C1,2,3), 3.26 
(td, 2H, H-C4, 3J = 8.1, 3.8), 3.14 (t, 4H, H2-C3”, 3J = 7.0), 3.11 (td, 2H, H-C6, 3J = 8.1, 3.8), 2.87 (t, 
4H, H2-C1”, 3J = 7.0), 2.26 (dt, 2H, H2-C5, 3J =3.8, 2J = 12.5), 1.76-1.65 (m, 4H, H2-C2”), 1.64 (d, 2H, 
H2-C5, 2J = 12.5) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 175.1 (s, C1’), 83.7 (d, C1, 1J = 143), 77.5, 74.8 (2d, C2,3, 1J = 146, 
149), 73.1 (t, C2’, 1J = 146), 52.3, 51.5 (2d, C4,6, 1J = 143, 146), 47.7 (t, C1”, 1J = 142), 38.3 (t, C3”, 1J = 
140), 30.6 (t, C5, 1J = 134), 28.1 (t, C2”, 1J = 130) ppm. 
 
ESI-HRMS for (C22H45N7O8 + H)+: calculated 536.3408; found 536.3411. 
 
C22H45N7O8 (535.635). 
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Data for intermediate of 197: 
N,N’-(Iminodipropane-3,1-diyl)bis(2-{[(1S,2S,3R,4S,6R)-4,6-diazido-2,3-
dihydroxycyclohexyl]oxy}acetamide) 
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IR (film): ν~  = 3320, 3095, 2940, 2105, 1670, 1440, 1370, 1260, 1135, 1065, 840, 800 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 4.30 (2d AB, 4H, H2-C2’, 2J = 3.1), 3.57 (ddd, 2H, H-C4, 3J = 4.3, 
8.6, 12.9), 3.0-3.3 (m, 8H, H-C2,6, H2-C3”), 3.23 (t, 2H, H-C1, 3J = 9.4), 3.12 (t, 2H, H-C3, 3J = 9.4), 
2.98 (t, 4H, H2-C1”, 3J = 7.2), 2.10 (dt, 2H, H2-C5, 3J = 4.3, 2J = 12.5), 1.95-1.83 (m, 4H, H2-C2”), 1.28 
(d, 2H, H2-C5, 2J = 12.5) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 173.0 (s, C1’), 85.5 (d, C1, 1J = 142), 76.7, 75.3 (2d, C2,3, 1J = 142, 
143), 71.4 (t, C2’, 1J = 146), 61.0, 60.8 (2d, C4,6, 1J = 143, 143), 45.5 (t, C1”, 1J = 143), 35.5 (t, C2”, 1J = 
135), 32.1 (t, C5, 1J = 133), 26.5 (t, C3”, 1J = 129) ppm. 
 
MALDI-TOF-HRMS for (C22H37N15O8 + H)+: calculated 640.3028; found 640.3025. 
 
C22H37N15O8 (639.625). 
 
1H NMR spectrum of intermediate of 197 
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N,N’-[Butane-1,4-diylbis(iminopropane-3,1-diyl)]bis(2-{[(1S,2S,3R,4S,6R)-4,6-diamino-2,3-
dihydroxycyclohexyl]oxy}acetamide) (198) 
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Starting from spermine (46mg, 0.229 mmol), intermediate of 198 (21 mg, 33%) was obtained a pale 
yellow oil. Following method A, starting from intermediate of 198 (90 mg, 0.114 mmol), 198 (40 mg, 
58% over 2 steps) was obtained as a white foam.  
 
IR (KBr): ν~  = 2965, 2790, 1650, 1590, 1455, 1005, 1290, 1195, 1145, 1100, 1060, 1005, 900 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 4.29, 4.20 (2d AB, 4H, H2-C2’, 2J = 15.4), 3.5-3.25 (m, 8H, H-C1,2,4,5), 
3.23-3.1 (m, 6H, H-C3, H2-C1”), 2.91 (brs, 8H, H2-C3”,1”’), 2.37-2.25 (m, 2H, H2-C6), 1.83-1.72 (m, 4H, 
H2-C2”), 1.68 (d, 2H, H2-C6, 2J = 12.4), 1.51 (brs, 4H, H2-C2”’) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 172.5 (s, C1’), 82.6, 75.4, 72.7 (3d, C1,2,3, 1J = 147, 146, 147), 71.0 (t, 
C2’, 1J = 147), 50.2, 49.3 (2d, C6,4, 1J = 143, 147), 47.3, 45.5 (2t, C2”’,3”, 1J = 148), 28.4 (t, C5, 1J = 
132), 26.2 (t, C1”, 1J = 140), 25.9 (t, C2”, 1J = 131), 23.2 (t, C2”’, 1J = 132) ppm. 
 
ESI-HRMS for (C26H54N8O8 + H)+: calculated 607.4143; found 607.4147. 
 
C26H54N8O8 (606.756). 
 
 
1H NMR spectrum of 198 
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Data for intermediate of 198: 
N,N’-[Butane-1,4-diylbis(iminopropane-3,1-diyl)]bis(2-{[(3aR,4S,5R,7S,7aR)-5,7-diazido-2,2-
dimethylhexahydro-1,3-benzodioxolo-4-yl]oxy}acetamide)  
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IR (film): ν~  = 2930, 2105, 1670, 1550, 1535, 1450, 1380, 1230, 1105, 1050, 840, 750 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 4.32, 4.22 (2d AB, 4H, H2-C2’, 2J = 15.5), 3.81 (m, 4H, H-C5,7), 
3.64, 3.59 (2t, 4H, H-C3a,7a, 3J = 9.4, 9.4), 3.35 (t, 2H, H-C4, 3J = 9.4), 3.46-3.40, 3.33-3.28 (2m, 4H, 
H2-C1”), 3.07-2.95 (m, 8H, H2-C3”,4”’), 2.27, 2.23 (dt, 2H, H2-C6, 3J = 4.9, 2J = 13.3), 1.97-1.88 (m, 4H, 
H2-C2”), 1.83-1.76 (m, 4H, H2-C3”’), 1.45, 1.44 (2s, 12H, CH3-C2), 1.43, 1.37 (2d, 2H, H2-C6, 2J = 13.3) 
ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 172.3 (s, C1’), 112.6 (s, C2), 82.4 (d, C3a, 1J = 145), 80.0 (d, C4, 1J = 
147), 79.5 (d, C7a, 1J = 148), 69.9 (t, C2’, 1J = 145), 61.4, 57.6 (2d, C5,7, 1J = 143), 47.4, 45.4 (2t, C4”’,3”, 
1J = 138, 137), 35.7 (t, C1”, 1J = 138), 33.6 (t, C6, 1J = 133), 26.9 (t, C2", 1J = 125), 26.1 (q, CH3-C2, 1J 
= 127), 23.8 (t, C3”’, 1J = 126) ppm. 
 
ESI-HRMS for (C32H54N16O8 + H)+: calculated 791.4389; found 791.4393. 
 
C32H54N16O8 (790.874). 
 
 
1H NMR spectrum of intermediate of 198 
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2-{[(1RS,2SR,3RS,4SR,6RS)-4,6-Diamino-2,3-dihydroxycyclohexyl]oxy}-N-
{(3RS,5SR,7RS,9SR,11SR,13RS)-15-[({[(1RS,2SR,3RS,4SR,6RS)-4,6-diamino-2,3-
dihydroxycyclohexyl]oxy}acetyl)amino]-3,5,7,9,11,13-hexahydroxypentadecyl}acetamide) (199) 
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Starting from protected diamine 9 (85 mg, 0.129 mmol), intermediate of 199 (84 mg, 52%) was 
obtained a pale yellow oil. Following method B, starting from intermediate of 199 (84 mg, 0.067 
mmol), 199 (4 mg, 8% yield over 2 steps) was obtained as a white foam. Described as the most 
abundant diastereoisomer. 
 
IR (KBr): ν~  = 3415, 2940, 1680, 1650, 1200, 1140, 840, 800, 670 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 4.41-4.20 (m, 4H, H2-C2’), 4.05-3.72 (2m, 6H, H-C3”,5”,7”,9”,11”,13”), 3.6-
3.10 (3m, 14H, H-C1,2,3,4,6, H2-C1”,15”), 2.55-2.30 (2m, 2H, H2-C5), 1.70-1.4 (m, 16H, H2-C5, H2-
C2”,4”,6”,8”,10”,12”,14”) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 140 (s, C1’), 81.7, 81.5, 81.4 (3d, C1,2,3), 75.2, 75.3 (2t, C1”,15”), 72.4, 
71.1 (2t, C2’), 66.6, 66.5, 66.3, 66.1, 65.1, 65.0 (6d, C3”,5”,7”,9”,11”,13”), 59.2, 52.3, 52.1, 50.1, 49.8, 45.0, 
44.9 (7d, C2”,4”,6”,8”,10”,12”,14”, H2-C5), 37.2, 33.2 (2d, C4,6) ppm. 
 
ESI-HRMS for (C31H62N6O14 + H)+: calculated 743.4402; found 743.4401. 
 
C31H62N6O14 (742.85). 
 
 
 
1H NMR spectrum of 199 
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Data for intermediate of 199: 
2-{[(3aRS,4SR,5RS,7SR,7aRS)-5,7-Diazido-2,2-dimethylhexahydro-1,3-benzodioxolo-4-yl]oxy}-
N-[(3RS)-4-[(4SR,6RS)-6-({(4SR,6SR)-6-[(2RS)-4-[({[(3aRS,4SR,5RS,7SR,7aRS)-5,7-diazido-2,2-
dimethylhexahydro-1,3-benzodioxolo-4-yl]oxy}acetyl)amino]-2-
({[(phenylmethyl)oxy]methyl}oxy)butyl]-2,2-dimethyl-1,3-dioxane-4-yl}methyl)-2,2-dimethyl-
1,3-dioxane-4-yl]-3-({[(phenylmethyl)oxy]methyl}oxy)butyl]acetamide 
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Described as the most abundant diastereoisomer. 
 
1H-NMR (400 MHz, MeOD): δ = 7.4-7.2 (m, 10Harom.), 4.87-4.8 (m, 4H, CH2(BOM)), 4.73-4.57 (m, 
4H, CH2Ph), 4.23, 4.21 (2d AB, 4H, H2-C2’, 2J = 9.5), 4.1-3.75 (4m, 6H, H-C3”,4’”,6’”,4V,6V,2VI), 3.72-3.53 
(2m, 6H, H-C3a,4,7a), 3.52-3.44 (m, 8H, H-C5,7, H2-C1”,4VI), 2.26-2.17, 1.39-1.34 (2m, 4H, H2-C6), 1.9-
1.47 (3m, 14H, H2-C2”,4”,5”’,1IV,5V,1VI,3VI), 1.42 (brs, 12H, CH3-C2), 1.36-1.3 (2brs, 12H, CH3-C2”’,2V) 
ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 172.3 (s, C1’), 139.4, 139.3 (2s, Carom.), 129.5, 128.9, 128.8 (3d, 
Carom.), 113.6 (2t, CH2(BOM)), 101.5, 99.9 (2s, C2”’,2V), 96.1, 95.9 (2s, C2), 83.2, 83.1, 83.0, 82.9, 80.9, 
80.6 (6d, C3a,7a,4), 75.5, 74.6, 67.0, 66.9, 64.8, 64.3 (6d, C3”,4”’,6”’,4V,6V,2VI), 71.0 (t, CH2Ph), 70.9, 70.8 
(2t, H2-C2’), 62.3, 62.2, 58.6, 58.5 (4d, C5,7), 43.6, 43.4, 43.3, 42.8, 42.6, 39.6, 38.5 (7t, 
C2”,4”,5”’,1IV,5V,1VI,3VI), 36.7, 36.6 (2t, C1”,4VI), 34.6 (t, C6), 30.5, 20.2 (2q, CH3-C2V), 25.4, 25.3 (2q, CH3-
C2”’)), 27.2, 27.1 (2q, CH3-C2) ppm. 
 
C59H86N14O16 (1247.398). 
 
1H NMR spectrum of intermediate of 199 
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2-{[(1RS,2SR,3RS,4SR,6RS)-4,6-Diamino-2,3-dihydroxycyclohexyl]oxy}-N-{2-[(2SR,4RS,6RS)-6-
{(2RS,4SR)-5-[(2RS,4RS,6SR)-6-{2-[({[(1RS,2SR,3RS,4SR,6RS)-4,6-diamino-2,3-
dihydroxycyclohexyl]oxy}acetyl)amino]ethyl}-4-hydroxytetrahydro-2H-pyran-2-yl]-2,4-
dihydroxypentyl}-4-hydroxytetrahydro-2H-pyran-2-yl]ethyl}acetamide) (200) 
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Starting from protected diamine 188 (95 mg, 0.141 mmol), intermediate of 200 (107 mg, 60%) was 
obtained a pale yellow oil. Following method B, starting from protected azide intermediate of 200 
(107 mg, 0.086 mmol), 200 (26 mg, 38% yield over 2 steps) was obtained as a white foam. Described 
as the most abundant diastereoisomer. 
 
IR (KBr): ν~  = 2940, 2855, 2810, 1600, 1455, 1360, 1305, 1270, 1115, 1070, 1005, 915, 865 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 4.29, 4.21 (2d AB, 4H, H2-C2’, 2J = 15.3), 4.17-3.75 (2m, 12H, H-
C2IV,4IV,6IV,2V,4V,2VI,4VI,6VI, H2-C1”,2”’), 3.47-3.28 (3m, 6H, H-C1,2,3), 3.27-3.13 (m, 4H, H-C4,6), 2.51-2.17 
(2m, 2H, H2-C5), 2.07-1.8 (2m, 4H, H2-C1V,5V), 1.83-1.70 (m, 2H, H2-C5), 1.2-1.06 (m, 2H, H2-C3V), 
1.67-1.43 (m, 8H, H2-C3IV,5IV,5VI,3VI) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 172.4 (s, C1’), 81.6, 75.5, 72.7 (3d, C1,2,3), 70.9 (t, C2’), 67.4, 67.0, 
65.9, 66.8, 63.9, 63.8 (6d, C2IV,4IV,6IV,2V,4V,2VI,4VI,6VI), 57.1 (d, C4,6), 50.1, 49.3 (2t, C1’’,2’’’), 44.4 (t, C3V), 
42.7, 42.6 (2t, C1V,5V), 40.4, 39.8 (2t, C5IV,3VI), 37.0, 36.3 (2t, C3IV,5VI), 30.3, 30.0 (2t, C1”’,2’’), 28.5 (t, 
C5) ppm. 
 
ESI-HRMS for (C35H66N6O14 + H)+: calculated 795.4715; found 795.4720. 
 
C35H66N6O14 (794.93). 
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1H NMR spectrum of 200 
 
 
 
 
 
1H NMR spectrum of intermediate of 200 
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Data for intermediate of 200: 
N,N’-([(4RS,6SR)-2,2-Dimethyl-1,3-dioxane-4,6-diyl]bis{methanediyl[(2SR,4RS,6SR)-4-
({[(phenylmethyl)oxy]methyl}oxy)tetrahydro-2H-pyran-2,6-diyl]ethane-2,1-diyl})bis(2-
{[(3aRS,4SR,5RS,7SR,7aRS)-5,7-diazido-2,2-dimethylhexahydro-1,3-benzodioxolo-4-
yl]oxy}acetamide) 
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Described as the most abundant diastereoisomer. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.27 (m, 10Harom.), 4.81 (brs, 4H, CH2(BOM)), 4.60 (brs, 4H, 
CH2Ph), 4.23, 4.21 (2d AB, 4H, H2-C2, 2J = 15.6), 4.15-4.02 (m, 6H, H-C4’”,6’”,4V,6V), 4.02-3.92 (m, 2H, 
H-C2”’), 3.9-3.8 (m, 2H, H-C4’), 3.78-3.63 (2m, 4H, H-C5’,7’), 3.6-3.47 (m, 4H, H-C1a,3a), 2.28-2.23 (m, 
2H, H2-C6’), 1.92-1.73 (2m, 6H, H2-C1IV,5V), 1.7-1.5 (m, 8H, H2-C3”’,5’”), 1.5-1.4 (m, 2H, H2-C6’), 1.44 
(brs, 18H, CH3-C2’,2V), 1.37-1.26 (m, 8H, H2-C1”,2”) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 172.3 (s, C1), 138.4 (2s, Carom.), 128.4, 128.0, 127.7 (3d, Carom.), 
112.7, 99.0 (2s, C2’,2V), 92.9, 92.8 (2t, CH2(BOM)), 82.2, 79.9, 79.6 (3d, C1a,3a,4’), 70.1 (t, C2), 69.6 (t, 
CH2Ph), 67.9, 66.5, 66.1, 65.6, 65.2 (5d, C2”’,4”’,6”’,4V,6V), 61.4, 61.3 (2d, C7’,4’), 35.9 (t, C6’), 33.6 (t, 
C1”), 31.7, 31.6, 31.5, 31.4 (4t, C3’",5”’,1IV,5V), 29.6 (t, C2”), 26.2, 26.0 (2q, CH3(C2’)), 29.6, 19.4 (2q, 
CH3-C2V) ppm. 
 
ESI-MS: 1248.3 (M+H)+. 
 
C59H86N14O16 (1247.398). 
 
 
(3aRS,4SR,5RS,7SR,7aRS)-5,7-Diazido-4[({4-bis(methoxy)methyl]phenyl}methyl)oxy]-2,2-
dimethylhexahydro-1,3-benzodioxole (214) 
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To a solution of methyl 4-(bromomethyl)benzoate 212 (1.5 g, 6.550 mmol) in CH2Cl2 (7 mL), under 
argon, was added a 1M solution of DIBAL-H in hexane (16 mL, 16 mmol, 2.5 eq) and the solution 
was stirred at 25°C for 15 h. MeOH was then added dropwise until gas evolution has stopped, the 
reaction mixture was poured in 1M HCl (100 mL) and extracted with EtOAc (70 mL, 3 times). The 
combined organic layers were washed with brine (80 mL), dried over MgSO4 and concentrated in 
vacuo. Purification of the residue by flash chomatography (30% of EtOAc in pentane) afforded an 
intermediate alcohol as a colourless oil (927 mg, 70%). 
To a solution of oxalyl chloride (684μL, 7.958 mmol, 2 eq.) in CH2Cl2 (8 mL) at -78°C under argon 
was added dropwise DMSO (1.14 mL, 16 mmol, 4 eq.), the solution was stirred for 10 mn before the 
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addition of the above alcohol (800 mg, 4.020 mmol, 1 eq.) in CH2Cl2 (8 mL). After 20 mn, NEt3 (3.34 
mL, 24 mmol, 6 eq.) was added and the temperature was raised to 25°C for 1 h. The reaction mixture 
was concentrated in vacuo. Purification of the residue by flash chomatography (20% of EtOAc in 
pentane) afforded the corresponding aldehyde as a colourless oil (400 mg, 50%). To a solution of this 
aldehyde (400 mg, 2.010 mmol) in CH2Cl2 (3 mL) and trimethyl orthoformate (3 mL) was added 
APTS (38 mg, 0.210 mmol, 0.1 eq.) at 25°C. The resulting solution was stirred for 2 h. The mixture 
was then poured into a saturated aqueous solution of NaHCO3 (20 mL) and extracted with EtOAc (30 
mL, 3 times). The combined organic layers were washed with brine (50 mL), dried over MgSO4 and 
concentrated in vacuo. Purification of the residue by flash chomatography (10% of EtOAc in pentane) 
afforded 1-(bromomethyl)-4-(dimethoxymethyl) benzene as a colourless oil (480 mg, 97%). 
To a solution of alcohol 190 (367 mg, 1.441 mmol) in CH3CN (8 mL) was added NaH 60% mineral 
oil (115 mg, 2.88 mmol, 2 eq.), Bu4NI (958 mg, 2.595 mmol, 1.7 eq.) and 1-(bromomethyl)-4-
(dimethoxymethyl) benzene (424 mg, 1.73 mmol, 1.2 eq.) at 25°C for 15 h. The reaction mixture was 
then poured into water (20 mL) and extracted with EtOAc (30 mL, 3 times). The organic layers were 
washed with brine (40 mL), dried over MgSO4 and concentrated in vacuo. Purification of the residue 
by flash chomatography (20% of EtOAc in pentane) afforded diazide 214 as a colourless oil (394 mg, 
65%). 
 
IR (film): ν~  = 2920, 2935, 2830, 2100, 1650, 1455, 1370, 1260, 1225, 1100, 1055, 840 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 7.5-7.35 (m, 4Harom.), 5.41 (s, 1H, H-C1”), 4.93, 4.76 (2d AB, 2H, H2-
C1’, 2J = 11.5), 3.63 (ddd, 1H, H-C7, 3J = 4.4, 10.4, 11.2), 3.59-3.47 (m, 3H, H-C7a,3a,5), 3.39 (d, 1H, H-
C4, 3J = 12.4), 3.34 (s, 6H, CH3(OMe)), 2.25 (dt, 1H, H2-C6, 3J = 4.4, 2J = 13.9), 1.49, 1.48 (2s, 6H, 
CH3-C2), 1.40 (td, 1H, H2-C6, 3J = 11.9, 2J = 13.9) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 137.8, 137.6 (2s, Carom.), 127.9, 126.8 (2d, Carom., 1J = 160, 159), 
112.4 (s, C2), 102.9 (d, C1”, 1J = 161), 80.4, 80.3 (2d, C3a,7a, 1J = 146), 79.5 (d, C4, 1J = 146), 72.6 (t, 
C1’, 1J = 145), 60.0, 57.3 (2d, C7,5, 1J = 141, 143), 52.7, 52.6 (2q, CH3(OMe), 1J = 145), 33.9 (t, C6, 1J 
= 132), 26.9, 26.7 (2q, CH3-C2, 1J = 126) ppm. 
 
ESI-HRMS for (C19H26N6O5 + Na)+: calculated 441.1862; found 441.1863. 
 
C19H26N6O5 (418.447). 
 
1H NMR spectrum of 214 
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4-({[(1SR,2SR,3RS,4SR,6RS)-4,6-Diamino-2,3-dihydroxycyclohexyl]oxy}methyl)benzaldehyde 
(215) 
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To a solution of diazide 214 (80 mg, 0.191 mmol) in MeOH (3 mL) was added a catalytic amount of 
Pd(OH)2 on activated charcoal. The resulting suspension was stirred at 25°C under 1 atm. of hydrogen 
for 2 h. The reaction mixture was filtered through a pad of celite® and the filtrate was concentrated in 
vacuo. The crude oil was dissolved in TFA/H2O/CH2Cl2 5/1/1 (1.5 mL) and stirred at 25°C for 1 h. 
The reaction mixture was then concentrated in vacuo. Purification of the residue by semi-preparative 
HPLC (0-100% of CH3CN in H2O/TFA in 30 mn at 18 mL/mn) afforded aldehyde 215 as a colourless 
oil (48 mg, 95%, 2 steps). 
 
IR (film): ν~  = 3500, 3000, 1790, 1700, 1675, 1640, 1555, 1530, 1505, 1490, 1470, 1310, 1200, 1135, 
1060, 840 cm-1. 
 
1H-NMR (400 MHz, DMSO): δ = 10.01 (s, 1H, H-C1”), 8.12, 8.06 (2brs, 6H, H-O, H2-N), 7.89, 7.65 
(2d, 4Harom., 3J = 7.7), 4.91 (2d AB, 2H, H2-C1’, 3J = 12.4), 3.5-3.4 (m, 2H, H-C1,2), 3.4-3.25 (m, 2H, 
H-C3,6), 3.2-3.1 (m, 1H, H-C4), 2.25-2.15 (m, 1H, H2-C5), 1.56 (dt, 1H, H2-C5, 3J = 12.1, 2J = 12.1) 
ppm. 
 
13C-NMR (100 MHz, DMSO): δ = 193.1 (d, C1”), 145.6 (s, Carom.), 135.5 (s, Carom.), 129.5, 128.2 (2d, 
Carom.), 81.0, 75.5 (2d, C1,2), 73.2 (t, C1’), 73.0 (d, C3), 49.6, 48.7 (2d, C4,6), 28.9 (t, C5) ppm. 
 
ESI-HRMS for (C19H26N6O5 + H)+: calculated 281.1501; found 281.1501. 
 
C19H26N6O5 (418.447). 
 
 
1H NMR spectrum of 215 
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1,1-Dimethylethyl(2S,4R)-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-2-
(hydroxymethyl)pyrrolidine-1-carboxylate (223) 
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To a solution of N-BOC-trans-4-hydroxyl-L-proline methyl ester 222 (1 g, 4.077 mmol) in DMF (18 
mL) were added imidazole (694 mg, 10 mmol, 2.5 eq.), TBDMSCl (922 mg, 6.115 mmol, 1.5 eq.) and 
DMAP (200 mg, 1.631 mmol, 0.4 eq.). The mixture was stirred at 25°C for 7h. The reaction mixture 
was poured into water (50 mL) and extracted with Et2O (20 mL). The organic layer was washed with 
brine (10 mL), dried over MgSO4 and concentrated in vacuo. The residual oil was dissolved in EtOH 
(18 mL) and treated with NaBH4 (617 mg, 16.3 mmol, 4 eq.) at 25°C for 14h. The reaction mixture 
was poured into water (30 mL) and extracted with EtOAc (50 mL, 3 times). The combined organic 
layer were washed with brine (70 mL), dried over MgSO4 and concentrated in vacuo. Purification of 
the residue by flash chomatography (20% of EtOAc in pentane) afforded alcohol 223 as a colourless 
oil (1 g, 74% over 2 steps). 
 
[ ]23405α = -71, [ ]23435α = -61, [ ]23577α = -35, [ ]23589α = -33 (c = 1.73, CHCl3). 
 
IR (film): ν~  = 3415, 2955, 2930, 2840, 1700, 1685, 1470, 1415, 1370, 1255, 1165, 1115, 1085, 1060, 
1030, 905, 840, 775 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 4.27 (brs, 1H, H-C4), 4.14-4.10 (m, 1H, H-C2), 3.80-3.55 (2m, 2H, 
H2-C3), 3.33 (dd, 2H, H2-C5, 3J = 11.2, 31.6), 2.0-1.95 (m, 1H, H2-C1), 1.62-1.55 (m, 1H, H2-C6), 1.46 
(s, 9H, tBu(Boc)), 0.86 (s, 9H, tBuMe2Si(TBDMS)), 0.06 (s, 6H, tBuMe2Si(TBDMS)) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 157.4 (s, C=O(Boc)), 80.4 (s, tBu(Boc)), 69.8 (d, C4, 1J = 147), 67.3 
(t, C3, 1J = 142), 59.1 (d, C2, 1J = 143), 56.1 (t, C5, 1J = 143), 37.9 (t, C6, 1J = 134), 28.4 (q, tBu(Boc)), 
1J = 126), 25.6 (q, tBuMe2Si(TBDMS)), 1J = 130), 17.9 (s, tBuMe2Si(TBDMS)), -4.8, -4.9 (2q, 
tBuMe2Si(TBDMS), 1J = 120) ppm. 
 
ESI-MS: 332.4 (M+H)+. 
 
ESI-HRMS for (C16H33NO4Si + H)+: calculated 332.2257; found 332.2257. 
 
Anal. for C16H33NO4Si (331.52): calculated C 57.97, H 10.03, N 4.22; found C 57.88, H 9.99, N 4.30. 
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1H NMR spectrum of 223 
 
 
 
 
1H NMR spectrum of 224 
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1,1-Dimethylethyl(2S,4R)-2-(aminomethyl)-4-{[(1,1-
dimethylethyl)(dimethyl)silyl]oxy}pyrrolidine-1-carboxylate (224) 
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To a solution of alcohol 223 (948 mg, 2.860 mmol) in CH2Cl2 (8 mL) were added NEt3 (1.8 mL, 12.9 
mmol, 4.5 eq.) and methanesulfonyl chloride (560 μL, 5.719 mmol, 2 eq.). The mixture was stirred at 
0°C for 2h. The reaction mixture was poured into water (20 mL) and extracted with CH2Cl2 (30 mL, 3 
times). The organic layers were washed with brine (40 mL), dried over MgSO4 and concentrated in 
vacuo. The residual oil was dissolved in DMF (8 mL) and treated with NaN3 (1.84 g, 28.6 mmol, 10 
eq.) at 60°C for 14h. The reaction mixture was poured into water (30 mL) and extracted with EtOAc 
(50 mL, 3 times). The combined organic layers were washed with brine (70 mL), dried over MgSO4 
and concentrated in vacuo. Purification of the residue by flash chomatography (5% of EtOAc in 
pentane) afforded an intermediate azide as a colourless oil (688 mg, 67% over 2 steps). This azide was 
dissolved in MeOH (10 mL), treated with a catalytic amount of Pd(OH)2 on activated charcoal and 
stirred at 25°C under 1 atm. of hydrogen for 1 h. The reaction mixture was then filtered through a pad 
of celite® and the filtrate was concentrated in vacuo. Purification of the residue by flash 
chomatography (5% of MeOH in CH2Cl2) afforded amine 224 as a colourless oil (450 mg, 68%). 
 [ ]23405α = -40, [ ]23435α = -34, [ ]23589α = -18 (c = 1.2, CHCl3). 
 
IR (film): ν~  = 3375, 2940, 2860, 1695, 1680, 1470, 1395, 1365, 1255, 1170, 1110, 1025, 905, 840, 
775 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 4.39 (brs, 1H, H-C4), 3.93 (brs, 1H, H-C2), 3.52-3.47, 3.37-3.28 (m, 
2H, H2-C5), 2.89-2.80, 2.78-2.70 (m, 2H, H2-C1), 2.05-1.84 (2m, 2H, H2-C3), 1.47 (s, 9H, tBu(Boc)), 
0.99 (s, 9H, tBuMe2Si(TBDMS)), 0.1 (s, 6H, tBuMe2Si(TBDMS)) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 158.2 (s, C=O(Boc)), 80.2, 80.0 (2s, tBu(Boc)), 70.7, 69.6 (2d, C4, 
1J = 148), 58.3, 58.1 (2d, C2, 1J = 139), 56.5, 56.0 (2t, C5, 1J = 141), 44.6 (t, C1, 1J = 137), 38.8, 38.5 
(2t, C3, 1J = 139), 27.7 (q, Me(-tBu(Boc)), 1J = 127), 25.2 (q, tBuMe2Si(TBDMS)), 1J = 125), 17.7 (s, 
tBuMe2Si(TBDMS)), -4.8 (2q, tBuMe2Si(TBDMS)), 1J = 149) ppm. 
 
ESI-MS: 331.3 (M+H)+. 
 
ESI-HRMS for (C16H34N2O3Si + H)+: calculated 331.2417; found 331.2418. 
 
Anal. for C16H34N2O3Si (330.54): calculated C 58.14, H 10.37, N 8.48; found C 58.00, H 10.18, N 
8.55. 
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(3R,5S)-5-(Aminomethyl)pyrrolidin-3-ol (220) 
 
5
2 N
H
HO NH2
6
 
 
A solution of amine 224 (100 mg, 0.302 mmol) in 4M HCl (3 mL) was stirred at 25°C for 2 h. The 
reaction mixture was then concentrated in vacuo. Purification of the residue by flash chomatography 
(2-4% of aqueous NH4OH in CH3CN) afforded aminoalcohol 220 as a colourless oil (32 mg, 91%). 
 [ ]23435α = +20, [ ]23589α = +12 (c = 0.3, MeOH). 
 
IR (film): ν~  = 3200, 1515, 1240, 1115, 985 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 4.66 (brs, 1H, H-C3), 4.14-4.08 (m, 1H, H-C5), 3.54-3.30 (m, 4H, H2-
C2,6), 2.32 (dd, 1H, H2-C4, 3J = 5.6, 13.6) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 71.7 (d, C3, 1J = 156), 58.4 (d, C5, 1J = 150), 55.9 (t, C2, 1J = 149), 
42.7 (t, C6, 1J = 144), 39.9 (t, C4, 1J = 136) ppm. 
 
ESI-MS: 117.33 (M+H)+. 
 
ESI-HRMS for (C5H12N2O + H)+: calculated 117.1028; found 117.1029. 
 
C5H12N2O (116.16). 
 
 
 
1H NMR spectrum of 220 
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[4-({[(3aRS,4SR,5RS,7SR,7aRS)-5,7-Diazido-2,2-dimethylhexahydro-1,3-benzodioxol-4-
yl]oxy}methyl)phenyl]methanol (226) 
 
6
5
3a
2
N3
N3
O
OO
7a
OH
1"1'
 
 
To a solution of methyl 4-(bromomethyl)benzoate 212 (2 g, 8.731 mmol) in CH2Cl2 (9 mL) was added 
a 1M solution of DIBAL in hexane (22 mL, 22 mmol, 2.5 eq). The mixture was stirred at 25°C for 15 
h and MeOH was then added dropwise until gas evolution stopped. The reaction mixture was poured 
in 1M HCl (100 mL) and extracted with EtOAc (70 mL, 3 times). The combined organic layers were 
washed with brine (80 mL), dried over MgSO4 and concentrated in vacuo. The residue was dissolved 
in DMF (30 mL) and treated with imidazole (1.5 g, 22 mmol, 2.5 eq.), TBDMSCl (1.97 g, 13 mmol, 
1.5 eq.) and DMAP (320 mg, 2.619 mmol, 0.3 eq.) at 25°C for 7h. The reaction mixture was then 
poured into water (50 mL) and extracted with Et2O (40 mL). The organic layer was washed with brine 
(20 mL), dried over MgSO4 and concentrated in vacuo. Purification of the residue by flash 
chomatography (3% of EtOAc in pentane) afforded {[4-(bromomethyl)benzyl]oxy}(tert-butyl) 
dimethylsilane as a colourless oil (1.245g, 45%, 2 steps). 
To a solution of alcohol 190 (473 mg, 1.860 mmol) in CH3CN (7 mL) were added NaH 60% mineral 
oil (149 mg, 3.72 mmol, 2 eq.), Bu4NI (1.34 g, 3.627 mmol, 1.7 eq.) and {[4-
(bromomethyl)benzyl]oxy}(tert-butyl) dimethylsilane (760 mg, 2.418 mmol, 1.3 eq.) at 25°C for 15 h. 
The reaction mixture was then poured ino water (20 mL) and extracted with EtOAc (30 mL, 3 times). 
The combined organic layers were washed with brine (40 mL), dried over MgSO4 and concentrated in 
vacuo. Purification of the residue by flash chomatography (5% of EtOAc in pentane) afforded a 
silylated intermediate with some impurities as a yellow oil. This intermediate was dissolved in THF (6 
mL) and treated with a 1M TBAF solution in THF (3.7 mL, 3.720 mmol, 2 eq.) at 25°C for 1 h. The 
reaction mixture was then concentrated in vacuo. Purification of the residue by flash chomatography 
(30-60% of EtOAc in pentane) afforded alcohol 226 as a colourless oil (612 mg, 88%, 2 steps). 
 
IR (film): ν~  = 3100, 2935, 2100, 1660, 1465, 1320, 1260, 1100, 1055, 840 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 7.41, 7.37 (2d, 4Harom., 3J = 7.9), 4.92, 4.72 (2d AB, 2H, H2-C1’, 2J = 
11.2), 4.69 (s, 2H, H2-C1”), 3.60 (ddd, 1H, H-C7, 3J = 4.8, 7.2, 14.6), 3.57-3.45 (m, 3H, H-C5,4,3a), 3.36 
(dd, 1H, H-C7a, 3J = 4.8, 5.6), 2.24 (dt, 1H, H2-C6, 3J = 4.8, 2J = 14.6), 1.49, 1.48 (2s, 6H, CH3-C2), 
1.38 (td, 1H, H2-C6, 3J = 14.6, 2J = 14.6) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 140.5, 137.0 (2s, Carom.), 128.4, 127.0 (2d, Carom., 1J = 144), 112.4 (s, 
C2), 80.3, 80.2, 79.5 (3d, C4,3a,7a, 1J = 145, 147), 72.6 (t, C1’, 1J = 144), 65.1 (t, C1”, 1J = 137), 61.0, 57.2 
(2d, C7,5, 1J = 141, 142), 33.9 (t, C6, 1J = 132), 26.9, 26.7 (2q, CH3-C2, 1J = 124) ppm. 
 
ESI-MS: 375.5 (M+H)+. 
 
Anal. for C17H22N6O4 (374.39): calculated C 54.54, H 5.92, N 22.45; found C 54.58, H 5.95, N 22.41. 
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1H NMR spectrum of 226 
 
 
 
 
1H NMR spectrum of 228 
 
New efficient synthetic routes toward functionalised polyketides.  
   
 
190
General procedure for the synthesis of reductive amination adducts 228-233 
 
1 eq. of oxalyl chloride per alcohol were diluted in CH2Cl2 (0.7 M solution) at -78°C under argon. 4 
eq. of DMSO were slowly added and the solution was stirred 10 mn before the addition of alcohol 226 
in solution in CH2Cl2 at 0.4 M. After 20 mn, 6 eq. of NEt3 were added and the temperature was raised 
to 25°C for 1 h. The reaction mixture was then concentrated in vacuo. Purification of the residue by 
flash chomatography (20% of EtOAc in pentane) afforded the corresponding aldehyde as a colourless 
oil. 1 Eq. of this aldehyde was dissolved in 1,2-dichloroethane at 25°C, 1.5 eq. of amine and 1.5 eq. 
NaHB(OAc)3 were added. The reaction mixture was stirred for 15 h. After completion of the reaction, 
the reaction mixture was concentrated in vacuo. Purification of the residue by flash chomatography (2-
10% of MeOH in CH2Cl2) afforded the corresponding amine as a colourless oil. This amine was 
dissolved in TFA/H2O 4/1 (2 to 4 mL) and stirred at 25°C for 3 h. After completion of the reaction, the 
reaction mixture was concentrated in vacuo. The residue was dissolved in MeOH (2 to 4 mL) with a 
catalytic amount of Pd(OH)2 on activated charcoal and stirred at 25°C under 1 atm. of hydrogen for 3 
h. After completion of the reaction, the mixture was filtered though a pad of celite® and the filtrate was 
concentrated in vacuo. Purification of the residue by flash chomatography (20-60% of aqueous 
NH4OH in CH3CN) afforded products as pale yellow oils. 
 
 
(1RS,2SR,3SR,4RS,6SR)-4,6-Diamino-3-{[(4-
{[(phenylmethyl)amino]methyl}phenyl)methyl]oxy}cyclohexane-1,2-diol (228) 
 
1'''
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Starting from 226 (199 mg, 0.531 mmol), 228 (75 mg, 38% over 4 steps) was obtained as a pale 
yellow oil.  
 
IR (KBr): ν~  = 3570, 3420, 3200, 2130, 1685, 1650, 1630, 1440, 1400, 1070 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 7.52-7.44 (m, 9Harom.), 5.0-4.9 (2d AB, 2H, H2-C1’, 2J = 10.8), 4.24, 
4.23 (2s, 4H, H2-C1”,1”’), 3.6-3.48 (m, 3H, H-C1,2,3), 3.27, 3.24 (2td, 2H, H-C4,6, 3J = 4, 12.8), 3.37 (dt, 
1H, H2-C5, 3J = 4, 12.4), 1.74 (td, 1H, H2-C6, 3J = 12.4, 12.4) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 141.0, 133.2, 133.1 (3s, Carom.), 132.6, 132.3, 132.1, 131.7 (4d, Carom., 
1J = 160, 158, 169), 83.3 (d, C3, 1J = 143), 77.9, 75.4 (2d, C1,2, 1J = 144, 145), 76.7 (t, C1’, 1J = 150), 
53.1, 52.7 (2t, C1”,1”’, 1J = 127), 52.5, 51.7 (2d, C4,6, 1J = 127), 31.5 (t, C5, 1J = 131) ppm. 
 
ESI-MS: 372.3 (M+H)+. 
 
ESI-HRMS for (C21H29N3O3 + H)+: calculated 372.2287; found 372.2290. 
 
C21H29N3O3 (371.473). 
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(1RS,2SR,3SR,4RS,6SR)-4,6-Diamino-3-{[(4-{[(pyridin-2-
ylmethyl)amino]methyl}phenyl)methyl]oxy}cyclohexane-1,2-diol (229) 
 
1'''
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Starting from 226 (201 mg, 0.537 mmol), 229 (52 mg, 26% over 4 steps) was obtained as a pale 
yellow oil.  
 
IR (KBr): ν~  = 3385, 2920, 1665, 1635, 1435, 1405, 1405, 1315, 1020, 955 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 8.29 (d, 1Harom., 3J = 4.4), 7.67 (t, 1Harom., 3J = 7.6), 7.22,7.18 (2d, 
2Harom., 3J = 8, 7.2), 7.27,7.18 (2d, 2Harom., 3J = 7.6, 7.2), 4.79, 4.54 (2d AB, 2H, H2-C1’, 2J = 10.8), 
3.65, 3.57 (2s, 4H, H2-C1”,1”’), 3.33 (t, 1H, H-C1, 3J = 8.9), 3.07, 3.05 (2t, 2H, H-C2,3, 3J = 8.9), 2.63-
2.53 (m, 2H, H-C4,6), 1.85-1.80 (2m, 1H, H2-C5), 1.06 (dt, 1H, H2-C5, 3J = 12.3, 12.3) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 158.1 (s, Carom.), 148.7, 138.5, 123.5, 123.3 (4d, Carom., 1J = 178, 160, 
162, 165), 139.2, 136.9 (2s, Carom.), 129.4, 129.2 (2d, Carom., 1J = 164), 86.6 (d, C3, 1J = 139), 78.1, 76.3 
(2d, C1,2, 1J = 145, 141), 75.0 (t, C1’, 1J = 147), 53.2, 51.9 (2t, C1”,1”’, 1J = 132), 50.0, 48.6 (2d, C4,6, 1J = 
134, 135), 35.9 (t, C5, 1J = 153) ppm. 
 
ESI-HRMS for (C20H28N4O3 + H)+: calculated 373.2239; found 373.2238. 
 
C20H28N4O3 (372.46). 
 
 
1H NMR spectrum of 229 
 
New efficient synthetic routes toward functionalised polyketides.  
   
 
192
(1RS,2SR,3SR,4RS,6SR)-4,6-Diamino-3-{[(4-{[(1,3-benzodioxol-4-
ylmethyl)amino]methyl}phenyl)methyl]oxy}cyclohexane-1,2-diol (230) 
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Starting from 226 (144 mg, 0.385 mmol), 230 (16 mg, 10% over 4 steps) was obtained as a pale 
yellow oil.  
 
IR (KBr): ν~  = 3380, 2950, 1660, 1640, 1420, 1310, 1020, 955 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 7.31, 7.25 (2d, 6Harom., 3J = 9.4), 6.86 (d, 1Harom., 3J = 9.3), 4.88, 4.64 
(2d AB, 2H, H2-C1’, 2J = 10.7), 3.93, 3.86 (2s, 4H, H2-C1”,1”’), 3.4 (t, 1H, H-C1, 3J = 9.3), 3.23, 3.21 (2t, 
2H, H-C2,3, 3J = 9.3), 2.8 (ddd, 2H, H-C4,6, 3J = 3.1, 11.8, 18), 2.3 (s, 2H, H2-C1IV), 2.05-1.97 (m, 1H, 
H2-C5), 1.26 (dt, 1H, H2-C5, 3J = 12.4, 12.4) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 141.3, 138.6, 136.8, 135.6, 131.6 (5s, Carom.), 131.9, 131.8, 131.7, 
131.5, 112.0 (5d, Carom.), 87.5 (d, C3), 78.7, 78.3 (2d, C1,2), 77.3 (t, C1’), 52.9, 52.0 (2t, C1”,1”’), 36.4 (t, 
C5), 22.7 (t, C1IV) ppm. 
 
ESI-HRMS for (C22H29N3O5 + H)+: calculated 416.2107; found 416.2185. 
 
C22H29N3O5 (415.483). 
 
 
1H NMR spectrum of 230 
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(1RS,2SR,3SR,4RS,6SR)-4,6-Diamino-3-({[4-({[1-(phenylmethyl)piperidin-4-
yl]amino}methyl)phenyl]methyl}oxy)cyclohexane-1,2-diol (231) 
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Starting from 226 (176 mg, 0.471 mmol), 231 (15 mg, 7% over 4 steps) was obtained as a pale yellow 
oil.  
 
IR (KBr): ν~  = 3385, 2920, 1660, 1650, 1435, 1405, 1315, 1020, 955 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 7.46-7.35 (m, 9Harom.), 4.92, 4.69 (2d AB, 2H, H2-C1’, 2J = 10.8), 3.96, 
3.73 (2brs, 4H, H2-C1”, H2- C1IV), 3.42 (t, 1H, H-C3, 3J = 9.5), 3.26, 3.23 (2t, 2H, H-C1,2, 3J = 9.5), 3.03 
(m, 2H, H-C3”’,5”’), 2.9-2.75 (m, 3H, H-C4,6,4”’), 2.34 (m, 2H, H2-C3”’,5”’), 2.07-2.0 (m, 3H, H2-C5,2”’,6”’), 
1.51 (td, 2H, H2-C2”’,6”’, 3J = 10.8, 16), 1.29 (td, 1H, H2-C5, 3J = 12, 2J = 18) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 137.8, 135.8, 134.2 (3s, Carom.), 130.9, 129.7, 129.0, 128.8 (4d, Carom.), 
85.5 (d, C1), 76.3 (d, C2), 76.1 (d, C3), 74.9 (t, C1’), 61.5 (t, C1”), 53.3 (d, C1”’), 51.1 (t, C5”’,3’’), 50.8, 
49.8 (2d, C4,6), 48.9 (t, C1IV), 34.0 (t, C5), 28.8 (t, C2”,6”’) ppm. 
 
ESI-HRMS for (C26H38N4O3 + H)+: calculated 455.3024; found 455.3022. 
 
C26H38N4O3 (454.605). 
 
 
1H NMR spectrum of 231 
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(1RS,2SR,3SR,4RS,6SR)-4,6-Diamino-3-[({4-[({[(2S,4R)-4-hydroxypyrrolidin-2-
yl]methyl}amino)methyl]phenyl}methyl)oxy]cyclohexane-1,2-diol (232) 
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Starting from 226 (179 mg, 0.478 mmol), 232 (40 mg, 22% over 4 steps) was obtained as a pale 
yellow oil. 
 
IR (KBr): ν~  = 3420, 2260, 2130, 1660, 1645, 1050, 1025, 995, 830, 765 cm-1. 
 
1H-NMR (400 MHz, DMSO): δ = 7.25, 7.23 (2s, 4Harom.), 4.85-4.52 (2d AB, 2H, H2-C1’, 2J = 12), 4.07 
(brs, 1H, H-C4IV), 3.6 (brs, 2H, H2-C5IV), 3.17 (m, 1H, H2-C2IV), 2.85-2.68 (m, 4H, H-C1,2,3, H2-C3IV), 
2.60-2.49 (m, 2H, H-C6, H2-C3IV), 2.47-2.30 (m, 3H, H2-C1”’, H-C4), 1.73-1.65 (m, 1H, H2-C5), 0.95 
(td, 1H, H2-C5, 2J = 12, 3J = 12) ppm. 
 
13C-NMR (100 MHz, DMSO): δ = 138.7 (s, Carom.), 128.9, 128.5 (2d, Carom., 1J = 155), 88.4 (d, C3, 1J = 
142), 79.6 (d, C2, 1J = 145), 77.4 (d, C1, 1J = 139), 74.5 (t, C1’, 1J = 144), 72.0 (d, C4IV, 1J = 150), 57.3 
(d, C2IV, 1J = 141), 55.5 (t, C3IV, 1J = 142), 54.6 (t, C1”’, 1J = 137), 53.8 (t, C5IV, 1J = 133), 52.5, 51.6 
(2d, C4,6, 1J = 132, 133), 40.6 (t, C1”, 1J = 128), 38.7 (t, C5, 1J = 127) ppm. 
 
ESI-HRMS for (C19H32N4O4 + H)+: calculated 381.2502; found 381.2506. 
 
C19H32N4O4 (380.482). 
 
1H NMR spectrum of 232 
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(3RS,4RS,5RS)-5-[({[4-({[(1SR,2SR,3RS,4SR,6RS)-4,6-Diamino-2,3-
dihydroxycyclohexyl]oxy}methyl)phenyl]methyl}amino)methyl]-3,4-dihydroxy-1-
methylpyrrolidin-2-one (233) 
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Starting from 226 (100 mg, 0.268 mmol), 233 (25 mg, 22% over 4 steps) was obtained as a pale 
yellow oil. 
 
IR (KBr): ν~  = 3415, 2530, 2100, 1660, 1630, 1575, 1450, 1060, 985 cm-1. 
 
1H-NMR (400 MHz, D2O): δ = 7.35, 7.28 (2d, 4Harom., 3J = 8), 4.85, 4.6 (2d AB, 2H, H2-C1’”, 2J = 
10.8), 4.36, 4.17 (2m, 2H, H-C3,4), 3.7 (2d AB, 2H, H2-C1”, 3J = 12), 3.41-3.3 (m, 2H, H-C1IV,5), 3.21-
3.10 (m, 2H, H-C3IV,2IV), 2.80-2.63, 2.63-2.53 (2m, 7H, H-C4IV,6IV, H2-C1’, CH3(NMe)), 2.01-1.90 (m, 
1H, H2-C5IV), 1.27-1.20 (m, 1H, H2-C5IV) ppm. 
 
13C-NMR (100 MHz, D2O): δ = 174.7 (s, C2), 139.2, 136.9 (2s, Carom.), 129.2, 129.3 (2d, Carom.), 85.3, 
76.2 (2d, C3IV,2IV), 75.2, 66.5 (2d, C1IV,5), 74.5 (t, C1”’), 70.4, 69.7 (2d, C3,4), 52.7 (t, C1”), 50.8, 49.9 
(2d, C4IV,6IV), 46.4 (t, C1’), 33.9 (t, C5IV), 29.2 (q, CH3(NMe)) ppm. 
 
ESI-HRMS for (C20H32N4O6 + H)+: calculated 425.2400; found 425.2401. 
 
C20H32N4O6 (424.491). 
 
1H NMR spectrum of 233 
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General method for DCL experiments 
 
LC-MS: Waters 2525 Binary Gradient Module with a Waters 2767 Sample Manager and a 2996 
Photodiode Array detector, with a Waters Atlantis® HILIC Silica 3 μm column (4.6 X 150mm). Mass 
spectrometer: Waters Micromass ZQ, ESI detection mode positive. Flow rates of 1 mL.min-1 were 
used. Gradient was linear 95% A, 5% B to 40% A, 60% B in 40 min (eluent A 0.1% formic acid in 
acetonitrile; eluent B 0.1% formic acid in water). 
Experiments were performed in 1.5 mL vials with 20 mM phosphate buffer. A 55 mM stock solution 
of aldehyde 215 in DMSO was diluted to 1 mM, 3 eq. of each amine in buffer solution were added, 14 
eq. of a freshly prepared NaBH3CN solution in buffer were added. The volume was completed either 
with buffer solution or with 0.03 eq. of the 37.15 μM RNA aqueous stock solution. The resulting 
mixtures were kept at 25°C for 21 d before direct injection on LC-MS. 
 
 Without RNA With RNA With RNA and Neomycin 
 229 235 229 235 229 235 
Peak area 1885 474 2475 1770 2591 650 
Total 2359 4245 3241 
 
 Without RNA With RNA 
 229 231 229 231 
Peak area 651 140 262 218 
Total 791 880 
 
 Without RNA With RNA 
 228 232 237 228 232 237 
Peak area 1331 831 0 1752 6579 173 
Total 2162 8504 
 
The compositions of the mixtures were calculated as described below: 
 
100
)(
)( ×=
RNAoutwithareapeaktotal
RNAoutwithXofareapeakXinnCompositio  
 
Amplification factors were calculated as described below: 
 
100×+
−=
RNAwithoutXofareapeakRNAwithXofareapeak
RNAwithoutXofareapeakRNAwithXofareapeakXofionAmplificat  
 
Calibration line was measured for compound 229, this calibration line is reproduced below: 
 
 
Calibration line
linearisation:
y = 6,6999x + 146,05
R2 = 0,9917
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3 Synthesis of macrolide-like derivatives 
 
(1S,3S,5S)-1-{[(1R,3R,5R)-3-Hydroxy-8-oxabicyclo[3.2.1]oct-6-en-1-yl]methyl}-8-
oxabicyclo[3.2.1]oct-6-en-3-yl acetate ((-)-266) 
 
O
OH
O
OAc
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3
 
 
Diol 265 (140 mg, 0.530 mmol), in vinyl acetate (6.6 mL), was treated with lipase from Candida 
Cylindracea (1.06 g, 2 u.mg-1, 4000 u.mmol-1). The resulting suspension was stirred at 40°C for 10 h. 
The heterogeneous solution was filtered through a pad of celite®. Removal of the solvent in vacuo and 
purification of the residue by flash chromatography (3%-10% methanol in CH2Cl2) afforded (-)-266 as 
a pale yellow oil (71 mg, 44 %) and recovery of the starting material 265 as a pale yellow solid (75 
mg, 54 %). 
 [ ]23405α = -20, [ ]23435α = -19, [ ]23577α = -9, [ ]23589α = -8 (c = 0.46, CHCl3). 
 
IR (film): ν~  = 3452, 3075, 2940, 1345, 1255, 1030, 745, 740 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.49 (d, 1H, H-C7’, 3J = 5.9), 6.36 (dd, 1H, H-C6’, 3J = 5.9, 1.6), 6.15 
(d, 1H, H-C7, 3J = 6.0), 6.11 (dd, 1H, H-C6, 3J = 6.0, 1.3), 5.05 (t, 1H, H-C3, 3J = 5.8), 4.78 (brs, 1H, 
H-C5’), 4.76 (brs, 1H, H-C5), 3.97 (m, 1H, H-C3’), 2.25 (d, 1H, OH-C3’ , 3J = 10.4), 2.21-2.02 (2m, 2H, 
H-C4exo,4’exo), 2.07 (d, 1H, H-C2exo, 2J = 15.3), 2.00 (d, 1H, H-C2’exo, 2J = 12.1 Hz), 1.98 (s, 3H, 
CH3(OAc)), 1.95 (AB, 2H, H2-C8, 2J = 14.5), 1.91 (d, 1H, H-C2’endo, 2J = 12.1), 1.72 (d, 1H, H-C2endo, 
2J = 15.3), 1.68, 1.57 (2d, 2H, H-C4endo,4’endo, 2J = 15.7, 10.6) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 170.4 (s, C=O(OAc)), 138.8 (d, C7’, 1J = 168), 134.6 (d, C6’, 1J = 
169), 136.5 (d, C7, 1J = 178), 132.5 (d, C6, 1J = 170), 84.3 (s, C1’), 83.6 (s, C1), 77.9 (s, C5’), 77.8 (s, 
C5), 67.2 (d, C3’, 1J = 161), 65.6 (d, C3, 1J = 142), 44.4 (t, C8, 1J = 123), 41.9 (d, C2’, 1J = 129), 38.0 (t, 
C2, 1J = 129), 31.7 (t, C4, 1J = 127), 35.5 (t, C4’, 1J = 125), 21.5 (q, CH3(OAc), 1J = 127) ppm. 
 
MALDI-TOF-MS: 329.5 (M+Na)+. 
 
Anal. for C17H22O5 (306.36): calculated C 66.42, H 7.20; found C 66.02, H 7.28. 
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1H NMR spectrum of (-)-266 
 
 
 
 
1H NMR spectrum of MTPA ester of (-)-266 
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(1R,3R,5R)-1-{[(1S,3S,5S)-3-(Acetyloxy)-8-oxabicyclo[3.2.1]oct-6-en-1-yl]methyl}-8-
oxabicyclo[3.2.1]oct-6-en-3-yl (2S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (MTPA ester 
of (-)-266) 
 
O
O
O
OAc
1'
3'
5'15
3
O
OMeF3C
 
 
To a solution of (-)-266 (0.033 mmol) in CH2Cl2 (10 mg, 0.5 mL) were added DMAP (2.5 mg, 0.020 
mmol, 0.7 eq.), pyridine (10 μL) and (1S)-(-)-α-methoxy-α-(trifluoromethyl)-phenylacetyl chloride (7 
μL, 0.036 mmol, 1.1 eq.). The resulting mixture was stirred at 25°C for 12 h. The solution was diluted 
with CH2Cl2 (2 mL), treated with a saturated aqueous solution of NaHCO3 (3 mL) and extracted with 
CH2Cl2 (3mL, 3 times). The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The residue was purified by flash chromatography (silica gel, 3 % methanol in CH2Cl2) 
affording MTPA ester of (-)-266 as a colourless oil (9 mg, 96 %). 
 [ ]23405α = -55, [ ]23435α = -45, [ ]23577α = -24, [ ]23589α = -26 (c = 0.65, CHCl3).  
 
IR (film): ν~  = 2920, 1730, 1680, 1455, 1360, 1255,1185, 1120, 1030, 700 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 7.50-7.46, 7.43-7.37 (2m, 6Harom.), 6.16 (d, 1H, H-C7’, 3J = 6.0), 6.11 
(dd, 1H, H-C6’, 3J = 6.0, 1.6), 5.85 (s, 2H, H-C6,7), 5.30, 5.03 (2t, 2H, H-C3’,3, 3J = 5.1, 5.3), 4.72 (d, 
2H, H-C5’,5, 3J = 3.0), 3.50 (s, 3H, CH3(OMe)), 2.23, 2.14 (2ddd, 2H, H-C4’exo,4exo, 2J = 15.2, 15.0, 3J = 
5.3, 5.1, 3J = 4.0, 4.1), 1.61, 1.55 (2d, 2H, H-C4’endo,4endo, 2J = 15.2, 15.0), 2.13 (dd, 1H, H-C2’exo, 2J = 
15.2, 3J = 6.0), 2.01 (d, 1H, H-C2exo, 2J = 15.0), 1.75, 1.71 (2d, 2H, H-C2’endo,2’’endo, 2J = 15.2, 15.0), 
1.98 (AB, 2H, H2-C8, 2J = 15.0), 1.97 (s, 3H, CH3(OAc)) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 170.4 (s, C=O(OAc), 165.5 (s, C=O(MTPA)), 136.5 (d, C7’, 1J = 
166), 136.3 (d, C7’, 1J = 166), 132.3 (d, C6’, 1J = 171), 131.9 (d, C6, 1J = 178), 129.5, 128.4, 127.3 (3d, 
Carom., 1J = 160, 159, 160), 124.8 (s, C(CF3)), 121.9 (s, C(CF3)), 83.7, 83.6 (2s, C1’,1), 77.7, 77.4 (2m, 
C5’,5), 70.0 (2d, C3,3’, 1J = 152, 145), 55.2 (q, CH3(OMe), 1J = 129), 44.1 (t, C8, 1J = 124), 38.0, 37.3 
(2t, C2’,2, 1J = 127, 127), 31.6, 31.5 (2t, C4’,4, 1J = 128), 21.5 (q, CH3(OAc), 1J = 129) ppm. 
 
19F NMR (376.5 Hz, CDCl3): -71.69 ppm. 
 
MALDI-TOF-MS: 545.7 (M+Na)+. 
 
Anal. for C27H29F3O7 (522.51): calculated C 62.06, H 5.59; found C 61.49, H 5.64. 
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(1R,6R)-6-(Acetyloxy)-4-({(4S,6S)-4,6-bis[(4-methoxybenzoyl)oxy]cyclohept-1en-
yl}methyl)cyclohept-3-en-1-yl 4-methoxybenzoate ((+)-268) 
 
OPMBz OAc
OPMBzPMBzO
1'
2'
4'
6'
1
3
4
6
 
 
To a solution of alcohol (-)-266 (300 mg, 0.979 mmol) in pyridine (5 mL), were added DMAP (10 mg, 
0.082 mmol, 0.09 eq.) and p-methoxybenzoyl chloride (334 mg, 1.958 mmol, 2 eq.). The resulting 
mixture was stirred at 25°C for 12 h. The solvent was removed in vacuo. The residue was taken up in 
CH2Cl2 (30 mL) and treated with a saturated aqueous solution of NaHCO3 (30 mL). The aqueous 
phase was extracted with CH2Cl2 (30 mL, 3 times). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. Purification of the residue by flash chromatography (silica gel, 50 
% EtOAc in pentane) afforded 267 (368 mg, 85 %) as a pale yellow oil. A solution of 267 (130 mg, 
0.295 mmol) in CH2Cl2 (3 mL) was treated with a 1M solution of BCl3 in CH2Cl2 (0.890 mL, 3 eq.) at 
0°C. The resulting mixture was stirred at 0°C for 1 h. The reaction mixture was then diluted with a 
saturated aqueous solution of NaHCO3 (3 mL) and extracted with CH2Cl2 (3mL, 3 times). The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue was taken up 
in pyridine (3 mL) and treated with DMAP (3.5 mg, 0.029 mmol, 0.1 eq.) and p-methoxybenzoyl 
chloride (150 mg, 0.885 mmol, 3 eq.). The resulting mixture was stirred at 25°C for 12 h. The solvent 
was concentrated in vacuo. The residue was taken up in CH2Cl2 (10 mL) and treated with a saturated 
aqueous solution of NaHCO3 (10 mL). The aqueous phase was extracted with CH2Cl2 (10 mL, 3 
times). The combined organic layers were dried over MgSO4 and concentrated in vacuo. Purification 
of the residue by flash chromatography (silica gel, 30 % EtOAc in pentane) afforded a dichloro 
intermediate (191 mg, 82 %) as a pale yellow oil. A stirred solution of this dichloro derivative (190 
mg, 0.244 mmol) in toluene (600 μL) was treated with Bu3SnH (200 μL, 0.073 mmol, 0.3 eq.) and 
AIBN (5 mg, 0.001 mmol, 0.04 q.). The resulting mixture was stirred at 80°C for 3 h. The reaction 
mixture was diluted with CH3CN (10 mL) and extracted with pentane (10 mL, 3 times). The solvent 
was concentrated in vacuo and the resulting oil was purified by flash chromatography (30 % EtOAc in 
pentane) affording (+)-268 (139 mg, 85 %) as a pale yellow oil. 
 [ ]23405α = +154, [ ]23435α = +116, [ ]23577α = +50, [ ]23589α = +44 (c = 0.47, CHCl3). 
 
IR (film): ν~  = 3410, 2960, 2840, 1730, 1710, 1700, 1605, 1510, 1255, 1165, 1100, 1030, 850, 770, 
695 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 8.05-7.95 (m, 6Harom.), 6.94-6.88 (m, 6Harom.), 5.62, 5.53 (2t, 2H, H-
C2’,3, 3J = 6.3, 6.5), 5.31 (m, 2H, H-C4’,1), 5.21, 5.02 (2m, 2H, H-C6,6’), 3.85 (2s, 9H, CH3(PMBz)), 
2.70 (AB, 2H, H2-C8, 2J = 14.2), 2.37, 2.19 (2t, 4H, H-C7,5’, 3J = 5.6, 5.1), 2.55 (m, 2H, H-C3’), 2.63-
2.47 (m, 2H, H-C2), 2.63-2.52 (m, 4H, H-C5,7’), 1.99 (s, 3H, CH3(OAc)) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 170.2 (s, C=O(OAc)), 165.4, 165.3 (3s, C=O(PMBz)), 163.3, 163.2 
(3s, Carom.), 137.6, 137.2 (2s, C1’,4), 131.6, 131.5 (2d, Carom., 1J = 161, 162), 123.5, 123.4 (2d, C2’,3, 1J = 
150), 122.9, 122.8, 122.7 (3s, Carom.), 113.6, 113.5 (2d, Carom.), 69.0, 68.9 (2d, C4’,1, 1J = 147), 68.4, 
68.2 (2d, C6,6’, 1J = 148), 55.4, 55.3 (q, CH3(PMBz), 1J = 144), 50.5 (t, C3’,2, 1J = 122), 41.7, 41.5 (2t, 
C5’,7, 1J = 118, 124), 36.4 (t, C8, 1J = 124), 32.4, 32.1 (2t, C7’,5, 1J = 128, 127), 21.2 (q, CH3(OAc), 1J = 
129) ppm. 
 
MALDI-TOF-MS: 735.3 (M+Na)+, 751.3 (M+K)+. 
 
Anal. for C41H50O8 (712.78): calculated C 69.09, H 6.22; found C 69.07, H 6.36. 
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1H NMR spectrum of (+)-268 
 
 
 
 
1H NMR spectrum of (+)-269 
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(1R,3R,5R)-1-{[(1S,3S,5S)-3-Hydrox-8-oxabicyclo[3.2.1]oct-6-en-1-yl]methyl}-8-
oxabicyclo[3.2.1]oct-6-en-3-yl 2,2-dimethylpropanoate ((+)-269) 
 
OH
O O1'
3'
5'15
3
O
O  
 
To a solution of alcohol (-)-266 (710 mg, 0.232 mmol) in a 3/1 mixture of CH2Cl2/pyridine (8 mL) 
was added pivaloyl chloride (430 μL, 0.348 mmol, 1.5 eq.). The resulting solution was stirred at 25°C 
for 12 h. The reaction was then diluted with CH2Cl2 (10 mL), treated with a saturated aqueous solution 
of NaHCO3 (15 mL) and extracted with CH2Cl2 (15 mL, 3 times). The combined organic layers were 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (2 % 
methanol in CH2Cl2) affording a diester (615 mg, 68 %) as a colourless oil. A solution of this acetate 
(465 mg, 0.119 mmol) in methanol (6 mL) was treated with K2CO3 (250 mg, 0.179 mmol, 1.5 eq.). 
The resulting mixture was stirred at 25°C for 12 h. The reaction was then diluted with EtOAc (10 mL), 
treated with a saturated aqueous solution of NaHCO3 (10 mL) and extracted with EtOAc (20 mL, 3 
times). The combined organic layers were dried over MgSO4, concentrated in vacuo and purified by 
flash chromatography (2 % methanol in CH2Cl2) to afford (+)-269 (338 mg, 81 %) as a white solid. 
 
m.p. = 95°C. 
 [ ]23405α =+23, [ ]23435α = +20, [ ]23577α = +10, [ ]23589α = +8 (c = 0.49, CHCl3). 
 
IR (KBr): ν~  = 3590, 2940, 1720, 1655, 1560, 1460, 1290, 1165, 1030, 670 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.47 (d, 1H, H-C7’, 3J = 5.9), 6.35 (d, 1H, H-C6’, 3J = 5.9), 6.16 (d, 
1H, H-C7, 3J = 5.7), 6.11 (d, 1H, H-C6, 3J = 5.7), 5.03 (t, 1H, H-C3, 3J = 5.7), 4.76 (brs, 2H, H-C5,5’), 
3.96 (m, 1H, H-C3’), 2.25 (d, 1H, OH, 3J = 10.2), 2.16 (2dt, 2H, H-C4exo,4’exo, 3J = 14.7, 4.7), 2.07 (m, 
2H, H-C2exo,2’exo), 2.03 (AB, 2H, H2-C8, 2J = 15.0), 1.91 (d, 1H, H-C2’endo, 2J = 14.6), 1.67 (brd, 1H, H-
C2endo, 2J = 14.8), 1.67, 1.52 (2d, 2H, H-C4endo,4’endo, 2J = 14.7), 1.14 (s, 9H, CH3(Piv)) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 177.4 (s, C=O(Piv), 138.8 (d, C7’, 1J = 169), 136.5 (d, C7, 1J = 179), 
134.6 (d, C6’, 1J = 170), 132.4 (d, C6, 1J = 170), 84.3, 83.8 (2s, C1,1’), 78.0, 77.9 (2s, C5,5’), 66.7 (d, C3’, 
1J = 162), 65.6 (d, C3, 1J = 142), 44.4 (t, C8, 1J = 123.2), 41.9 (d, C2’, 1J = 129), 38.7 (s, CMe3(Piv)), 
38.1 (t, C2, 1J = 129), 35.6 (t, C4, 1J = 127), 31.7 (t, C4’, 1J = 125), 27.0 (q, CH3(Piv), 1J = 127) ppm. 
 
MALDI-TOF-MS: 371.5 (M+Na)+. 
 
Anal. for C17H22O5 (348.43): calculated C 68.94, H 8.10; found C 68.97, H 8.03. 
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(1R,6R)-6-(Acetyloxy)-4-({(4S,6S)-4,6-bis[(4-methoxybenzoyl)oxy]cyclohept-1en-
yl}methyl)cyclohept-3-en-1-yl 4-methoxybenzoate ((-)-270) 
 
PMBzO OPMBz
1' 4'
6'
1 4
6
OPMBzO
O  
 
To a solution of alcohol (+)-269 (300 mg, 0.861 mmol) in pyridine (4 mL) were added DMAP (300 
mg, 0.082, 0.1 eq.) and p-methoxybenzoyl chloride (295 mg, 1.722 mmol, 2 eq.). The resulting 
mixture was stirred at 25°C for 12 h. The solvent was removed in vacuo and the residue was taken up 
in CH2Cl2 (30 mL). The organic layer was treated with a saturated aqueous solution of NaHCO3 (30 
mL) and the aqueous phase was extracted with CH2Cl2 (30 mL, 3 times). The combined organic layers 
were dried over MgSO4, concentrated in vacuo and purified by flash chromatography (3 % MeOH in 
CH2Cl2) affording a diester (389 mg, quant.) as a pale yellow oil. A 1M solution of BCl3 in CH2Cl2 
(2.3 mL, 2.362 mmol, 3 eq.) were added dropwise at 0°C to a solution of the diester (380 mg, 0.787 
mmol) in CH2Cl2 (7.5 mL). The resulting mixture was stirred at 0°C for 1 h. The reaction mixture was 
diluted with a saturated aqueous solution of NaHCO3 (10 mL) and extracted with CH2Cl2 (10 mL, 3 
times). The combined organic layers were dried over MgSO4 and solvents were concentrated in vacuo. 
The residue was taken up in pyridine (5 mL), treated with DMAP (10 mg, 0.079 mmol, 0.1 eq.), and p-
methoxybenzoyl chloride (403 mg, 2.362 mmol, 3 eq.). The resulting mixture was stirred at 25°C for 
12 h. The solvent was concentrated in vacuo. The residue was taken up in CH2Cl2 (20 mL), treated 
with a saturated aqueous solution of NaHCO3 (20 mL) and extracted with CH2Cl2 (20 mL, 3 times). 
The combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography (30 % EtOAc in pentane) affording a dichloro derivative (685 mg, 
quant.) as a pale yellow oil. A stirred solution of the dichloro derivative (680 mg, 0.825 mmol) in 
toluene (2.5 mL) was treated with Bu3SnH (655 μL, 2.476 mmol, 3 eq.) and AIBN (7 mg, 0.004 
mmol, 0.02 eq.). The resulting mixture was stirred at 80°C for 3 h. The reaction was then diluted with 
CH3CN (20 mL) and extracted with pentane (20 mL, 3 times). The solvents were concentrated in 
vacuo and the residue was purified by flash chromatography (25 % EtOAc in pentane) affording (-)-
270 as a pale yellow oil (135 mg, 22 %). 
 [ ]23405α = -116, [ ]23435α = -88, [ ]23589α = -35 (c = 0.55, CHCl3). 
 
IR (film): ν~  = 2955, 1710, 1605, 1510, 1255, 1165, 1100, 1030, 845, 770, 695 cm-1. 
 
1H NMR (400 MHz, CDCl3): δ = 8.06-7.94 (m, 6Harom.), 6.94-6.87 (m, 6Harom.), 5.59, 5.45 (2t, 2H, H-
C2’,3, 3J = 6.6, 6.9), 5.32 (m, 2H, H-C4’,1), 5.18-5.01 (2m, 2H, H-C6,6’), 3.86, 3.83 (2s, 9H, 
CH3(PMBz)), 2.87, 2.67 (AB, 2H, H2-C8, 2J = 14.4), 2.64-2.40 (m, 4H, H-C5,7’), 2.57-2.37 (m, 2H, H-
C2), 2.47-2.43, 2.38-2.35 (m, 4H, H-C7,5’), 2.38-2.35, 2.22-2.20 (2m, 4H, H-C7,5’), 2.35 (m, 2H, H-C3’), 
1.18 (s, 9H, CH3(Piv)) ppm. 
 
13C NMR (100 MHz, CDCl3): δ = 177.6 (s, C=O(OPiv)), 165.5, 165.4 (2s, C=O(PMBz)), 163.4, 163.3 
(3s, Carom.), 137.6, 137.5 (2s, C1’,4), 131.6, 131.5 (3d, Carom., 1J = 162, 161, 162), 123.4, 123.1 (2d, C2’,3, 
1J = 150), 122.9, 122.8 (2s, Carom.), 113.6, 113.5 (2d, Carom., 1J = 160, 159), 69.1, 68.8 (2d, C4’,1, 1J = 
148, 147), 68.6, 68.0 (2d, C6,6’, 1J = 146, 148), 55.4 (q, CH3(PMBz), 1J = 144), 50.6 (t, C2,3’, 1J = 122), 
41.7, 41.4 (2t, C5’,7, 1J = 134), 32.6 (t, C8, 1J = 127), 38.7 (s, CMe3(Piv)), 36.4, 36.0 (2t, C7’,5, 1J = 128, 
127), 26.8 (q, CH3(Piv), 1J = 127) ppm. 
 
MALDI-TOF-MS: 777.7 (M+Na)+, 793.7 (M+K)+. 
 
Anal. for C44H50O11 (754.34): calculated C 70.01, H 6.68; found C 69.32, H 6.73. 
New efficient synthetic routes toward functionalised polyketides.  
   
 
204
 
1H NMR spectrum of (-)-270 
 
 
 
 
1H NMR spectrum of (-)-271 
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(1R,3R,5R)-1-{[(1S,3S,5S)-3-(Acetyloxy)-8-oxabicyclo[3.2.1]oct-6-en-1-yl]methyl}-8-
oxabicyclo[3.2.1]oct-6-en-3-yl 4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate ((-
)-271) 
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O
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To a solution of alcohol (-)-266 (21 mg, 0.068 mmol) in CH2Cl2 (1 mL) were added DMAP (2.5 mg, 
0.020 mmol, 0.3 eq.), pyridine (100 μL) and (1S)-(-)-camphanic chloride (23 mg, 0.103 mmol, 1.5 
eq.). The resulting mixture was stirred at 25°C for 12 h. The reaction mixture was diluted with CH2Cl2 
(2 mL), treated with a saturated aqueous solution of NaHCO3 (3 mL) and extracted with CH2Cl2 (3mL, 
3 times). The combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue 
was purified by flash chromatography (3 % methanol in CH2Cl2) affording (-)-271 (34 mg, 96 %) as a 
colourless oil. This oil crystallised as a white solid in cyclopentane (3 mL) at 4°C. 
 
m.p. = 162°C. 
 [ ]23405α = -8, [ ]23435α = -6, [ ]23589α = -3 (c = 0.24, CHCl3).  
 
IR (KBr): ν~  = 2960, 2845, 1715, 1700, 1610, 1505, 1420, 1290, 1160, 1120, 1035, 770, 670 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.19 (d, 1H, H-C7’, 3J = 5.9), 6.15 (d, 2H, H-C6’,7’’, 3J = 5.9), 6.09 
(dd, 1H, H-C6’’, 3J = 5.9, 1.0), 5.22 (t, 1H, H-C3’, 3J = 5.9), 5.03 (t, 1H, H-C3’’, 3J = 5.7), 4.75 (brs, 1H, 
H-C5’), 4.71 (brs, 1H, H-C5’’), 2.39-2.35, 2.15-2.07 (2m, 2H, H-C6exo,6endo), 2.26-2.19 (m, 1H, H-C4’exo), 
2.16-2.14 (m, 1H, H-C4’’exo), 2.16-2.05, 2.13-2.01 (2m, 2H, H-C2’exo,2’’exo), 2.00 (AB, 2H, H2-C8’, 2J = 
14.7), 1.97 (s, 3H, CH3(OAc)), 1.94-1.89, 1.72-1.64 (2m, 2H, H-C5endo,5exo), 1.76, 1.71 (2dd, 2H, H-
C2’endo,2’’endo, 2J = 15.2, 14.8), 1.60, 1.55 (2d, 2H, H-C4’endo,4’’endo, 2J = 15.5, 15.2), 1.11, 1.03, 0.93 (3s, 
9H, CH3-C4,7) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 178.1 (s, C=O, camphanoyl), 170.4 (s, C=O(OAc)), 166.6 (s, 
C=O(OAc)), 136.6 (d, C7’, 1J = 171), 136.5 (d, C7’’, 1J = 171), 132.5 (d, C6’, 1J = 170), 132.3 (d, C6’’, 1J 
= 170), 90.9 (s, C7), 83.7, 83.6 (2s, C1’,1’’), 77.7, 77.4 (2s, C5’,5’’), 68.8 (d, C3’, 1J = 146), 67.2 (d, C3’’, 1J 
= 151), 54.8, 54.1 (2s, C1,4), 44.2 (t, C8’, 1J = 124), 38.0, 37.9 (2t, C2’,2’’, 1J = 129), 31.7 (2t, C4’,4’’, 1J = 
128), 30.4 (t, C6, 1J = 128), 28.9 (t, C5, 1J = 136), 21.4 (q, CH3(OAc), 1J = 129), 16.9 (2q, CH3-C7, 1J = 
127), 9.6 (q, CH3-C4, 1J = 127) ppm.  
 
MALDI-TOF-MS: 509.6 (M+Na)+. 
 
Anal. for C27H34O8 (486.55): calculated C 66.65, H 7.04; found C 66.65, H 7.16. 
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(1S,5S)-1-({(1S,3S,5R)-3-[(Triethylsyl)oxy]-8-oxabicyclo[3.2.1]oct-6-en-1-yl}methyl)-8-
oxabicyclo[3.2.1]oct-6-en-3-one ((-)-273) 
 
3'
51'5'
3
1O O
OTES O  
 
To a solution of alcohol (-)-272 (5 g, 16.3 mmol) in DMF (80 mL) were added imidazole (1.7 g, 24.4 
mmol, 1.5 eq.), TESCl (3.56 mL, 21.2 mmol, 1.3 eq.) and DMAP (200 mg, 1.631 mmol, 0.1 eq.) at 
25°C for 18 h. The reaction mixture was poured into water (150 mL) and extracted with Et2O (70 mL, 
2 times). The combined organic layers were washed with brine (40 mL), dried over MgSO4 and 
concentrated in vacuo. The residual oil was dissolved in MeOH (100 mL) and treated under argon 
with a 0.8 M solution of MeONa in MeOH (60 mL, 49.9 mmol, 3 eq.) at 25°C for 12 h. The reaction 
mixture was poured into a saturated aqueous solution of NH4Cl in methanol (100 mL) and 
concentrated in vacuo. The residue was dissolved in water (70 mL) and extracted with EtOAc (70 mL, 
3 times). The combined organic layers were washed with brine (100 mL), dried over MgSO4 and 
concentrated in vacuo. The residual oil was dissolved in CH2Cl2 (115 mL) and treated under argon 
with NMO (2.6 g, 19.56 mmol, 1.2 eq.), 8.2 g of 4 Ǻ MS and TPAP (280 mg, 0.815 mmol, 0.05 eq.) at 
25°C for 1 h. The reaction mixture was filtered through a pad of celite® and the filtrate was 
concentrated in vacuo. The residue was purified by flash chromatography (3% of MeOH in CH2Cl2) 
affording (-)-273 (3.133 g, 61% over 3 steps) as a colourless oil. 
 [ ]23405α = -7, [ ]23435α = -6, [ ]23589α = -3 (c = 0.67, CHCl3). 
 
IR (film): ν~  = 2950, 1720, 1460, 1410, 1340, 1290, 1235, 1115, 1010, 930, 830, 730 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.23 (d, 1H, H-C7’, 3J = 6), 6.10-6.03 (m, 3H, H-C6’,6,7), 4.99 (d, 1H, 
H-C5, 3J = 4.8), 4.70 (s, 1H, H-C5’), 4.07 (t, 1H, H-C3’, 3J = 4.9), 2.66 (dd, 1H, H-C4exo, 2J = 16, 3J = 
4.8), 2.24 (d, 1H, H-C4endo, 2J = 16), 2.54 (AB, 2H, H2-C2, 2J = 16), 2.13 (s, 2H, H2-C8), 2.06 (m, 1H, 
H-C4’exo), 1.47 (d, 1H, H-C4’endo, 2J = 14), 1.97 (dd, 1H, H-C2’exo, 2J = 14, 3J = 4.9), 1.66 (d, 1H, H-
C2’endo, 2J = 14), 0.90 (t, 9H, CH3CH2Si(TES), 3J = 7.9), 0.49 (q, 6H, CH3CH2Si(TES), 3J = 7.9) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 206.8 (s, C3), 136.3 (d, C7’, 1J = 170), 135.8 (d, C7, 1J = 168), 133.2 
(d, C6’, 1J = 177), 131.7 (d, C6, 1J = 172), 85.4 (s, C1’), 84.2 (s, C1), 78.5 (d, C5’, 1J = 150), 77.0 (d, C5, 
1J = 166), 65.0 (d, C3’, 1J = 136), 52.9 (t, C2, 1J = 129), 45.8 (t, C4, 1J = 128), 44.0 (t, C8, 1J = 120), 
42.9 (t, C2’, 1J = 116), 35.7 (t, C4’, 1J = 126), 7.2 (q, CH3CH2Si(TES), 1J = 125), 5.1 (t, 
CH3CH2Si(TES)), 1J = 127) ppm. 
 
MALDI-TOF-MS: 377.2 (M+H)+, 399.1 (M+Na)+. 
 
Anal. for C21H32O4Si (376.573): calculated C 66.98, H 8.57, Si 7.46; found C 66.84, H 8.55, Si 7.49. 
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1H NMR spectrum of (-)-273 
 
 
 
 
1H NMR spectrum of (-)-274 
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(1R,5S)-1-({(1R,3R,5R)-3-[(Triethylsyl)oxy]-8-oxabicyclo[3.2.1]oct-6-en-1-yl}methyl)-8-
oxabicyclo[3.2.1]oct-6-en-3-one ((-)-274) 
 
3'
51'5'
3
1O O
OTES O  
 
Following the same procedure described above, starting from (-)-266 (17.1 mmol, 5.6 g), (-)-274 (4.32 
g, 67% over 3 steps) was released as a pale yellow oil. 
 [ ]23405α = -14, [ ]23435α = -9, [ ]23589α = -4 (c = 2.5, CHCl3). 
 
IR (film): ν~  = 2950, 1720, 1460, 1410, 1400, 1240, 1195, 1075, 1010, 930, 830, 735 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.28 (d, 1H, H-C7’, 3J = 5.9), 6.10-6.03 (m, 3H, H-C6’,6,7), 5.02 (d, 
1H, H-C5, 3J = 4.6), 4.71 (s, 1H, H-C5’), 4.07 (t, 1H, H-C3’, 3J = 5.2), 2.66 (dd, 1H, H-C4exo, 2J = 15.8, 
3J = 4.6), 2.26 (d, 1H, H-C4endo, 2J = 15.8), 2.55 (AB, 2H, H2-C2, 2J = 16), 2.14 (AB, 2H, H2-C8, 2J = 
15), 2.08 (2t, 1H, H-C4’exo, 2J = 13.9, 3J = 5.2 ), 1.48 (d, 1H, H-C4’endo, 2J = 13.9), 1.97 (dd, 1H, H-
C2’exo, 2J = 13.9, 3J = 5.2), 1.65 (d, 1H, H-C2’endo, 2J = 13.9), 0.91 (t, 9H, CH3CH2Si(TES), 3J = 7.9), 
0.50 (q, CH3CH2Si(TES), 3J = 7.9) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 206.5 (s, C3), 136.9 (d, C7’, 1J = 174), 136.0 (d, C7, 1J = 175), 133.2 
(d, C6’, 1J = 171), 131.7 (d, C6, 1J = 173), 85.1 (s, C1’), 83.8 (s, C1), 78.4 (d, C5’, 1J = 159), 76.8 (d, C5, 
1J = 153), 64.7 (d, C3’, 1J = 142), 51.9 (t, C2, 1J = 130), 45.5 (t, C4, 1J = 132), 43.7 (t, C8, 1J = 125), 
42.2 (t, C2’, 1J = 110), 35.4 (t, C4’, 1J = 123), 6.8 (q, CH3CH2Si(TES), 1J = 126), 4.8 (t, 
CH3CH2Si(TES), 1J = 117) ppm. 
 
MALDI-TOF-MS: 377.2 (M+H)+, 399.1 (M+Na)+. 
 
Anal. for C21H32O4Si (376.573): calculated C 66.98, H 8.57, Si 7.46; found C 67.02, H 8.66, Si 7.32. 
 
 
(1R,2R,4S,5S)-2,4-dimethyl-1-({(1R,3R,5R)-3-[(triethylsyl)oxy]-8-oxabicyclo[3.2.1]oct-6-en-1-
yl}methyl)-8-oxabicyclo[3.2.1]oct-6-en-3-one ((-)-277) 
 
3'
51'5'
3
1O O
OTES O
MeMe
 
 
To a solution of ketone (-)-273 (1.5 g, 3.984 mmol) in THF (10 mL) was added a 1M solution of LDA 
in THF (6 mL, 5.975 mmol, 1.5 eq.) at -78°C under argon. The temperature was raised to 25°C for 30 
mn. At -78°C, TMEDA (720 μL, 4.781 mmol, 1.2 eq.) and 1 mL of MeI (16 mmol, 4 eq.) were added 
and the temperature was raised to 25°C for 1 h. The reaction mixture was poured into water (30 mL) 
and extracted with EtOAc (30 mL, 3 times). The combined organic layers were washed with a citric 
acid solution (50 mL), a saturated aqueous solution of NaHCO3 (50 mL) and brine (50 mL), dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (EtOAc/Pentane 
1/7) affording dimethylated product (-)-277 as a colourless oil (71 mg, 5%), monomethylated product 
275 as a colourless oil (877 mg, 60%) and starting material (90mg, 6%). 
To a solution of monomethylated product 275 (877 mg, 2.247 mmol) in THF (6 mL) was added a 1M 
solution of LDA in THF (2.5 mL, 2.472 mmol, 1.1 eq.) at -78°C under argon. The temperature was 
raised to 25°C for 30 mn. At -78°C, TMEDA (410 μL, 2.696 mmol, 1.2 eq.) and MeI (560 μL, 8.988 
mmol, 4 eq.) were added and the temperature was raised to 25°C for 1 h. After The reaction mixture 
was poured into water (30 mL) and extracted with EtOAc (30 mL, 3 times). The combined organic 
layers were washed with a citric acid solution (50 mL), a saturated aqueous solution of NaHCO3 (50 
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mL) and brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by 
flash chromatography (EtOAc/Pentane 1/7) affording trimethylated product 276 (63 mg, 7%) as a 
colourless oil, dimethylated product (-)-277 (683 mg, 81%) as a colourless oil. 
 
[ ]23405α = -7, [ ]23435α = -4, [ ]23589α = -2 (c = 0.9, CHCl3). 
 
IR (film): ν~  = 2920, 1720, 1365, 1220, 1070, 1025, 795 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.30 (d, 1H, H-C7’, 3J = 6), 6.12 (d, 1H, H-C7, 3J = 6), 6.02 (d, 1H, 
H-C6’, 3J = 6), 6.00 (d, 1H, H-C6, 3J = 6), 4.66 (s, 1H, H-C5’), 4.59 (s, 1H, H-C5), 4.07 (t, 1H, H-C3’, 3J 
= 4.9), 2.29 (q, 1H, H-C4, 3J = 7.4), 2.15 (q, 1H, H-C2, 3J = 7.4), 2.08 (AB, 2H, H2-C8, 2J = 15.2), 2.02 
(m, 1H, H-C4’exo), 1.46 (d, 1H, H-C4’endo, 2J = 14.2), 1.92 (dd, 1H, H-C2’exo, 2J = 14, 3J = 4.9), 1.67 (d, 
1H, H-C2’endo, 2J = 14), 1.31 (d, 3H, CH3-C4, 3J = 7.4), 1.26 (d, 3H, CH3-C2, 3J = 7.4), 0.91 (t, 9H, 
CH3CH2Si(TES), 3J = 7.9), 0.50 (q, 6H, CH3CH2Si(TES), 3J = 7.9) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 215 (s, C3), 136.7 (d, C7’, 1J = 170), 135.7 (d, C7, 1J = 173), 132.2 
(d, C6’, 1J = 164), 131.3 (d, C6, 1J = 172), 86.3 (s, C1), 84.0 (s, C1), 81.5 (d, C5, 1J = 157), 78.0 (d, C5’, 
1J = 155), 64.8 (d, C3’, 1J = 143), 54.0 (d, C4, 1J = 132), 49.2 (d, C2, 1J = 132), 42.8 (t, C2’, 1J = 126), 
40.1 (t, C8, 1J = 125), 35.5 (t, C4’, 1J = 127), 17.3 (q, CH3-C4, 1J = 128), 14.7 (q, CH3-C2, 1J = 128), 6.8 
(q, CH3CH2Si(TES), 1J = 121), 4.8 (t, CH3CH2Si(TES), 1J = 114) ppm. 
 
MALDI-TOF-MS: 405.1 (M+Na)+, 427.0 (M+K)+. 
 
Anal. for C23H36O4Si (404.24): calculated C 68.27, H 8.97, Si 6.94; found C 68.10, H 8.96. 
 
 
1H NMR spectrum of (-)-277 
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(1R,2R,5S)-2,4,4-Trimethyl-1-({(1R,3R,5R)-3-[(triethylsyl)oxy]-8-oxabicyclo[3.2.1]oct-6-en-1-
yl}methyl)-8-oxabicyclo[3.2.1]oct-6-en-3-one A (276) 
(1R,4S,5S)-2,2,4-Trimethyl-1-({(1R,3R,5R)-3-[(triethylsyl)oxy]-8-oxabicyclo[3.2.1]oct-6-en-1-
yl}methyl)-8-oxabicyclo[3.2.1]oct-6-en-3-one B (276) 
 
3'
51'5'
3
1O O
OTES O
MeMe
Me
3'
51'5'
3
1O O
OTES O
MeMe
Me
 
A/B 7.6/1 
 
IR (film): ν~  = 2950, 1720, 1460, 1420, 1375, 1345, 1295, 1235, 1130, 1080, 1015, 735 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.31 (d, 1H, H-C7’, 3J = 6), 6.1-6.05 (m, 2H, H-C7,6), 5.96 (d, 1H, H-
C6’, 3J = 4.9), 4.64 (s, 1H, H-C5’), 4.34 (s, 1H, H-C5), 4.05 (t, 1H, H-C3’, 3J = 5), 2.34 (q, 1H, H-C2, 3J 
= 7.4), 2.04 (dd, 1H, H-C2’exo, 3J = 5), 2.02 (AB, 2H, H2-C8, 2J = 15.4), 2.02 (m, 1H, H-C4’exo), 1.67 (d, 
1H, H-C2’endo, 2J = 14), 1.46 (d, 1H, H-C4’endo, 2J = 14), 1.26 (d, 3H, CH3-C2, 2J = 7.4), 1.36 (s, 3H, 
CH3-C4), 0.87 (s, 3H, CH3-C4), 0.90 (t, 9H, CH3CH2Si(TES), 3J = 4), 0.48 (q, 6H, CH3CH2Si(TES), 3J 
= 8) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 215 (s, C3), 137.6 (d, C7’, 1J = 173), 135.7 (d, C7, 1J = 173), 132.2 
(d, C6’, 1J = 164), 130.5 (d, C6, 1J = 171), 85.2 (d, C5, 1J = 160), 78.0 (d, C5’, 1J = 150), 86.9 (s, C1), 
83.9 (s, C1’), 64.8 (d, C3’, 1J = 143), 53.0 (d, C2, 1J = 132), 42.8 (t, C2’, 1J = 127), 40.2 (t, C8, 1J = 125), 
35.5 (t, C4’, 1J = 127), 25.8, 15.0 (2q, CH3-C2,4, 1J = 128, 129), 20.4 (q, CH3-C4, 1J = 127), 6.8 (q, 
CH3CH2Si(TES), 1J = 126), 4.8 (t, CH3CH2Si(TES), 1J = 117) ppm. 
 
MALDI-TOF-MS: 441.2 (M+Na)+. 
 
Anal. for C24H38O4Si (418.64): calculated C 68.86, H 9.15, Si 6.71; found C 68.33, H 9.18, Si 6.46. 
 
 
1H NMR spectrum of 276 
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(1R,4R,5R)-4-Methyl-1-({(1R,3R,5R)-3-[(triethylsyl)oxy]-8-oxabicyclo[3.2.1]oct-6-en-1-
yl}methyl)-8-oxabicyclo[3.2.1]oct-6-en-3-one A (278) 
(1S,2S,5R)-4-Methyl-1-({(1R,3R,5R)-3-[(triethylsyl)oxy]-8-oxabicyclo[3.2.1]oct-6-en-1-
yl}methyl)-8-oxabicyclo[3.2.1]oct-6-en-3-one B (278) 
 
3'
51'5'
3
1O O
OTES O
Me 3'
51'5'
3
1O O
OTES O
Me
 
A/B 6/1 
 
To a solution of ketone (-)-274 (1.5 g, 3.984 mmol) in THF (10 mL) was added a 1M solution of LDA 
in THF (6 mL, 5.975 mmol, 1.5 eq.) at -78°C under argon. The temperature was raised to 25°C for 30 
mn. At -78°C, TMEDA (720 μL, 4.781 mmol, 1.2 eq.) and 1 mL of MeI (16 mmol, 4 eq.) were added 
and the temperature was raised to 25°C for 1 h. After The reaction mixture was poured into water (30 
mL) and extracted with EtOAc (30 mL, 3 times). The combined organic layers were washed with a 
citric acid solution (50 mL), a saturated aqueous solution of NaHCO3 (50 mL) and brine (50 mL), 
dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography 
(EtOAc/Pentane 1/7) affording dimethylated product (-)-279 as a colourless oil (42 mg, 5%), 
monomethylated product 278 as a colourless oil (965 mg, 60%) and starting material (60mg, 6%). 
 
IR (film): ν~  = 3080, 2950, 1710, 1460, 1415, 1340, 1240, 1190, 1125, 1080, 1015, 960, 920, 885, 
830, 735 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.25 (d, 1H, H-C7’, 3J = 5.9), 6.16-6.03 (m, 3H, H-C6’,6,7), 4.71 (s, 
1H, H-C5’), 4.64 (s, 1H, H-C5), 4.07 (t, 1H, H-C3’, 3J = 5.2), 2.54 (2d, 2H, H2-C2, 2J = 16.4), 2.23 (q, 
1H, H-C4, 3J = 7.3), 2.11 (AB, 2H, H2-C8, 2J = 15), 2.03 (d, 1H, H-C4’exo, 3J = 5.2), 1.46 (d, 1H, H-
C4’endo, 2J = 14), 1.96 (dd, 1H, H-C2’exo, 2J = 14, 3J = 5.2), 1.64 (d, 1H, H-C2’endo, 2J = 14), 1.27 (d, 3H, 
CH3(C4), 3J = 7.3), 0.90 (t, 9H, CH3CH2Si(TES), 3J = 7.9), 0.49 (q, 6H, CH3CH2Si(TES), 3J = 7.9) 
ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 210.6 (s, C3), 137.1 (d, C7’, 1J = 174), 135.9 (d, C7, 1J = 175), 132.9 
(d, C6’, 1J = 172), 132.0 (d, C6, 1J = 171), 85.2 (s, C1), 83.8 (s, C1), 81.8 (d, C5, 1J = 160), 77.3 (d, C5’, 
1J = 155), 64.7 (d, C3’, 1J = 143), 49.4 (t, C2, 1J = 112), 48.9 (d, C4, 1J = 132), 43.4 (q, CH3(C4), 1J = 
124), 42.2 (t, C2’, 1J = 110), 35.4 (t, C4’, 1J = 141), 15.5 (t, C8, 1J = 125), 6.8 (q, CH3CH2Si(TES), 1J = 
126), 4.8 (t, CH3CH2Si(TES), 1J = 117) ppm. 
 
MALDI-TOF-MS: 391.4 (M+H)+, 413.3 (M+Na)+. 
 
Anal. for C22H34O4Si (390.22): calculated C 67.65, H 8.77, Si 7.19; found C 67.73, H 8.76, Si 7.03. 
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1H NMR spectrum of 278 
 
 
 
 
1H NMR spectrum of (-)-279 
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(1S,2S,4R,5R)-2,4-Dimethyl-1-({(1R,3R,5R)-3-[(triethylsyl)oxy]-8-oxabicyclo[3.2.1]oct-6-en-1-
yl}methyl)-8-oxabicyclo[3.2.1]oct-6-en-3-one ((-)-279) 
 
3'
51'5'
3
1O O
OTES O
MeMe
 
 
Following the same procedure described above, starting from (-)-278 (5.1 mmol, 2 g), (-)-279 (1.12 g, 
54% over 4 steps) was released as a pale yellow oil. Trimethylated compound was not characterised. 
 [ ]23405α = -44, [ ]23435α = -34, [ ]23577α = -15, [ ]23589α = -14 (c = 0.9, CHCl3). 
 
IR (film): ν~  = 2950, 2880, 1715, 1460, 1415, 1340, 1240, 1190, 1125, 1080, 1050, 1015, 960, 920, 
885, 830, 735 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.39 (d, 1H, H-C7’, 3J = 6), 6.10-6.03 (m, 3H, H-C6’,6,7), 4.72 (d, 1H, 
H-C5’, 3J = 3.5), 4.63 (s, 1H, H-C5), 4.06 (t, 1H, H-C3’, 3J = 5.3), 2.34 (q, 1H, H-C4, 3J = 7.5), 2.21 (q, 
1H, H-C2, 3J = 7.5), 2.09 (AB, 2H, H2-C8, 2J = 15), 2.02 (d, 1H, H-C2’exo, 3J = 5.3), 1.66 (d, 1H, H-
C2’endo, 2J = 14), 2.07 (dd, 1H, H-C4’exo, 2J = 14, 3J = 5.3), 1.47 (d, 1H, H-C4’endo, 2J = 14), 1.33 (d, 3H, 
CH3-C4, 2J = 14, 3J = 7.5 Hz), 1.26 (d, 3H, CH3-C2, 3J = 7.5), 0.91 (t, 9H, CH3CH2Si(TES), 3J = 7.9), 
0.51 (q, 6H, CH3CH2Si(TES), 3J = 7.9) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 214.7 (s, C3), 137.2 (d, C7’, 1J = 170), 135.8 (d, C7, 1J = 173), 133.7 
(d, C6’, 1J = 164), 131.6 (d, C6, 1J = 172), 86.1 (s, C1), 84.0 (s, C1), 84.5 (d, C5, 1J = 157), 78.3 (d, C5’, 
1J = 155), 64.8 (d, C3’, 1J = 143), 53.5 (d, C4, 1J = 132), 49.2 (d, C2, 1J = 132), 41.7 (t, C2’, 1J = 126), 
40.5 (t, C8, 1J = 125), 35.5 (t, C4’, 1J = 127), 17.4 (q, CH3-C4, 1J = 128), 14.8 (q, CH3-C2, 1J = 128), 6.8 
(q, CH3CH2Si(TES), 1J = 121), 4.8 (t, CH3CH2Si(TES), 1J = 114) ppm. 
 
MALDI-TOF-MS: 427.3 (M+Na)+. 
 
Anal. for C23H36O4Si (404.24): calculated C 68.27, H 8.97, Si 6.94; found C 68.20, H 8.85, Si 6.93. 
 
 
(1,1-Dimethylethyl){[(1R,2S,3S,4S,5S)-2,4-dimethyl-1-({(1R,3R,5R)-3-[(triethylsyl)oxy]-8-
oxabicyclo[3.2.1]oct-6-en-1-yl}methyl)-8-oxabicyclo[3.2.1]oct-6-en-3-yl]oxy}dimethylsilane ((-)-
280) 
 
3'
51'5'
3
1O O
OTES OTBDMS
MeMe
 
 
To a solution of ketone (-)-277 (300 mg, 0.742 mmol) in CH2Cl2 (4 mL) was treated with a 1M 
solution of DIBAL-H in hexane (1.1 mL, 1.1 mmol, 1.5 eq.) at 0°C under argon during 14 h. MeOH 
was added dropwise until the end of gas evolution. The reaction mixture was poured into a 1M HCl 
solution (30 mL) and extracted with CH2Cl2 (30 mL, 3 times). The combined organic layers were 
washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residual oil, dissolved 
in CH2Cl2 (4 mL), was treated with 2,6-lutidine (190 μL, 1.6 mmol, 3 eq.) and TBDMSOTf (230 μL, 
0.997 mmol, 1.8 eq.) at 0°C during 1 h. The reaction mixture was poured into a saturated aqueous 
solution of NaHCO3 (30 mL), extracted with EtOAc (30 mL, 3 times). The combined organic layers 
were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography 
(30% of EtOAc in pentane) affording (-)-280 (190 mg, 49% over 2 steps) as a colourless oil. 
 
[ ]23405α = -4, [ ]23435α = -6, [ ]23577α = -7, [ ]23589α = -10 (c = 0.76, CHCl3). 
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IR (film): ν~  = 2950, 2880, 1465, 1415, 1380, 1350, 1250, 1085, 1010, 890, 835, 740, 670 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.15 (d, 1H, H-C7’, 3J = 6), 6.13 (d, 1H, H-C7’, 3J = 6), 5.95 (d, 1H, 
H-C6’, 3J = 6), 5.87 (d, 1H, H-C6, 3J = 6), 4.66 (s, 1H, H-C5’), 4.47 (s, 1H, H-C5), 4.07 (t, 1H, H-C3’, 3J 
= 5.7), 4.04 (t, 1H, H-C3, 3J = 6.4), 2.06-2 (m, 1H, Hexo-C4’), 2.0 (AB, 2H, H2-C8, 2J = 16.4), 1.89 (dd, 
1H, Hexo-C2’, 2J = 14.1, 3J =5.7), 1.68-1.52 (2m, 2H, H2-C2,4), 1.67 (d, 1H, Hendo-C2’, 3J = 5.7), 1.46 (d, 
1H, Hendo-C4’, 2J = 14.1), 1.07, 1.05 (2d, 6H, CH3-C2,4, 2J = 10.8, 10.6), 0.90 (t, 9H, CH3CH2Si(TES), 
2J = 8), 0.89 (s, 9H, tBuMe2Si(TBDMS)), 0.48 (q, 6H, CH3CH2Si(TES), 2J = 8), -0.02 (s, 6H, 
tBuMe2Si(TBDMS)) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 136.0 (d, C7, 1J = 184), 134.1 (d, C7’, 1J = 175), 131.6 (d, C6’, 1J = 
172), 128.5 (d, C6, 1J = 170), 87.1 (s, C1’), 84.4 (s, C1), 83 (d, C5’, 1J = 135), 77.8 (d, C5’, 1J = 155), 
67.8 (d, C3, 1J = 139), 64.8 (d, C3’, 1J = 143), 42.8 (d, C2’, 1J = 127), 41.9 (t, C8, 1J = 125), 40.3, 35.1 
(2d, C2,4, 1J = 126, 125), 35.6 (t, C4’, 1J = 127), 25.8 (q, tBuMe2Si(TBDMS), 1J = 125), 18.1 (s, 
tBuMe2Si(TBDMS)), 13.9, 9.8 (2q, CH3-C2,4, 1J = 136, 126), 6.8 (q, CH3CH2Si(TES), 1J = 126), 4.8 (t, 
CH3CH2Si(TES), 1J = 124), -4.9 (t, tBuMe2Si(TBDMS), 1J = 123) ppm. 
 
MALDI-TOF-MS: 521.4(M+H)+, 543.4 (M+Na)+, 559.3 (M+K)+. 
 
Anal. for C29H52O4Si2 (520.892): calculated C 66.87, H 10.06, Si 10.78; found C 66.84, H 10.12, Si 
10.67. 
 
 
1H NMR spectrum of (-)-280 
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(1R,3R,5R)-1-{[(1R,2R,3S,4R,5S)-3-(Acetyloxy)-2,4-dimethyl-8-oxabicyclo[3.2.1]oct-6-en-1-
yl]methyl}-8-oxabicyclo[3.2.1]oct-6-en-3-yl acetate ((+)-281) 
 
3'
5 1' 5'
3
1O O
OAc OAc
MeMe
 
 
To a solution of ketone (-)-277 (750 mg, 1.854 mmol) in CH2Cl2 (10 mL) was added a 1M solution of 
DIBAL-H in hexane (2.4 mL, 2.41 mmol, 1.3 eq.) at 25°C under argon during 14 h. MeOH was added 
dropwise until the end of gas evolution. The reaction mixture was poured into a 1M HCl solution (30 
mL) and extracted with CH2Cl2 (30 mL, 3 times). The combined organic layers were washed brine (50 
mL), dried over MgSO4 and concentrated in vacuo. The residual oil, dissolved in CH3CN (12 mL), 
was treated with a 40% solution of HF in water (1.2 mL) at 0°C during 1 h. The reaction mixture was 
poured into a saturated aqueous solution of NaHCO3 (50 mL), extracted with EtOAc (50 mL, 3 times). 
The combined organic layers were washed with brine (50 mL), dried over MgSO4 and concentrated in 
vacuo. The residual oil was dissolved in a 1/1 mixture of pyridine/acetic anhydride (14 mL) and 
treated with DMAP (70 mg, 0.556 mmol, 0.3 eq.) at 25°C for 5 h. Solvents were concentrated in 
vacuo. The residue was purified by flash chromatography (2% of MeOH in CH2Cl2) affording 
diacetate (+)-281 (460 mg, 66% over 3 steps) as a yellow solid. 
 
m.p.: 112-115°C. 
 [ ]23405α = +5, [ ]23577α = +2, [ ]23589α = +1 (c = 0.6, CHCl3). 
 
IR (film): ν~  = 2950, 1710, 1460, 1415, 1345, 1235, 1080, 1010, 890, 810, 735 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 6.19, 6.17 (2d, 2H, H-C7’,7, 3J = 6), 6.0, 5.97 (2d, 2H, H-C6’,6, 3J = 6), 
5.12 (t, 1H, H-C3’, 3J = 6.6), 5.04 (t, 1H, H-C3, 3J = 5.5), 4.69 (s, 1H, H-C5), 4.50 (s, 1H, H-C5’), 2.07, 
1.96 (2s, 6H, CH3(OAc)), 2.02 (AB, 2H, H2-C8, 2J = 15.2), 1.96 (m, 2H, H-C2’,4’), 2.13 (dt, 1H, H-
C4exo, 2J = 15, 3J = 5.5), 1.54 (d, 1H, H-C4endo, 2J = 15), 1.98 (m, 1H, H-C2exo), 1.72 (d, 1H, H-C2endo, 2J 
= 15), 1.11, 1.08 (2d, 6H, CH3-C2’,4’, 3J = 7.1, 7.1) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 170.7, 170.6 (2s, C=O(OAc)), 136.3 (d, C7, 1J = 175), 134.5 (d, C7’, 
1J = 173), 132.0 (d, C6’, 1J = 172), 129.5 (d, C6, 1J = 168), 87.4 (s, C1’), 84.2 (s, C1), 83.4 (d, C5’, 1J = 
152), 77.0 (d, C5, 1J = 159), 71.5 (d, C3’, 1J = 152.0), 67.7 (d, C3, 1J = 152), 41.5 (t, C8, 1J = 125), 39.1 
(t, C2, 1J = 130), 37.1 (t, C4’, 1J = 132), 32.5 (t, C2’, 1J = 127), 31.9 (t, C4, 1J = 128), 21.8 (q, 
CH3(OAc), 1J = 129), 21.5 (q, CH3(OAc), 1J = 129), 14.7, 10.9 (2q, CH3-C2’,4’, 1J = 127, 126) ppm. 
 
MALDI-TOF-MS: 399.2 (M+Na)+, 415.2 (M+K)+. 
 
Anal. for C21H28O6 (376.44): calculated C 67.00, H 7.50; found C 66.95, H 7.50. 
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1H NMR spectrum of (+)-281 
 
 
 
1H NMR spectrum of (+)-282 
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(1R,3R,6S)-6-(Acetyloxy)-4-{[(3S,4R,5S,6R,7R)-6-(acetyloxy)-3-chloro-4-hydroxy-5,7-
dimethylcyclohept-1-en-1-yl]methyl}-2-chlorocyclohept-3-en-1-yl 4-(methyloxy)benzoate ((+)-
282) 
 
1'
6 6'
4'41
Cl
PMBzO
OAc OAc
OH
Cl
8
 
 
To a solution of diacetate (+)-281 (235 mg, 0.624 mmol) in CH2Cl2 (15 mL) was added a 1M solution 
of BCl3 in CH2Cl2 (1.9 mL, 1.873 mmol, 3 eq.) at 0°C during 3 h. The reaction mixture was poured 
into a saturated aqueous solution of NaHCO3 (30 mL) and extracted with EtOAc (30 mL, 3 times). 
The combined organic layers were washed with brine (50 mL), dried over MgSO4 and concentrated in 
vacuo. The residual oil, dissolved in pyridine (6 mL), was treated with PMBzCl (320 mg, 3.746 mmol, 
6 eq.) and DMAP (15 mg, 0.187 mmol, 0.2 eq.) during 24 h. Solvents were concentrated in vacuo. The 
residue was purified by flash chromatography (2% of MeOH in CH2Cl2) affording (+)-282 (205 mg, 
56% over 2 steps) as a yellow oil. 
 
[ ]23405α = +23, [ ]23577α = +16, [ ]23589α = +14 (c = 1, CHCl3). 
 
IR (film): ν~  = 2970, 2940, 2255, 1735, 1605, 1510, 1455, 1430, 1375, 1255, 1170, 1105, 1030, 910, 
850, 770, 730 cm-1. 
 
1H-NMR (400 MHz, C6D6): δ = 8.24 (d, 2H, H-Carom., 3J = 8.8), 6.65 (d, 2H, H-Carom., 3J = 8.8), 5.74 
(d, 1H, H-C1, 3J = 8.4), 5.67 (d, 1H, H-C2’, 3J = 4.4), 5.50 (d, 1H, H-C3, 3J = 7.1), 5.12 (m, 1H, H-C6), 
4.80 (d, 1H, H-C6’, 3J = 2.6), 4.57 (d, 1H, H-C2, 3J = 7.1), 4.41 (d, 1H, H-C3’, 3J = 4.4), 3.63 (d, 1H, H-
C4’, 3J = 9.7), 3.13 (s, 3H, CH3(PMBz)), 2.64 (ddd, 1H, H-C7exo, 3J = 3.2, 8.4, 2J = 13.5), 2.54 (AB, 
2H, H2-C8, 3J = 10.2), 2.31 (brs, 1H, H-C5exo), 2.18-2.0 (m, 2H, H-C5endo,7endo), 1.89 (d, 1H, H-C5’, 3J = 
11.4), 1.83, 1.63 (2s, 6H, CH3(OAc)), 1.17 (m, 1H, H-C7’), 0.92, 0.84 (2d, 6H, CH3(C5’,7’), 3J = 7.1, 
7.0) ppm. 
 
13C-NMR (100 MHz, C6D6): δ = 170.2, 170.5 (2s, C=O(OAc)), 169.8 (s, Carom.), 169.5 (s, 
C=O(PMBz)), 140.9, 139.3 (2s, C4,1’), 132.2 (2d, 2Carom., 1J = 163), 128.9, 126.4 (2d, C3,2’, 1J = 165, 
158), 122.9 (s, Carom.), 77.4 (d, C6’, 1J = 154), 77.0 (d, C4’, 1J = 140), 70.9 (d, C1, 1J = 138), 68.1 (d, C6, 
1J = 150), 62.3 (d, C3’, 1J = 126), 60.9 (d, C2, 1J = 125), 54.8 (q, CH3(PMBz), 1J = 144), 44.7 (t, C8, 1J 
= 124), 43.5 (t, C5, 1J = 127), 39.4 (d, C5’, 1J = 119), 37.2 (d, C7’, 1J = 121), 36.1 (t, C7, 1J = 127), 20.9, 
20.1 (q, CH3(OAc), 1J = 130), 16.8, 16.4 (2q, CH3(C5’,7’), 1J = 132) ppm. 
 
MALDI-TOF-HRMS for (C29H36Cl2O8 + Na)+: calculated 583.1865; found 583.1876. 
 
C29H36Cl2O8 (583.497). 
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(1R,3R,6S)-6-(Acetyloxy)-4-{[(3S,4R,5R,6R,7R)-6-(acetyloxy)-3-chloro-5,7-dimethyl-4-({[4-
(methyloxy)phenyl]carbonyl}oxy)cyclohept-1-en-1-yl]methyl}-2-chlorocyclohept-3-en-1-yl 4-
(methyloxy)benzoate ((+)-283) 
 
1'
6 6'
4'41
Cl
PMBzO
OAc OAc
OPMBz
Cl
8
 
 
To a solution of alcohol (+)-281 (100 mg, 0.171 mmol) dissolved in pyridine (2 mL) were added with 
PMBzCl (88 mg, 1.026 mmol, 6 eq.) and DMAP (21 mg, 0.171 mmol, 1 eq.) during 24 h. Solvents 
were concentrated in vacuo. The residue was purified by flash chromatography (2% of MeOH in 
CH2Cl2) affording (+)-283 (17 mg, 14%) as a pale yellow solid and the remaining starting material. 
 
m.p.: 122-125°C. 
 [ ]23405α = +9, [ ]23577α = +4, [ ]23589α = +2 (c = 0.6, CHCl3). 
 
IR (film): ν~  = 2845, 1790, 1735, 1690, 1660, 1605, 1520, 1455, 1270, 1190, 1160, 1040 cm-1. 
 
1H-NMR (400 MHz, CDCl3): δ = 8.0 (d, 4H, H-Carom., 3J = 8.8), 6.93 (d, 4H, H-Carom., 3J = 8.8), 5.76 
(d, 1H, H-C2’, 3J = 7.2), 5.56 (m, 2H, H-C3,1), 5.16 (m, 1H, H-C6’), 5.06 (s, 1H, H-C6), 4.87 (d, 1H, H-
C3’, 3J = 7.2), 4.81 (d, 1H, H-C2), 3.86 (s, 6H, CH3(PMBz), 3.83 (d, 1H, H-C4’, 3J = 7.2), 2.84 (d, 1H, 
H-C5’, 3J = 7.2), 2.80-2.61 (2d, 2H, H2-C8, 3J = 10.2), 2.84-2.78, 2.58-2.52 (2m, 2H, H2-C5), 2.75-2.63, 
2.30-2.25 (2m, 2H, H2-C7), 2.10 (brs, 6H, CH3(OAc)), 1.98 (d, 1H, H-C7’, 3J = 11.6), 1.14, 1.18 (2d, 
6H, CH3(C5’,7’), 3J = 6.8) ppm. 
 
13C-NMR (100 MHz, CDCl3): δ = 170.2, 170.5 (2s, C=O(OAc)), 164.7, 164.6 (2s, 2Carom.), 163.2, 
162.3 (2s, C=O(PMBz)), 141.5, 139.3 (2s, C4,1’), 131.9, 131.7 (2d, Carom., 1J = 164, 162), 129.0, 125.4 
(2d, C3,2’, 1J = 162), 122.6, 121.3 (2s, Carom.), 77.7, 68.3 (2d, C6,6’, 1J = 143, 149), 77.5, 70.2 (2d, C1,4’, 
1J = 143, 145), 61.7, 60.3 (2d, C2,3’, 1J = 140, 146), 55.5 (q, CH3(PMBz), 1J = 145), 44.9 (t, C8, 1J = 
125), 39.5, 43.6 (2d, C5’,7’, 1J = 123, 127), 36.7, 35.7 (2t, C5,7, 1J = 129, 130), 21.3, 20.8 (q, CH3(OAc), 
1J = 129), 16.8, 16.6 (q, CH3(C5’,7’), 1J = 129) ppm. 
 
ESI-HRMS for (C37H42Cl2O10 + H)+: calculated 717.2233, found 717.2234. 
 
C37H42Cl2O10 (717.629). 
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1H NMR spectrum of (+)-283 
 
 
 
 
 
1H NMR spectrum of 287 
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(3RS)-4-[(4SR,6SR)-6-({(4RS,6SR)-6-[(2RS)-4-{[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}-2-
({[(phenylmethyl)oxy]methyl}oxy)butyl]-2,2-dimethyl-1,3-dioxan-4-yl}methyl)-2,2-dimethyl-1,3-
dioxan-4-yl]-3-({[(phenylmethyl)oxy]methyl}oxy)butan-1-ol (287) 
 
2 4 5'
2'
1"
2"'
5"' 3IV1IV
OH OTBDMSOP O OPO O O
4IV
 
 
To a solution of polyol 137 (72 mg, 0.104 mmol) in dried CH2Cl2 (2 mL), at -20°C, were added 2,6-
lutidine (37 μL, 0.311 mmol, 3 eq.) and a 1 M solution of TBDMSOTf in CH2Cl2 (125 μL, 0.125 
mmol, 1.2 eq.). After 40 mn, the solution was poured into a saturated aqueous solution of NaHCO3 (10 
mL) and extracted with EtOAc (20 mL, 3 times). The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. The crude product was purified by flash chromatography (1% of 
MeOH in CH2Cl2) affording 287 (33 mg, 34%) as a pale yellow oil. 287 was a mixture of two 
inseparable diastereoisomers in a ratio 1/1. 
 
IR (film): ν~  = 3485, 2950, 1380, 1255, 1220, 1200, 1170, 1100, 1040 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.25 (2m, 10Harom.), 4.83-4.77 (m, 4H, CH2(BOM)), 4.64-4.59 
(m, 4H, CH2Ph), 4.14-3.91 (m, 6H, H-C3,4’,6’,4’”,6”’,2IV), 3.74 (t, 2H, H2-C1, 3J = 6.5), 3.67 (t, 2H, H2-
C4IV, 3J = 6.7), 1.83-1.72 (m, 4H, H2-C2,3IV), 1.70-1.44, 1.19-1.05 (m, 10H, H2-C4,5’,5”’,1”,1IV), 1.29, 1.28 
(2s, 12H, CH3-C2’,2”’), 0.90 (s, 9H, tBuMe2Si(TBDMS)), 0.13 (2s, 6H, tBuMe2Si(TBDMS)) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 139.3 (s, Carom.), 129.4, 128.9, 128.7 (3d, Carom., 1J = 159, 160, 145), 
101.4, 99.8 (2s, C2’,2”’), 95.7 (2t, CH2(BOM), 1J = 167), 74.8, 73.9 (2d, C3,2IV, 1J = 144, 139), 67.1, 
66.4, 64.8, 64.3 (4d, C4’,6’,4”,6”, 1J = 142, 148, 150, 144), 60.6, 59.4 (2t, C1,4IV, 1J = 141, 141), 43.9, 
43.7, 43.4, 43.3 (4t, C5’,5”’,4,1IV, 1J = 132, 138, 130, 134), 40.1, 39.8, 37.3 (3t, C2,1”,3IV, 1J = 132, 134, 
137), 30.6, 20.3 (2q, CH3-C2’, 1J = 127, 129), 25.4 (q, CH3-C2”’, 1J = 125), 26.5 (q, 
tBuMe2Si(TBDMS), 1J = 125), 17.5 (s, tBuMe2Si(TBDMS)), -5.2 (q, tBuMe2Si(TBDMS), 1J = 118) 
ppm. 
 
MALDI-TOF-MS: 797.4 (M + Na)+, 813.6 (M + K)+. 
 
Anal. for C43H70O10Si (775.117): calculated C 66.63, H 9.10; found C 66.05, H 9.17. 
 
 
(3RS)-4-[(4SR,6RS)-6-({(4SR,6SR)-6-[(2RS)-4-Hydroxy-2-
({[(phenylmethyl)oxy]methyl}oxy)butyl]-2,2-dimethyl-1,3-dioxan-4-yl}methyl)-2,2-dimethyl-1,3-
dioxan-4-yl]-3-({[(phenylmethyl)oxy]methyl}oxy)butyl acetate (291) 
 
OH OAcOP O OPO O O
1
245'
2'
1"
2"'
5"'1IV3IV
4IV
 
 
Polyol 137 (231 mg, 0.349 mmol, 1 eq.) was dissolved in vinyl acetate (3.5 mL) and vigorously stirred 
with Candida Cylindracea (700 mg, 2 u.mg-1, 4000 u.mmol-1) at 25°C. After 40 mn, the suspension 
was filtered over a pad of celite® and washed with EtOAc (20 mL). The filtrate was concentrated in 
vacuo and the crude oil was purified by flash chromatography (2% of MeOH in CH2Cl2) affording 
diacetate 146 (96 mg, 12 % yield), polyol 137 (46 mg, 20%) and mono-acetate 291 (138 mg, 55 %) as 
a pale yellow oil. 291 was a mixture of two inseparable diastereoisomers in a ratio 1/1. 
 
IR (film): ν~  = 3490, 2945, 1735, 1380, 1225, 1165, 1040 cm-1. 
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1H-NMR (400 MHz, MeOD): δ = 7.35-7.34 (m, 10Harom.), 4.81, 4.80 (2s, 4H, CH2(BOM)), 4.66-4.58 
(m, 4H, CH2Ph), 4.18 (t, 2H, H2-C1, 3J = 6.8), 4.16-3.90 (m, 6H, H-C3,6’,6“’,4’,4“’,2IV), 3.66 (t, 2H, H2-
C4IV, 3J = 6.6), 2.01 (s, 3H, CH3(OAc)), 1.34, 1.33, 1.29 (3s, 12H, CH3-C2’,2”’), 1.89-1.85 (m, 4H, H2-
C2,3IV), 1.84-1.44 (4m, 8H, H2-C4,5’,5“’,1IV), 1.18-1.08 (m, 2H, H2-C1“) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 172.9 (s, C=O(OAc)), 139.2 (s, Carom.), 129.4, 128.9, 128.7 (3d, 
Carom., 1J = 160, 161, 145), 101.5, 99.8 (2s, C2’,2“’), 95.6 (2t, CH2(BOM), 1J = 162), 70.7 (t, CH2Ph, 1J = 
141), 74.1, 73.8 (2d, C3,2IV, 1J = 132, 138), 67.1, 66.3, 64.8, 64.3 (4d, C4’,6’,4“,6“, 1J = 141, 147, 149, 
143), 62.4 (t, C1, 1J = 151), 59.4 (t, C4IV, 1J = 142), 43.7, 43.1 (2t, C4,1IV, 1J = 131, 137), 39.4, 38.4 (2t, 
C5’,5“’, 1J = 137, 135), 38.5 (t, C1“, 1J = 126), 35.1, 34.8 (t, C2,3IV, 1J = 128), 20.9 (q, CH3(OAc), 1J = 
129), 30.5, 20.2 (2q, CH3-C2’, 1J = 127, 128), 25.3 (q, CH3-C2“’, 1J = 125) ppm. 
 
MALDI-TOF-MS: 725.2 (M + Na)+, 741.4 (M + K)+. 
 
Anal. for C39H58O11 (702.891): calculated C 66.64, H 8.32; found C 66.63, H 8.39. 
 
 
1H NMR spectrum of 291 
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(3SR)-4-[(4SR,6SR)-6-({(4RS,6SR)-6-[(2RS)-4-{[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}-2-
({[(phenylmethyl)oxy]methyl}oxy)butyl]-2,2-dimethyl-1,3-dioxan-4-yl}methyl)-2,2-dimethyl-1,3-
dioxan-4-yl]-3-({[(phenylmethyl)oxy]methyl}oxy)butanoic acid (292) 
 
2 4 5'
2'
1"
2"'
5"' 3IV1IV
O OTBDMSOP O OPO O O
4IVHO
 
 
A solution of alcohol 287 (30 mg, 0.039 mmol) in dried CH2Cl2 (2 mL) was treated with NMO (10 
mg, 0.077 mmol, 2 eq.), TPAP (3 mg, 0.008 mmol, 0.2 eq.) and 20 mg of 4 Ǻ MS. After 1 h, the 
solution was filtered over a pad of silica gel and washed with CH2Cl2 (50 mL). The solvent was 
concentrated in vacuo. The residual oil was taken up in a mixture of tert-butanol/water 1/1 (4 mL) and 
stirred at 25°C with sodium chlorite (53 mg, 0.585 mmol, 15 eq.), NaH2PO4 (73 mg, 0.468 mmol, 12 
eq.) and 30 μL of 2-methylbut-2-ene. After 1 h the solution was poured into brine (30 mL) and 
extracted with EtOAc (30 mL, 3 times). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude oil was purified by flash chromatography (10% of MeOH in CH2Cl2) 
affording 292 (10 mg, 33% over two steps) as a pale yellow oil. 292 was a mixture of two inseparable 
diastereoisomers in a ratio 1/1. 
 
IR (film): ν~  = 3065, 2935, 1735, 1710, 1380, 1255, 1220, 1200, 1165, 1100, 1040, 940 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.42-7.35 (m, 10Harom.), 4.93-4.85 (m, 4H, CH2(BOM)), 4.73-4.65 
(m, 4H, CH2Ph), 4.13-3.98 (m, 6H, H-C3,6’,6”’,4’,4”’,2IV), 3.81 (m, 2H, H2-C4IV), 2.63-2.60 (m, 2H, H2-
C2), 2.23-1.85 (m, 2H, H2-C3IV), 1.83-1.68 (m, 4H, H2-C4,1IV), 1.58-1.50 (m, 4H, H2-C5’,5”’), 1.42, 1.40, 
1.37 (3s, 12H, CH3-C2’,2“’), 1.30-1.13 (m, 2H, H2-C1”), 0.98 (s, 9H, tBuMe2Si(TBDMS)), 0.13 (2s, 6H, 
tBuMe2Si(TBDMS)). 
 
13C-NMR (100 MHz, MeOD): δ = 175.9 (s, C1=O), 139.4 (s, Carom.), 129.4, 129, 128.7 (3d, Carom., 1J = 
159, 162, 157), 101.5, 99.8 (2s, C2’,2”’), 95.8-95.6 (t, CH2(BOM), 1J = 141), 70.7 (t, CH2Ph, 1J = 144), 
74.1, 73.9 (2d , C3,2IV, 1J = 141, 147), 66.7, 66.2, 65.4, 64.7 (4d, C4’,6’,4”’,6”’, 1J = 142, 147, 145, 138), 
60.7 (t, C4IV, 1J = 140), 43.6, 43.2 (2t, C4,1IV, 1J = 142, 138), 39.6, 39.4, 39.2, 38.9, 38.5 (5t, 
C1”,5’,5”’,2,3IV, 1J = 132, 133, 131, 129, 127), 30.6, 20.3 (2q, CH3-C2’, 1J = 126, 128), 25.4 (q, CH3-C2“’, 
1J = 125), 26.4 (q, tBuMe2Si(TBDMS), 1J = 125), 17.4 (s, tBuMe2Si(TBDMS)),-5.1 (q, 
tBuMe2Si(TBDMS), 1J = 118). 
 
MALDI-TOF-MS: 811.3 (M + Na)+, 827.5 (M + K)+. 
 
Anal. for C43H68O11Si (789.099): calculated C 65.45, H 8.68; found C 65.60, H 8.67. 
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1H NMR spectrum of 292 
 
 
 
 
1H NMR spectrum of 294 and 295 
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(3RS,5RS,7SR,9SR,11RS,13RS)-5,7,9,11-Tetrakis(methyloxy)-3,13-
bis({[(phenylmethyl)oxy]methyl}oxy)-15-hydroxy-pentadecyl acetate (294) 
(3RS,5RS,7SR,9RS,11RS,13RS)-5,7,9,11-Tetrakis(methyloxy)-3,13-
bis({[(phenylmethyl)oxy]methyl}oxy)-15-hydroxy-pentadecyl acetate (295) 
 
OH OAcOP OMe OPOMe OMe OMe
115
 
 
Diolefine 134 (500 mg, 0.861 mmol) was dissolved in dry CH2Cl2 (26 mL) and ozonolysed at -78°C 
for 5 mn. A stream of dry O2 was then passed through the solution for 2 mn, and Me2S (250 μL, 3.445 
mmol, 4 eq.) was added dropwise. The mixture was stirred at -78°C for 10 mn and the solvent was 
concentrated at 0°C in vacuo. The residue was taken up in a 3/1 mixture of THF/MeOH (16 mL) at 
0°C and a 1 M solution of diethylmethoxyborane in THF (5.2 mL, 5.766 mmol, 6 eq.) was added. The 
resulting mixture was stirred for an additional hour at 25°C. NaBH4 (260 mg, 6.891 mmol, 8 eq.) was 
then added portionwise and the resulting mixture was stirred for 2 h. The reaction mixture was poured 
into water (25 mL) and extracted with EtOAc (20 mL, 3 times). The combined organic layers were 
dried over MgSO4 and concentrated in vacuo. The resulting oil was taken up in DMF (9 mL) and 
stirred at 0°C with imidazole (293 mg, 0.430 mmol, 5 eq.) and TBDMSCl (364 mg, 0.241 mmol, 2.8 
eq.). After 1h, the solution was poured into water (100 mL) and extracted with Et2O (40 mL, 3 times). 
The combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography (5% of MeOH in CH2Cl2) affording tetrol 145 (344 mg, 53% over 4 
steps) as a yellow oil. 
Tetrol 145 was taken up in THF (10 mL) and cooled to 0°C. NaH (365 mg, 60% in mineral oil, 9.127 
mmol, 20 eq.) and MeI (4.5 mL, 7.302 mmol, 16 eq.) were added and the reaction mixture was stirred 
for 12 h at 25°C. The mixture was poured into a saturated aqueous solution of NaHCO3 (50 mL) and 
extracted with EtOAc (30 mL, 3 times). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was taken up in CH3CN (3.5 mL) and cooled to -30°C. Aqueous 
HF solution (60 % in water, 350 μL) was added and the reaction was stirred for 1 h. The mixture was 
poured into a saturated aqueous solution of NaHCO3 (50 mL) and extracted with EtOAc (30 mL, 3 
times). The combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue 
was purified by flash chromatography (2% of MeOH in CH2Cl2) affording diol 293 (145 mg, 50 % 
over 2 steps) as a yellow oil. The diol 293 was taken up in vinyl acetate (10 mL) and stirred 40 mn at 
25°C with lipase from Candida Cylindracea (455 mg, 2 u.mg-1, 4000 u.mmol-1). The suspension was 
filtered over a pad of celite® and washed with EtOAc (40 mL), the filtrate was concentrated in vacuo. 
The residue was purified by flash chromatography (2% of MeOH in CH2Cl2) affording mono-acetates 
294 and 295 (80 mg, 52 %) as a mixture of two inseparable diastereoisomers in a ratio 2/1. 
 
IR (film): ν~  = 3450, 2920, 1740, 1710, 1380, 1255, 1200, 1165, 1040, 940 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.36-7.26 (m, 10Harom.), 4.86-4.79 (m, 4H, CH2(BOM)), 4.66-4.61 
(m, 4H, CH2Ph), 4.19 (t, 2H, H2-C1, 3J = 6.3), 3.95-3.91 (m, 2H, H-C3,13), 3.67 (t, 2H, H2-C15, 3J = 6.4), 
3.60-3.39 (3m, 6H, H-C7,11,5,9), 3.35-3.25 (4s, 12H, CH3(OMe)), 2.00 (s, 3H, CH3(OAc)), 1.95-1.85 
(m, 2H, H2-C2), 1.85-1.78 (m, 2H, H2-C14), 1.78-1.55 (m, 10H, H2-C4,6,8,10,12). 
 
13C-NMR (100 MHz, MeOD): δ = 170.4 (s, C=O(OAc)), 139.1 (s, Carom.), 129.4, 128.9, 128.7 (3d, 
Carom., 1J = 159, 158, 158), 95.3, 95.2 (2t, CH2(BOM), 1J = 162), [95.1, 95.0 (2t, CH2(BOM)Min., 1J = 
162)], 76.8, 76.6, 76.3, 76.1 (4d, C5,7,9,11, 1J = 135, 136, 136, 137), 74.4, 74.0 (2d, C3,13, 1J = 139, 137), 
[74.3, 73.9 (2d, C3,13Min., 1J = 139, 137)], 70.9 (t, CH2Ph, 1J = 146), [70.8 (t, CH2PhMin., 1J = 146)], 62.4 
(t, C1, 1J = 145), 59.4 (t, C15, 1J = 140), 56.9, 56.5, 56.3 (3q, CH3(OMe), 1J = 140, 141, 142), 41.6, 
41.4, 41.1, 40.9, 40.7 (5t, C4,6,8,10,12, 1J = 137, 136, 134, 140,137), 39.2 (t, C14, 1J = 125), [39.0 (t, 
C14Min., 1J = 125)], 35.3 (t, C2, 1J = 128), 20.9 (q, CH3(OAc), 1J = 129). 
 
MALDI-TOF-MS: 702.4 (M + Na)+, 718.8 (M + K)+. 
 
Anal. for C37H58O11 (678.398): calculated C 65.46, H 8.61; found C 64.49, H 8.63. 
New efficient synthetic routes toward functionalised polyketides.  
   
 
225
(3RS,5RS,7SR,9RS,11RS,13SR)-5,7,9,11-Tetrakis(methyloxy)-3,13-
bis({[(phenylmethyl)oxy]methyl}oxy)-15-hydroxypentadecanoic acid (296) 
(3SR,5RS,7SR,9RS,11RS,13RS)-5,7,9,11-Tetrakis(methyloxy)-3,13-
bis({[(phenylmethyl)oxy]methyl}oxy)-15-hydroxy-pentadecanoic acid (296) 
 
115
OH OOP OMe OPOMe OMe OMe
OH
 
 
Diols 294 and 295 (25 mg, 0.037 mmol) were dissolved in dried CH2Cl2 (2 mL). NMO (10 mg, 0.077 
mmol, 2 eq.), TPAP (4 mg, 0.012 mmol, 0.2 eq.) and 40 mg of 4 Ǻ MS were added. After stirring for 
1 h, the solution was filtered on a pad of silica gel and washed with EtOAc (50 mL). The solvent was 
concentrated in vacuo. The residue was taken up into a 1/1 mixture of tert-butanol/water (3 mL) and 
stirred at 25°C with sodium chlorite (50 mg, 0.553 mmol, 15 eq.), NaH2PO4 (69 mg, 0.442 mmol, 12 
eq.) and 20 μL of 2-methylbut-2-ene. After 1 h the solution was poured into brine (30 mL) and 
extracted with EtOAc (30 mL, 3 times). The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The crude oil was taken up in MeOH (5 mL) and stirred at 25°C with a 
catalytic amount of K2CO3. After 4 h the mixture was poured into water (50 mL) and extracted with 
EtOAc (30 mL, 3 times). The crude oil was purified by flash chromatography (4% of MeOH in 
CH2Cl2) affording 296 (8 mg, 33 % over 3 steps), as a mixture of two inseparable diastereoisomers in 
a ratio 2/1. 
 
IR (film): ν~  = 3450, 2940, 2600, 250, 1555, 1455, 1385, 1080, 1035, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 6.71-6.10 (m, 10Harom.), 4.52-4.45 (m, 4H, CH2(BOM)), 4.37-4.30 
(m, 4H, CH2Ph), 4.01-3.97 (m, 1H, H-C3), 3.78-3.974 (m, 1H, H-C13), 3.51 (m, 2H, H2-C15), 3.46-3.22 
(m, 4H, H-C5,7,9,11), 3.19 (m, 12H, CH3(OMe)), 2.64-2.31 (2m, 2H, H2-C2) 1.96-1.56 (m, 12H, H2-
C4,6,8,10,12,14) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 175.7 (s, C1=O), 139.3 (s, Carom.), 129.4, 128.9, 128.7 (3d, Carom.), 
95.4 (t, CH2(BOM)), 76.7, 76.5, 76.2, 76.1 (2d, C5,7,9,11), 74.5, 74.3 (2d, C3,13), 70.8 (t, CH2Ph),59.4 
(2d, C15), 56.3, 56.1, 56.0, 55.7 (4q, CH3(OMe)), 43.9, 42.0, 41.6, 40.7, 39.3, 39.2 (6t, C4,6,8,10,12,14), 
43.8 (t, C2) ppm. 
 
MALDI-TOF-MS: 676.4 (M + Na)+, 690.6 (M + K)+. 
 
MALDI-TOF-HRMS for (C35H54O11 + Na)+: calculated 673.3564; found 673.3561. 
 
C35H54O11 (650.806). 
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1H NMR spectrum of 296 
 
 
 
 
1H NMR spectrum of 297 and 298 
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(4SR,6RS,8SR,10RS,12RS,14RS)-6,8,10,12-Tetrakis(methyloxy)-4,14-
bis({[(phenylmethyl)oxy]methyl}oxy)oxacyclohexadecan-2-one (297) 
(4SR,6RS,8RS,10SR,12RS,14RS)-6,8,10,12-Tetrakis(methyloxy)-4,14-
bis({[(phenylmethyl)oxy]methyl}oxy)oxacyclohexadecan-2-one (298) 
 
1
16
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Seco-acid 296 (10 mg, 0.015 mmol) was dissolved in CH3CN (1 mL). A 0.4 M solution of DIPEA in 
benzene (1.1 mL, 0.460 mmol, 30 eq.) and a 0.4 M solution of 2,4,6-trichlorobenzoyl chloride in 
benzene (770 μL, 0.307 mmol, 20 eq.) were added. The resulting mixture was stirred at 25°C for 3 h 
and then diluted with benzene (9 mL). This mixture was added via a syringe pump to a refluxing 
solution of DMAP (91 mg, 0.75 mmol, 50 eq.) in benzene (18 mL) over 6 h. The reaction medium was 
poured into water (30 mL) and extracted with EtOAc (30 mL, 3 times). The combined organic layers 
were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography 
(3% of MeOH in CH2Cl2) affording 297 and 298 as a pale yellow oil (9.5 mg, quant., 2/1 ratio). 
 
IR (film): ν~  = 2930, 1730, 1650, 1580, 1455, 1385, 1280, 1165, 1100, 860 cm-1. 
 
1H-NMR (400 MHz, C6D6): δ = 7.35-7.27 (m, 6Harom.), 7.12-7.08 (m, 4Harom.),4.79, 4.76 (2d, 4H, 
CH2(BOM), 2J = 6.8), 4.63, 4.57 (2s, 4H, CH2Ph), 4.42-4.38 (m, 1H, H-C4), 4.32-4.23 (2m, 2H, H2-
C16), 4.06-4.04 (m, 1H, H-C14), 3.63-3.39 (m, 4H, H-C6,8,10,12), 3.15-3.12 (m, 12H, CH3(OMe)), 2.69-
2.40 (m, 2H, H2-C3), 2.09-1.47 (m, 12H, H2-C5,7,9,11,13,15) ppm. 
 
13C-NMR (100 MHz, C6D6): δ = 170.3 (s, C2), 138.7, 138.6 (2s, Carom.), 128.4, 128.0, 127.7 (3d, 
Carom.), 94.1, 93.5 (t, CH2(BOM)), 75.8, 75.6, 74.7, 74.4 (4d, C6,8,10,12), 72.7, 72.3 (2d, C14), 71.8, 71.4 
(2d, C4), 69.6, 69.5 (2t, CH2Ph), 60.7, 60.6 (2t, C16), 56.4, 56.2, 55.8, 55.7 (q, CH3(OMe)), 41.2, 39.8 
(2t, C3), 40.6, 39.4, 38.8, 38.4, 37.9, 36.8 (6t, C5,7,9,11,13,15) ppm. 
 
MALDI-TOF-MS: 655.7 (M+Na)+, 671.7 (M+K)+. 
 
Anal. for C35H52O10 (632.79): calculated C 66.40, H 8.33; found C 66.63, H 8.39. 
 
 
Methyl (2E,5RS,7RS,9SR,11RS,13RS,15RS)-7,9,11,13,17-pentahydroxy-5,15-
bis({[(phenylmethyl)oxy]methyl}oxy)heptadec-2-enoate (301) 
Methyl (2E,5RS,7RS,9RS,11SR,13RS,15RS)-7,9,11,13,17-pentahydroxy-5,15-
bis({[(phenylmethyl)oxy]methyl}oxy)heptadec-2-enoate (301) 
 
1
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To a solution of 154 (180 mg, 0.312 mmol) in MeOH (3 mL) cooled to -20°C, NaBH4 (32 mg, 0.858 
mmol, 2.75 eq.) was added and the resulting mixture was kept below -20°C for 2 h. The mixture was 
poured into water (15 mL) and extracted with EtOAc (10 mL, 3 times). The combined organic layers 
were dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography 
(5% to 10% of MeOH in CH2Cl2) affording 299 (100 mg, 71% based on recovered starting material) 
as a colourless oil. 
New efficient synthetic routes toward functionalised polyketides.  
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Phosphonium salt 300 was prepared according to the procedure of Aspinall2. 
Hemiketal 299 (200 mg, 0.345 mmol) dissolved in toluene (3 mL) was added to the phosphorus ylide 
300 (0.862 mmol, 2.5 eq.). The resulting mixture was heated at 80°C for 3 h. The reaction mixture was 
concentrated in vacuo and the crude oil was purified by flash chromatography (3 to 7% MeOH in 
CH2Cl2) affording α,β-unsaturated methyl ester 301 (115 mg, 74% based on recovered staring 
material) as a pale yellow oil (mixture of E/Z 10/1, diastereoisomers in 1/1 ratio). 
 
IR (film): ν~  = 3415, 2945, 1720, 1655, 1435, 1380, 1325, 1275, 1205, 1165, 1100, 1040, 740, 700 
cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.25 (m, 10Harom.), 7.06-6.98 (m, 1H, H-C3E), 6.45-6.35 (m, 
1H, H-C3Z), 5.92 (d, 1H, H-C2E, 3J = 16), 4.84 (s, 4H, CH2(BOM)), 4.66-4.62 (m, 4H, CH2Ph), 4.10-
3.90 (m, 6H, H-C5,7,9,11,13,15), 3.75-3.65 (m, 5H, H2-C17, CH3(OMe)), 3.05-2.95 (m, 2H, H2-C4Z), 2.60-
2.45 (m, 2H, H2-C4E), 1.86-1.60 (m, 12H, H2-C6,8,10,12,14) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 167.4 (s, C1=O), 146.2, 146.1 (2d, C3, 1J = 156), 138.2 (s, Carom.), 
128.4, 127.9, 127.8 (3d, Carom., 1J = 159, 158, 160), 123.2, 123.1 (2d, C2, 1J = 163), 94.5, 94.4 (2t, 
CH2(BOM), 1J = 163), 74.3, 73.3 (2d, C5,15, 1J = 142, 145), 69.9, 69.8 (t, CH2Ph, 1J = 143), 69.2, 67.2, 
66.8, 64.7 (4d, C7,9,11,13, 1J = 143, 142, 140, 145), 58.5 (t, C17, 1J = 137), 51.0 (q, CH3(OMe), 1J = 146), 
45.3, 44.9, 43.6, 43.3, 42.9 (5t, C6,8,10,12,14, 1J = 124, 127, 126, 120), 38.4 (t, C16, 1J = 123), 38.1 (t, C4, 
1J = 122) ppm. 
 
MALDI-TOF-HRMS for (C33H48O8 + Na)+: calculated 657.3251; 657.3221 found. 
 
Anal. for C33H48O8 (634.754): calculated C 64.33, H 7.94; found C 64.26, H 7.96. 
 
 
1H NMR spectrum of 301 
 
                                                 
2 Aspinall, I. H.; Cowley, P. M.; Mitchell, G; Raynor, C. M.; Stoodley, R. J. Chem. Soc., Perkin Trans. 1 1999, 
2591-2599. 
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(6RS,8RS,10RS,12SR,14RS,16RS)-8,10,12,14-Tetrahydroxy-6,16-
bis({[(phenylmethyl)oxy]methyl}oxy)oxacyclooctadecan-2-one (302) 
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A solution of 301 (60 mg, 0.094 mmol) in EtOAc (3 mL) was stirred in the presence of a catalytic 
amount of Pd(OH)2 on activated charcoal at 25°C under 1 atm. of hydrogen. After 1 h, the resulting 
mixture was filtered over a pad of celite®. The solvent was concentrated in vacuo to afford a crude oil 
which was diluted in a 2 M solution of LiOH in MeOH (3 mL). The resulting mixture was stirred for 3 
h at 25°C and then poured into water (15 mL). The aqueous layer was acidified to pH 6 with a 3 M 
solution of HCl and extracted with EtOAc (10 mL, 3 times). The combined organic layers were 
washed with brine (30 mL), dried over MgSO4 and concentrated in vacuo. The crude intermediate was 
dissolved in CH3CN (2 mL). A 0.4 M solution of DIPEA in benzene (3.9 mL, 1.55 mmol, 30 eq.) and 
a 0.4 M solution of 2,4,6-trichlorobenzoyl chloride in benzene (2.6 mL, 1.05 mmol, 20 eq.) were 
added and the solution was stirred at 25°C for 3 h and then diluted with benzene (12.5 mL). This 
mixture was added via a syringe pump to a refluxing solution of DMAP (315 mg, 2.55 mmol, 50 eq.) 
in benzene (25 mL) over 6 h. The reaction mixture was poured into water (30 mL) and extracted with 
EtOAc (30 mL, 3 times). The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The residue was purified by two successive flash chromatographies (2% of MeOH in CH2Cl2) 
affording 302 (19 mg, 32% over 4 steps) as a pale yellow oil as a single diastereoisomer. 
 
IR (film): ν~  = 3420, 2930, 1735, 1580, 1450, 1375, 1275, 1160, 1120, 1040, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.27 (10Harom.), 4.77-4.74, 4.68-4.66 (2m, 4H, CH2(BOM)), 
4.66-4.59 (m, 4H, CH2Ph), 4.56-4.52 (m, 2H, H2-C18), 4.05-3.87 (m, 6H, H-C6,8,10,12,14,16), 2.40-2.30 
(m, 2H, H2-C3), 2.10-1.90 (2m, 16H, H2-C4,5,7,9,11,13,15,17) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 164.3 (s, C2=O), 138.3, 138.2 (2s, Carom.), 128.4, 128.0, 127.7 (3d, 
Carom.), 94.5, 94.3 (2t, CH2(BOM)), 75.2, 73.4 (2d, C6,16), 69.8 (t, CH2Ph), 69.2, 67.1, 66.9, 64.9 (4d, 
C8,10,12,14), 58.5 (t, C18), 45.3, 45.0, 44.9, 43.6, 42.8 (5t, C7,9,11,13,15), 38.4, 38.3 (2t, C5,17), 34.7 (t, C3), 
20.6 (t, C4) ppm. 
 
MALDI-TOF-MS: 627.1 (M+Na)+, 643.1 (M+K)+. 
 
MALDI-TOF-HRMS for (C33H48O10 + Na)+: calculated 657.3251; found 627.3142. 
 
C33H48O10 (604.727). 
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1H NMR spectrum of 302 
 
 
 
1H NMR spectrum of 303 
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(4RS,6SR,4’SR,6’SR)-4,4’-Methanediylbis{2,2-dimethyl-6-[(2R)-2-({[(phenyl 
methyl)oxy]methyl}oxy)pent-4-en-1-yl]-1,3-dioxane} (303) 
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To a solution of 136 (245 mg, 0.371 mmol) in dry CH2Cl2 (2 mL) were added 185 mg of 4 Ǻ MS, 4-
methylmorpholine N-oxide (105 mg, 0.778 mmol, 2.1 eq.) and tetrapropylammonium perruthenate (13 
mg, 0.037 mmol, 0.1 eq.). After stirring for 1 h, the resulting mixture was filtered over a pad of celite®. 
Removal of the solvent in vacuo and purification of the residue through a short flash chromatography 
(6% MeOH in CH2Cl2) afforded dialdehyde (280 mg) as a black oil. Triphenylphosphonium methyl 
bromide (450 mg, 1.256 mmol, 5 eq.) was dissolved in anhydrous THF (2 mL). The mixture was 
cooled at -78°C and a 1.5 M solution of butyllithium in THF (800 μL, 1.256 mmol, 5 eq.) was added. 
The reaction mixture was stirred at 25°C for 1 h. A solution of the previously formed dialdehyde in 
THF (1 mL) was added to the resulting yellow mixture at -78°C. At the end of the addition the cooling 
bath was removed and the reaction mixture was stirred for 3 h at 25°C. The mixture was poured into 
water (15 mL) and extracted with EtOAc (20 mL, 3 times). The combined organic layers were washed 
with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash 
chromatography (EtOAc/EP 1/7) to afford diolefine 303 (85 mg, 35% over two steps) as a colourless 
oil. 
 
IR (film): ν~  = 2940, 1640, 1440, 1390, 1100, 1040, 915, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.27 (m, 10Harom.), 5.85 (ddt, 2H, H-C4’’,4”’, 3J = 17.2, 10.0, 
6.4), 5.08, 5.03 (2d, 4H, H-C5’’,5”’, 3J = 17.2, 10.0), 4.82, 4.78 (2d, 4H, CH2(BOM), 2J = 6.0, 7.0), 4.63, 
4.61 (2d, 4H, CH2Ph, 2J = 5.2, 4.9), 4.12-3.92 (m, 4H, H-C6,4,4’,6’), 3.91-3.88, 3.87-3.78 (2m, 4H, H-
C2”,2”’), 2.34, 2.32 (2dd, 4H, H2-C3’’,3”’, 3J = 6.4, 5.6), 1.62-1.37 (m, 10H, H2-C1”’,5,1,5’,1”), 1.33, 1.29, 
1.27 (3s, 12H, CH3-C2,2’) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 138.4, 138.3 (2s, Carom.), 134.8 (d, C4’’,4”’, 1J = 151), 128.4, 127.8, 
127.7 (3d, Carom., 1J = 160, 154, 157), 116.7 (t, C5’’,5”’, 1J = 154), 100.5, 98.8 (2s, C2,2’), 94.5, 94.2 (2t, 
CH2(BOM), 1J = 162), 75.2, 74.1 (2d, C2”,2”’, 1J = 142, 143), 69.7, 69.6 (t, CH2Ph, 1J = 141), 66.0, 
65.8, 63.7, 63.3 (4d, C4,6,4’,6’, 1J = 141, 139, 144, 143), 43.3, 42.3, 42.1 (3t, C1,5,15, 1J = 125, 134, 127), 
40.0, 39.9 (2t, C3’’,3”’, 1J = 120), 38.6, 37.5 (2t, C1’’,1”’, 1J = 136, 137), 29.5, 19.2 (q, CH3-C2’, 1J = 126, 
128), 24.4, 24.3 (q, CH3-C2, 1J = 123) ppm. 
 
MALDI-TOF-MS: 675.4 (M+Na)+. 
 
Anal. for C39H56O8 (652.857): calculated C 71.75, H 8.65; found C 71.78, H 8.67. 
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(5RS,7RS,9RS,11RS,13RS,15RS)-1,19-Diphenyl-5,15-diprop-2-en-1-yl-2,4,16,18-
tetraoxanonadecane-7,9,11,13-tetrol (305) 
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To a solution of 303 (75 mg, 0.115 mmol) in MeOH (1.5 mL) was added p-toluenesulfonic acid (9 mg, 
0.046 mmol, 0.4 eq.). After stirring for 2 h at 25°C, the mixture was poured into a saturated aqueous 
solution of NaHCO3 (10 mL) and extracted with EtOAc (10 mL, 3 times). The combined organic 
layers were washed with brine (20 mL), dried over MgSO4 and concentrated in vacuo. The residue 
was purified by flash chromatography (6% MeOH in CH2Cl2) to afford tetrol 305 (25 mg, 42%) as a 
colourless oil. 
 
IR (film): ν~  = 3415, 2935, 1640, 1435, 1375, 1100, 1035, 915, 740, 695 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.27 (m, 10Harom.), 5.88-5.82 (m, 2H, H-C2’), 5.11-5.03 (m, 4H, 
H-C3’), 4.83 (s, 4H, CH2(BOM)), 4.64, 4.62 (2s, 4H, CH2Ph), 4.10-3.95 (m, 6H, H-C5,7,9,11,13,15), 2.39-
2.33 (m, 4H, H2-C1’), 1.62-1.50 (m, 10H, H2-C6,8,10,12,14) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 138.3 (s, Carom.), 134.9, 134.8 (2d, C2’, 1J = 153), 128.4, 128.0, 
127.7 (3d, Carom., 1J = 159, 153, 158), 116.7 (t, C3’, 1J = 150), 94.2 (t, CH2(BOM), 1J = 163), 75.0, 74.8 
(2d, C5,15, 1J = 132), 69.8, 69.7 (2t, CH2Ph, 1J = 136), 69.2, 67.1, 66.8, 64.7 (4d, C7,9,11,13, 1J = 134, 
142, 144, 141), 45.3, 45.0, 44.9, 43.0, 42.6 (5t, C6,8,10,12,14, 1J = 126, 125, 126, 126, 127), 39.9, 39.8 (2t, 
C1’, 1J = 126) ppm. 
 
MALDI-TOF-MS: 573.8 (M+Na)+. 
 
C33H48O8 (572.729). 
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1H NMR spectrum of 305 
 
 
 
1H NMR spectrum of 306 
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(1SR,3RS,5SR,7SR,9SR,14SR,16SR,18SR,20RS,22SR,24SR,29SR)-9,14,24,29-
Tetrakis({[(phenylmethyl)oxy]methyl}oxy)cyclotriacontane-1,3,5,7,16,18,20,22-octol (306) 
(1SR,3RS,5SR,7SR,9SR,14SR,16SR,18RS,20SR,22SR,24SR,29SR)-9,14,24,29-
Tetrakis({[(phenylmethyl)oxy]methyl}oxy)cyclotriacontane-1,3,5,7,16,18,20,22-octol (306) 
 
1
OP
OP
OH OH OH
OPOH
OH OP
OHOHOH
30
 
 
To a solution of diolefin 305 (25 mg, 0.044 mmol) in dry CH2Cl2 (25 mL) was added 
tricyclohexylphosphine [1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene][benzylidine] 
ruthenium (IV) dichloride (7.5 mg, 8.731 μmol, 0.2 eq.). The resulting pink solution was heated at 
50°C for 7 h. The solvent was concentrated in vacuo and the residue was purified by flash 
chromatography (3% to 10% MeOH in CH2Cl2) to afford an intermediate diolefine as a dark oil 
containing impurities. This oil was dissolved in EtOAc (2 mL) and treated at 25°C with a catalytic 
amount of palladium on activated charcoal under 1 atm. of hydrogen. After 1 h, the resulting mixture 
was filtered over a pad of celite® and the solvent was removed in vacuo. The residue was purified by 
flash chromatography (3% to 10% MeOH in CH2Cl2) affording 306 (7.5 mg, 32% over 2 steps) as a 
pale yellow oil (mixture of diastereoisomers in a ratio 1/1). 
 
IR (film): ν~  = 3410, 2940, 2515, 1425, 1380, 1165, 1100, 1040, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.34-7.25 (m, 20Harom.), 4.79 (s, 8H, CH2(BOM)), 4.58 (s, 8H, 
CH2Ph), 4.10-3.90 (m, 8H, H-C1,3,5,7,16,18,20,22), 3.90-3.80 (m, 4H, H-C9,14,24,29), 1.8-1.5 (m, 28H, H2-
C2,4,6,8,10,13,15,17,19,21,23,25,28,30), 1.5-1.35 (m, 8H, H2-C11,12,26,27) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 138.5, 138.4, 138.3, 138.2 (4s, Carom.), 128.4, 127.9, 127.7 (3d, 
Carom.), 94.2, 94.1, 93.9, 93.1 (4t, CH2(BOM)), 75.4, 75.2, 75.1, 75.0 (4d, C9,14,24,29), 69.7, 69.6 (4t, 
CH2Ph), 68.3, 68.2, 66.8, 66.7, 66.6, 66.5, 65.1, 64.9 (8t, C1,3,5,7,16,18,20,22), 45.4, 45.3, 45.1, 45.0, 44.9, 
43.1, 42.8, 42.7, 42.1, 42.0, 37.8, 37.2, 35.6, 34.9 (14d, C2,4,6,8,10,13,15,17,19,21,23,25,28,30), 25.1, 25.0, 24.9, 
24.8 (4t, C11,12,26,27) ppm. 
 
MALDI-TOF-MS: 1116.3 (M+Na)+, 1131.4 (M+K)+. 
 
MALDI-TOF-HRMS for (C62H92O16 + Na)+: calculated 1115.6287; found 1115.6283. 
 
Anal. for C62H92O16 (1092.638): calculated C 68.11, H 8.51; found C 68.00, H 8.48. 
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(1RS,3SR)-3-(Acetyloxy)-4-[(2SR,4RS,6SR)-6-(2-hydroxyetyl)-4-
({[(phenylmethyl)oxy]methyl}oxy)tetrahydro-2H-pyran-2-yl]-1-{[(2S,4R,6S)-6-
({[(phenylmethyl)oxy]methyl}oxy)tetrahydro-2H-pyran-2-yl]methyl}butyl acetate (309) 
 
4
O OOAc OAc
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2"
1'
6"
1 2"'
4"'
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A
B
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O3 was passed through a solution of diolefine 185 (200 mg, 0.282 mmol) in CH2Cl2 (9 mL) during 5 
mn at –78°C. When a blue coloration persisted, O2 was passed through the solution to eliminate the 
excess of O3. DMS (83 μL, 1.128 mmol, 4 eq.) was added and the mixture was stirred for an additional 
10 mn. The solvent was evaporated in vacuo at 0°C. The residual oil was dissolved in MeOH (4 mL) 
and treated at 25°C with NaBH4 (65 mg, 1.693 mmol, 6 eq.) for 2 h. The reaction mixture was then 
poured into water (30 mL) and extracted with EtOAc (40 mL, 3 times). The combined organic layers 
were washed with a saturated aqueous solution of NaCl (40 mL), dried over MgSO4 and concentrated 
in vacuo. The residue was purified by flash chromatography (3% of MeOH in CH2Cl2) affording diol 
309 (122 mg, 60% over 3 steps) as a colourless oil. 
 
IR (film): ν~  = 3400, 2940, 2890, 1735, 1450, 1370, 1240, 1165, 1100, 1045, 1025, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.38-7.29 (m, 10Harom.), 5.18-5.03 (m, 2H, H-C1,3), 4.83, 4.82 (2s, 
4H, CH2(BOM)), 4.64, 4.63 (2s, 4H, CH2Ph), 4.23-4.11 (m, 2H, H-C2”,2”’), 4.07-3.96 (m, 2H, H-
C4”,4”’), 3.86-3.7 (m, 2H, H-C6”,6”’), 3.65, 3.62 (2t, 4H, H-CB,B’, 3J = 6.1, 7.2), 2.09 (2s, 6H, CH3(OAc)), 
2.07-1.83, 1.82-1.5, 1.42-1.29 (3m, 18H, H2-CA,A’,2,4,1’,3”,3”’,5”,5”’) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 175.1, 175.0 (s, C=O(OAc)), 142.1 (s, Carom.), 131.9, 131.5, 131.2 
(3d, Carom., 1J = 159, 156, 154), 96.5, 96.4 (2t, CH2(BOM), 1J = 162), 73.5, 73.2 (t, CH2Ph, 1J = 142), 
73.0, 72.4 (2d, C1,3, 1J = 141, 140), 71.6, 71.7 (2d, C4”,4”’, 1J = 137), 70.3, 69.3 (2d, C6”,6”’, 1J = 140, 
139), 62.6, 62.4 (2t, CB,B’, 1J = 142), 43.5, 43.1, 42.4, 41.1, 40.7, 39.5, 39.3, 38.8, 38.7 (9t, 
CA,A’,2,4,1’,3”,3”’,5”,5”’, 1J = 135, 125, 127, 126, 125, 126, 124, 128, 129), 23.9, 23.8 (2q, CH3(OAc), 1J = 
129) ppm. 
 
ESI-HRMS for (C39H56O12 + H)+: calculated 717.3850; found 717.3856. 
 
Anal. for C39H56O12 (716.87): calculated C 65.34, H 7.87; found C 65.27, H 7.77. 
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1H NMR spectrum of 309 
 
 
 
1H NMR spectrum of 310 
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[(2RS,4SR,6SR)-6-{(2RS,4SR)-2,4-Bis(acetyloxy)-5-[(2S,4S,6R)-6-(carboxymethyl)-4-
({[(phenylmethyl)oxy]methyl}oxy)tetrahydro-2H-pyran-2-yl]pentyl}-4-
({[(phenylmethyl)oxy]methyl}oxy)tetrahydro-2H-pyran-2-yl]acetic acid (310) 
 
5"
O OOAc OAc
OPPO
OO
4'
6'
1"
2'
4"'
2"'
6"'
OH OH
1
2 1IV
2IV
 
 
O3 was passed through a solution of diolefine 185 (200 mg, 0. 0.282 mmol) in CH2Cl2 (9 mL) during 5 
mn at -78°C. When a blue coloration persisted in the mixture, O2 was passed through the solution to 
eliminate the excess of O3. DMS (83 μL, 1.128 mmol, 4 eq.) was added and the mixture was stirred for 
an additional 10 mn. The solvent was evaporated in vacuo at 0°C. The residual oil was dissolved in a 
1/1 mixture of tert-butanol/water (4 mL) and treated with KH2PO4 (461 mg, 3.385 mmol, 12 eq.), 
NaClO2 (383 mg, 4.231 mmol, 15 eq.) and 2-methyl but-2-ene (200 μL, 4.231 mmol, 15 eq.) at 25°C 
for 12 h. The mixture was then poured into brine (20 mL) and extracted with EtOAc (20 mL, 3 times). 
The combined organic layers were dried over MgSO4 and concentrated in vacuo. The residue was 
purified by flash chromatography (5-20% of MeOH in CH2Cl2) affording di-carboxylic acid 310 (74 
mg, 35% over 3 steps) as a yellow oil. 
 
IR (film): ν~  = 3440, 2940, 1740, 1715, 1680, 1375, 1245, 1100, 1140, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.34-7.24 (m, 10Harom.), 5.16-5.10 (m, 2H, H-C2”,4”), 4.78 (d, 4H, 
CH2(BOM), 2J = 3.9), 4.61 (s, 4H, CH2Ph), 4.57-4.49 (m, 2H, H-C2’,6’”), 4.04-3.93 (m, 2H, H-C4’,4”’), 
3.91-3.83, 3.78-3.67 (2m, 2H, H-C6’,2”’), 2.65-2.54, 2.35-2.27 (2m, 4H, H2-C2,1IV), 2.05, 2.03 (2s, 6H, 
CH3(OAc)), 1.98-1.87, 1.86-1.61 (3m, 14H, H2-C3’,5’,1”,3”,5”,3”’,5”’) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 181.7, 181.6 (2s, C1,2IV), 174.2, 173.3 (2s, C=O(OAc)), 139.4 (s, 
Carom.), 129.4, 128.9, 128.7 (3d, Carom.), 93.8 (t, CH2(BOM)), 71.3, 70.9 (2d, C4”,4”’), 70.9, 70.6 (2d, 
C2’,6”’), 70.6 (t, CH2Ph), 70.3, 69.8 (2d, C2”,4”), 68.2, 67.6 (2d, C6’,2”’), 42.2, 41.7 (2t, C2,1IV), 41.6, 39.8, 
39.3, 38.5, 37.8, 36.7, 36.6 (7t, C3’,5’,1”,3”,5”,3”’,5”’), 21.6, 21.5 (2q, CH3(OAc)) ppm. 
 
ESI-HRMS for (C39H52O14 + K)+: calculated 783.2994, found 783.3040. 
 
C39H52O14 (744.82). 
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General procedure for the synthesis of macrocycles 47 and 48:  
 
Di-carboxylic acid 310 (25 mg, 0.033 mmol) in DMF (1.4 mL) was treated with DIPEA (15 μL, 0.081 
mmol, 2.4 eq.) and PyBOP (40 mg, 0.081 mmol, 2.4 eq.) at 25°C. Diamine (1 eq.) in solution in DMF 
(0.033 M) was added dropwise at 0°C over 6 h. After completion of the reaction, the solvent was 
evaporated in vacuo. The crude oil was dissolved in MeOH (1.5 mL) and treated with K2CO3 (20 mg, 
0.145 mmol, 4 eq.) at 25°C for 4 h. The reaction mixture was poured into water (20 mL) and extracted 
with EtOAc (20 mL, 3 times). The combined organic layers were washed with brine (40 mL), dried 
over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (2-4% of 
MeOH in CH2Cl2) affording compound 311 and 312 in a 37 and 46% yield respectively.  
 
 
(1RS,3RS,5SR,7RS,9SR,11RS,23RS,25SR)-3,5-Dihydroxy-9,25-
bis({[(phenylmethyl)oxy]methyl}oxy)-27,28-dioxa-14,20-diazatricyclo[21.3.1.17,11]octacosane-
13,21-dione (311) 
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311 (7 mg, 37% over 2 steps) was obtained as a pale yellow oil. 
 
IR (film): ν~  = 3440, 2930, 1740, 1715, 1410, 1355, 1245, 1180, 1100, 1140, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.5-7.25 (m, 10Harom.), 4.86 (brs, 4H, CH2(BOM)), 4.60 (brs, 4H, 
CH2Ph), 4.59-4.53, 4.49-4.44 (2m, 2H, H-C11,23), 4.07-3.92 (m, 6H, H-C1,3,5,7,9,25), 3.12-2.97, 2.87-2.78 
(2m, 4H, H2-C15,19), 2.2-1.94 (m, 4H, H2-C12,22), 1.78-1.66 (m, 4H, H2-C8,26), 1.65-1.52 (m, 6H, H2-
C16,17,18), 1.5-1.2 (m, 10H, H2-C2,4,6,10,24) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 176.4, 175.7 (2s, C13,21), 142.0 (s, Carom.), 131.9, 131.5, 131.2 (3d, 
Carom.), 96.2 (t, CH2(BOM)), 75.7, 73.3, 73.2, 72.7, 71.7, 68.9 (6d, C1,3,5,7,9,25), 73.1 (t, CH2Ph), 73.7, 
73.5 (2d, C11,23), 47.8, 47.1, 46.9 (3t, C2,4,6), 42.7 (t, C15,19), 42.5, 42.2 (2t, C12,22), 42.1, 42.0 (2t, C10,24), 
39.8, 39.1 (2t, C8,26), 32.5, 32.2, 27.2 (3t, C16,17,18) ppm. 
 
ESI-HRMS for (C40H58N2O10 + Na)+: calculated 749.3989; found 749.3995. 
 
C40H58N2O10 (726.89). 
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1H NMR spectrum of 311 
 
 
 
 
1H NMR spectrum of 312 
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(1RS,3RS,5SR,7RS,9SR,11RS,27RS,29SR)-3,5-Dihydroxy-9,29-
bis({[(phenylmethyl)oxy]methyl}oxy)-31,32-dioxa-14,24-diazatricyclo[25.3.1.17,11]dotriacontane-
13,25-dione (312) 
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312 (9 mg, 46% over 2 steps) was obtained as a pale yellow oil. 
 
IR (film): ν~  = 3365, 2960, 1610, 1570, 1410, 1335, 1070, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.37-7.28 (m, 10Harom.), 4.84 (brs, 4H, CH2(BOM)), 4.64 (s, 4H, 
CH2Ph), 4.59-4.40 (m, 2H, H-C11,27), 4.07-3.85 (m, 6H, H-C1,3,5,7,9,29), 3.15-2.97, 2.85-2.75 (2m, 4H, 
H2-C15,23), 2.21-1.97 (m, 4H, H2-C12,26), 1.82-1.66 (m, 4H, H2-C8,30), 1.64-1.46 (m, 10H, H2-C2,4,6,10,16), 
1.43-1.23 (m, 14H, H2-C16,17,18,19,20,21,22) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 176.3, 176.0 (2s, C13,25), 142.0 (s, Carom.), 131.9, 131.5, 131.2 (3d, 
Carom.), 96.4 (t, CH2(BOM)), 73.8, 73.2, 72.0, 71.7, 70.1, 69.6 (6d, C1,3,5,7,9,29), 73.4 (d, C11,27), 73.1 (t, 
CH2Ph), 48.0, 46.8, 46.7 (3t, C2,4,6), 42.9 (t, C15,23), 42.5, 42.4 (2t, C12,26), 41.9, 41.4 (2t, C10,28), 39.6, 
39.4 (2t, C8,30), 32.8, 32.7, 32.6, 30.2, 30.1, 29.9 (7t, C16,17,18,19,20,21,22) ppm. 
 
ESI-HRMS for (C44H66N2O10 + Na)+: calculated 805.4615; found 805.4620. 
 
C44H66N2O10 (783.00). 
 
 
(2RS,4SR)-1,15-Bis{(2RS,4RS,6SR)-4-({[(phenylmethyl)oxy]methyl}oxy)-6-[2-(prop-2-en-1-
ylamino)ethyl]tetrahydro-2H-pyran-2-yl}pentane-2,4-diol (313) 
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To a solution of diol 308 (70 mg, 0.097 mmol) in CH2Cl2 (1 mL) were added NEt3 (122 μL, 0.879 
mmol, 9 eq.) and methanesulfonyl chloride (28 μL, 0.293 mmol, 3 eq.) at 0°C. After 2 h, the reaction 
mixture was poured into a saturated aqueous solution of NaHCO3 (20 mL) and extracted with EtOAc 
(20 mL, 3 times). The combined organic layers were washed with brine (40 mL), dried over MgSO4 
and concentrated in vacuo. The residual oil was dissolved in a 3/1 mixture of DMF/allylamine (4 mL) 
and treated at 60°C with K2CO3 (120 mg, 0.879 mmol, 9 eq.) for 12 h. Solvents were evaporated in 
vacuo. The residual oil was taken up in MeOH (3 mL) and the reaction mixture was stirred during 3 h 
at 25°C. The reaction mixture was then poured into water (20 mL) and extracted with EtOAc (20 mL, 
3 times). The combined organic layers were washed with brine (40 mL), dried over MgSO4 and 
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concentrated in vacuo. The residue was purified by flash chromatography (4% of NH4OH in CH3CN) 
affording diamine 313 (28 mg, 42% over 3 steps) as a colourless oil. 
 
IR (film): ν~  = 3440, 2950, 1740, 1715, 1455, 1370, 1240, 1165, 1100, 1040, 740, 700 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.34-7.26 (m, 10Harom.), 5.99-5.85 (m, 2H, H-C2”’), 4.31, 5.28 (2d, 
4H, H-C3”’, 3J = 16.8, 10.4), 4.82 (s, 4H, CH2(BOM)), 4.61 (s, 4H, CH2Ph), 4.15-3.87 (m, 8H, H-
C2,4,2’,4’,6’), 3.37, 3.35 (2d, 4H, H2-C1”’, 3J = 6.0, 6.4), 2.92-2.74 (m, 4H, H2-C2”), 2.13-2.5 (3m, 14H, 
H2-C1,3,5,3’,5’), 1.5-1.22 (m, 4H, H2-C1”) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 139.4 (s, Carom.), 134.3, 134.2 (2d, C2’”, 1J = 155), 129.4, 128.9, 
128.7 (3d, Carom., 1J = 160, 156, 159), 119.9, 119.8 (2t, C3’”, 1J = 160), 93.9, 93.8 (2t, CH2(BOM), 1J = 
163), 71.4, 70.8, 70.0, 69.4, 67.7 (5d, C2,4,2’,4’,6’, 1J = 127, 132, 131, 129, 130), 70.6 (t, CH2Ph, 1J = 
140), 52.4, 52.3 (2t, C1’”, 1J = 137), 47.0, 46.8 (2t, C2”, 1J = 126), 45.7, 44.3, 43.8 (3t, C1,3,5, 1J = 125, 
126), 39.3, 38.3 (2t, C3’, 1J = 124, 122), 37.1, 37.0 (2t, C1”, 1J = 125), 31.8, 31.3 (2t, C5’, 1J = 125, 126) 
ppm. 
 
ESI-HRMS for (C41H62N2O8 + H)+: calculated 711.4584; found 711.4588. 
 
C41H62N2O8 (710.94). 
 
 
 
1H NMR spectrum of 313 
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(1R,3R,5S,7R,9R,11S,22S,24R)-3,5-Dihydroxy 9,24-bis({[(phenylmethyl)oxy]methyl}oxy)-26,27-
dioxa-14,19-diazatricyclo[20.3.1.17,11]heptacosane-13,20-dione (314) 
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To a solution of diolefine 313 (25 mg, 0.035 mmol) in CH2Cl2 (15 mL) was added Grubbs II catalyst 
(6 mg, 0.007 mmol, 0.2 eq.) at 50°C during 9 h. After completion of the reaction, the solvent was 
concentrated in vacuo. The crude oil was dissolved in a 1/3 mixture of MeOH/AcOEt (3 mL) and 
treated at 25°C for 4 h with a catalytic amount of Pd(OH)2 on activated charcoal under 1 atm. of 
hydrogen. The reaction mixture was then filtered through a pad of celite®. The filtrate was 
concentrated in vacuo. The residue was purified by flash chromatography (5% of NH4OH in CH3CN) 
affording 314 (18 mg, 48%) as a pale yellow oil. 
 
IR (film): ν~  = 3405, 2955, 1730, 1605, 1510, 1450, 1370, 1250, 1170, 1110, 1030, 850, 775 cm-1. 
 
1H-NMR (400 MHz, MeOD): δ = 7.35-7.27 (m, 10Harom.), 4.82 (s, 4H, CH2(BOM)), 4.62 (s, 4H, 
CH2Ph), 4.15-3.85 (m, 8H, H-C1,3,5,7,9,11,22,24), 3.21-3.83 (2m, 8H, H2-C13,15,18,20), 2.12-1.91, 1.9-1.5 
(2m, 18H, H2-C2,4,6,8,10,12,21,23,25), 1.52-1.23 (m, 4H, H2-C16,17) ppm. 
 
13C-NMR (100 MHz, MeOD): δ = 130 (s, Carom.), 128.4, 127.9, 126.9 (3d, Carom.), 93.0, 92.9 (2t, 
CH2(BOM)), 69.7, 69.6 (2t, CH2Ph), 70.0, 69.9, 69.6, 69.5, 69.2, 68.5, 66.3, 65.6 (8d, C1,3,5,7,9,11,22,24), 
49.8, 49.7, 46.3, 45.8 (4t, C13,15,18,20), 45.3, 42.9, 42.2, 38.0, 36.3, 35.9, 26.6, 26.5, 26.3 (9t, 
C2,4,6,8,10,12,21,23,25) ppm. 
 
ESI-HRMS for (C39H60N2O8 + Na)+: calculated 707.4247; found 707.4234. 
 
C39H60N2O8 (684.90). 
New efficient synthetic routes toward functionalised polyketides.  
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1H NMR spectrum of 314 
 
 
 
  
  
2 4 5'
2'
1"
2"'
5"'
2IV 4IV
OH OHOP O OPO O O
137, p 134 
2 14
TBSO OTBSOP OH OPOH OH OH 145, p 135 
2 4 5'
2'
1"
2"'
5"' 2IV4IV
OAc OAcOP O OPO O O
146, p 136 
2 4 5'
2'
1"
2"'
5"' 2IV4IV
OAc OAcOH O OHO O O
147, p 138 
2'
4'
5'
6'1
2 4 6
OH OHOP OH O O OPOH
8 1" 3"
4"
148, p 138 
2'
4'
5'
6' 1
246
OH OHOP O OH OH OPO
81"3"
4"
149, p 140 
2'
4'
5'
6'
15 37
OTBS OTBSOP OH O O OPOH
8
1" 3"
4"
151, p 141 
OAc OAcOP OH OPOH OH OH
1
2468101214
15
152, p 142 
OAc OAcOPOOOHOHOP
8"
7" 5" 3" 1"
6' 4'
2'
4 2
1
153, p143 
1'
2
5
4 6
1"
3"
O O
OMeOMe
PO
O O
OP
1'
5"1"
3"
5"
155, p144 
1
6
OP OH OH OH OPOH
1214
3
81016
17
4
OMe
O
OMe
O
19
157, p 146 
OH OHOP OTBS OH OH OPOH
1 15
169, p 146 
4' 6'
84 62
OH OHOP OTBS O O OPOH
1
1'' 3''
4''
2'
171, p 148 
1
24
NH2 NH2OH OH OH OH OHNH2
101214
15
68
176, p 150 
1
2 4 10 12 14
15
6 8
NH2 NH2OH OH OH OH OHOH 177, p 151 
6812 1014
OAc OAcOP OTBS OH OH OPOH
15
4 2
1
178, p 152 
15
1412
OH OHOH OH NH2 NH2 OHNH2
642
1
108
179, p 153 
53
2' 4'
O O
OMeOMe
PO
NH2 NH2
OP12'4'
6' 6'
181, p 154 
1"'
2"
4" 6" 2' 4'
O O
OMeOMe
HO
O O
OH
1'"
24
6 6'
182, p 156 
5'3'
2" 4"
O O
OMeOMe
HO
NH2 NH2
OH1'24
6 6"
183, p 156 
O OOH OH
NH2
OMe
H2N
OMe
4"
6"
5
2"
3
2'4'
6'
1
184, p 158 
4
3
2
1
O OOAc OAc
OPPO 4" 2"
1'
6"
C' B'
4"'2"'
6"'
A'
C
A
B
185, p 160 
2O OO O
OPPO 4" 2"
1'
6"
4 6
1"'
2"'
3'"
186, p 161 
2"'O OO O
OPPO
OHHO
4' 6'
1"
2'
4"' 6"'
2
1 187, p 163 
2"O OO O
OPPO
NH2H2N
4IV 6IV
1"'
3IV
4" 6"
2
1 188, p 163 
O OOH OH
OHHO
NH2H2N
4'
6'
5
2' 3
1"
2"
1
189, p 165 
6
5 3a
2
N3
N3
OH
O
O7a
190, p166 
6
5 3a
2
N3
N3
O
O
O7a
CO2H1'
2'
191, p 168 
2 4 5'
2'
1"
2"'
5"'
2IV 4IV
NH2 NH2OP O OPO O O
195, p 168 
5
6 2
NH2
H2N
O
OH
OH3
O
HN
H
N
O
NH2
H2N
O
OH
OH
2'
1'
1''
3''
5''
2''
4''
196, p 170 
  
5
6 2
NH2
H2N
O
OH
OH3
O
HN
2'
1'
1''
3''
2''
NH2
H2N
O
OH
OH
HN
HN
O
3''
2''
1''
197, p 173
 
N
H
N
H
O
H2N NH2
O
OH
HO
2"
1"
1'
2'
1
4
5
24"'
3"'
2"'
1"'
NH2
NH2
O
HO
OH
O
H
N
H
N
3"
198, p 175 
2"
1"
1'
2'
8" 10" 12"
1
4'' 6" 14"
15"
OH OH OH OH OH
NH
O O
O
OH
HO
H2N
NH2
O
HO
HO
NH2
NH2
HN
OH
3
5
199, p 177 
2"
1"
2'
3IV
1IV
1
5
O O NH O
NH
O
HO
HO
HOHO
O
O HO OH
HO
HO
H2N
NH2
NH2
H2N
1'
5IV
1IV
5V
4V 3V
1V
3
3IV
5IV
2V
1"'
2"'
200, p 179
 
6
5
3a
2
N3
N3
O
OO
7a
O
O
1"1'
214, p 181 
5
6
2
H2N
NH2
O
OHHO
3
O
1"
1'
215, p 183 
5 2
1
N
TBSO OH
O
O
223, p 185 
5 2
1
N
TBSO NH2
O
O
224, p 186 
5
2 N
H
HO NH2
6
220, p 187 
6
5
3a
2
N3
N3
O
OO
7a
OH
1"1'
226, p 188 
1'''
5 1
1'
NH2
H2N
O
OH
OH
1''
H
N
4 2
228, p 190 
1'''
5 1
1'
NH2
H2N
O
OH
OH
1''
H
N
4 2
N
229, p 191 
1'''
5 1
1'
NH2
H2N
O
OH
OH
1''
H
N
4 2
O
O
1IV  230, p 192 
  
5 1
1'
5"' 6"'
3"' 1'''
NH2
H2N
O
OH
OH
1'' 1IV
H
N
N
4 2
231, p 193 
5 1
NH2
H2N
O
OH
OH
3
1'
1''
3IV
5IV
1'''
H
N
NH
OH
232, p 194 
3IV
5
4
NH2
H2N
O
OH
OH
3
1'
1''
1IV
5IV
1'''
H
N
N
OH
Me
HO
O
233, p 195 
 
O
OH
O
OAc
1'
3'
5' 1 5
3
266, p 195 
OPMBz OAc
OPMBzPMBzO
1'
2'
4'
6'
1
3
4
6
268, p200 
OH
O O1'
3'
5'15
3
O
O 269, p 202 
PMBzO OPMBz
1' 4'
6'
1 4
6
OPMBzO
O 270, p 203 
O
O
O
OAc
1'
3'
5' 1'' 5''
3''
O
O
O
1
3
45
6
7 271, p 205 
3'
51'5'
3
1O O
OTES O 273, p 206 
3'
51'5'
3
1O O
OTES O 274, p 208 
3'
51'5'
3
1O O
OTES O
MeMe
277, p 208
 
3'
51'5'
3
1O O
OTES O
MeMe
Me
3'
51'5'
3
1O O
OTES O
MeMe
Me
276, p 210 
3'
51'5'
3
1O O
OTES O
Me 3'
51'5'
3
1O O
OTES O
Me
278, p 211
 
3'
51'5'
3
1O O
OTES O
MeMe
279, p 213 
3'
51'5'
3
1O O
OTES OTBDMS
MeMe
280, p 213 
3'
5 1' 5'
3
1O O
OAc OAc
MeMe
281, p 215 
1'
6 6'
4'41
Cl
PMBzO
OAc OAc
OH
Cl
8
282, p 217 
1'
6 6'
4'41
Cl
PMBzO
OAc OAc
OPMBz
Cl
8
283, p 218 
2 4 5'
2'
1"
2"'
5"' 3IV1IV
OH OTBDMSOP O OPO O O
4IV
287, p 220 
OH OAcOP O OPO O O
1
245'
2'
1"
2"'
5"'1IV3IV
4IV
291, p 222 
2 4 5'
2'
1"
2"'
5"' 3IV1IV
O OTBDMSOP O OPO O O
4IVHO
292, p 224 
OH OAcOP OMe OPOMe OMe OMe
115
295, p 222 
  
115
OH OOP OMe OPOMe OMe OMe
OH
296, p 225 
1
16
O
PO
OMe OMe OMe
OMe
OPO
297, p 227 
1
OP OH OH OH OPOH
17
OH
OMe
O
301, p 227 
1
O
PO
HO
OH
OH
OH
PO
O
18
302, p 229 
5
2'OP O O O OPO
5'
2
1"'3"'
5"'
1
5"
3"1"
303, p 231 
1
3'
5
1'
O OH OH OH OOH
151'
3'
2OO 18
19
305, p 232 
1
OP
OP
OH OH OH
OPOH
OH OP
OHOHOH
30
306, p 234 
4
O OOAc OAc
OPPO
OHHO
4"
2"
1'
6"
1 2"'
4"'
6"'
A
B
A'
B' 309, p 235 
5"
O OOAc OAc
OPPO
OO
4'
6'
1"
2'
4"'
2"'
6"'
OH OH
1
2 1IV
2IV
310, p 237 
21
15
7 5
9
13 3
11
1
18
HN
N
H
O
O
O
O
OH
OH
OP
OP
23 25
311, p 238 
 
 
1
O O
HN
O
HN
O
HO OH
PO OP
15
7
13
23
29
25
312, p 240 
1"'
2"
1'
5
3'
1"
5'
1
3"'
O O
NH HN
PO OP
HO OH
1'
3'
5'
1"'
2"
1"
3"' 313, p 240 
20
7
5
13
3
1
O O
HN NH
PO OP
HO OH
O O
314, p 242
  
  
 
Gérald COSTE 
Route du Chasseur, 30b 
CH-1008 PRILLY 
?: +33 (0)6 10 42 74 37 
E-Mail: geraldcoste@yahoo.fr
Born: 16.09.1980 
Nationality: French 
 
 
EDUCATION  
 
2003-2007: PhD in Organic Chemistry 
  Ecole Polytechnique Fédérale de Lausanne (Switzerland) 
 
2003:  Diplôme d’Etudes Approfondies (DEA) in Organic Chemistry 
  Université Louis Pasteur, Strasbourg (France) 
 
2000-2003: Master of Chemistry-Ingénieur diploma with a specialisation in Organic Chemistry 
  Ecole Européenne de Chimie, Polymères et Matériaux (ECPM), Strasbourg (France) 
 
1998-2000:  “Classes Préparatoires”, post-baccalaureat scientific preparatory courses, (France) 
June 1998:  Baccalauréat Scientifique, equivalent of High School Diploma, Honors, (France) 
 
 
PROFESSIONAL EXPERIENCE  
 
• 2003-2007: Ecole Polytechnique Fédérale de Lausanne, Lausanne (Switzerland) 
 PhD: under the supervision of Dr. Sandrine Gerber 
 Discovery of new RNA binders as new potential antibiotics 
 Multi steps organic synthesis  
 Tutorial work supervision 
 
 
• 2003:  Louis Pasteur University, Strasbourg (France)  
 Internship 
Resolution method of amino acids 
Organometallic chemistry, photochemistry 
 
 
• 2002:  BASF, Ludwigshafen (Germany)  
Internship as research scientist 
New methodologies for the synthesis of herbicides 
Aromatic and heteroaromatic chemistry 
Synthesis of a patented new family of herbicides 
 
 
• 2001:  Air Liquide, Chalon-sur-Saône (France)  
 Internship in manufacturing 
 
 
FOREIGN LANGUAGES  
 
English: Advanced level. 
  
German: Advanced level. 
  
